<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Antibiotics for secondary prevention of coronary heart disease - Sethi, NJ - 2021 | Cochrane Library</title> <meta content="Antibiotics for secondary prevention of coronary heart disease - Sethi, NJ - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003610.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Antibiotics for secondary prevention of coronary heart disease - Sethi, NJ - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003610.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD003610.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Antibiotics for secondary prevention of coronary heart disease" name="citation_title"/> <meta content="Naqash J Sethi" name="citation_author"/> <meta content="The Capital Region of Denmark, Rigshospitalet, Copenhagen University Hospital" name="citation_author_institution"/> <meta content="naqash.sethi@ctu.dk" name="citation_author_email"/> <meta content="Sanam Safi" name="citation_author"/> <meta content="The Capital Region of Denmark, Rigshospitalet, Copenhagen University Hospital" name="citation_author_institution"/> <meta content="Steven Kwasi Korang" name="citation_author"/> <meta content="The Capital Region of Denmark, Rigshospitalet, Copenhagen University Hospital" name="citation_author_institution"/> <meta content="Asbjørn Hróbjartsson" name="citation_author"/> <meta content="Maria Skoog" name="citation_author"/> <meta content="Christian Gluud" name="citation_author"/> <meta content="Janus C Jakobsen" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="2" name="citation_issue"/> <meta content="10.1002/14651858.CD003610.pub4" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/02/23" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003610.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003610.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003610.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anti-Bacterial Agents [*adverse effects, therapeutic use]; Cardiovascular Diseases [mortality]; Cause of Death; Coronary Disease [mortality, *prevention &amp; control]; Death, Sudden, Cardiac [epidemiology]; Macrolides [adverse effects, therapeutic use]; Myocardial Infarction [epidemiology]; Quinolones [adverse effects, therapeutic use]; Randomized Controlled Trials as Topic; Secondary Prevention [*methods]; Stroke [epidemiology]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003610.pub4&amp;doi=10.1002/14651858.CD003610.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003610.pub4&amp;doi=10.1002/14651858.CD003610.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003610.pub4&amp;doi=10.1002/14651858.CD003610.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003610.pub4&amp;doi=10.1002/14651858.CD003610.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003610.pub4&amp;doi=10.1002/14651858.CD003610.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003610.pub4&amp;doi=10.1002/14651858.CD003610.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003610.pub4&amp;doi=10.1002/14651858.CD003610.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003610.pub4&amp;doi=10.1002/14651858.CD003610.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003610.pub4&amp;doi=10.1002/14651858.CD003610.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003610.pub4&amp;doi=10.1002/14651858.CD003610.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003610.pub4&amp;doi=10.1002/14651858.CD003610.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003610.pub4&amp;doi=10.1002/14651858.CD003610.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003610.pub4&amp;doi=10.1002/14651858.CD003610.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003610.pub4&amp;doi=10.1002/14651858.CD003610.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003610.pub4&amp;doi=10.1002/14651858.CD003610.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003610.pub4&amp;doi=10.1002/14651858.CD003610.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003610.pub4&amp;doi=10.1002/14651858.CD003610.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003610.pub4&amp;doi=10.1002/14651858.CD003610.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003610.pub4&amp;doi=10.1002/14651858.CD003610.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003610.pub4&amp;doi=10.1002/14651858.CD003610.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003610.pub4&amp;doi=10.1002/14651858.CD003610.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003610.pub4&amp;doi=10.1002/14651858.CD003610.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003610.pub4&amp;doi=10.1002/14651858.CD003610.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="Ko3zGe0H";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD003610\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD003610\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003610\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003610\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","pt","ms","ja","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD003610.pub4",title:"Antibiotics for secondary prevention of coronary heart disease",firstPublishedDate:"Feb 23, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Heart Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Ko3zGe0H&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003610.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003610.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD003610.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD003610.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003610.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD003610.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD003610.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD003610.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD003610.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD003610.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3350 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD003610.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003610.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003610.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003610.pub4/full#CD003610-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003610.pub4/full#CD003610-sec-0140"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003610.pub4/full#CD003610-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003610.pub4/full#CD003610-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003610.pub4/full#CD003610-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003610.pub4/full#CD003610-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003610.pub4/full#CD003610-sec-0052"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003610.pub4/full#CD003610-sec-0126"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003610.pub4/appendices#CD003610-sec-0145"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/table_n/CD003610StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/table_n/CD003610StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003610.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003610.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003610.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003610.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003610.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD003610.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2021 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Antibiotics for secondary prevention of coronary heart disease</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003610.pub4/information#CD003610-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Naqash J Sethi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003610.pub4/information#CD003610-cr-0005">Sanam Safi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003610.pub4/information#CD003610-cr-0006">Steven Kwasi Korang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003610.pub4/information#CD003610-cr-0007">Asbjørn Hróbjartsson</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003610.pub4/information#CD003610-cr-0008">Maria Skoog</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003610.pub4/information#CD003610-cr-0009">Christian Gluud</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003610.pub4/information#CD003610-cr-0010">Janus C Jakobsen</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/information/en#CD003610-sec-0150">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 23 February 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD003610.pub4">https://doi.org/10.1002/14651858.CD003610.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD003610-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003610-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003610-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003610-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD003610-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/pt#CD003610-abs-0006">Português</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003610-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD003610-abs-0001" lang="en"> <section id="CD003610-sec-0001"> <h3 class="title" id="CD003610-sec-0001">Background</h3> <p>Coronary heart disease is the leading cause of mortality worldwide with approximately 7.4 million deaths each year. People with established coronary heart disease have a high risk of subsequent cardiovascular events including myocardial infarction, stroke, and cardiovascular death. Antibiotics might prevent such outcomes due to their antibacterial, antiinflammatory, and antioxidative effects. However, a randomised clinical trial and several observational studies have suggested that antibiotics may increase the risk of cardiovascular events and mortality. Furthermore, several non‐Cochrane Reviews, that are now outdated, have assessed the effects of antibiotics for coronary heart disease and have shown conflicting results. No previous systematic review using Cochrane methodology has assessed the effects of antibiotics for coronary heart disease. </p> </section> <section id="CD003610-sec-0002"> <h3 class="title" id="CD003610-sec-0002">Objectives</h3> <p>We assessed the benefits and harms of antibiotics compared with placebo or no intervention for the secondary prevention of coronary heart disease. </p> </section> <section id="CD003610-sec-0003"> <h3 class="title" id="CD003610-sec-0003">Search methods</h3> <p>We searched CENTRAL, MEDLINE, Embase, LILACS, SCI‐EXPANDED, and BIOSIS in December 2019 in order to identify relevant trials. Additionally, we searched TRIP, Google Scholar, and nine trial registries in December 2019. We also contacted 11 pharmaceutical companies and searched the reference lists of included trials, previous systematic reviews, and other types of reviews. </p> </section> <section id="CD003610-sec-0004"> <h3 class="title" id="CD003610-sec-0004">Selection criteria</h3> <p>Randomised clinical trials assessing the effects of antibiotics versus placebo or no intervention for secondary prevention of coronary heart disease in adult participants (≥18 years). Trials were included irrespective of setting, blinding, publication status, publication year, language, and reporting of our outcomes. </p> </section> <section id="CD003610-sec-0005"> <h3 class="title" id="CD003610-sec-0005">Data collection and analysis</h3> <p>Three review authors independently extracted data. Our primary outcomes were all‐cause mortality, serious adverse event according to the International Conference on Harmonization ‐ Good Clinical Practice (ICH‐GCP), and quality of life. Our secondary outcomes were cardiovascular mortality, myocardial infarction, stroke, and sudden cardiac death. Our primary time point of interest was at maximum follow‐up. Additionally, we extracted outcome data at 24±6 months follow‐up. We assessed the risks of systematic errors using Cochrane 'Rosk of bias' tool. We calculated risk ratios (RRs) with 95% confidence intervals (CIs) for dichotomous outcomes. We calculated absolute risk reduction (ARR) or increase (ARI) and number needed to treat for an additional beneficial outcome (NNTB) or for an additional harmful outcome (NNTH) if the outcome result showed a beneficial or harmful effect, respectively. The certainty of the body of evidence was assessed by GRADE. </p> </section> <section id="CD003610-sec-0006"> <h3 class="title" id="CD003610-sec-0006">Main results</h3> <p>We included 38 trials randomising a total of 26,638 participants (mean age 61.6 years), with 23/38 trials reporting data on 26,078 participants that could be meta‐analysed. Three trials were at low risk of bias and the 35 remaining trials were at high risk of bias. Trials assessing the effects of macrolides (28 trials; 22,059 participants) and quinolones (two trials; 4162 participants) contributed with the vast majority of the data. </p> <p>Meta‐analyses at maximum follow‐up showed that antibiotics versus placebo or no intervention seemed to increase the risk of all‐cause mortality (RR 1.06; 95% CI 0.99 to 1.13; P = 0.07; I<sup>2</sup> = 0%; ARI 0.48%; NNTH 208; 25,774 participants; 20 trials; high certainty of evidence), stroke (RR 1.14; 95% CI 1.00 to 1.29; P = 0.04; I<sup>2</sup> = 0%; ARI 0.73%; NNTH 138; 14,774 participants; 9 trials; high certainty of evidence), and probably also cardiovascular mortality (RR 1.11; 95% CI 0.98 to 1.25; P = 0.11; I<sup>2</sup>= 0%; 4674 participants; 2 trials; moderate certainty of evidence). Little to no difference was observed when assessing the risk of myocardial infarction (RR 0.95; 95% CI 0.88 to 1.03; P = 0.23; I<sup>2</sup> = 0%; 25,523 participants; 17 trials; high certainty of evidence). No evidence of a difference was observed when assessing sudden cardiac death (RR 1.08; 95% CI 0.90 to 1.31; P = 0.41; I<sup>2</sup> = 0%; 4520 participants; 2 trials; moderate certainty of evidence). </p> <p>Meta‐analyses at 24±6 months follow‐up showed that antibiotics versus placebo or no intervention increased the risk of all‐cause mortality (RR 1.25; 95% CI 1.06 to 1.48; P = 0.007; I<sup>2</sup> = 0%; ARI 1.26%; NNTH 79 (95% CI 335 to 42); 9517 participants; 6 trials; high certainty of evidence), cardiovascular mortality (RR 1.50; 95% CI 1.17 to 1.91; P = 0.001; I<sup>2</sup> = 0%; ARI 1.12%; NNTH 89 (95% CI 261 to 49); 9044 participants; 5 trials; high certainty of evidence), and probably also sudden cardiac death (RR 1.77; 95% CI 1.28 to 2.44; P = 0.0005; I<sup>2</sup> = 0%; ARI 1.9%; NNTH 53 (95% CI 145 to 28); 4520 participants; 2 trials; moderate certainty of evidence). No evidence of a difference was observed when assessing the risk of myocardial infarction (RR 0.95; 95% CI 0.82 to 1.11; P = 0.53; I<sup>2</sup> = 43%; 9457 participants; 5 trials; moderate certainty of evidence) and stroke (RR 1.17; 95% CI 0.90 to 1.52; P = 0.24; I<sup>2</sup> = 0%; 9457 participants; 5 trials; high certainty of evidence). </p> <p>Meta‐analyses of trials at low risk of bias differed from the overall analyses when assessing cardiovascular mortality at maximum follow‐up. For all other outcomes, meta‐analyses of trials at low risk of bias did not differ from the overall analyses. </p> <p>None of the trials specifically assessed serious adverse event according to ICH‐GCP.</p> <p>No data were found on quality of life.</p> </section> <section id="CD003610-sec-0007"> <h3 class="title" id="CD003610-sec-0007">Authors' conclusions</h3> <p>Our present review indicates that antibiotics (macrolides or quinolones) for secondary prevention of coronary heart disease seem harmful when assessing the risk of all‐cause mortality, cardiovascular mortality, and stroke at maximum follow‐up and all‐cause mortality, cardiovascular mortality, and sudden cardiac death at 24±6 months follow‐up. Current evidence does, therefore, not support the clinical use of macrolides and quinolones for the secondary prevention of coronary heart disease. </p> <p>Future trials on the safety of macrolides or quinolones for the secondary prevention in patients with coronary heart disease do not seem ethical. In general, randomised clinical trials assessing the effects of antibiotics, especially macrolides and quinolones, need longer follow‐up so that late‐occurring adverse events can also be assessed. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD003610-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003610-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003610-abs-0016">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003610-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD003610-abs-0014">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD003610-abs-0010">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD003610-abs-0009">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD003610-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pt#CD003610-abs-0007">Português</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003610-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD003610-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD003610-abs-0002" lang="en"> <h3>Benefits and harms of antibiotics for secondary prevention of coronary heart disease</h3> <p><b>Background</b> </p> <p>Coronary heart disease, also known as cardiovascular disease, is the leading cause of death worldwide with approximately 7.4 million deaths each year. Coronary heart disease is caused by decreased blood supply to the heart. The severity of the disease ranges from chest pain during exercise to heart attack. Antibiotics might help patients with coronary heart disease and reduce their risk of heart attacks, strokes, chest pain, revascularisation procedures, and death. However, a randomised clinical trial and several observational studies suggested that antibiotics increased the risk of cardiovascular events and death. </p> <p><b>Review question</b> </p> <p>The aim of this Cochrane systematic review was to assess the benefits and harms of antibiotics in adult patients with coronary heart disease. </p> <p>We primarily assessed the benefits and harms at maximum follow‐up and secondly at 24±6 months follow‐up. </p> <p><b>Study characteristics</b> </p> <p>We searched various scientific databases from their inception to December 2019 and found 38 trials where people with coronary heart disease were randomly allocated to antibiotics versus placebo or no intervention. The 38 trials included 26,638 adults with a mean age of 61.6 years. 23 out of the 38 trials reported data on 26,078 participants that could be analysed. The vast majority of the data was contributed by trials assessing the effects of macrolide antibiotics (28 trials; 22,059 participants) and quinolone antibiotics (two trials; 4162 participants), while insufficient data were contributed by trials assessing the effects of tetracycline antibiotics (eight trials; 417 participants). Three trials were at low risk of bias and the remaining trials were at high risk of bias. </p> <p><b>Key results and conclusion</b> </p> <p>Patients receiving antibiotics (macrolide antibiotics or quinolone antibiotics) compared with patients receiving placebo or no intervention seemed at a slightly higher risk of death from all causes, death from a cardiac cause, and having a stroke at maximum follow‐up. Moreover, a slightly higher risk was also observed when assessing death from all causes, death from a cardiac cause, and sudden death from a cardiac cause at 24±6 months follow‐up. None of the trials sufficiently reported the number of participants with serious adverse events. No data were provided on quality of life. </p> <p>Future trials on the safety of macrolide antibiotics or quinolone antibiotics for the secondary prevention in adult patients with coronary heart disease do not seem ethical. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD003610-sec-0140" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD003610-sec-0140"></div> <h3 class="title" id="CD003610-sec-0141">Implications for practice</h3> <section id="CD003610-sec-0141"> <p>Our present review indicates that antibiotics (macrolides or quinolones) for secondary prevention of coronary heart disease seem harmful when assessing the risk of all‐cause mortality, cardiovascular mortality, and stroke at maximum follow‐up and all‐cause mortality, cardiovascular mortality, and sudden cardiac death at 24±6 months follow‐up. Current evidence does, therefore, not support the clinical use of macrolides and quinolones for the secondary prevention of coronary heart disease. </p> </section> <h3 class="title" id="CD003610-sec-0142">Implications for research</h3> <section id="CD003610-sec-0142"> <p>Future trials on the safety of macrolides or quinolones for the secondary prevention in patients with coronary heart disease do not seem ethical. In general, randomised clinical trials assessing the effects of antibiotics, especially macrolides and quinolones, need longer follow‐up so that late‐occurring adverse events can also be assessed. Trials ought to be designed according to the SPIRIT statement (<a href="https://www.spirit-statement.org/" target="_blank">https://www.spirit-statement.org/</a>) and reported according to the CONSORT statement (<a href="http://www.consort-statement.org/" target="_blank">http://www.consort-statement.org/</a>). Moreover, trials need to be registered and fully and transparently reported including both benefits and harms (<a href="./references#CD003610-bbs2-0185" title="SkoogM , SaarimäkiJ , GluudC , ScheininM , ErlendssonK , AamdalS . Transparency and registration in clinical research in the Nordic countries (Report). Nordic Trial Alliance. NordForsk. Oslo. Norway: Nordic Trial Alliance, 2015: 1-108.">Skoog 2015</a>). </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD003610-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD003610-sec-0008"></div> <div class="table" id="CD003610-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Antibiotics versus placebo or no intervention for secondary prevention of patients with coronary heart disease at maximum follow‐up</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Antibiotics compared with placebo or no intervention for coronary heart disease at maximum follow‐up</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with coronary heart disease </p> <p><b>Settings:</b> any setting </p> <p><b>Intervention:</b> any antibiotic </p> <p><b>Comparison:</b> placebo or no intervention </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo or no intervention</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with antibiotics</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality at maximum follow‐up.</p> <p>Follow‐up: mean 21.4 months (range 3 to 120 months).</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>100 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>106 per 1000<br/>(99 to 113) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.06 (0.99 to 1.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25,774 (20 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall low risk of bias due to the four trials carrying most of the weight were either at overall low risk of bias or were low risk of bias in the majority of domains. </p> <p>Low risk of imprecision due to inclusion of more participants than the estimated optimal information size<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse event at maximum follow‐up.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data were reported in the included trials.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life at maximum follow‐up.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data were reported in the included trials.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiovascular mortality at maximum follow‐up.</p> <p>Follow‐up: mean 72.0 months (range 24 to 120 months).</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>167 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>185 per 1000<br/>(164 to 209) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.11 (0.98 to 1.25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4674 (2 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The sensitivity analysis only including low risk of bias trials differed from the overall analysis. Hence, for this outcome, we based our primary analysis and primary conclusion on trials at low risk of bias. </p> <p>Overall low risk of bias due to the three trials carrying most of the weight were either at overall low risk of bias or were low risk of bias in the majority of domains. </p> <p>Low risk of imprecision due to the sample size being very large (&gt; 4000 participants)<sup>3</sup>. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Myocardial infarction at maximum follow‐up.</p> <p>Follow‐up: mean 20.7 months (range 3 to 120 months).</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>80 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>76 per 1000<br/>(71 to 83) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.95 (0.88 to 1.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25,523 (17 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall low risk of bias due to the four trials carrying most of the weight were either at overall low risk of bias or were low risk of bias in the majority of domains. </p> <p>Low risk of imprecision due to inclusion of more participants than the estimated optimal information size<sup>4</sup>. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stroke at maximum follow‐up.</p> <p>Follow‐up: mean 31.9 months (range 6 to 120 months).</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>55 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>62 per 1000<br/>(55 to 70) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.14 (1.00 to 1.29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14,774 (9 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall low risk of bias due to the three trials carrying most of the weight were either at overall low risk of bias or were low risk of bias in the majority of domains. </p> <p>Low risk of imprecision due to the sample size being very large (&gt; 4000 participants)<sup>5</sup>. </p> <p>The risk of publication bias could not be assessed due to too few included trials.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sudden cardiac death at maximum follow‐up.</p> <p>Follow‐up: mean 69.3 months (range 18.5 to 120 months).</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>84 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>90 per 1000 (75 to 109)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.08 (0.90 to 1.31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4520 (2 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall low risk of bias due to both trials included in the meta‐analyses being at overall low risk of bias or low risk of bias in the majority of domains, respectively. </p> <p>Low risk of imprecision due to the sample size being very large (&gt; 4000 participants)<sup>6</sup>. </p> <p>The risk of publication bias could not be assessed due to too few included trials.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High</b> certainty<b>:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate</b> certainty<b>:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low</b> certainty<b>:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low</b> certainty<b>:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of the effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>No downgrading for imprecision: the optimal information size according to the GRADE Handbook using a RRR of 15%, an incidence in the control group of 10.0%, an alpha of 2.5%, and a beta of 10% was estimated to be 18,576 participants and we included 25,774 participants. </p> <p><sup>2</sup>Downgrading one level due to serious indirectness: risk of difference between the population of interest and the included participants, and between the intervention of interest and the included interventions. </p> <p><sup>3</sup>No downgrading for imprecision: the optimal information size according to the GRADE Handbook using a RRR of 15%, an incidence of 16.7%, an alpha of 2.0%, and a beta of 10% was estimated to be 10,883 participants and we only included 4674 participants. Nevertheless, the sample size was very large (&gt;4000 participants). </p> <p><sup>4</sup>No downgrading for imprecision: the optimal information size according to the GRADE Handbook using a RRR of 15%, an incidence of 8.09%, an alpha of 2.0%, and a beta of 10% was estimated to be 24,627 participants and we included 25,523 participants. </p> <p><sup>5</sup>No downgrading for imprecision: the optimal information size according to the GRADE Handbook using a RRR of 15%, an incidence of 5.49%, an alpha of 2.0%, and a beta of 10% was estimated to be 37,339 participants and we only included 14,774 participants. Nevertheless, the sample size was very large (&gt;4000 participants). </p> <p><sup>6</sup>No downgrading for imprecision. the optimal information size according to the GRADE Handbook using a RRR of 15%, an incidence of 8.36%, an alpha of 2.0%, and a beta of 10% was estimated to be 23,782 participants and we only included 4520 participants. Nevertheless, the sample size was very large (&gt;4000 participants). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003610-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Antibiotics versus placebo or no intervention for secondary prevention of patients with coronary heart disease at 24±6 months follow‐up</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Antibiotics compared with placebo or no intervention for coronary heart disease at 24±6 months follow‐up</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with coronary heart disease </p> <p><b>Settings:</b> any setting </p> <p><b>Intervention:</b> any antibiotic </p> <p><b>Comparison:</b> placebo or no intervention </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo or no intervention</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with antibiotics</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality at 24±6 months follow‐up.</p> <p>Follow‐up: mean 23.3 months (range 18 to 30 months).</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>62 per 1000<br/>(53 to 74) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.25 (1.06 to 1.48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9517 (6 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall low risk of bias due to the three trials carrying most of the weight were either at overall low risk of bias or were low risk of bias in the majority of domains. </p> <p>Low risk of imprecision due to the sample size being very large (&gt; 4000 participants)<sup>1</sup>. </p> <p>The risk of publication bias could not be assessed due to too few included trials.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse event at 24±6 months follow‐up.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data were reported in the included trials.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life at 24±6 months follow‐up.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data were reported in the included trials.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiovascular mortality at 24±6 months follow‐up.</p> <p>Follow‐up: mean 23.1 months (range 18 to 30 months).</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>23 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>34 per 1000<br/>(26 to 43) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.50 (1.17 to 1.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9044 (5 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall low risk of bias due to the three trials carrying most of the weight were either at overall low risk of bias or were low risk of bias in the majority of domains. </p> <p>Low risk of imprecision due to the sample size being very large (&gt; 4000 participants)<sup>2</sup>. </p> <p>The risk of publication bias could not be assessed due to too few included trials.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Myocardial infarction at 24±6 months follow‐up.</p> <p>Follow‐up: mean 24.3 months (range 18.5 to 30.0 months).</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>68 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>65 per 1000<br/>(56 to 76) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.95 (0.82 to 1.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9457 (5 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall low risk of bias due to the two trials carrying most of the weight were either at overall low risk of bias or were low risk of bias in the majority of domains. </p> <p>Low risk of imprecision due to the sample size being very large (&gt; 4000 participants)<sup>4</sup>. </p> <p>The risk of publication bias could not be assessed due to too few included trials.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stroke at 24±6 months follow‐up.</p> <p>Follow‐up: mean 24.3 months (range 18.5 to 30 months).</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>21 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>25 per 1000<br/>(19 to 32) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.17 (0.90 to 1.52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9457 (5 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall low risk of bias due to the three trials carrying most of the weight were either at overall low risk of bias or were low risk of bias in the majority of domains. </p> <p>Low risk of imprecision due to the sample size being very large (&gt; 4000 participants)<sup>5</sup>. </p> <p>The risk of publication bias could not be assessed due to too few included trials.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sudden cardiac death at 24±6 months follow‐up.</p> <p>Follow‐up: mean 24.3 months (range 18.5 to 30 months).</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>44 per 1000 (33 to 63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.77 (1.28 to 2.44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4520 (2 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall low risk of bias due to both trials included in the meta‐analyses being at overall low risk of bias or low risk of bias in the majority of domains, respectively. </p> <p>Low risk of imprecision due to the sample size being very large (&gt; 4000 participants)<sup>7</sup>. </p> <p>The risk of publication bias could not be assessed due to too few included trials.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High</b> certainty<b>:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate</b> certainty<b>:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low</b> certainty<b>:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low</b> certainty<b>:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of the effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>No downgrade for imprecision: the optimal information size according to the GRADE Handbook using a RRR of 15%, an incidence of 4.98%, an alpha of 2.5%, and a beta of 10% was estimated to be 38,771 participants and we only included 9509 participants. Nevertheless, the sample size was very large (&gt;4000 participants). </p> <p><sup>2</sup>No downgrade for imprecision: the optimal information size according to the GRADE Handbook using a RRR of 15%, an incidence of 2.25%, an alpha of 2.0%, and a beta of 10% was estimated to be 91,738 participants and we only included 9036 participants. Nevertheless, the sample size was very large (&gt;4000 participants). </p> <p><sup>3</sup>Downgrading one level due to serious inconsistency: the statistical heterogeneity was I<sup>2</sup> = 43%; P = 0.14. Moreover, the forest plot showed trials with results in opposite direction. </p> <p><sup>4</sup>No downgrade for imprecision: the optimal information size according to the GRADE Handbook using a RRR of 15%, an incidence of 6.85%, an alpha of 2.0%, and a beta of 10% was estimated to be 96,669 participants and we only included 9457 participants. Nevertheless, the sample size was very large (&gt;4000 participants). </p> <p><sup>5</sup>No downgrade for imprecision: The optimal information size according to the GRADE Handbook using a RRR of 15%, an incidence of 2.11%, an alpha of 2.0%, and a beta of 10% was estimated to be 97,219 participants and we only included 9449 participants. Nevertheless, the sample size was very large (&gt;4000 participants). </p> <p><sup>6</sup>Downgrading one level due to serious indirectness: Risk of difference between the population of interest and the included participants, and between the intervention of interest and the included interventions. </p> <p><sup>7</sup>No downgrade for imprecision: the optimal information size according to the GRADE Handbook using a RRR of 15%, an incidence of 2.59%, an alpha of 2.0%, and a beta of 10% was estimated to be 80,024 participants and we only included 4520 participants. Nevertheless, the sample size was very large (&gt;4000 participants). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD003610-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD003610-sec-0009"></div> <section id="CD003610-sec-0010"> <h3 class="title" id="CD003610-sec-0010">Description of the condition</h3> <p>Coronary heart disease is the collective term for a group of diseases consisting of stable angina, unstable angina, myocardial infarction, and sudden cardiac death (<a href="./references#CD003610-bbs2-0202" title="WongND . Epidemiological studies of CHD and the evolution of preventive cardiology. Nature Reviews Cardiology2014;11(5):276-89.">Wong 2014</a>). Coronary heart disease is estimated to be the leading cause of death worldwide (<a href="./references#CD003610-bbs2-0198" title="MendisS , PuskaP , Norrving B (editors). Global Atlas on Cardiovascular Disease Prevention and Control. Geneva: World Health Organization, 2011.">WHO 2011</a>; <a href="./references#CD003610-bbs2-0199" title="World Health organization. Cardiovascular diseases - Fact sheet N 317. WHO - Available from: www.who.int/mediacentre/factsheets/fs317/en/ Updated 2016 Jun; cited 2016 Aug 20].">WHO 2016</a>), and 15.5 million people in the USA alone suffer from coronary heart disease (<a href="./references#CD003610-bbs2-0157" title="MozaffarianD , BenjaminEJ , GoAS , ArnettDK , BlahaMJ , CushmanM , et al. Heart Disease and Stroke Statistics-2016 Update: a report from the American Heart Association. Circulation2016;133(4):e38-360.">Mozaffarian 2016</a>). The World Health Organization (WHO) has estimated that 7.4 million people die each year globally because of coronary heart disease with over three quarters of the deaths occurring in low‐ and middle‐income countries (<a href="./references#CD003610-bbs2-0198" title="MendisS , PuskaP , Norrving B (editors). Global Atlas on Cardiovascular Disease Prevention and Control. Geneva: World Health Organization, 2011.">WHO 2011</a>; <a href="./references#CD003610-bbs2-0199" title="World Health organization. Cardiovascular diseases - Fact sheet N 317. WHO - Available from: www.who.int/mediacentre/factsheets/fs317/en/ Updated 2016 Jun; cited 2016 Aug 20].">WHO 2016</a>). Coronary heart disease also has a significant impact on healthcare costs and accounts for approximately EUR 196 billion in Europe and USD 207.3 billion in the USA (<a href="./references#CD003610-bbs2-0098" title="Ferreira-GonzalezI . The epidemiology of coronary heart disease. Revista Espanola de Cardiologia (English Edition)2014;67(2):139-44.">Ferreira‐Gonzalez 2014</a>; <a href="./references#CD003610-bbs2-0157" title="MozaffarianD , BenjaminEJ , GoAS , ArnettDK , BlahaMJ , CushmanM , et al. Heart Disease and Stroke Statistics-2016 Update: a report from the American Heart Association. Circulation2016;133(4):e38-360.">Mozaffarian 2016</a>). </p> <p>The pathogenesis of coronary heart disease is related to the narrowing or blockage of the coronary arteries supplying the heart with blood. This process is usually caused by build‐up of fatty material and plaque in the walls of the coronary arteries leading to atherosclerosis (<a href="./references#CD003610-bbs2-0173" title="RossR . Atherosclerosis--an inflammatory disease. NEJM1999;340(2):115-26.">Ross 1999</a>; <a href="./references#CD003610-bbs2-0140" title="LibbyP , OkamotoY , RochaVZ , FolcoE . Inflammation in atherosclerosis: transition from theory to practice. Circulation Journal2010;74(2):213-20.">Libby 2010</a>; <a href="./references#CD003610-bbs2-0141" title="LibbyP , RidkerPM , HanssonGK . Progress and challenges in translating the biology of atherosclerosis. Nature2011;473(7347):317-25.">Libby 2011</a>; <a href="./references#CD003610-bbs2-0063" title="AmbroseJA , SinghM . Pathophysiology of coronary artery disease leading to acute coronary syndromes. F1000Prime Reports2015;7:08.">Ambrose 2015</a>). Atherosclerosis is a chronic immune‐mediated inflammatory disease that usually develops over years, ultimately limiting perfusion to the heart, which may cause shortages of oxygen and glucose, leading to symptoms such as chest pain (angina) and shortness of breath (<a href="./references#CD003610-bbs2-0173" title="RossR . Atherosclerosis--an inflammatory disease. NEJM1999;340(2):115-26.">Ross 1999</a>; <a href="./references#CD003610-bbs2-0063" title="AmbroseJA , SinghM . Pathophysiology of coronary artery disease leading to acute coronary syndromes. F1000Prime Reports2015;7:08.">Ambrose 2015</a>). </p> <p>People with established coronary heart disease have a high risk of subsequent cardiovascular events including cardiovascular death, myocardial infarction, and stroke (<a href="./references#CD003610-bbs2-0186" title="Smith SC Jr, BenjaminEJ , BonowRO , BraunLT , CreagerMA , FranklinBA , et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association. Journal of the American College of Cardiology2011;58(23):2432-46.">Smith 2011</a>; <a href="./references#CD003610-bbs2-0198" title="MendisS , PuskaP , Norrving B (editors). Global Atlas on Cardiovascular Disease Prevention and Control. Geneva: World Health Organization, 2011.">WHO 2011</a>; <a href="./references#CD003610-bbs2-0091" title="EckelRH , JakicicJM , ArdJD , deJesusJM , Houston MillerN , HubbardVS , et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation2014;129(25 Suppl 2):S76-99.">Eckel 2014</a>; <a href="./references#CD003610-bbs2-0160" title="PiepoliMF , HoesAW , AgewallS , AlbusC , BrotonsC , CatapanoAL , et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention &amp; Rehabilitation (EACPR). European Heart Journal2016;37(29):2315-81.">Piepoli 2016</a>; <a href="./references#CD003610-bbs2-0201" title="WinkelP , HildenJ , HansenJF , KastrupJ , KolmosHJ , KjollerE , et al. Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular mortality and cerebrovascular morbidity over 10 years in the CLARICOR randomised, blinded clinical trial. International Journal of Cardiology2015;182:459-65.">Winkel 2015</a>). Therapeutic lifestyle changes (e.g. increased physical activity; weight reduction; dietary modification; smoking cessation; and alcohol intake reduction) and adjunctive drug therapies (e.g. antithrombotic treatment; managing hypertension, diabetes, dyslipidaemia, and chronic kidney disease) are necessary to improve quality of life, reduce recurrent events and the need for revascularisation procedures, and improve survival (<a href="./references#CD003610-bbs2-0186" title="Smith SC Jr, BenjaminEJ , BonowRO , BraunLT , CreagerMA , FranklinBA , et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association. Journal of the American College of Cardiology2011;58(23):2432-46.">Smith 2011</a>; <a href="./references#CD003610-bbs2-0198" title="MendisS , PuskaP , Norrving B (editors). Global Atlas on Cardiovascular Disease Prevention and Control. Geneva: World Health Organization, 2011.">WHO 2011</a>; <a href="./references#CD003610-bbs2-0091" title="EckelRH , JakicicJM , ArdJD , deJesusJM , Houston MillerN , HubbardVS , et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation2014;129(25 Suppl 2):S76-99.">Eckel 2014</a>; <a href="./references#CD003610-bbs2-0160" title="PiepoliMF , HoesAW , AgewallS , AlbusC , BrotonsC , CatapanoAL , et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention &amp; Rehabilitation (EACPR). European Heart Journal2016;37(29):2315-81.">Piepoli 2016</a>). Nonetheless, even complete adherence to the aforementioned therapies is reported to not completely eliminate the person's risk of subsequent cardiovascular events (<a href="./references#CD003610-bbs2-0072" title="BertrandMJ , TardifJC . Inflammation and beyond: new directions and emerging drugs for treating atherosclerosis. Expert Opinion on Emerging Drugs2016;22(1):1-26.">Bertrand 2016</a>). This residual risk may result, in part, from the failure of current therapies to efficiently address inflammation (<a href="./references#CD003610-bbs2-0072" title="BertrandMJ , TardifJC . Inflammation and beyond: new directions and emerging drugs for treating atherosclerosis. Expert Opinion on Emerging Drugs2016;22(1):1-26.">Bertrand 2016</a>). </p> <p>Studies have shown that inflammation seems to be a predictor for the development and progression of atherosclerosis (<a href="./references#CD003610-bbs2-0139" title="LibbyP , RidkerPM , MaseriA . Inflammation and atherosclerosis. Circulation2002;105(9):1135-43.">Libby 2002</a>; <a href="./references#CD003610-bbs2-0131" title="KaptogeS , Di AngelantonioE , LoweG , PepysMB , ThompsonSG , CollinsR , et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet2010;375(9709):132-40.">Kaptoge 2010</a>; <a href="./references#CD003610-bbs2-0136" title="LawsonJS . Multiple Infectious Agents and the Origins of Atherosclerotic Coronary Artery Disease. Frontiers in Cardiovascular Medicine2016;3:30.">Lawson 2016</a>) and the inflammatory process may be induced by stimuli from infectious agents (<a href="./references#CD003610-bbs2-0152" title="MendallMA , PatelP , BallamL , StrachanD , NorthfieldTC . C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. BMJ1996;312(7038):1061-5.">Mendall 1996</a>; <a href="./references#CD003610-bbs2-0172" title="RosenfeldME , CampbellLA . Pathogens and atherosclerosis: update on the potential contribution of multiple infectious organisms to the pathogenesis of atherosclerosis. Thrombosis and Haemostasis2011;106(5):858-67.">Rosenfeld 2011</a>; <a href="./references#CD003610-bbs2-0136" title="LawsonJS . Multiple Infectious Agents and the Origins of Atherosclerotic Coronary Artery Disease. Frontiers in Cardiovascular Medicine2016;3:30.">Lawson 2016</a>). The infectious agents might induce the inflammatory process by infecting vascular cells within the atheromatous plaque and consequently activating an innate immune response (<a href="./references#CD003610-bbs2-0172" title="RosenfeldME , CampbellLA . Pathogens and atherosclerosis: update on the potential contribution of multiple infectious organisms to the pathogenesis of atherosclerosis. Thrombosis and Haemostasis2011;106(5):858-67.">Rosenfeld 2011</a>). The activated innate immune response then contributes to the inflammation within the plaque (<a href="./references#CD003610-bbs2-0172" title="RosenfeldME , CampbellLA . Pathogens and atherosclerosis: update on the potential contribution of multiple infectious organisms to the pathogenesis of atherosclerosis. Thrombosis and Haemostasis2011;106(5):858-67.">Rosenfeld 2011</a>). Moreover, infectious agents may induce inflammation at non‐vascular places, which might lead to increased secretion of cytokines and other acute‐phase proteins. The cytokines and other acute‐phase proteins then add to the inflammation within the plaque (<a href="./references#CD003610-bbs2-0172" title="RosenfeldME , CampbellLA . Pathogens and atherosclerosis: update on the potential contribution of multiple infectious organisms to the pathogenesis of atherosclerosis. Thrombosis and Haemostasis2011;106(5):858-67.">Rosenfeld 2011</a>). Hence, an association between coronary heart disease and various infectious agents has been suggested and a number of studies have investigated the validity of this possible association. </p> <p><i>Chlamydia pneumoniae</i> (<i>C pneumoniae</i>) bacteria have been identified in atheromatous plaques (<a href="./references#CD003610-bbs2-0184" title="ShorA , KuoCC , PattonDL . Detection of Chlamydia pneumoniae in coronary arterial fatty streaks and atheromatous plaques. South African Medical Journal1992;82(3):158-61.">Shor 1992</a>; <a href="./references#CD003610-bbs2-0134" title="KuoCC , GownAM , BendittEP , GraystonJT . Detection of Chlamydia pneumoniae in aortic lesions of atherosclerosis by immunocytochemical stain. Arteriosclerosis and Thrombosis1993;13(10):1501-4.">Kuo 1993</a>; <a href="./references#CD003610-bbs2-0158" title="MuhlesteinJB , HammondEH , CarlquistJF , RadickeE , ThomsonMJ , KaragounisLA , et al. Increased incidence of Chlamydia species within the coronary arteries of patients with symptomatic atherosclerotic versus other forms of cardiovascular disease. Journal of the American College of Cardiology1996;27(7):1555-61.">Muhlestein 1996</a>; <a href="./references#CD003610-bbs2-0068" title="AssarO , NejatizadehA , DehghanF , KargarM , ZolghadriN . Association of Chlamydia pneumoniae infection with atherosclerotic plaque formation. Global Journal of Health Science2015;8(4):260-7.">Assar 2015</a>; <a href="./references#CD003610-bbs2-0161" title="PigarevskiiPV , Mal'tsevaSV , SnegovaVA , DavydovaNG , GusevaVA . Chlamydia pneumoniae and immunoinflammatory reactions in an unstable atherosclerotic plaque in humans. Bulletin of Experimental Biology and Medicine2015;159(2):278-81.">Pigarevskii 2015</a>). Moreover, seroepidemiological studies (<a href="./references#CD003610-bbs2-0174" title="SaikkuP , LeinonenM , MattilaK , EkmanMR , NieminenMS , MakelaPH , et al. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet1988;2(8618):983-6.">Saikku 1988</a>; <a href="./references#CD003610-bbs2-0192" title="ThomDH , WangSP , GraystonJT , SiscovickDS , StewartDK , KronmalRA , et al. Chlamydia pneumoniae strain TWAR antibody and angiographically demonstrated coronary artery disease. Arteriosclerosis and Thrombosis1991;11(3):547-51.">Thom 1991</a>; <a href="./references#CD003610-bbs2-0142" title="LinnanmakiE , LeinonenM , MattilaK , NieminenMS , ValtonenV , SaikkuP . Chlamydia pneumoniae-specific circulating immune complexes in patients with chronic coronary heart disease. Circulation1993;87(4):1130-4.">Linnanmaki 1993</a>; <a href="./references#CD003610-bbs2-0132" title="Kazar J,  Kovacova E,  Koncova K,  CvachovaS ,  MongiellovaV ,  LietavaJ ,  et al. Chlamydia pneumoniae antibodies and markers of inflammation in patients with cardiovascular diseases. Bratislavské Lekárske Listy2005;106(11):341-4.">Kazar 2005</a>; <a href="./references#CD003610-bbs2-0171" title="Romano CarratelliC ,  NuzzoI ,  CozzolinoD ,  BentivoglioC ,  PaolilloR ,  RizzoA . Relationship between Chlamydia pneumoniae infection, inflammatory markers, and coronary heart diseases. International Immunopharmacology2006;6(5):848-53.">Romano Carratelli 2006</a>; <a href="./references#CD003610-bbs2-0175" title="Sakurai-KomadaN , IsoH , KoikeKA , IkedaA , UmesawaM , IkeharaS , et al. Association between Chlamydophila pneumoniae infection and risk of coronary heart disease for Japanese: the JPHC study. Atherosclerosis2014;233(2):338-42.">Sakurai‐Komada 2014</a>) and a meta‐analysis of seroepidemiological studies (<a href="./references#CD003610-bbs2-0082" title="DaneshJ , CollinsR , PetoR . Chronic infections and coronary heart disease: is there a link?Lancet1997;350(9075):430-6.">Danesh 1997</a>) have all shown increased levels of <i>C pneumoniae</i> antibodies in people with coronary heart disease. In vivo studies and a meta‐analysis of observational studies have shown that <i>C pneumoniae</i> may contribute to atherosclerosis (<a href="./references#CD003610-bbs2-0076" title="BurnettMS , GaydosCA , MadicoGE , GladSM , PaigenB , QuinnTC , et al. Atherosclerosis in apoE knockout mice infected with multiple pathogens. Journal of Infectious Diseases2001;183(2):226-31.">Burnett 2001</a>; <a href="./references#CD003610-bbs2-0096" title="EzzahiriR , Nelissen-VranckenHJ , KurversHA , StassenFR , VliegenI , GraulsGE , et al. Chlamydophila pneumoniae (Chlamydia pneumoniae) accelerates the formation of complex atherosclerotic lesions in Apo E3-Leiden mice. Cardiovascular Research2002;56(2):269-76.">Ezzahiri 2002</a>; <a href="./references#CD003610-bbs2-0097" title="EzzahiriR , StassenFR , KurversHA , Van PulMM , KitslaarPJ , BruggemanCA . Chlamydia pneumoniae infection induces an unstable atherosclerotic plaque phenotype in LDL-receptor, ApoE double knockout mice. European Journal of Vascular and Endovascular Surgery2003;26(1):88-95.">Ezzahiri 2003</a>; <a href="./references#CD003610-bbs2-0100" title="FilardoS , Di PietroM , FarcomeniA , SchiavoniG , SessaR . Chlamydia pneumoniae-mediated inflammation in atherosclerosis: a meta-analysis. Mediators of Inflammation2015;2015:378658.">Filardo 2015</a>). Contrary to these findings, prospective seroepidemiological studies (<a href="./references#CD003610-bbs2-0169" title="RidkerPM , KundsinRB , StampferMJ , PoulinS , HennekensCH . Prospective study of Chlamydia pneumoniae IgG seropositivity and risks of future myocardial infarction. Circulation1999;99(9):1161-4.">Ridker 1999</a>; <a href="./references#CD003610-bbs2-0084" title="DaneshJ , WhincupP , WalkerM , LennonL , ThomsonA , ApplebyP , et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ2000;321(7255):199-204.">Danesh 2000a</a>; <a href="./references#CD003610-bbs2-0085" title="DaneshJ , WhincupP , WalkerM , LennonL , ThomsonA , ApplebyP , et al. Chlamydia pneumoniae IgG titres and coronary heart disease: prospective study and meta-analysis. BMJ2000;321(7255):208-13.">Danesh 2000b</a>; <a href="./references#CD003610-bbs2-0086" title="DaneshJ , WhincupP , LewingtonS , WalkerM , LennonL , ThomsonA , et al. Chlamydia pneumoniae IgA titres and coronary heart disease: prospective study and meta-analysis. European Heart Journal2002;23(5):371-5.">Danesh 2002</a>), retrospective seroepidemiological studies (<a href="./references#CD003610-bbs2-0163" title="PrasadA , ZhuJ , HalcoxJP , WaclawiwMA , EpsteinSE , QuyyumiAA . Predisposition to atherosclerosis by infections: role of endothelial dysfunction. Circulation2002;106(2):184-90.">Prasad 2002</a>; <a href="./references#CD003610-bbs2-0062" title="Al-YounesHM , Abu AbeelehMA , JaberBM . Lack of strong association of Chlamydia pneumoniae and atherosclerosis in a Jordanian population. Journal of Infection in Developing Countries2016;10(5):457-64.">Al‐Younes 2016</a>), and meta‐analyses of seroepidemiological studies (<a href="./references#CD003610-bbs2-0084" title="DaneshJ , WhincupP , WalkerM , LennonL , ThomsonA , ApplebyP , et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ2000;321(7255):199-204.">Danesh 2000a</a>; <a href="./references#CD003610-bbs2-0085" title="DaneshJ , WhincupP , WalkerM , LennonL , ThomsonA , ApplebyP , et al. Chlamydia pneumoniae IgG titres and coronary heart disease: prospective study and meta-analysis. BMJ2000;321(7255):208-13.">Danesh 2000b</a>; <a href="./references#CD003610-bbs2-0086" title="DaneshJ , WhincupP , LewingtonS , WalkerM , LennonL , ThomsonA , et al. Chlamydia pneumoniae IgA titres and coronary heart disease: prospective study and meta-analysis. European Heart Journal2002;23(5):371-5.">Danesh 2002</a>; <a href="./references#CD003610-bbs2-0073" title="BloemenkampDG , MaliWP , VisserenFL , Van der GraafY . Meta-analysis of sero-epidemiologic studies of the relation between Chlamydia pneumoniae and atherosclerosis: does study design influence results?American Heart Journal2003;145(3):409-17.">Bloemenkamp 2003</a>) did not show any association between <i>C pneumoniae</i> antibodies and coronary heart disease. </p> <p><i>Porphyromonas gingivalis</i> (<i>P gingivalis</i>) bacteria have also been identified in atheromatous plaques (<a href="./references#CD003610-bbs2-0164" title="PucarA , MilasinJ , LekovicV , VukadinovicM , RisticM , PutnikS , et al. Correlation between atherosclerosis and periodontal putative pathogenic bacterial infections in coronary and internal mammary arteries. Journal of Periodontology2007;78(4):677-82.">Pucar 2007</a>; <a href="./references#CD003610-bbs2-0205" title="ZarembaM , GorskaR , SuwalskiP , KowalskiJ . Evaluation of the incidence of periodontitis-associated bacteria in the atherosclerotic plaque of coronary blood vessels. Journal of Periodontology2007;78(2):322-7.">Zaremba 2007</a>; <a href="./references#CD003610-bbs2-0102" title="Gaetti-Jardim E Jr, MarcelinoSL , FeitosaAC , RomitoGA , Avila-CamposMJ . Quantitative detection of periodontopathic bacteria in atherosclerotic plaques from coronary arteries. Journal of Medical Microbiology2009;58(Pt 12):1568-75.">Gaetti‐Jardim 2009</a>; <a href="./references#CD003610-bbs2-0147" title="MahendraJ , MahendraL , KurianVM , JaishankarK , MythilliR . Prevalence of periodontal pathogens in coronary atherosclerotic plaque of patients undergoing coronary artery bypass graft surgery. Journal of Maxillofacial and Oral Surgery2009;8(2):108-13.">Mahendra 2009</a>). Moreover, studies have shown increased levels of antibodies or higher amount of oral bacterial burden of <i>P gingivalis</i> in people with coronary heart disease (<a href="./references#CD003610-bbs2-0165" title="PussinenPJ , AlfthanG , TuomilehtoJ , AsikainenS , JousilahtiP . High serum antibody levels to Porphyromonas gingivalis predict myocardial infarction. European Journal of Cardiovascular Prevention and Rehabilitation2004;11(5):408-11.">Pussinen 2004</a>; <a href="./references#CD003610-bbs2-0167" title="RenvertS , PetterssonT , OhlssonO , PerssonGR . Bacterial profile and burden of periodontal infection in subjects with a diagnosis of acute coronary syndrome. Journal of Periodontology2006;77(7):1110-9.">Renvert 2006</a>; <a href="./references#CD003610-bbs2-0107" title="GotsmanI , LotanC , SoskolneWA , RassovskyS , PugatschT , LapidusL , et al. Periodontal destruction is associated with coronary artery disease and periodontal infection with acute coronary syndrome. Journal of Periodontology2007;78(5):849-58.">Gotsman 2007</a>; <a href="./references#CD003610-bbs2-0148" title="MahendraJ , MahendraL , NagarajanA , MathewK . Prevalence of eight putative periodontal pathogens in atherosclerotic plaque of coronary artery disease patients and comparing them with noncardiac subjects: a case-control study. Indian Journal of Dental Research2015;26(2):189-95.">Mahendra 2015</a>). In vivo studies have shown that <i>P gingivalis</i> may contribute to atherosclerosis (<a href="./references#CD003610-bbs2-0075" title="BrodalaN , MerricksEP , BellingerDA , DamrongsriD , OffenbacherS , BeckJ , et al. Porphyromonas gingivalis bacteremia induces coronary and aortic atherosclerosis in normocholesterolemic and hypercholesterolemic pigs. Arteriosclerosis, Thrombolysis, and Vascular Biology2005;25(7):1446-51.">Brodala 2005</a>; <a href="./references#CD003610-bbs2-0145" title="MaekawaT , TakahashiN , TabetaK , AokiY , MiyashitaH , MiyauchiS , et al. Chronic oral infection with Porphyromonas gingivalis accelerates atheroma formation by shifting the lipid profile. PLoS One2011;6(5):e20240.">Maekawa 2011</a>). Contrary to these findings, retrospective studies (<a href="./references#CD003610-bbs2-0188" title="SpahrA , KleinE , KhuseyinovaN , BoeckhC , MucheR , KunzeM , et al. Periodontal infections and coronary heart disease: role of periodontal bacteria and importance of total pathogen burden in the Coronary Event and Periodontal Disease (CORODONT) study. Archives of Internal Medicine2006;166(5):554-9.">Spahr 2006</a>; <a href="./references#CD003610-bbs2-0159" title="PesonenE , El-SegaierM , PerssonK , PuolakkainenM , SarnaS , OhlinH , et al. Infections as a stimulus for coronary occlusion, obstruction, or acute coronary syndromes. Therapeutic Advances in Cardiovascular Diseases2009;3(6):447-54.">Pesonen 2009</a>; <a href="./references#CD003610-bbs2-0067" title="AndriankajaO , TrevisanM , FalknerK , DornJ , HoveyK , SarikondaS , et al. Association between periodontal pathogens and risk of nonfatal myocardial infarction. Community Dentistry and Oral Epidemiology2011;39(2):177-85.">Andriankaja 2011</a>) and a prospective study (<a href="./references#CD003610-bbs2-0087" title="De BoerSP , ChengJM , RangeH , Garcia-GarciaHM , HeoJH , AkkerhuisKM , et al. Antibodies to periodontal pathogens are associated with coronary plaque remodeling but not with vulnerability or burden. Atherosclerosis2014;237(1):84-91.">De Boer 2014</a>) did not show any association between <i>P gingivalis and</i> coronary heart disease<i>.</i> </p> <p><i>Helicobacter pylori</i> (<i>H pylori</i> ) is another infectious agent that might induce an inflammatory process and lead to coronary heart disease. The association between coronary heart disease and <i>H pylori</i> has been assessed in seroepidemiological studies (<a href="./references#CD003610-bbs2-0151" title="MendallMA , GogginPM , MolineauxN , LevyJ , ToosyT , StrachanD , et al. Relation of Helicobacter pylori infection and coronary heart disease. British Heart Journal1994;71(5):437-9.">Mendall 1994</a>; <a href="./references#CD003610-bbs2-0138" title="Lenzi C,  Palazzuoli A,  GiordanoN ,  AlegenteG ,  GonnelliC ,  CampagnaMS ,  et al. H pylori infection and systemic antibodies to CagA and heat shock protein 60 in patients with coronary heart disease. World Journal of Gastroenterology2006;12(48):7815-20.">Lenzi 2006</a>; <a href="./references#CD003610-bbs2-0193" title="VcevA , NakicD , MrdenA , MiratJ , BalenS , RuzicA , et al. Helicobacter pylori infection and coronary artery disease. Collegium Antropologicum2007;31(3):757-60.">Vcev 2007</a>; <a href="./references#CD003610-bbs2-0183" title="ShmuelyH , WattadM , SolodkyA , YahavJ , SamraZ , ZafrirN . Association of Helicobacter pylori with coronary artery disease and myocardial infarction assessed by myocardial perfusion imaging. Israel Medicine Association Journal2014;16(6):341-6.">Shmuely 2014</a>; <a href="./references#CD003610-bbs2-0150" title="MatusiakA , ChalubinskiM , BroncelM , RechcinskiT , RudnickaK , MiszczykE , et al. Putative consequences of exposure to Helicobacter pylori infection in patients with coronary heart disease in terms of humoral immune response and inflammation. Archives of Medical Science2016;12(1):45-54.">Matusiak 2016</a>), a meta‐analysis of seroepidemiological studies (<a href="./references#CD003610-bbs2-0082" title="DaneshJ , CollinsR , PetoR . Chronic infections and coronary heart disease: is there a link?Lancet1997;350(9075):430-6.">Danesh 1997</a>), and meta‐analyses of prospective studies (<a href="./references#CD003610-bbs2-0191" title="SunJ , RanganP , BhatSS , LiuL . A meta-analysis of the association between Helicobacter pylori infection and risk of coronary heart disease from published prospective studies. Helicobacter2016;21(1):11-23.">Sun 2016</a>; <a href="./references#CD003610-bbs2-0129" title="JiangJ , ChenY , ShiJ , SongC , ZhangJ , WangK . Population attributable burden of Helicobacter pylori-related gastric cancer, coronary heart disease, and ischemic stroke in China. European Journal of Clinical Microbiology &amp; Infectious Diseases2017;36(2):199-212.">Jiang 2017</a>). These studies have shown that infection with <i>H pylori</i> increases the risk of coronary heart disease. Contrary to these findings, prospective studies (<a href="./references#CD003610-bbs2-0196" title="WhincupPH , MendallMA , PerryIJ , StrachanDP , WalkerM . Prospective relations between Helicobacter pylori infection, coronary heart disease, and stroke in middle aged men. Heart1996;75(6):568-72.">Whincup 1996</a>; <a href="./references#CD003610-bbs2-0101" title="FolsomAR , NietoFJ , SorlieP , ChamblessLE , GrahamDY . Helicobacter pylori seropositivity and coronary heart disease incidence. Atherosclerosis Risk In Communities (ARIC) Study Investigators. Circulation1998;98(9):845-50.">Folsom 1998</a>; <a href="./references#CD003610-bbs2-0170" title="RoivainenM , Viik-KajanderM , PalosuoT , ToivanenP , LeinonenM , SaikkuP , et al. Infections, inflammation, and the risk of coronary heart disease. Circulation2000;101(3):252-7.">Roivainen 2000</a>; <a href="./references#CD003610-bbs2-0207" title="ZhuJ , NietoFJ , HorneBD , AndersonJL , MuhlesteinJB , EpsteinSE . Prospective study of pathogen burden and risk of myocardial infarction or death. Circulation2001;103(1):45-51.">Zhu 2001</a>; <a href="./references#CD003610-bbs2-0208" title="ZhuJ , QuyyumiAA , MuhlesteinJB , NietoFJ , HorneBD , Zalles-GanleyA , et al. Lack of association of Helicobacter pylori infection with coronary artery disease and frequency of acute myocardial infarction or death. American Journal of Cardiology2002;89(2):155-8.">Zhu 2002</a>; <a href="./references#CD003610-bbs2-0130" title="JinSW , HerSH , LeeJM , YoonHJ , MoonSJ , KimPJ , et al. The association between current Helicobacter pylori infection and coronary artery disease. Korean Journal of Internal Medicine2007;22(3):152-6.">Jin 2007</a>) and a meta‐analysis of seroepidemiological studies (<a href="./references#CD003610-bbs2-0083" title="DaneshJ , PetoR . Risk factors for coronary heart disease and infection with Helicobacter pylori: meta-analysis of 18 studies. BMJ1998;316(7138):1130-2.">Danesh 1998</a>) did not show any association between <i>H pylori and</i> coronary heart disease. </p> <p>A possible association between <i>Escherichia coli</i> (<i>E coli</i> ) and cardiovascular disease has been investigated. However, a cohort study found that infection with <i>E coli</i> did not increase the risk of cardiovascular disease in the decade following infection (<a href="./references#CD003610-bbs2-0120" title="Hizo-AbesP , ClarkWF , SontropJM , YoungA , HuangA , Thiessen-PhilbrookH , et al. Cardiovascular disease after Escherichia coli O157:H7 gastroenteritis. Canadian Medical Association Journal2013;185(1):E70-7.">Hizo‐Abes 2013</a>). Further, a seroepidemiological study did not show any association between <i>E coli</i> and coronary heart disease <i>(</i><a href="./references#CD003610-bbs2-0146" title="MahdiOS , HorneBD , MullenK , MuhlesteinJB , ByrneGI . Serum immunoglobulin G antibodies to chlamydial heat shock protein 60 but not to human and bacterial homologs are associated with coronary artery disease. Circulation2002;106(13):1659-63.">Mahdi 2002</a>). </p> <p>According to the studies referred to, there are some findings speaking in favour of an association between various bacteria and coronary heart disease, but there are also a number of observations pointing against such associations. If, however, one could find an intervention that could cure the bacterial activity and this had a beneficial effect on the course of coronary heart disease, such an intervention could have very important effects on morbidity and mortality of coronary heart disease. Antibiotics could be such an intervention. </p> </section> <section id="CD003610-sec-0011"> <h3 class="title" id="CD003610-sec-0011">Description of the intervention</h3> <p>Antibiotics are antimicrobial drugs of chemical origin that treat and prevent bacterial infections by either killing or inhibiting the growth of the bacteria (<a href="./references#CD003610-bbs2-0194" title="WaksmanSA . What is an antibiotic or an antibiotic substance?Mycologia1947;39(5):565-9.">Waksman 1947</a>). Antibiotics can be classified based on their mechanism of action (bactericidal or bacteriostatic), bacterial spectrum (broad or narrow), and chemical structure (e.g. penicillins, macrolides, quinolones, or tetracyclines) (<a href="./references#CD003610-bbs2-0071" title="BerdyJ . Bioactive microbial metabolites. The Journal of Antibiotics2005;58(1):1-26.">Berdy 2005</a>). The optimal dose and duration of antibiotic therapy depends on various factors (e.g. the patient's immune status, the infecting agent, and the focus of infection) (<a href="./references#CD003610-bbs2-0162" title="PolkR . Optimal use of modern antibiotics: emerging trends. Clinical Infectious Diseases1999;29(2):264-74.">Polk 1999</a>). </p> <p>Macrolides (e.g. azithromycin, clarithromycin, and erythromycin), quinolones (e.g. gatifloxacin and ciprofloxacin), and tetracyclines (e.g. doxycycline) have been the primary antibiotic classes used to investigate the effects of antibiotics as secondary prevention in people with coronary heart disease, presumably because <i>C pneumoniae</i> and <i>H pylori</i> are known to be sensitive to macrolides, quinolones, and tetracyclines (<a href="./references#CD003610-bbs2-0079" title="ChirgwinK , RoblinPM , HammerschlagMR . In vitro susceptibilities of Chlamydia pneumoniae (Chlamydia sp. strain TWAR). Antimicrobial Agents and Chemotherapy1989;33(9):1634-5.">Chirgwin 1989</a>; <a href="./references#CD003610-bbs2-0149" title="MalfertheinerP , MegraudF , O'MorainC , BazzoliF , El-OmarE , GrahamD , et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut2007;56(6):772-81.">Malfertheiner 2007</a>). Macrolides' mechanism of action is to inhibit the protein synthesis through binding to the 50S subunit of the ribosome (<a href="./references#CD003610-bbs2-0103" title="GaynorM , MankinAS . Macrolide antibiotics: binding site, mechanism of action, resistance. Current Topics in Medicinal Chemistry2003;3(9):949-61.">Gaynor 2003</a>); quinolones' mechanism of action is to prevent bacterial DNA from unwinding and duplicating through targeting the bacterial type II topoisomerases, gyrase, and topoisomerase IV (<a href="./references#CD003610-bbs2-0059" title="AldredKJ , KernsRJ , OsheroffN . Mechanism of quinolone action and resistance. Biochemistry2014;53(10):1565-74.">Aldred 2014</a>); and tetracyclines' mechanism of action is to inhibit protein synthesis by preventing the attachment of aminoacyl‐tRNA to the ribosomal acceptor site (<a href="./references#CD003610-bbs2-0080" title="ChopraI , RobertsM . Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiology and Molecular Biology Reviews2001;65(2):232-60.">Chopra 2001</a>). </p> </section> <section id="CD003610-sec-0012"> <h3 class="title" id="CD003610-sec-0012">How the intervention might work</h3> <p>Antibiotics might prevent the development of coronary heart disease through antibacterial activity. In addition, animal studies and in‐vitro studies suggest that several classes of antibiotics (e.g. macrolides, tetracyclines, or quinolones) seem to exert anti‐inflammatory and anti‐oxidative effects, which might slow down the atherogenesis independently of any antibacterial effect (<a href="./references#CD003610-bbs2-0064" title="AndersonR , TheronAJ , FeldmanC . Membrane-stabilizing, anti-inflammatory interactions of macrolides with human neutrophils. Inflammation1996;20(6):693-705.">Anderson 1996</a>; <a href="./references#CD003610-bbs2-0166" title="RajagopalanS , MengXP , RamasamyS , HarrisonDG , GalisZS . Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. Journal of Clinical Investigation1996;98(11):2572-9.">Rajagopalan 1996</a>; <a href="./references#CD003610-bbs2-0081" title="DalhoffA , ShalitI . Immunomodulatory effects of quinolones. The Lancet Infectious Diseases2003;3(6):359-71.">Dalhoff 2003</a>; <a href="./references#CD003610-bbs2-0176" title="SapadinAN , FleischmajerR . Tetracyclines: nonantibiotic properties and their clinical implications. Journal of the American Academy of Dermatology2006;54(2):258-65.">Sapadin 2006</a>; <a href="./references#CD003610-bbs2-0189" title="SteelHC , TheronAJ , CockeranR , AndersonR , CharlesF . Pathogen- and host-directed anti-inflammatory activities of macrolide antibiotics. Mediators of Inflammation2012.">Steel 2012</a>). However, the use of macrolides has been reported in both observational studies and in a randomised clinical trial to increase the risk of cardiovascular morbidity and mortality (see <a href="#CD003610-sec-0013">Why it is important to do this review</a>). The increased risk of cardiovascular morbidity and mortality might be associated with macrolides' pro‐arrhythmic effects (i.e. QT prolongation) leading to torsades de pointes (polymorphic ventricular tachycardia in patients with a long QT interval) (<a href="./references#CD003610-bbs2-0074" title="BrilF , GonzalezCD , Di GirolamoG . Antimicrobial agents-associated with QT interval prolongation. Current Drug Safety2010;5(1):85-92.">Bril 2010</a>). Further, in contrast to the findings in animal studies and in‐vitro studies, the use of macrolides might lead to an inflammatory cascade resulting in more vulnerable plaques that over time increase the risk of plaque rupture and, hence, leads to increased risk of cardiovascular events and mortality (<a href="./references#CD003610-bbs2-0200" title="WinkelP , HildenJ , Fischer HansenJ , HildebrandtP , KastrupJ , KolmosHJ , et al. Excess sudden cardiac deaths after short-term clarithromycin administration in the CLARICOR trial: why is this so, and why are statins protective?Cardiology2011;118(1):63-7.">Winkel 2011</a>). The use of quinolones have also been associated with an increased risk of ventricular arrhythmias and cardiovascular death (<a href="./references#CD003610-bbs2-0135" title="LapiF , WilcheskyM , KezouhA , BenistyJI , ErnstP , SuissaS . Fluoroquinolones and the risk of serious arrhythmia: a population-based study. Clinical Infectious Diseases2012;55(11):1457-65.">Lapi 2012</a>; <a href="./references#CD003610-bbs2-0143" title="LiuX , MaJ , HuangL , ZhuW , YuanP , WanR , et al. Fluoroquinolones increase the risk of serious arrhythmias: A systematic review and meta-analysis. Medicine (Baltimore)2017;96(44):e8273.">Liu 2017</a>), but these findings were not found in another study (<a href="./references#CD003610-bbs2-0123" title="InghammarM , SvanstromH , MelbyeM , PasternakB , HviidA . Oral fluoroquinolone use and serious arrhythmia: bi-national cohort study. BMJ2016;352:i843.">Inghammar 2016</a>). The risk of cardiovascular morbidity and mortality has not been adequately assessed for tetracyclines. </p> </section> <section id="CD003610-sec-0013"> <h3 class="title" id="CD003610-sec-0013">Why it is important to do this review</h3> <p>Coronary heart disease is the leading cause of death worldwide with about 7.4 million deaths each year (<a href="./references#CD003610-bbs2-0198" title="MendisS , PuskaP , Norrving B (editors). Global Atlas on Cardiovascular Disease Prevention and Control. Geneva: World Health Organization, 2011.">WHO 2011</a>; <a href="./references#CD003610-bbs2-0199" title="World Health organization. Cardiovascular diseases - Fact sheet N 317. WHO - Available from: www.who.int/mediacentre/factsheets/fs317/en/ Updated 2016 Jun; cited 2016 Aug 20].">WHO 2016</a>). People with established coronary heart disease have a high risk of subsequent cardiovascular events including cardiovascular death, myocardial infarction, and stroke (<a href="./references#CD003610-bbs2-0186" title="Smith SC Jr, BenjaminEJ , BonowRO , BraunLT , CreagerMA , FranklinBA , et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association. Journal of the American College of Cardiology2011;58(23):2432-46.">Smith 2011</a>; <a href="./references#CD003610-bbs2-0198" title="MendisS , PuskaP , Norrving B (editors). Global Atlas on Cardiovascular Disease Prevention and Control. Geneva: World Health Organization, 2011.">WHO 2011</a>; <a href="./references#CD003610-bbs2-0091" title="EckelRH , JakicicJM , ArdJD , deJesusJM , Houston MillerN , HubbardVS , et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation2014;129(25 Suppl 2):S76-99.">Eckel 2014</a>; <a href="./references#CD003610-bbs2-0160" title="PiepoliMF , HoesAW , AgewallS , AlbusC , BrotonsC , CatapanoAL , et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention &amp; Rehabilitation (EACPR). European Heart Journal2016;37(29):2315-81.">Piepoli 2016</a>). Prevention and management of the common risk factors for coronary heart disease are necessary to improve quality of life, reduce recurrent events and the need for revascularisation procedures, and improve survival (<a href="./references#CD003610-bbs2-0186" title="Smith SC Jr, BenjaminEJ , BonowRO , BraunLT , CreagerMA , FranklinBA , et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association. Journal of the American College of Cardiology2011;58(23):2432-46.">Smith 2011</a>; <a href="./references#CD003610-bbs2-0198" title="MendisS , PuskaP , Norrving B (editors). Global Atlas on Cardiovascular Disease Prevention and Control. Geneva: World Health Organization, 2011.">WHO 2011</a>; <a href="./references#CD003610-bbs2-0091" title="EckelRH , JakicicJM , ArdJD , deJesusJM , Houston MillerN , HubbardVS , et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation2014;129(25 Suppl 2):S76-99.">Eckel 2014</a>; <a href="./references#CD003610-bbs2-0160" title="PiepoliMF , HoesAW , AgewallS , AlbusC , BrotonsC , CatapanoAL , et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention &amp; Rehabilitation (EACPR). European Heart Journal2016;37(29):2315-81.">Piepoli 2016</a>). Nonetheless, even complete adherence to the before‐mentioned therapies may not completely eliminate the person's risk of subsequent cardiovascular events (<a href="./references#CD003610-bbs2-0072" title="BertrandMJ , TardifJC . Inflammation and beyond: new directions and emerging drugs for treating atherosclerosis. Expert Opinion on Emerging Drugs2016;22(1):1-26.">Bertrand 2016</a>). </p> <p>The use of antibiotics for secondary prevention of coronary heart disease is not mentioned in any guidelines, indicating that it is not conventional therapy (<a href="./references#CD003610-bbs2-0099" title="FihnSD , GardinJM , AbramsJ , BerraK , BlankenshipJC , DallasAP , et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Journal of the American College of Cardiology2012;60(24):e44-e164.">Fihn 2012</a>; <a href="./references#CD003610-bbs2-0155" title="MontalescotG , SechtemU , AchenbachS , AndreottiF , ArdenC , BudayA , et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. European Heart Journal2013;34(38):2949-3003.">Montalescot 2013</a>). However, a very large number of people with coronary heart disease receive antibiotics each year to treat proven or suspected bacterial infections. In the first instance, the antibiotics may help them. In the second instance, any adverse event may be as likely as any benefits. In both instances, we need to know the impact of antibiotic intervention on long‐term health. </p> <p>The first trials that investigated the use of antibiotics for secondary prevention of coronary heart disease were published in the late 1990s. The trials compared macrolide versus placebo in people with coronary heart disease. The trials showed conflicting results (<a href="./references#CD003610-bbs2-0010" title="GuptaS , LeathamEW , CarringtonD , MendallMA , KaskiJC , CammAJ . Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation1997;96(2):404-7. ">Gupta 1997</a>; <a href="./references#CD003610-bbs2-0065" title="AndersonJL , MuhlesteinJB , CarlquistJ , AllenA , TrehanS , NielsonC , et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) study. Circulation1999;99(12):1540-7.">Anderson 1999</a>; <a href="./references#CD003610-bbs2-0035" title="TorganoG , CosentiniR , MandelliC , PerondiR , BlasiF , BertinieriG , et al. Treatment of Helicobacter pylori and Chlamydia pneumoniae infections decreases fibrinogen plasma level in patients with ischemic heart disease. Circulation1999;99:1555-9. ">Torgano 1999</a>; <a href="./references#CD003610-bbs2-0110" title="GurfinkelE , BozovichG , BeckE , TestaE , LivellaraB , MautnerB . Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. The final report of the ROXIS Study. European Heart Journal1999;20(2):121-7.">Gurfinkel 1999</a>) and made clear the need for larger trials. </p> <p>Several meta‐analyses of randomised clinical trials have assessed the effects of antibiotics for secondary prevention of coronary heart disease (<a href="./references#CD003610-bbs2-0095" title="EtminanM , CarletonB , DelaneyJA , PadwalR . Macrolide therapy for Chlamydia pneumoniae in the secondary prevention of coronary artery disease: a meta-analysis of randomized controlled trials. Pharmacotherapy2004;24(3):338-43.">Etminan 2004</a>; <a href="./references#CD003610-bbs2-0066" title="AndrawsR , BergerJS , BrownDL . Effects of antibiotic therapy on outcomes of patients with coronary artery disease: a meta-analysis of randomized controlled trials. JAMA2005;293(21):2641-7.">Andraws 2005</a>; <a href="./references#CD003610-bbs2-0069" title="BakerWL , CouchKA . Azithromycin for the secondary prevention of coronary artery disease: a meta-analysis. American Journal of Health-System Pharmacy2007;64(8):830-6.">Baker 2007</a>; <a href="./references#CD003610-bbs2-0105" title="GluudC , Als-NielsenB , DamgaardM , Fischer HansenJ , HansenS , HeløOH , et al, CLARICOR Trial Group. Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease. Cardiology2008;111(4):280-7.">Gluud 2008</a>). <a href="./references#CD003610-bbs2-0095" title="EtminanM , CarletonB , DelaneyJA , PadwalR . Macrolide therapy for Chlamydia pneumoniae in the secondary prevention of coronary artery disease: a meta-analysis of randomized controlled trials. Pharmacotherapy2004;24(3):338-43.">Etminan 2004</a> included nine trials with 12,032 participants; <a href="./references#CD003610-bbs2-0066" title="AndrawsR , BergerJS , BrownDL . Effects of antibiotic therapy on outcomes of patients with coronary artery disease: a meta-analysis of randomized controlled trials. JAMA2005;293(21):2641-7.">Andraws 2005</a> included 11 trials with 19,217 participants; and <a href="./references#CD003610-bbs2-0069" title="BakerWL , CouchKA . Azithromycin for the secondary prevention of coronary artery disease: a meta-analysis. American Journal of Health-System Pharmacy2007;64(8):830-6.">Baker 2007</a> included six trials with 13,778 participants. All of these reviews compared antibiotics versus placebo. None of the reviews showed any benefits or harms of antibiotic therapy for secondary prevention of coronary heart disease. <a href="./references#CD003610-bbs2-0105" title="GluudC , Als-NielsenB , DamgaardM , Fischer HansenJ , HansenS , HeløOH , et al, CLARICOR Trial Group. Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease. Cardiology2008;111(4):280-7.">Gluud 2008</a> included 17 trials with 25,271 participants comparing antibiotics versus placebo, and found a significantly increased relative risk of all‐cause mortality of 10% in the antibiotic group. Moreover, <a href="./references#CD003610-bbs2-0105" title="GluudC , Als-NielsenB , DamgaardM , Fischer HansenJ , HansenS , HeløOH , et al, CLARICOR Trial Group. Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease. Cardiology2008;111(4):280-7.">Gluud 2008</a> did a meta‐analysis of the three trials that reported more than two years' follow‐up (i.e. PROVE‐IT (<a href="./references#CD003610-bbs2-0077" title="CannonCP , BraunwaldE , McCabeCH , GraystonJT , MuhlesteinB , GiuglianoRP , et al. Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. NEJM2005;352(16):1646-54.">Cannon 2005</a>), ACES (<a href="./references#CD003610-bbs2-0109" title="GraystonJT , KronmalRA , JacksonLA , ParisiAF , MuhlesteinJB , CohenJD , et al. Azithromycin for the secondary prevention of coronary events. NEJM2005;352(16):1637-45.">Grayston 2005</a>), and CLARICOR (<a href="./references#CD003610-bbs2-0105" title="GluudC , Als-NielsenB , DamgaardM , Fischer HansenJ , HansenS , HeløOH , et al, CLARICOR Trial Group. Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease. Cardiology2008;111(4):280-7.">Gluud 2008</a>)) and showed a significantly increased relative risk of all‐cause mortality of 17% in the antibiotic group. </p> <p><a href="./references#CD003610-bbs2-0078" title="ChengYJ , NieXY , ChenXM , LinXX , TangK , ZengWT , et al. The role of macrolide antibiotics in increasing cardiovascular risk. Journal of the American College of Cardiology2015;66(20):2173-84.">Cheng 2015</a> included 33 studies of various designs with 20,779,963 participants in a review comparing macrolides with or to placebo or no intervention. The review included any type of participant and did not focus on a specific infectious agent or disease. The authors of the review found no significant effect of macrolides on all‐cause mortality. However, the participants treated with macrolide had a significantly higher relative risk of sudden cardiac death of 152% and a higher relative risk of dying from cardiovascular problems of 31%. </p> <p>Currently, no guidelines report whether antibiotics should be used or avoided as secondary prevention of coronary heart disease (<a href="./references#CD003610-bbs2-0099" title="FihnSD , GardinJM , AbramsJ , BerraK , BlankenshipJC , DallasAP , et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Journal of the American College of Cardiology2012;60(24):e44-e164.">Fihn 2012</a>; <a href="./references#CD003610-bbs2-0155" title="MontalescotG , SechtemU , AchenbachS , AndreottiF , ArdenC , BudayA , et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. European Heart Journal2013;34(38):2949-3003.">Montalescot 2013</a>). This might be because the use of antibiotic therapy for secondary prevention of coronary heart disease lost momentum a decade ago, possibly as a consequence of the majority of previous evidence showing no effects ‐ either beneficial or harmful. Nevertheless, the public‐health aspect of administration of antibiotics to people with coronary heart disease is not to be neglected. Furthermore, our preliminary literature search has identified several new trials that were not included in the former attempts to review the literature, and more trials may be identified during the literature search. Accordingly, the benefits and harms of antibiotics in people with coronary heart disease seem unclear based on current evidence. Furthermore, antibiotics, including macrolide, are commonly used interventions in people with coronary heart disease and any beneficial or harmful effects of administering antibiotics in this group of people is of urgent importance. The CLARICOR trial, as mentioned previously, showed that clarithromycin versus placebo for secondary prevention of coronary heart disease significantly increased the risk of death (<a href="./references#CD003610-bbs2-0128" title="JespersenCM , Als-NielsenB , DamgaardM , HansenJF , HansenS , HeloOH , et al. Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial. BMJ2006;332(7532):22-7.">Jespersen 2006</a>; <a href="./references#CD003610-bbs2-0105" title="GluudC , Als-NielsenB , DamgaardM , Fischer HansenJ , HansenS , HeløOH , et al, CLARICOR Trial Group. Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease. Cardiology2008;111(4):280-7.">Gluud 2008</a>; <a href="./references#CD003610-bbs2-0201" title="WinkelP , HildenJ , HansenJF , KastrupJ , KolmosHJ , KjollerE , et al. Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular mortality and cerebrovascular morbidity over 10 years in the CLARICOR randomised, blinded clinical trial. International Journal of Cardiology2015;182:459-65.">Winkel 2015</a>). We, therefore, find it very important to investigate whether antibiotics have a beneficial, neutral, or harmful effect for secondary prevention of coronary heart disease. </p> <p>No former relevant review has used Cochrane methodology and the GRADE approach to take into account both risks of random errors and risk of systematic errors (<a href="./references#CD003610-bbs2-0117" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011a</a>; <a href="./references#CD003610-bbs2-0111" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck-YtterY , Alonso-CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924-6.">Guyatt 2008</a>). Therefore, it is still unclear whether antibiotics have a beneficial, neutral, or harmful effect for secondary prevention of coronary heart disease. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD003610-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD003610-sec-0014"></div> <p>We assessed the beneficial and harmful effects of antibiotics versus placebo or no intervention for the secondary prevention of coronary heart disease. </p> <p>As a secondary objective, we assessed the effects of individual types of antibiotics versus placebo or no intervention for the secondary prevention of coronary heart disease. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD003610-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD003610-sec-0015"></div> <section id="CD003610-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD003610-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included all randomised clinical trials assessing the beneficial and harmful effects of antibiotics for the secondary prevention of coronary heart disease irrespective of setting, blinding, publication status, publication year, language, and reporting of our outcomes. </p> </section> <section id="CD003610-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included adult participants (≥ 18 years) with any diagnosis of coronary heart disease, that is, acute myocardial infarction, previous myocardial infarction, unstable angina, or stable angina. We accepted the definitions used by the individual trialists. We included participants irrespective of sex and antibody status (e.g. for <i>C</i> <i>pneumoniae,</i> <i>H pylori, P gingivalis</i> , or <i>E coli</i> )<i>.</i> </p> <p>We excluded trials including participants with any other cause of chronic inflammatory disease (e.g. lupus erythematosus, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, polymyositis/dermatomyositis, and inflammatory bowel disease). We only included trials that included a subset of eligible participants if separate data for the eligible participants were available or if the majority of participants (i.e. more than 80%) were eligible. </p> </section> <section id="CD003610-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We included all trials comparing antibiotics with either placebo or no intervention. We did not include trials comparing antibiotics with any active drug. </p> <p>We accepted any type of antibiotic (e.g. azithromycin, clarithromycin, erythromycin, spiramycin, doxycycline, gatifloxacin, penicillin, amoxicillin, or metronidazole) as the experimental intervention, irrespective of dose, route of administration, or duration. We assessed the effects of the individual types of antibiotics in subgroup analyses. </p> <p>We accepted any type of co‐intervention when such co‐intervention was intended to be delivered similarly to the antibiotics and the control group. We assumed that the effects of the co‐interventions would 'even out' in both groups so that the possible effects of the antibiotic would be reflected in the results. We did a check of co‐interventions after randomisation in both intervention groups and considered any major differences in our conclusions. As optimal medical therapy plays an important role for the secondary prevention of coronary heart disease, we performed a sensitivity analysis excluding trials with sub‐optimal medical therapy. Optimal medical therapy indicated at least one drug for angina/ischaemic relief (e.g. short‐acting nitrates, beta blockers, and calcium channel blockers) plus drugs for event prevention (e.g. aspirin, clopidogrel, statins, ACE inhibitors, and angiotensin receptor blockers) (<a href="./references#CD003610-bbs2-0155" title="MontalescotG , SechtemU , AchenbachS , AndreottiF , ArdenC , BudayA , et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. European Heart Journal2013;34(38):2949-3003.">Montalescot 2013</a>). </p> </section> <section id="CD003610-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>We extracted outcome data at two time points:</p> <p> <ul id="CD003610-list-0001"> <li> <p>maximum follow‐up (the time point of primary interest);</p> </li> <li> <p>24±6 months follow‐up.</p> </li> </ul> </p> <p>We chose 24±6 months follow‐up based on the Kaplan‐Meier curve made by <a href="./references#CD003610-bbs2-0201" title="WinkelP , HildenJ , HansenJF , KastrupJ , KolmosHJ , KjollerE , et al. Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular mortality and cerebrovascular morbidity over 10 years in the CLARICOR randomised, blinded clinical trial. International Journal of Cardiology2015;182:459-65.">Winkel 2015</a>. We believed that 24±6 months follow‐up was long enough to show any possible secondary prevention effects of antibiotics. Furthermore, 24±6 months follow‐up was not so long that other factors, unrelated to the given trial but affecting the outcomes, might have decreased the statistical power, that is, that the results were 'diluted' by events unrelated to the trial. </p> <section id="CD003610-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD003610-list-0002"> <li> <p>All‐cause mortality.</p> </li> <li> <p>Serious adverse event. We defined a serious adverse event as any untoward medical occurrence that resulted in death; was life‐threatening; required hospitalisation or prolongation of existing hospitalisation; resulted in persistent or significant disability; or jeopardised the patient (<a href="./references#CD003610-bbs2-0121" title="ICH-GCP. 1997 CFR &amp; ICH Guidelines. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice. 1 edition. Vol. 1. PA 19063-2043, USA: Barnett International/PAREXEL, 1997.">ICH‐GCP 1997</a>). None of the trials specifically assessed serious adverse events according to this definition by ICH‐GCP. Instead, the trials either reported composites of several specific serious adverse events or one specific serious adverse event. </p> </li> <li> <p>Quality of life measured on any valid continuous scale. None of the trials assessed quality of life. </p> </li> </ul> </p> </section> <section id="CD003610-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p>Definitions for secondary outcomes was according to the individual trialists.</p> <p> <ul id="CD003610-list-0003"> <li> <p>Cardiovascular mortality.</p> </li> <li> <p>Myocardial infarction.</p> </li> <li> <p>Stroke.</p> </li> <li> <p>Sudden cardiac death.</p> </li> </ul> </p> <section id="CD003610-sec-0023"> <h6 class="title">Additional post hoc outcomes</h6> <p>Definitions for the additional post hoc outcomes was according to the individual trialists.</p> <p> <ul id="CD003610-list-0004"> <li> <p>Hospitalisation for any cause.</p> </li> <li> <p>Revascularisation.</p> </li> <li> <p>Unstable angina pectoris.</p> </li> </ul> </p> </section> </section> </section> </section> <section id="CD003610-sec-0024"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD003610-sec-0025"> <h4 class="title">Electronic searches</h4> <p>The following electronic databases were searched to identify reports of relevant randomised clinical trials on 9 December 2019. </p> <p> <ul id="CD003610-list-0005"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library (2019, Issue 12 of 12) </p> </li> <li> <p>Epub Ahead of Print, In‐Process &amp; Other Non‐Indexed Citations, MEDLINE Daily and MEDLINE (Ovid, 1946 to 6 December 2019) </p> </li> <li> <p>Embase (Ovid, 1980 to 2019 week 49)</p> </li> <li> <p>SCI‐Expanded (Web of Science) (Clarivate Analytics, 1900 to 9 December 2019)</p> </li> <li> <p>BIOSIS (Web of Science) (Clarivate Analytics, 1926 to 9 December 2019)</p> </li> <li> <p>LILACS (Bireme, 1982 to 9 December 2019)</p> </li> </ul> </p> <p>We adapted the preliminary search strategy for MEDLINE (Ovid) for use in the other databases. We applied the Cochrane sensitivity‐maximising RCT filter (<a href="./references#CD003610-bbs2-0137" title="LefebvreC , ManheimerE , GlanvilleJ . Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Lefebvre 2011</a>) to MEDLINE (Ovid) and adaptations of it to all the other databases, except CENTRAL. The search strategy can be found in <a href="./appendices#CD003610-sec-0146">Appendix 1</a>. </p> <p>We searched all databases from their inception to the present and we imposed no restriction on language of publication or publication status. We assessed non‐English language papers by asking individuals that fluently speak the language for help. We did not perform a separate search for adverse effects of antibiotics used for the treatment of coronary heart disease. We only considered the adverse effects described in the included trials. </p> </section> <section id="CD003610-sec-0026"> <h4 class="title">Searching other resources</h4> <p>We searched the reference lists of included randomised clinical trials, previous systematic reviews, and other types of reviews for any unidentified randomised clinical trials. We contacted the authors of included randomised clinical trials for further information and we contacted the following major pharmaceutical companies by email asking them for any unpublished randomised clinical trials: </p> <p> <ul id="CD003610-list-0006"> <li> <p><a href="http://www.merck.com/index.html" target="_blank">Merck &amp; Co.</a>; </p> </li> <li> <p><a href="http://www.roche.com/" target="_blank">Roche Holding AG</a>; </p> </li> <li> <p><a href="http://www.pfizer.com/" target="_blank">Pfizer Inc.</a>; </p> </li> <li> <p><a href="https://www.novartis.com/" target="_blank">Novartis AG</a>; </p> </li> <li> <p><a href="https://www.gsk.com/" target="_blank">GlaxoSmithKline Plc</a>; </p> </li> <li> <p><a href="https://www.astrazeneca.com/" target="_blank">AstraZeneca Plc</a>; </p> </li> <li> <p><a href="https://www.bms.com/" target="_blank">Bristol-Myers Squibb Co.</a>; </p> </li> <li> <p><a href="http://en.sanofi.com/" target="_blank">Sanofi-Aventis</a>; </p> </li> <li> <p><a href="http://www.abbott.com/" target="_blank">Abbott Laboratories</a>; </p> </li> <li> <p><a href="http://www.taisho-holdings.co.jp/en/" target="_blank">Taisho Pharmaceutical</a>; and </p> </li> <li> <p><a href="http://www.pliva.com/" target="_blank">Pliva</a>. </p> </li> </ul> </p> <p>Furthermore, we searched the following databases for ongoing and unidentified randomised clinical trials on 25 December 2019: </p> <p> <ul id="CD003610-list-0007"> <li> <p><a href="https://scholar.google.com/" target="_blank">Google Scholar</a>; </p> </li> <li> <p><a href="https://www.tripdatabase.com/" target="_blank">The Turning Research into Practice (TRIP) Database</a>; </p> </li> <li> <p><a href="https://clinicaltrials.gov/" target="_blank">ClinicalTrials.gov</a>; </p> </li> <li> <p><a href="https://www.clinicaltrialsregister.eu/" target="_blank">EU Clinical Trial Register</a>; </p> </li> <li> <p><a href="http://www.chictr.org.cn/enIndex.aspx" target="_blank">Chinese Clinical Trial Registry (ChCTR)</a>; </p> </li> <li> <p><a href="https://www.isrctn.com/" target="_blank">International Standard Randomised Controlled Trial Number (ISRCTN) registry</a>; </p> </li> <li> <p><a href="https://www.gsk-clinicalstudyregister.com/" target="_blank">GSK Clinical Study Register</a>; </p> </li> <li> <p><a href="http://www.pactr.org/" target="_blank">Pan African Clinical Trials Registry (PACTR)</a>; </p> </li> <li> <p><a href="http://www.anzctr.org.au/" target="_blank">Australian New Zealand Clinical Trials Registry (ANZCTR)</a>; </p> </li> <li> <p><a href="http://ctri.nic.in/Clinicaltrials/login.php" target="_blank">Clinical Trials Registry - India (CTRI)</a>; and </p> </li> <li> <p><a href="http://apps.who.int/trialsearch/" target="_blank">the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) search portal</a>. </p> </li> </ul> </p> <p>We also examined relevant retraction statements and errata for included trials.</p> </section> </section> <section id="CD003610-sec-0027"> <h3 class="title" id="CD003610-sec-0027">Data collection and analysis</h3> <p>We performed this review following the recommendations of Cochrane (<a href="./references#CD003610-bbs2-0117" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011a</a>). The analyses were performed using Review Manager 5.4.1 (<a href="./references#CD003610-bbs2-0168" title="The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.4. The Cochrane Collaboration, 2020.">RevMan 2020</a>). </p> <section id="CD003610-sec-0028"> <h4 class="title">Selection of studies</h4> <p>Two review authors (NJS and SS) independently screened titles and abstracts for inclusion of all the potentially eligible trials. We coded all these studies as 'retrieve' (eligible or potentially eligible/unclear) or 'do not retrieve'. If there were any disagreements, a third review author were asked to arbitrate (JCJ). We retrieved the full‐text trial reports/publications and three review authors (NJS, SS, and SKK) independently screened the full‐text and identified trials for inclusion. Reasons for exclusion of the ineligible studies were reported (<a href="#CD003610-sec-0056">Excluded studies</a>). We resolved any disagreement through discussion or, if required, we consulted a fourth person (JCJ). We identified and excluded duplicated and collated multiple reports of the same trial so that each trial rather than each report was the unit of interest in the review. We recorded the selection process in sufficient detail to complete a PRISMA flow diagram (<a href="./references#CD003610-bbs2-0154" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG , PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Journal of Clinical Epidemiology2009;62(10):1006-12.">Moher 2009</a>) and '<a href="./references#CD003610-sec-0157" title="">Characteristics of excluded studies</a>' table. </p> </section> <section id="CD003610-sec-0029"> <h4 class="title">Data extraction and management</h4> <p>Three authors (NJS, SS, and SKK) extracted and validated data independently from included trials. Any disagreements concerning the extracted data were discussed between the three authors. If no agreement could be reached, a fourth author (JCJ) resolved the issue. In case of relevant data not being available, we contacted the trial authors. </p> <p>We extracted the following data mentioned below.</p> <section id="CD003610-sec-0030"> <h5 class="title">Trial characteristics</h5> <p>Bias risk components (as defined below); trial design (parallel, factorial, or cross‐over); number of intervention arms; length of follow‐up; estimation of sample size; and inclusion and exclusion criteria. </p> </section> <section id="CD003610-sec-0031"> <h5 class="title">Participant characteristics and diagnosis</h5> <p>Number of randomised participants; number of analysed participants; number of participants lost to follow‐up; age range (mean and median) and sex ratio; presence of cardiovascular risk factors (i.e. diabetes mellitus, hypertension, hyperlipidaemia, or smoking); and antibody status (i.e. for <i>C pneumoniae, H pylori, P gingivalis</i> , or <i>E coli).</i> </p> </section> <section id="CD003610-sec-0032"> <h5 class="title">Intervention characteristics</h5> <p>Type of antibiotic; dose of antibiotic; duration of antibiotic therapy; and mode of administration. </p> </section> <section id="CD003610-sec-0033"> <h5 class="title">Control characteristics</h5> <p>Placebo or no intervention.</p> </section> <section id="CD003610-sec-0034"> <h5 class="title">Co‐intervention characteristics</h5> <p>Type of co‐intervention; dose of co‐intervention; duration of co‐intervention; and mode of administration. </p> </section> <section id="CD003610-sec-0035"> <h5 class="title">Outcomes</h5> <p>We extracted all outcomes listed above from each randomised clinical trial, and we identified whether outcomes were incomplete or selectively reported according to the criteria described in <a href="#CD003610-tbl-0003">Table 1</a>. </p> <div class="table" id="CD003610-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Cochrane tool for assessing risk of bias</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Domain</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Description</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Random sequence generation</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0008"> <li> <p>Low risk: if sequence generation was achieved using computer random number generator or a random numbers table. Drawing lots, tossing a coin, shuffling cards, and throwing dice were also considered adequate if performed by an independent adjudicator. </p> </li> <li> <p>Unclear risk: if the method of randomisation was not specified, but the trial was still presented as being randomised. </p> </li> <li> <p>High risk: if the allocation sequence was not randomised or only quasi‐randomised. We excluded these trials. </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Allocation concealment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0009"> <li> <p>Low risk: if the allocation of participants was performed by a central independent unit, on‐site locked computer, identical‐looking numbered sealed envelopes, drug bottles, or containers prepared by an independent pharmacist or investigator. </p> </li> <li> <p>Uncertain risk: if the trial was classified as randomised but the allocation concealment process was not described. </p> </li> <li> <p>High risk: if the allocation sequence was familiar to the investigators who assigned participants. </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Blinding of participants and personnel</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0010"> <li> <p>Low risk: if the participants and the personnel were blinded to intervention allocation and this was described. </p> </li> <li> <p>Uncertain risk: if the procedure of blinding was insufficiently described.</p> </li> <li> <p>High risk: if blinding of participants and the personnel was not performed.</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Blinding of outcome assessment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0011"> <li> <p>Low risk of bias: if it was mentioned that outcome assessors were blinded and this was described. </p> </li> <li> <p>Uncertain risk of bias: if it was not mentioned if the outcome assessors in the trial were blinded, or the extent of blinding was insufficiently described. </p> </li> <li> <p>High risk of bias: if no blinding or incomplete blinding of outcome assessors was performed. </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Incomplete outcome data</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0012"> <li> <p>Low risk of bias: if missing data were unlikely to make treatment effects depart from plausible values. This could either be: 1) there were no dropouts or withdrawals for all outcomes, or 2) the numbers and reasons for the withdrawals and dropouts for all outcomes were clearly stated and could be described as being similar in both groups. Generally, the trial was judged as at low risk of bias due to incomplete outcome data if dropouts were less than 5%. However, the 5% cut‐off was not definitive. </p> </li> <li> <p>Uncertain risk of bias: if there was insufficient information to assess whether missing data were likely to induce bias on the results. </p> </li> <li> <p>High risk of bias: if the results were likely to be biased due to missing data either because the pattern of dropouts could be described as being different in the two intervention groups or the trial used improper methods in dealing with the missing data (e.g. last observation carried forward). </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Selective outcome reporting</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0013"> <li> <p>Low risk of bias: if a protocol was published/registered before or at the time the trial was begun and the outcomes specified in the protocol were reported on. If there was no protocol or the protocol was published/registered after the trial had begun, reporting of all‐cause mortality and various types of serious adverse event granted the trial a grade of low risk of bias. </p> </li> <li> <p>Uncertain risk of bias: if no protocol was published and the outcomes all‐cause mortality and serious adverse event were not adequately reported on. </p> </li> <li> <p>High risk of bias: if the outcomes in the protocol were not reported on.</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Other risks of bias</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0014"> <li> <p>Low risk of bias: if the trial appeared to be free of other components that could put it at risk of bias. </p> </li> <li> <p>Unclear risk of bias: if the trial might or might not be free of other components that could put it at risk of bias. </p> </li> <li> <p>High risk of bias: if there were other factors in the trial that could put it at risk of bias. </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Overall risk of bias</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0015"> <li> <p>Low risk of bias: the trial was classified as at overall 'low risk of bias' only if all of the bias domains described in the above paragraphs were classified as at 'low risk of bias'. </p> </li> <li> <p>High risk of bias: the outcome result was classified as at overall 'high risk of bias' if any of the bias risk domains described in the above were classified as at 'unclear' or 'high risk of bias'. </p> </li> </ul> </p> </td> </tr> </tbody> </table> </div> </section> <section id="CD003610-sec-0036"> <h5 class="title">Notes</h5> <p>We extracted details on funding of the trial and notable conflicts of interest of trial authors, if available. </p> <p>We noted in the '<a href="./references#CD003610-sec-0156" title="">Characteristics of included studies</a>' table if outcome data were not reported in a usable way. </p> </section> </section> <section id="CD003610-sec-0037"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We used the instructions given in <i>The</i> <i>Cochrane Handbook for Systematic Reviews of Interventions</i> in our evaluation of the methodology and hence the risk of bias of the included trials (<a href="./references#CD003610-bbs2-0119" title="HigginsJPT , AltmanDG , Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook.">Higgins 2017</a>). Three review authors (NJS, SS, SKK) assessed the included trials independently. We evaluated the risk of bias in the following risk of bias domains: </p> <p> <ul id="CD003610-list-0016"> <li> <p>random sequence generation;</p> </li> <li> <p>allocation concealment;</p> </li> <li> <p>blinding of participants and personnel;</p> </li> <li> <p>blinding of outcome assessment;</p> </li> <li> <p>incomplete outcome data;</p> </li> <li> <p>selective outcome reporting; and</p> </li> <li> <p>other risks of bias.</p> </li> </ul> </p> <p>This was done because these domains enable classification of randomised trials at low risk of bias and at high risk of bias. The latter trials tend to overestimate positive intervention effects (benefits) and underestimate negative effects (harms) (<a href="./references#CD003610-bbs2-0179" title="SchulzKF , ChalmersI , HayesRJ , AltmanDG . Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA1995;273(5):408-12.">Schulz 1995</a>; <a href="./references#CD003610-bbs2-0153" title="MoherD , PhamB , JonesA , CookDJ , JadadAR , MoherM , et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?Lancet1998;352(9128):609-13.">Moher 1998</a>; <a href="./references#CD003610-bbs2-0133" title="KjaergardLL , VillumsenJ , GluudC . Reported methodological quality and discrepancies between small and large randomized trials in meta-analyses. Annals of Internal Medicine2001;135:982-9.">Kjaergard 2001</a>; <a href="./references#CD003610-bbs2-0104" title="GluudLL . Bias in clinical intervention research. American Journal of Epidemiology2006;163(6):493-501.">Gluud 2006</a>; <a href="./references#CD003610-bbs2-0204" title="WoodL , EggerM , GluudLL , SchulzKF , JuniP , AltmanDG , et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ2008;336(7644):601-5.">Wood 2008</a>; <a href="./references#CD003610-bbs2-0177" title="SavovicJ , JonesHE , AltmanDG , HarrisRJ , JuniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine2012;157(6):429-38.">Savovic 2012</a>). </p> <p>We graded each potential source of bias as high, low, or unclear and provided evidence from the study report together with a justification for our judgement in the 'Risk of bias' table. We have summarised the 'Risk of bias' judgements across different trials for each of the domains listed. </p> <p>We classified a trial as at overall low risk of bias only if all of the bias domains mentioned above were classified as at low risk of bias. We classified a trial as at overall high risk of bias if any of the bias risk domains mentioned above were classified as at unclear or high risk of bias. For additional details on how risk of bias were assessed, please see <a href="#CD003610-tbl-0003">Table 1</a>. </p> <p>We conducted a sensitivity analysis only including trials at overall low risk of bias for all our outcomes (see below in '<a href="#CD003610-sec-0050">Sensitivity analysis</a>'). When considering the risk of blinding, we assessed each outcome individually (<a href="./references#CD003610-bbs2-0178" title="SavovicJ , TurnerRM , MawdsleyD , JonesHE , BeynonR , HigginsJPT , et al. Association between risk-of-bias assessments and results of randomized trials in Cochrane reviews: the ROBES meta-epidemiologic study. American Journal of Epidemiology2018;187(5):1113-22.">Savovic 2018</a>). </p> </section> <section id="CD003610-sec-0038"> <h4 class="title">Measures of treatment effect</h4> <section id="CD003610-sec-0039"> <h5 class="title">Dichotomous outcomes</h5> <p>We calculated risk ratios (RR) with 95% confidence interval (CI) for dichotomous outcomes. We calculated absolute risk reduction (ARR) or increase (ARI) and number needed to treat for an additional beneficial outcome (NNTB) or for an additional harmful outcome (NNTH) if the outcome result showed a beneficial or harmful effect, respectively. We only calculated the 95% CI of NNTB or NNTH when the results were either all positive or all negative (<a href="./references#CD003610-bbs2-0061" title="AltmanDG . Confidence intervals for the number needed to treat. BMJ1998;317(7168):1309-12.">Altman 1998</a>). </p> </section> <section id="CD003610-sec-0040"> <h5 class="title">Continuous outcomes</h5> <p>We planned to calculate the mean differences (MD) and the standardised mean difference (SMD) with 95% CI for continuous outcomes. However, none of the included trials reported quality of life (our only continuous outcome). </p> </section> </section> <section id="CD003610-sec-0041"> <h4 class="title">Unit of analysis issues</h4> <p>We only included randomised clinical trials. For trials using cross‐over design, we planned to only include data from the first period (<a href="./references#CD003610-bbs2-0093" title="Elbourne DR,  AltmanDG ,  HigginsJP ,  CurtinF ,  WorthingtonHV ,  VailA . Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology2002;31(1):140-9.">Elbourne 2002</a>; <a href="./references#CD003610-bbs2-0088" title="DeeksJJ , HigginsJPT , Altman DG (editors) on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook.">Deeks 2017</a>). However, none of the included trials used a cross‐over design. For trials where multiple trial intervention groups were reported, we included only the relevant groups. If two comparisons were combined in the same meta‐analysis, we halved the control group to avoid double‐counting (<a href="./references#CD003610-bbs2-0088" title="DeeksJJ , HigginsJPT , Altman DG (editors) on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook.">Deeks 2017</a>). </p> </section> <section id="CD003610-sec-0042"> <h4 class="title">Dealing with missing data</h4> <p>We contacted all trial authors to obtain missing data (i.e. for data extraction and for assessment of risk of bias, as specified above) (<a href="./references#CD003610-sec-0156" title="">Characteristics of included studies</a>). However, not all trial authors responded (<a href="./references#CD003610-sec-0156" title="">Characteristics of included studies</a>). </p> <section id="CD003610-sec-0043"> <h5 class="title">Dichotomous outcomes</h5> <p>We did not use intention‐to‐treat data if the original report did not contain them. We did not impute missing values for any outcomes in our primary analysis. In four of our sensitivity analyses ('best‐worst', 'worst‐best', modified 'best‐worst', and modified 'worst‐best' case analyses), we imputed data; see '<a href="#CD003610-sec-0050">Sensitivity analysis</a>'. </p> </section> <section id="CD003610-sec-0044"> <h5 class="title">Continuous outcomes</h5> <p>None of the included trials reported quality of life (our only continuous outcome). If continuous data were available, we would have dealt with missing data as following. </p> <p>If standard deviations (SDs) were not reported, we planned to calculate them using data from the trial if possible. We planned to not use intention‐to‐treat data if the original report did not contain such data. We planned to not impute missing values for any outcomes in our primary analyses. We planned to impute data in four of our sensitivity analyses ('best‐worst', 'worst‐best', modified 'best‐worst', and modified 'worst‐best' case analyses). </p> </section> </section> <section id="CD003610-sec-0045"> <h4 class="title">Assessment of heterogeneity</h4> <p>We primarily investigated forest plots to visually assess any sign of heterogeneity. Secondly, we assessed the presence of statistical heterogeneity by the Chi<sup>2</sup> test (threshold P &lt; 0.10) and measured the quantities of heterogeneity by the I<sup>2</sup> statistic (<a href="./references#CD003610-bbs2-0115" title="HigginsJP , ThompsonSG . Quantifying heterogeneity in a meta-analysis. Statistics in Medicine2002;21(11):1539-58.">Higgins 2002</a>; <a href="./references#CD003610-bbs2-0116" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327(7414):557-60.">Higgins 2003</a>). </p> <p>We followed the recommendations for thresholds in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD003610-bbs2-0088" title="DeeksJJ , HigginsJPT , Altman DG (editors) on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook.">Deeks 2017</a>): </p> <p> <ul id="CD003610-list-0017"> <li> <p>0% to 40%: might not be important;</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity;</p> </li> <li> <p>50% to 90% may represent substantial heterogeneity;</p> </li> <li> <p>75% to 100%: may represent considerable heterogeneity.</p> </li> </ul> </p> <p>We investigated possible heterogeneity through subgroup analyses. Ultimately, we might have decided that a meta‐analysis should be avoided (<a href="./references#CD003610-bbs2-0088" title="DeeksJJ , HigginsJPT , Altman DG (editors) on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook.">Deeks 2017</a>). However, none of the planned meta‐analyses were avoided. </p> </section> <section id="CD003610-sec-0046"> <h4 class="title">Assessment of reporting biases</h4> <p>We used funnel plots to assess reporting bias in the meta‐analyses including 10 or more trials. We visually inspected the funnel plots to assess the risk of bias. We were aware of the limitations of a funnel plot (i.e. a funnel plot assesses bias due to small sample size). From this information, we assessed possible reporting bias. For dichotomous outcomes, we tested asymmetry with the Harbord test (<a href="./references#CD003610-bbs2-0114" title="HarbordRM , EggerM , SterneJA . A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Statistics in Medicine2006;25(20):3443-57.">Harbord 2006</a>). For continuous outcomes, we planned to use the regression asymmetry test (<a href="./references#CD003610-bbs2-0092" title="EggerM , Davey-SmithG , SchneiderM , MinderC . Bias in meta-analysis detected by a simple, graphical test. BMJ1997;315(7109):629-34.">Egger 1997</a>) and the adjusted rank correlation (<a href="./references#CD003610-bbs2-0070" title="BeggCB , MazumdarM . Operating characteristics of a rank correlation test for publication bias. Biometrics1994;50(4):1088-101.">Begg 1994</a>). However, no data on our continuous outcome (i.e. quality of life) were included. </p> </section> <section id="CD003610-sec-0047"> <h4 class="title">Data synthesis</h4> <section id="CD003610-sec-0048"> <h5 class="title">Assessment of statistical and clinical significance</h5> <p>We undertook this systematic review according to the recommendations stated in <i>The</i> <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD003610-bbs2-0088" title="DeeksJJ , HigginsJPT , Altman DG (editors) on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook.">Deeks 2017</a>) for better validation of meta‐analytic results in systematic reviews. We used the Cochrane statistical software RevMan 5.4.1 (<a href="./references#CD003610-bbs2-0168" title="The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.4. The Cochrane Collaboration, 2020.">RevMan 2020</a>) to meta‐analyse data. </p> <p>We assessed our intervention effects with both random‐effects meta‐analyses (DerSimonian‐Laird model) (<a href="./references#CD003610-bbs2-0090" title="DerSimonianR , LairdN . Meta-analysis in clinical trials. Controlled Clinical Trials1986;7(3):177-88.">DerSimonian 1986</a>) and fixed‐effect meta‐analyses (<a href="./references#CD003610-bbs2-0089" title="DeMetsDL . Methods for combining randomized clinical trials: strengths and limitations. Statistics in Medicine1987;6(3):341-50.">DeMets 1987</a>) with the Mantel‐Haenszel method and chose the more conservative result as our primary result (<a href="./references#CD003610-bbs2-0125" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology2014;14:120.">Jakobsen 2014</a>). The more conservative result was the result with the highest P value and the widest 95% CI. If there was substantial discrepancy between the results of the two methods, we reported and discussed both results (<a href="./references#CD003610-bbs2-0125" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology2014;14:120.">Jakobsen 2014</a>). </p> </section> </section> <section id="CD003610-sec-0049"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We performed the following subgroup analyses when assessing each outcome (all‐cause mortality, cardiovascular mortality, myocardial infarction, and stroke) both at maximum follow‐up and 24±6 months' follow‐up. We were not able to perform subgroup analyses on 'serious adverse events' and 'quality of life' due to no available data. </p> <p>A: Comparison of the effects between trials with different types of antibiotic:</p> <p> <ul id="CD003610-list-0018"> <li> <p>azithromycin;</p> </li> <li> <p>roxithromycin;</p> </li> <li> <p>clarithromycin;</p> </li> <li> <p>doxycycline;</p> </li> <li> <p>gatifloxacin; or</p> </li> <li> <p>spiramycin.</p> </li> </ul> </p> <p>B: Comparison of the effects between trials with different antibody status:</p> <p> <ul id="CD003610-list-0019"> <li> <p>trials including participants with identified <i>C pneumoniae,</i> <i>H pylori, P gingivalis</i> , or <i>E coli</i> antibodies; </p> </li> <li> <p>trials including participants without any identified <i>C pneumoniae,</i> <i>H pylori, P gingivalis</i> , or <i>E coli</i> antibodies; and </p> </li> <li> <p>trials including both participants with and without identification of <i>C pneumoniae,</i> <i>H pylori, P gingivalis</i> , or <i>E coli</i> antibodies. </p> </li> </ul> </p> <p>C: Comparison of the effects between trials including participants on statins at entry compared to trials including participants not on statins at entry (<a href="./references#CD003610-bbs2-0127" title="JensenGB , HildenJ , Als-NielsenB , DamgaardM , HansenJF , HansenS , et al. Statin treatment prevents increased cardiovascular and all-cause mortality associated with clarithromycin in patients with stable coronary heart disease. Journal of Cardiovascular Pharmacology2010;55(2):123-8.">Jensen 2010</a>): </p> <p> <ul id="CD003610-list-0020"> <li> <p>trials including participants using statins at entry;</p> </li> <li> <p>trials including participants not using statins at entry; and</p> </li> <li> <p>trials including both participants who are using and not using statins at entry.</p> </li> </ul> </p> <p>D: Comparison of the effects between trials with different mean age of the participants:</p> <p> <ul id="CD003610-list-0021"> <li> <p>18 to 59 years;</p> </li> <li> <p>60 years and over.</p> </li> </ul> </p> <p>E: Comparison of the effects between trials with different clinical trial registration status: </p> <p> <ul id="CD003610-list-0022"> <li> <p>pre‐registration;</p> </li> <li> <p>post‐registration; or</p> </li> <li> <p>no registration.</p> </li> </ul> </p> <p>Additionally, we performed the following subgroup analysis when assessing each outcome (all‐cause mortality, cardiovascular mortality, myocardial infarction, and stroke) at maximum follow‐up. </p> <p>F: Comparison of trials with less than 12 months' follow‐up to trials with equal to or longer than 12 months' follow‐up: </p> <p> <ul id="CD003610-list-0023"> <li> <p>trials with less than 12 months' follow‐up; or</p> </li> <li> <p>trials with equal to or longer than 12 months' follow‐up.</p> </li> </ul> </p> <p><b>Post‐hoc subgroup analysis</b> </p> <p>After the publication of the protocol, we added three extra subgroups. We performed these three subgroups when assessing each outcome (all‐cause mortality, cardiovascular mortality, myocardial infarction, and stroke) both at maximum follow‐up and 24±6 months' follow‐up. </p> <p>To assess the potential difference in effect based on the different classes of antibiotics, we added the following subgroup: </p> <p>G: Comparison of the effects between trials with different classes of antibiotic:</p> <p> <ul id="CD003610-list-0024"> <li> <p>macrolides;</p> </li> <li> <p>tetracyclines; or</p> </li> <li> <p>quinolones.</p> </li> </ul> </p> <p>To assess the potential difference in effect based on the funding of the trial, we added the following subgroup: </p> <p>H: Comparison of the effects between industry funded trials or trials with unknown funding compared to non‐industry funded trials (<a href="./references#CD003610-bbs2-0144" title="LundhA , LexchinJ , MintzesB , SchrollJB , BeroL . Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews2017;2:Mr000033.">Lundh 2017</a>): </p> <p> <ul id="CD003610-list-0025"> <li> <p>industry funded trials or unknown funding; or</p> </li> <li> <p>non‐industry funded trials.</p> </li> </ul> </p> <p>To assess the potential difference in effect based on the control intervention, we added the following subgroup: </p> <p>I: Comparison of the effects between trials using either placebo or 'no intervention' as control intervention: </p> <p> <ul id="CD003610-list-0026"> <li> <p>placebo‐controlled trials; or</p> </li> <li> <p>no control intervention.</p> </li> </ul> </p> <p>We used the formal test for subgroup differences in RevMan 5.4.1 (<a href="./references#CD003610-bbs2-0168" title="The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.4. The Cochrane Collaboration, 2020.">RevMan 2020</a>). </p> </section> <section id="CD003610-sec-0050"> <h4 class="title">Sensitivity analysis</h4> <p>To assess the potential impact of bias, we performed a sensitivity analysis in which we only included trials at overall low risk of bias. </p> <p>To assess the potential impact of sub‐optimal medical therapy, we performed a sensitivity analysis in which we excluded trials with sub‐optimal medical therapy. </p> <p>To assess the potential impact of the missing data for dichotomous outcomes, we performed the following four sensitivity analyses when assessing each dichotomous outcome (all‐cause mortality, cardiovascular mortality, myocardial infarction, stroke, and sudden cardiac death). </p> <p> <ul id="CD003610-list-0027"> <li> <p>'Best‐worst‐case' scenario: we assumed that all participants lost to follow‐up in the experimental group survived, had no cardiovascular death, had no myocardial infarction, had no stroke, and had no sudden cardiac death; and all those participants lost to follow‐up in the control group did not survive, had a cardiovascular death, had a myocardial infarction, had a stroke, and had a sudden cardiac death. </p> </li> <li> <p>'Worst‐best‐case' scenario: we assumed that all participants lost to follow‐up in the experimental group did not survive, had a cardiovascular death, had a myocardial infarction, had a stroke, and had a sudden cardiac death; and that all those participants lost to follow‐up in the control group survived, had no cardiovascular death, had no myocardial infarction, had no stroke, and had no sudden cardiac death. </p> </li> <li> <p>A modified 'best‐worst‐case' scenario: we assumed that all participants lost to follow‐up in the experimental group survived, had no cardiovascular death, had no myocardial infarction, had no stroke, and had no sudden cardiac death; and that half of the participants lost to follow‐up in the control group did not survive, had a cardiovascular death, had a myocardial infarction, had a stroke, and had a sudden cardiac death. </p> </li> <li> <p>A modified 'worst‐best‐case' scenario: we assumed that half of the participants lost to follow‐up in the experimental group did not survive, had a cardiovascular death, had a myocardial infarction, had a stroke, and had a sudden cardiac death; and that all those participants lost to follow‐up in the control group survived, had no serious adverse event, had no cardiovascular death, had no myocardial infarction, had no stroke, and had no sudden cardiac death. </p> </li> </ul> </p> <p>Results from all four scenarios are presented in our review. We were not able to perform the above‐mentioned sensitivity analyses on 'serious adverse events' due to lack of data. </p> <p>We planned that when analysing quality of life, a ‘beneficial outcome’ would have been the group mean plus two standard deviations (SDs) (we would then have used one SD in another sensitivity analysis) of the group mean, and a ‘harmful outcome’ would have been the group mean minus two SDs (we would then have used one SD in another sensitivity analysis) of the group mean (<a href="./references#CD003610-bbs2-0125" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology2014;14:120.">Jakobsen 2014</a>). However, no data on quality of life were available in the included trials. </p> <p>To assess the potential impact of missing SDs for continuous outcomes, we planned to perform the following sensitivity analysis. </p> <p> <ul id="CD003610-list-0028"> <li> <p>Where SDs were missing and not possible to calculate, we planned to impute SDs from trials with similar populations and low risk of bias. If no such trials were found, we planned to impute SDs from trials with a similar population. As the final option, we planned to impute SDs from all trials. </p> </li> </ul> </p> <p>We planned to present results of this scenario in our review. However, no data on quality of life were available in the included trials. </p> </section> <section id="CD003610-sec-0051"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We used the GRADE system (<a href="./references#CD003610-bbs2-0111" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck-YtterY , Alonso-CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924-6.">Guyatt 2008</a>) to assess the certainty of the body of evidence associated with each of the primary (all‐cause mortality, serious adverse event, and quality of life) and secondary outcomes (cardiovascular mortality, myocardial infarction, stroke, and sudden cardiac death) at both maximum follow‐up and 24±6 months follow‐up constructing 'Summary of Findings' tables using the GRADEpro software (<a href="./references#CD003610-bbs2-0108" title="McMaster University (developed by Evidence Prime)GRADEpro GDT. Version accessed 10 August 2015. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. Available at gradepro.org.">GRADEpro GDT 2015</a>; <a href="./references#CD003610-bbs2-0181" title="SchunemannHJ , BrozekJ , GuyattG , OxmanAD , editors. GRADE handbook for grading quality of evidence and strength of recommendation. Available from http://gdt.guidelinedevelopment.org/app/handbook/handbook.html. The Grade Working Group2013.">Schunemann 2013</a>). The GRADE approach appraises the certainty of the body of evidence based on the extent to which one can be confident that an estimate of effect or association reflects the item being assessed (<a href="./references#CD003610-bbs2-0180" title="SchunemannHJ , BestD , VistG , OxmanAD . Letters, numbers, symbols and words: how to communicate grades of evidence and recommendations. Canadian Medical Association Journal2003;169(7):677-80.">Schunemann 2003</a>; <a href="./references#CD003610-bbs2-0111" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck-YtterY , Alonso-CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924-6.">Guyatt 2008</a>; <a href="./references#CD003610-bbs2-0112" title="GuyattGH , OxmanAD , SchunemannHJ , TugwellP , KnottnerusA . GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. Journal of Clinical Epidemiology2011;64(4):380-2.">Guyatt 2011</a>). We assessed the GRADE levels of evidence as high, moderate, low, and very low and downgraded the evidence by one or two levels depending on the following certainty measures: within‐study risk of bias, the directness of the evidence, heterogeneity of the data, precision of effect estimates, and risk of publication bias (<a href="./references#CD003610-bbs2-0180" title="SchunemannHJ , BestD , VistG , OxmanAD . Letters, numbers, symbols and words: how to communicate grades of evidence and recommendations. Canadian Medical Association Journal2003;169(7):677-80.">Schunemann 2003</a>; <a href="./references#CD003610-bbs2-0111" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck-YtterY , Alonso-CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924-6.">Guyatt 2008</a>; <a href="./references#CD003610-bbs2-0112" title="GuyattGH , OxmanAD , SchunemannHJ , TugwellP , KnottnerusA . GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. Journal of Clinical Epidemiology2011;64(4):380-2.">Guyatt 2011</a>). We used the methods and recommendations described in Chapter 8 (Section 8.5) (<a href="./references#CD003610-bbs2-0118" title="HigginsJPT , DeeksJJ , Altman DG (editors). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011b</a>) and Chapter 12 (<a href="./references#CD003610-bbs2-0182" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , AklE , Guyatt GH on behalf of the Cochrane Applicability and Recommendations Methods Group. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). Cochrane, 2017. Available from www.training.cochrane.org/handbook.">Schünemann 2017</a>) of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD003610-bbs2-0117" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011a</a>). We justified all decisions to downgrade the certainty of studies using footnotes and we made comments to aid the reader's understanding of the review where necessary. </p> <p>We included all trials in our analyses and conducted a sensitivity analysis only including low risk of bias trials. If the results were similar, we based our 'Summary of findings' tables and conclusions on the overall analysis. If they differed, we based our 'Summary of findings' tables and conclusions on trials at low risk of bias. </p> <p>We found three low risk of bias trials and reported their findings (<a href="./references#CD003610-bbs2-0001" title="AndersonJL , MuhlesteinJB , CarlquistJ , AllenA , TrehanS , NielsonC , et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection. The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) Study. Circulation1999;99:1540-7. MuhlesteinJB , AndersonJL , CarlquistJF , SalunkheK , HorneBD , PearsonRP , et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease. Primary clinical results of the ACADEMIC study. Circulation2000;102:1755-60. ">ACADEMIC 1999</a>; <a href="./references#CD003610-bbs2-0005" title="CercekB , ShahPK , NocM , ZahgerD , ZeymerU , MatetzkyS , et al. Effect of short-term treatment with azithromycin on recurrent ischaemic events in patients with acute coronary syndrome in the Azithromycin in Acute Coronary Syndrome (AZACS) trial: a randomised controlled trial. Lancet2003;361:809-13. ">AZACS 2003</a>; <a href="./references#CD003610-bbs2-0007" title="GluudC , Als-NielsenB , DamgaardB , HansenJF , HansenS , HeløOH , et al. Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease. Cardiology2008;111:280-7. HansenS , Als-NielsenB , DamgaardM , HeløOH , PetersenL , JespersenCM . Intervention with clarithromycin in patients with stable coronary heart disease. The CLARICOR trial design. Heart Drug2001;1:14-9. HildenJ , LindI , KolmosHJ , Als-NielsenB , DamgaardN , HansenJF , et al. Chlamydia pneumoniae IgG and IgA antibody titers and prognosis in patients with coronary heart disease: results from the CLARICOR trial. Diagnostic Microbiology and Infectious diseases2010;66(4):385-92. JensenGB , HildenJ , Als-NielsenB , DamgaardN , HansenJF , HansenS , et al. Statin treatment prevents increased cardiovascular and all-cause mortality associated with clarithromycin in patients with stable coronary heart disease. Journal of Cardiovascular Pharmacology2010;55(2):123-8. JespersenCM , Als-NielsenB , DamgaardM , HansenJF , HansenS , HeløOH , et al. Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with coronary heart disease: CLARICOR trial. BMJ2006;332(7532):22-7. JespersenCM , KolmosHJ , FrydendallN , HildenJ , GluudC , HansenJF . Compliance with and short-term adverse events from clarithromycin versus placebo in patients with stable coronary heart disease: the CLARICOR trial. Journal of Antimicrobial Chemotherapy2009;64(2):411-5. NCT00121550. The CLARICOR trial: effect of clarithromycin on mortality and morbidity in patients with ischemic heart disease. https://clinicaltrials.gov/ct2/show/NCT00121550 (first received 21 July 2005). WinkelP , HildenJ , Fischer HansenJ , HildebrandtP , KastrupJ , KolmosHJ , et al. Excess sudden cardiac deaths after short-term clarithromycin administration in the CLARICOR trial: why is this so, and why are statins protective?Cardiology2011;118(1):63-67. WinkelP , HildenJ , HansenJF , KastrupJ , KolmosHJ , KjøllerE , et al. Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular mortality and cerebrovascular mortality over 10 years in the CLARICOR randomised, blinded clinical trial. International Journal of Cardiology2015;182:459-65. ">CLARICOR 2006</a>). For cardiovascular mortality at maximum follow‐up, the sensitivity analyses differed from the overall analyses. Hence, we based our primary analyses and primary conclusions on trials at low risk of bias for this outcome. For all other outcomes, we based our primary analyses and primary conclusions on the overall analyses (<a href="./full#CD003610-tbl-0001">summary of findings Table 1</a> (maximum follow‐up) and <a href="./full#CD003610-tbl-0002">summary of findings Table 2</a> (24±6 months follow‐up)). </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD003610-sec-0052" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD003610-sec-0052"></div> <section id="CD003610-sec-0053"> <h3 class="title">Description of studies</h3> <p>We assessed all trials according to the <i>Cochrane Handbook</i> <i>for Systematic Reviews of Interventions</i>(<a href="./references#CD003610-bbs2-0117" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011a</a>), and the protocol for this review (<a href="./references#CD003610-bbs2-0210" title="SethiNJ , SafiS , KorangSK , HróbjartssonA , SkoogM , GluudC , et al. Antibiotics for secondary prevention of coronary heart disease. Cochrane Database of Systematic Reviews2017, Issue 7. Art. No: CD003610. [DOI: 10.1002/14651858.CD003610.pub3]">Sethi 2017</a>). Characteristics of each trial can be found in '<a href="./references#CD003610-sec-0156" title="">Characteristics of included studies</a>', '<a href="./references#CD003610-sec-0157" title="">Characteristics of excluded studies</a>', and '<a href="./references#CD003610-sec-0159" title="">Characteristics of ongoing studies</a>'. We identified four eligible ongoing studies (<a href="./references#CD003610-bbs2-0055" title="ACTRN12618000260224. Anti-chlamydophila antibiotic combination therapy in the treatment of patients with Coronary Heart Disease. https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=374503&amp;isReview=true (first received 13 February 2018). FrenchJ, newmanH , BorodyT , rajaratnamR , JuergensC , TsaylorD , et al. Protocol for a phase IIa, prospective study to evaluate the safety and measure efficacy of anti-chlamydophila antibiotic combination (ACAC) therapy comprising 100mg doxycycline, 500mg azithromycin and 300mg rifabutin in the treatment of patients with coronary heart disease (CHD). https://clinicaltrials.gov/ProvidedDocs/08/NCT03618108/Prot_SAP_000.pdf (version 8.2 dated 22 July 2018). ">ACAC‐CHD 2018</a>; <a href="./references#CD003610-bbs2-0056" title="NCT03508232. Doxycycline to protect heart muscle after heart attacks. https://clinicaltrials.gov/ct2/show/NCT03508232 (first received 25 April 2018). ">DOXY‐STEMI 2018</a>; <a href="./references#CD003610-bbs2-0057" title="NCT03960411. Effect of Doxycycline on cardiac remodelling in STEMI patients. https://clinicaltrials.gov/ct2/show/NCT03960411 (first received 23 May 2019). ">Fredy 2019</a>; <a href="./references#CD003610-bbs2-0058" title="ACTRN12618000467235. Doxycycline as a cardioprotective agent in ST-elevation myocardial infarction: a pilot study addressing pre- reperfusion administration. https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12618000467235 (first received 6 March 2018). ">SALVAGE MI 2018</a>). </p> <section id="CD003610-sec-0054"> <h4 class="title">Results of the search</h4> <p>We identified a total of 8093 potentially relevant references through searching the CENTRAL (The Cochrane Library) (n = 1368), MEDLINE (n = 3658), Embase (n = 2418), Science Citation Index Expanded (n = 425), BIOSIS (n = 219), and LILACS (n = 5) databases. The search strategy is presented in <a href="./appendices#CD003610-sec-0146">Appendix 1</a>. We found six potentially relevant references when searching Google Scholar, clinical trial registers, and reference lists of included trials, previous systematic reviews, and other types of reviews. After removing duplicates, 4772 records were screened, and 4688 references were excluded based on titles and abstracts. Eighty‐four full text articles were assessed for eligibility and we excluded 16 references reporting on 14 trials according to our inclusion criteria and exclusion criteria. Reasons for exclusion are listed in the table '<a href="./references#CD003610-sec-0157" title="">Characteristics of excluded studies</a>'. Of the remaining 68 references, we found five references reporting on four ongoing trials and two references reporting on two studies awaiting classification. Further information can be found in the table '<a href="./references#CD003610-sec-0159" title="">Characteristics of ongoing studies</a>' and '<a href="./references#CD003610-sec-0158" title="">Characteristics of studies awaiting classification</a>'. We therefore included 61 publications reporting results of 38 trials. Accordingly, 38 trials could be included in our analyses. The study flow chart can be seen in <a href="#CD003610-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD003610-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow chart." data-id="CD003610-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow chart.</p> </div> </div> </div> </section> <section id="CD003610-sec-0055"> <h4 class="title">Included studies</h4> <p>We included 61 publications reporting on 38 trials comparing antibiotics versus placebo or no intervention in patients with coronary heart disease (<a href="#CD003610-fig-0001">Figure 1</a>). The trials were conducted between 1997 and 2019. The trials took place at sites in 27 different countries: nine were from the USA; 6 from Germany; five from the UK; three each from Canada, Italy, and Finland; two each from France, Argentina, Spain, Turkey, India, South Korea, and Austria; and one each from Greece, Serbia, Romania, Australia, Thailand, the Netherlands, Denmark, Sweden, Poland, Japan, Brazil, Georgia, Slovenia, and Israel. The trials had a mean maximum follow‐up of 13.9 months (range 0.17 to 120.0 months). The vast majority of the data was contributed by trials assessing the effects of macrolides (28 trials randomising 22,059 participants) and quinolones (two trials randomising 4162 participants), while insufficient data were contributed by trials assessing the effects of tetracyclines (eight trials randomising 417 participants). A total of 23/38 trials with 26,078 participants reported data that could be meta‐analysed. For further details on included studies and baseline characteristics of included participants, see '<a href="./references#CD003610-sec-0156" title="">Characteristics of included studies</a>' and <a href="#CD003610-tbl-0004">Table 2</a>. </p> <div class="table" id="CD003610-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Baseline information of each included trial</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Year</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants currently smoking</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants with diabetes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants with hypertension</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants with hyperlipidaemia</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ACADEMIC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>112 out of 302</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34 out of 302</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>127 out of 302</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ACES</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>542 out of 4012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>883 out of 4012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2688 out of 4012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3309 of 4012</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aleksiadi 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ANTIBIO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>428 out of 851</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>139 out of 861</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>439 out of 851</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AZACS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>348 out of 1439</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>398 out of 1439</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>832 out of 1439</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>864 out of 1439</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Berg 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>92 out of 473</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74 out of 473</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>195 out of 473</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>278 out of 473</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CLARICOR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1572 out of 4372</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>678 out of 4372</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1761 out of 4372</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CLARIFY</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40 out of 148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28 out of 148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62 out of 148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>113 out of 148</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gabriel 2003l</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 out of 38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9 out of 38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14 out of 38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 out of 38</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gupta 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1997</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19 out of 60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 out of 60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11 out of 60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25 out of 60</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hillis 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25 out of 141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19 out of 141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57 out of 141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hyodo 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 out of 31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 out of 31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17 out of 31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17 out of 31</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ikeoka 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41 out of 82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 out of 82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46 out of 82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ISAR‐3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>224 out of 1010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>202 out of 1010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>771 out of 1010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Jackson 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kaehler 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67 out of 327</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18 out of 327</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>259 out of 327</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kim 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55 out of 129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38 out of 129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69 out of 129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35 out of 129</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kim 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26 out of 50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 out of 50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27 out of 50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 out of 50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kormi 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kuvin 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32 out of 58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 out of 58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34 out of 58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45 out of 58</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Leowattana 2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44 out of 84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37 out of 84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44 out of 84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53 out of 84</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MIDAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21 out of 50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 out of 50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39 out of 50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41 out of 50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parchure 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 out of 40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 out of 40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 out of 40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27 out of 40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pieniazek 2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PROVE‐IT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1529 out of 4162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>734 out of 4162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2091 out of 4162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Radoi 2003l</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39 out of 109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27 out of 109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67 out of 109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78 out of 109</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ROXIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1997</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53 out of 202</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26 out of 202</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>112 out of 202</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>129 out of 202</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sanati2019</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2019</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26 out of 68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27 out of 68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26 out of 68</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Schulze 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 out of 42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15 out of 42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37 out of 42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37 out of 42</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Semaan 2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sinisalo 1998</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1998</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11 out of 33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stojanovic 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18 out of 165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37 out of 165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29 out of 165</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thomaidou 2017</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2017</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 out of 40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15 out of 40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21 out of 40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TIPTOP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61 out of 80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23 out of 80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55 out of 80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54 out of 80</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Torgano 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23 out of 110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26 out of 110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15 out of 110</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tüter 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26 out of 36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WIZARD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1266 out of 7722</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1637 out of 7722</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3482 out of 7722</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4786 out of 7722</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ütük 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52 out of 113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 out of 113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34 out of 113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 out of 113</p> </td> </tr> </tbody> </table> </div> <p><b>Participants</b> </p> <p>A total of 26,638 participants with coronary heart disease were randomised in the 38 included trials. The number of participants in each trial ranged from 13 to 7747. The mean age was 61.6 years (range 53.8 years to 69.0 years). The mean proportion of women was 22.9%. The percentage of participants currently smoking was 25.6%, the percentage of participants with diabetes was 19.6%, the percentage of participants with hypertension was 51.0%, and the percentage of participants with hyperlipidaemia was 66.2%. </p> <p><b>Experimental intervention</b> </p> <p>The included trials used numerous types of antibiotics as their experimental intervention: 15 trials used azithromycin; eight trials used doxycycline; five trials used clarithromycin; five trials used roxithromycin; two trials used spiramycin; one trial used erythromycin; one trial used ciprofloxacin; and one trial used gatifloxacin. Accordingly, 29 trials used macrolides, eight trials used tetracyclines, and two trials used quinolones. The duration of therapy in each trial ranged from three days to 12 months. </p> <p><b>Control intervention</b> </p> <p>We included 31 trials where the control group received placebo. In the remaining seven trials, the control group received no intervention (apart from any co‐interventions also administered to the antibiotic group). </p> <p><b>Co‐interventions</b> </p> <p>We included 29 trials where the participants received a type of co‐intervention. In 18 trials, the co‐interventions consisted of anti‐anginal therapy, anti‐ischaemic therapy, anti‐thrombotic therapy, and anti‐lipidaemic therapy; in six trials, the co‐interventions consisted of anti‐anginal therapy, anti‐ischaemic therapy, and anti‐thrombotic therapy; in five trials, the co‐intervention consisted of anti‐thrombotic therapy. In seven trials, the participants also received either percutaneous coronary intervention (four trials) or coronary artery bypass surgery (three trials). In the remaining nine trials, there was no mention of any use of co‐interventions. For further details, see '<a href="./references#CD003610-sec-0156" title="">Characteristics of included studies</a>'. </p> </section> <section id="CD003610-sec-0056"> <h4 class="title">Excluded studies</h4> <p>We excluded 14 trials after full‐text assessment based on our inclusion and exclusion criteria: four trials were not randomised; four trials did not use an antibiotic as the experimental intervention; three trials gave additional co‐intervention (omeprazole) to the experimental group but not to the control group; two trials did not compare antibiotics versus placebo or no intervention; and one trial assessed the effects of antibiotics for primary prevention of postoperative infection and not for secondary prevention of coronary heart disease. For further details, see '<a href="./references#CD003610-sec-0157" title="">Characteristics of excluded studies</a>'. </p> </section> </section> <section id="CD003610-sec-0057"> <h3 class="title">Risk of bias in included studies</h3> <p>Based on the information that we collected from the published reports and information from authors, three trials were considered at low risk of bias (<a href="./references#CD003610-bbs2-0001" title="AndersonJL , MuhlesteinJB , CarlquistJ , AllenA , TrehanS , NielsonC , et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection. The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) Study. Circulation1999;99:1540-7. MuhlesteinJB , AndersonJL , CarlquistJF , SalunkheK , HorneBD , PearsonRP , et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease. Primary clinical results of the ACADEMIC study. Circulation2000;102:1755-60. ">ACADEMIC 1999</a>; <a href="./references#CD003610-bbs2-0005" title="CercekB , ShahPK , NocM , ZahgerD , ZeymerU , MatetzkyS , et al. Effect of short-term treatment with azithromycin on recurrent ischaemic events in patients with acute coronary syndrome in the Azithromycin in Acute Coronary Syndrome (AZACS) trial: a randomised controlled trial. Lancet2003;361:809-13. ">AZACS 2003</a>; <a href="./references#CD003610-bbs2-0007" title="GluudC , Als-NielsenB , DamgaardB , HansenJF , HansenS , HeløOH , et al. Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease. Cardiology2008;111:280-7. HansenS , Als-NielsenB , DamgaardM , HeløOH , PetersenL , JespersenCM . Intervention with clarithromycin in patients with stable coronary heart disease. The CLARICOR trial design. Heart Drug2001;1:14-9. HildenJ , LindI , KolmosHJ , Als-NielsenB , DamgaardN , HansenJF , et al. Chlamydia pneumoniae IgG and IgA antibody titers and prognosis in patients with coronary heart disease: results from the CLARICOR trial. Diagnostic Microbiology and Infectious diseases2010;66(4):385-92. JensenGB , HildenJ , Als-NielsenB , DamgaardN , HansenJF , HansenS , et al. Statin treatment prevents increased cardiovascular and all-cause mortality associated with clarithromycin in patients with stable coronary heart disease. Journal of Cardiovascular Pharmacology2010;55(2):123-8. JespersenCM , Als-NielsenB , DamgaardM , HansenJF , HansenS , HeløOH , et al. Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with coronary heart disease: CLARICOR trial. BMJ2006;332(7532):22-7. JespersenCM , KolmosHJ , FrydendallN , HildenJ , GluudC , HansenJF . Compliance with and short-term adverse events from clarithromycin versus placebo in patients with stable coronary heart disease: the CLARICOR trial. Journal of Antimicrobial Chemotherapy2009;64(2):411-5. NCT00121550. The CLARICOR trial: effect of clarithromycin on mortality and morbidity in patients with ischemic heart disease. https://clinicaltrials.gov/ct2/show/NCT00121550 (first received 21 July 2005). WinkelP , HildenJ , Fischer HansenJ , HildebrandtP , KastrupJ , KolmosHJ , et al. Excess sudden cardiac deaths after short-term clarithromycin administration in the CLARICOR trial: why is this so, and why are statins protective?Cardiology2011;118(1):63-67. WinkelP , HildenJ , HansenJF , KastrupJ , KolmosHJ , KjøllerE , et al. Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular mortality and cerebrovascular mortality over 10 years in the CLARICOR randomised, blinded clinical trial. International Journal of Cardiology2015;182:459-65. ">CLARICOR 2006</a>). The remaining 35 trials were considered at high risk of bias mainly because of domains being at unclear risk of bias. Many trials were judged to be at unclear risk of bias in several domains, and additional information could not be obtained from the authors when contacted. Additional information can be found in the 'Risk of bias' summary (<a href="#CD003610-fig-0002">Figure 2</a>), the 'Risk of bias' graph (<a href="#CD003610-fig-0003">Figure 3</a>), and '<a href="./references#CD003610-sec-0156" title="">Characteristics of included studies</a>'. </p> <div class="figure" id="CD003610-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. Multiple eligible treatments were used in two trials generating two further comparisons (= 38 trials reporting on 40 experimental groups)." data-id="CD003610-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. Multiple eligible treatments were used in two trials generating two further comparisons (= 38 trials reporting on 40 experimental groups). </p> </div> </div> </div> <div class="figure" id="CD003610-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD003610-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD003610-sec-0058"> <h4 class="title">Allocation</h4> <p>The generation of the random sequence was at low risk of bias in 12 trials. The remaining 26 trials were described as being randomised, but the method used for sequence generation was not described and were judged at unclear risk of bias. </p> <p>The method used to conceal allocation was adequate in 13 trials. In one trial, the concealment of allocation was not adequate and was judged at high risk of bias (<a href="./references#CD003610-bbs2-0034" title="CerisanoG , BuonamiciP , ParodiG , SantiniA , MoschiG , ValentiR , et al. Early changes of left ventricular filling pattern after reperfused ST-elevation myocardial infarction and doxycycline therapy: Insights from the TIPTOP trial. International Journal of Cardiology2017;240:43-8. CerisanoG , BuonamiciP , ValentiR , SciagráR , RaspantiS , SantiniA , et al. Early short-term doxycycline therapy in patients with acute myocardial infarction and left ventricular dysfunction to prevent the ominous progression to adverse remodelling: the TIPTOP trial. European Heart Journal2014;35(3):184-91. CerisanoG , BuonamiciP , ValentiR , SciagraR , RaspantiS , CarrabbaN , et al. Early short-term doxycycline therapy in patients with acute myocardial infarction and left ventricular dysfunction and the ominous progression to adverse remodeling (TIPTOP). A randomized controlled trial. Journal of the American College of Cardiology2012;59(13 (supplement)):E349. NCT00469261. Tetracycline (Doxycycline) and post myocardial infarction remodeling (TIPTOP). https://clinicaltrials.gov/ct2/show/NCT00469261 (first received 4 May 2007). ">TIPTOP 2014</a>). The remaining 24 trials were described as being randomised, but the method used for allocation concealment was either not described or insufficiently described and were judged to be of unclear risk of bias. </p> </section> <section id="CD003610-sec-0059"> <h4 class="title">Blinding</h4> <p>The blinding of participants and personnel was performed and adequately described in 22 trials and were judged at low risk of bias. Three trials described that they did not blind the participants and personnel and were judged at high risk of bias. The method for blinding of participants and personnel for the remaining 13 trials were either not described or insufficiently described and were judged at unclear risk of bias. </p> <p>The blinding of outcome assessors was performed and adequately described in 13 trials and were judged at low risk of bias. The methods for blinding of outcome assessors for the remaining 25 trials were either not described or insufficiently described and were judged at unclear risk of bias. </p> </section> <section id="CD003610-sec-0060"> <h4 class="title">Incomplete outcome data</h4> <p>Incomplete outcome data were addressed adequately in 19 trials and were judged at low risk of bias. Six trials did not properly deal with incomplete outcome data and were judged to be of high risk of bias. In the remaining 13 trials, incomplete outcome data were either not described or insufficiently described how they dealt with missing data and were judged at unclear risk of bias. </p> </section> <section id="CD003610-sec-0061"> <h4 class="title">Selective reporting</h4> <p>Eight trials reported the results of the outcomes stated in their respective protocols, or reported all‐cause mortality and various types of serious adverse events, resulting in low risk of bias according to our predefined bias risk assessment. One trial did not report the same outcomes, as stated in the protocol and was judged at high risk of bias (<a href="./references#CD003610-bbs2-0038" title="DunneMW . Rationale and design of a secondary prevention trial of antibiotic use in patients after myocardial infarction: the WIZARD (Weekly Intervention With Zithromax (azithromycin) for Atherosclerosis and its Related Disorders) trial. Journal of Infectious Diseases2000;181(Suppl 3):S572-8. O'ConnerCM , DunneMW , PfefferMA , MuhlesteinJB , YaoL , GuptaS , et al. Azithromycin for the secondary prevention of coronary heart disease events. The WIZARD study: a randomized controlled trial. JAMA2003;290(11):1459-66. ">WIZARD 2003</a>). In the remaining 29 trials, no protocol could be obtained and the trial did not report our primary outcomes sufficiently and were judged at unclear risk of bias. </p> </section> <section id="CD003610-sec-0062"> <h4 class="title">Other potential sources of bias</h4> <p>Thirty‐six trials had no other biases resulting in at low risk of bias. Two trials reported insufficient information to assess whether an important risk of bias exists. </p> </section> </section> <section id="CD003610-sec-0063"> <h3 class="title" id="CD003610-sec-0063">Effects of interventions</h3> <p>See: <a href="./full#CD003610-tbl-0001"><b>Summary of findings 1</b> Antibiotics versus placebo or no intervention for secondary prevention of patients with coronary heart disease at maximum follow‐up</a>; <a href="./full#CD003610-tbl-0002"><b>Summary of findings 2</b> Antibiotics versus placebo or no intervention for secondary prevention of patients with coronary heart disease at 24±6 months follow‐up</a> </p> <section id="CD003610-sec-0064"> <h4 class="title">Primary outcomes</h4> <section id="CD003610-sec-0065"> <h5 class="title">All‐cause mortality</h5> <section id="CD003610-sec-0066"> <h6 class="title">Maximum follow‐up</h6> <p>For this outcome, 20/38 trials with a total of 25,774 participants and a mean follow‐up of 21.4 months (range 3.0 to 120.0 months) reported all‐cause mortality at maximum follow‐up. The specific assessment time points in each trial are presented in <a href="#CD003610-tbl-0005">Table 3</a>. A total of 1354/12,895 (10.5%) antibiotic participants died versus 1291/12,879 (10.0%) control participants. Random‐effects meta‐analysis showed that antibiotics versus placebo or no intervention seemed to increase the risk of all‐cause mortality (risk ratio (RR) 1.06; 95% confidence interval (CI) 0.99 to 1.13; P = 0.07; I<sup>2</sup> = 0%; 25,774 participants; 20 trials; high certainty of evidence; <a href="./references#CD003610-fig-0007" title="">Analysis 1.1</a>). The corresponding absolute risk increase (ARI) was 0.48% and the number needed to treat for an additional harmful outcome (NNTH) was 208. </p> <div class="table" id="CD003610-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Time points used at maximum follow‐up</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Year</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All‐cause mortality (months)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cardiovascular mortality (months)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Myocardial infarction (months)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Stroke (months)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Sudden cardiac death (months)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Hospitalisation for any cause (months)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Revascularisation (months)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Unstable angina pectoris (months)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ACADEMIC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ACES</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aleksiadi 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ANTIBIO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AZACS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Berg 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CLARICOR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>120</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CLARIFY</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gabriel 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gupta 1997</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1997</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hillis 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hyodo2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ikeoka 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ISAR‐3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Jackson 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kaehler2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kim 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kim 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kormi 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kuvin 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Leowattana2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MIDAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parchure 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pieniazek 2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PROVE‐IT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Radoi et al</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ROXIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1997</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sanati 2019</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2019</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Schulze 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Semaan 2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sinisalo 1998</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1998</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stojanovic 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thomaidou 2017</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2017</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TIPTOP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Torgano 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tüter 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WIZARD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ütük 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>NR: Not reported.</p> </div> </div> <section id="CD003610-sec-0067"> <p><b>Heterogeneity</b></p> <p>Neither visual inspection of the forest plot nor tests for statistical heterogeneity (I<sup>2</sup> = 0%; P = 0.88) indicated any heterogeneity. </p> </section> <section id="CD003610-sec-0068"> <p><b>Risk of bias and sensitivity analyses</b></p> <p>Three trials were assessed at low risk of bias (<a href="./references#CD003610-bbs2-0001" title="AndersonJL , MuhlesteinJB , CarlquistJ , AllenA , TrehanS , NielsonC , et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection. The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) Study. Circulation1999;99:1540-7. MuhlesteinJB , AndersonJL , CarlquistJF , SalunkheK , HorneBD , PearsonRP , et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease. Primary clinical results of the ACADEMIC study. Circulation2000;102:1755-60. ">ACADEMIC 1999</a>; <a href="./references#CD003610-bbs2-0005" title="CercekB , ShahPK , NocM , ZahgerD , ZeymerU , MatetzkyS , et al. Effect of short-term treatment with azithromycin on recurrent ischaemic events in patients with acute coronary syndrome in the Azithromycin in Acute Coronary Syndrome (AZACS) trial: a randomised controlled trial. Lancet2003;361:809-13. ">AZACS 2003</a>; <a href="./references#CD003610-bbs2-0007" title="GluudC , Als-NielsenB , DamgaardB , HansenJF , HansenS , HeløOH , et al. Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease. Cardiology2008;111:280-7. HansenS , Als-NielsenB , DamgaardM , HeløOH , PetersenL , JespersenCM . Intervention with clarithromycin in patients with stable coronary heart disease. The CLARICOR trial design. Heart Drug2001;1:14-9. HildenJ , LindI , KolmosHJ , Als-NielsenB , DamgaardN , HansenJF , et al. Chlamydia pneumoniae IgG and IgA antibody titers and prognosis in patients with coronary heart disease: results from the CLARICOR trial. Diagnostic Microbiology and Infectious diseases2010;66(4):385-92. JensenGB , HildenJ , Als-NielsenB , DamgaardN , HansenJF , HansenS , et al. Statin treatment prevents increased cardiovascular and all-cause mortality associated with clarithromycin in patients with stable coronary heart disease. Journal of Cardiovascular Pharmacology2010;55(2):123-8. JespersenCM , Als-NielsenB , DamgaardM , HansenJF , HansenS , HeløOH , et al. Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with coronary heart disease: CLARICOR trial. BMJ2006;332(7532):22-7. JespersenCM , KolmosHJ , FrydendallN , HildenJ , GluudC , HansenJF . Compliance with and short-term adverse events from clarithromycin versus placebo in patients with stable coronary heart disease: the CLARICOR trial. Journal of Antimicrobial Chemotherapy2009;64(2):411-5. NCT00121550. The CLARICOR trial: effect of clarithromycin on mortality and morbidity in patients with ischemic heart disease. https://clinicaltrials.gov/ct2/show/NCT00121550 (first received 21 July 2005). WinkelP , HildenJ , Fischer HansenJ , HildebrandtP , KastrupJ , KolmosHJ , et al. Excess sudden cardiac deaths after short-term clarithromycin administration in the CLARICOR trial: why is this so, and why are statins protective?Cardiology2011;118(1):63-67. WinkelP , HildenJ , HansenJF , KastrupJ , KolmosHJ , KjøllerE , et al. Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular mortality and cerebrovascular mortality over 10 years in the CLARICOR randomised, blinded clinical trial. International Journal of Cardiology2015;182:459-65. ">CLARICOR 2006</a>). All other trials were assessed at high risk of bias. However, the overall outcome result was dominated by <a href="./references#CD003610-bbs2-0007" title="GluudC , Als-NielsenB , DamgaardB , HansenJF , HansenS , HeløOH , et al. Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease. Cardiology2008;111:280-7. HansenS , Als-NielsenB , DamgaardM , HeløOH , PetersenL , JespersenCM . Intervention with clarithromycin in patients with stable coronary heart disease. The CLARICOR trial design. Heart Drug2001;1:14-9. HildenJ , LindI , KolmosHJ , Als-NielsenB , DamgaardN , HansenJF , et al. Chlamydia pneumoniae IgG and IgA antibody titers and prognosis in patients with coronary heart disease: results from the CLARICOR trial. Diagnostic Microbiology and Infectious diseases2010;66(4):385-92. JensenGB , HildenJ , Als-NielsenB , DamgaardN , HansenJF , HansenS , et al. Statin treatment prevents increased cardiovascular and all-cause mortality associated with clarithromycin in patients with stable coronary heart disease. Journal of Cardiovascular Pharmacology2010;55(2):123-8. JespersenCM , Als-NielsenB , DamgaardM , HansenJF , HansenS , HeløOH , et al. Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with coronary heart disease: CLARICOR trial. BMJ2006;332(7532):22-7. JespersenCM , KolmosHJ , FrydendallN , HildenJ , GluudC , HansenJF . Compliance with and short-term adverse events from clarithromycin versus placebo in patients with stable coronary heart disease: the CLARICOR trial. Journal of Antimicrobial Chemotherapy2009;64(2):411-5. NCT00121550. The CLARICOR trial: effect of clarithromycin on mortality and morbidity in patients with ischemic heart disease. https://clinicaltrials.gov/ct2/show/NCT00121550 (first received 21 July 2005). WinkelP , HildenJ , Fischer HansenJ , HildebrandtP , KastrupJ , KolmosHJ , et al. Excess sudden cardiac deaths after short-term clarithromycin administration in the CLARICOR trial: why is this so, and why are statins protective?Cardiology2011;118(1):63-67. WinkelP , HildenJ , HansenJF , KastrupJ , KolmosHJ , KjøllerE , et al. Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular mortality and cerebrovascular mortality over 10 years in the CLARICOR randomised, blinded clinical trial. International Journal of Cardiology2015;182:459-65. ">CLARICOR 2006</a> (73.1% of weight), which was at low risk of bias in all domains. The next three highest‐weighted trials (<a href="./references#CD003610-bbs2-0002" title="GraystonJT , KronmalRA , JacksonLA , ParisiAF , MuhlesteinJB , CohenJD , et al. Azithromycin for the secondary prevention of coronary events. New England Journal of Medicine2005;352:1637-45. JacksonLA . Description and status of the azithromycin and coronary events study (ACES). Journal of Infectious Diseases2000;181(Suppl 3):S579-81. NCT00000617. Azithromycin and Coronary Events Study (ACES). https://clinicaltrials.gov/ct2/show/NCT00000617 (first received 28 October 1999). ">ACES 2005</a>; <a href="./references#CD003610-bbs2-0025" title="CannonCP , BraunwaldE , McCabeCH , GraystonJT , MuhlesteinB , GiuglianoRP , et al. Antibiotic treatment of chlamydia pneumoniae after acute coronary syndrome. New England Journal of Medicine2005;352:1646-54. CannonCP , BraunwaldE , McCabeCH , RaderDJ , RouleauJL , BelderR , et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. New England Journal of Medicine2004;350(15):1495-504. CannonCP , McCabeCH , BelderR , BreenJ , BraunwaldE . Design of the pravastatin or atorvastatin evaluation and infection therapy (PROVE IT)-TIMI 22 trial. American Journal of Cardiology2002;89:860-1. ">PROVE‐IT 2005</a>; <a href="./references#CD003610-bbs2-0038" title="DunneMW . Rationale and design of a secondary prevention trial of antibiotic use in patients after myocardial infarction: the WIZARD (Weekly Intervention With Zithromax (azithromycin) for Atherosclerosis and its Related Disorders) trial. Journal of Infectious Diseases2000;181(Suppl 3):S572-8. O'ConnerCM , DunneMW , PfefferMA , MuhlesteinJB , YaoL , GuptaS , et al. Azithromycin for the secondary prevention of coronary heart disease events. The WIZARD study: a randomized controlled trial. JAMA2003;290(11):1459-66. ">WIZARD 2003</a>) were all at low risk of bias in the majority of domains. We therefore decided to assess the risk of bias of the outcome result at low risk of bias. </p> <p>The sensitivity analysis of trials at low risk of bias showed that antibiotics versus placebo or no intervention seemed to increase the risk of all‐cause mortality (RR 1.07; 95% CI 0.99 to 1.15; P = 0.07; I<sup>2</sup> = 0%; 6113 participants; 3 trials; moderate certainty of evidence; <a href="./references#CD003610-fig-0008" title="">Analysis 1.2</a>). The corresponding ARI was 1.85% and the NNTH was 54. </p> <p>The sensitivity analyses on incomplete outcome data showed that incomplete outcome data bias alone had the potential to influence the results (best‐worst fixed‐effect meta‐analysis: RR 0.98; 95% CI 0.92 to 1.04; P = 0.46; 25,815 participants; 20 trials; <a href="./references#CD003610-fig-0009" title="">Analysis 1.3</a>); (worst‐best fixed‐effect meta‐analysis: RR 1.13; 95% CI 1.06 to 1.21; P = 0.0001; 25,815 participants; 20 trials; <a href="./references#CD003610-fig-0010" title="">Analysis 1.4</a>); (modified best‐worst fixed‐effect meta‐analysis: RR 1.01; 95% CI 0.95 to 1.08; P = 0.69; 25,815 participants; 20 trials; <a href="./references#CD003610-fig-0011" title="">Analysis 1.5</a>); (modified worst‐best random‐effects meta‐analysis: RR 1.09; 95% CI 1.02 to 1.16; P = 0.007; 25,815 participants; 20 trials; <a href="./references#CD003610-fig-0012" title="">Analysis 1.6</a>). Data were imputed for 9 trials. </p> <p>The sensitivity analysis on trials with optimal medical therapy showed that antibiotics versus placebo or no intervention seemed to increase the risk of all‐cause mortality (RR 1.06; 95% CI 0.99 to 1.13; P = 0.07; I<sup>2</sup> = 0%; 23,294 participants; 13 trials; high certainty of evidence; <a href="./references#CD003610-fig-0013" title="">Analysis 1.7</a>). The corresponding ARI was 0.56% and the NNTH was 179. </p> <p>Visual inspection of the funnel plot showed no signs of asymmetry (<a href="#CD003610-fig-0004">Figure 4</a>). Based on the visual inspection of the funnel plot, we assessed the risk of publication bias as low. </p> <div class="figure" id="CD003610-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, outcome: 1.1 ALL‐CAUSE MORTALITY." data-id="CD003610-fig-0004" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, outcome: 1.1 ALL‐CAUSE MORTALITY. </p> </div> </div> </div> </section> <section id="CD003610-sec-0069"> <p><b>Subgroup analyses</b></p> <p>We found no evidence of a difference in subgroups analyses according to antibiotic type (<a href="./references#CD003610-fig-0014" title="">Analysis 1.8</a>); antibody status (<a href="./references#CD003610-fig-0015" title="">Analysis 1.9</a>); use of statins (<a href="./references#CD003610-fig-0016" title="">Analysis 1.10</a>); age above or under 60 years (<a href="./references#CD003610-fig-0017" title="">Analysis 1.11</a>); clinical trial registration status (<a href="./references#CD003610-fig-0018" title="">Analysis 1.12</a>); length of follow‐up above or under 12 months follow‐up (<a href="./references#CD003610-fig-0019" title="">Analysis 1.13</a>); antibiotic class (<a href="./references#CD003610-fig-0020" title="">Analysis 1.14</a>); funding (<a href="./references#CD003610-fig-0021" title="">Analysis 1.15</a>); and control intervention (<a href="./references#CD003610-fig-0022" title="">Analysis 1.16</a>). </p> </section> </section> <section id="CD003610-sec-0070"> <h6 class="title">24±6 months follow‐up</h6> <p>At 24±6 months follow‐up, 6/38 trials with a total of 9517 participants and a mean follow‐up of 23.3 months (range 18.0 to 30.0 months) reported all‐cause mortality. The specific assessment time points in each trial are presented in <a href="#CD003610-tbl-0006">Table 4</a>. A total of 296/4750 (6.23%) antibiotic participants died versus 237/4767 (4.97%) control participants. Random‐effects meta‐analysis showed that antibiotics versus placebo or no intervention increased the risk of all‐cause mortality (RR 1.25; 95% CI 1.06 to 1.48; I<sup>2</sup> = 0%; P = 0.007; 9517 participants; 6 trials; high certainty of evidence; <a href="./references#CD003610-fig-0089" title="">Analysis 2.1</a>). The corresponding ARI was 1.26% and the NNTH was 79 (95% CI 335 to 42). </p> <div class="table" id="CD003610-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Time points used at 24±6 months follow‐up</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Year</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All‐cause mortality (months)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cardiovascular mortality (months)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Myocardial infarction (months)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Stroke (months)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Sudden cardiac death (months)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Hospitalisation for any cause (months)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Revascularisation (months)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Unstable angina pectoris (months)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ACADEMIC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ACES</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aleksiadi 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ANTIBIO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AZACS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Berg 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CLARICOR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CLARIFY</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gabriel 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gupta 1997</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1997</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hillis 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hyodo 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ikeoka 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ISAR‐3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Jackson 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kaehler 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kim 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kim 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kormi 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kuvin 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Leowattana 2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MIDAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parchure2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pieniazek 2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PROVE‐IT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Radoi 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ROXIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1997</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sanati 2019</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2019</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Schulze 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Semaan2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sinisalo 1998</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1998</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stojanovic 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thomaidou 2017</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2017</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TIPTOP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Torgano 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tüter 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WIZARD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ütük 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>NR: Not reported.</p> </div> </div> <section id="CD003610-sec-0071"> <p><b>Heterogeneity</b></p> <p>Neither visual inspection of the forest plot nor tests for statistical heterogeneity (I<sup>2</sup> = 0%; P = 0.90) indicated any heterogeneity. </p> </section> <section id="CD003610-sec-0072"> <p><b>Risk of bias and sensitivity analyses</b></p> <p>Two trials were assessed at low risk of bias (<a href="./references#CD003610-bbs2-0001" title="AndersonJL , MuhlesteinJB , CarlquistJ , AllenA , TrehanS , NielsonC , et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection. The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) Study. Circulation1999;99:1540-7. MuhlesteinJB , AndersonJL , CarlquistJF , SalunkheK , HorneBD , PearsonRP , et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease. Primary clinical results of the ACADEMIC study. Circulation2000;102:1755-60. ">ACADEMIC 1999</a>; <a href="./references#CD003610-bbs2-0007" title="GluudC , Als-NielsenB , DamgaardB , HansenJF , HansenS , HeløOH , et al. Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease. Cardiology2008;111:280-7. HansenS , Als-NielsenB , DamgaardM , HeløOH , PetersenL , JespersenCM . Intervention with clarithromycin in patients with stable coronary heart disease. The CLARICOR trial design. Heart Drug2001;1:14-9. HildenJ , LindI , KolmosHJ , Als-NielsenB , DamgaardN , HansenJF , et al. Chlamydia pneumoniae IgG and IgA antibody titers and prognosis in patients with coronary heart disease: results from the CLARICOR trial. Diagnostic Microbiology and Infectious diseases2010;66(4):385-92. JensenGB , HildenJ , Als-NielsenB , DamgaardN , HansenJF , HansenS , et al. Statin treatment prevents increased cardiovascular and all-cause mortality associated with clarithromycin in patients with stable coronary heart disease. Journal of Cardiovascular Pharmacology2010;55(2):123-8. JespersenCM , Als-NielsenB , DamgaardM , HansenJF , HansenS , HeløOH , et al. Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with coronary heart disease: CLARICOR trial. BMJ2006;332(7532):22-7. JespersenCM , KolmosHJ , FrydendallN , HildenJ , GluudC , HansenJF . Compliance with and short-term adverse events from clarithromycin versus placebo in patients with stable coronary heart disease: the CLARICOR trial. Journal of Antimicrobial Chemotherapy2009;64(2):411-5. NCT00121550. The CLARICOR trial: effect of clarithromycin on mortality and morbidity in patients with ischemic heart disease. https://clinicaltrials.gov/ct2/show/NCT00121550 (first received 21 July 2005). WinkelP , HildenJ , Fischer HansenJ , HildebrandtP , KastrupJ , KolmosHJ , et al. Excess sudden cardiac deaths after short-term clarithromycin administration in the CLARICOR trial: why is this so, and why are statins protective?Cardiology2011;118(1):63-67. WinkelP , HildenJ , HansenJF , KastrupJ , KolmosHJ , KjøllerE , et al. Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular mortality and cerebrovascular mortality over 10 years in the CLARICOR randomised, blinded clinical trial. International Journal of Cardiology2015;182:459-65. ">CLARICOR 2006</a>). All other trials were assessed at high risk of bias. However, the overall outcome result was dominated by <a href="./references#CD003610-bbs2-0007" title="GluudC , Als-NielsenB , DamgaardB , HansenJF , HansenS , HeløOH , et al. Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease. Cardiology2008;111:280-7. HansenS , Als-NielsenB , DamgaardM , HeløOH , PetersenL , JespersenCM . Intervention with clarithromycin in patients with stable coronary heart disease. The CLARICOR trial design. Heart Drug2001;1:14-9. HildenJ , LindI , KolmosHJ , Als-NielsenB , DamgaardN , HansenJF , et al. Chlamydia pneumoniae IgG and IgA antibody titers and prognosis in patients with coronary heart disease: results from the CLARICOR trial. Diagnostic Microbiology and Infectious diseases2010;66(4):385-92. JensenGB , HildenJ , Als-NielsenB , DamgaardN , HansenJF , HansenS , et al. Statin treatment prevents increased cardiovascular and all-cause mortality associated with clarithromycin in patients with stable coronary heart disease. Journal of Cardiovascular Pharmacology2010;55(2):123-8. JespersenCM , Als-NielsenB , DamgaardM , HansenJF , HansenS , HeløOH , et al. Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with coronary heart disease: CLARICOR trial. BMJ2006;332(7532):22-7. JespersenCM , KolmosHJ , FrydendallN , HildenJ , GluudC , HansenJF . Compliance with and short-term adverse events from clarithromycin versus placebo in patients with stable coronary heart disease: the CLARICOR trial. Journal of Antimicrobial Chemotherapy2009;64(2):411-5. NCT00121550. The CLARICOR trial: effect of clarithromycin on mortality and morbidity in patients with ischemic heart disease. https://clinicaltrials.gov/ct2/show/NCT00121550 (first received 21 July 2005). WinkelP , HildenJ , Fischer HansenJ , HildebrandtP , KastrupJ , KolmosHJ , et al. Excess sudden cardiac deaths after short-term clarithromycin administration in the CLARICOR trial: why is this so, and why are statins protective?Cardiology2011;118(1):63-67. WinkelP , HildenJ , HansenJF , KastrupJ , KolmosHJ , KjøllerE , et al. Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular mortality and cerebrovascular mortality over 10 years in the CLARICOR randomised, blinded clinical trial. International Journal of Cardiology2015;182:459-65. ">CLARICOR 2006</a> (73.5% of weight), which was at low risk of bias in all domains. The next two highest‐weighted trials (<a href="./references#CD003610-bbs2-0006" title="BergHF , MarahaB , SchefferGJ , PeetersMF , KluytmansJA . Effect of clarithromycin on inflammatory markers in patients with atherosclerosis. Clinical and Diagnostic Laboratory Immunology2003;10(4):525-8. BergHF , MarahaB , SchefferGJ , UffordMQ , Vandenbroucke-GraulsCME , PeetersMF , et al. Treatment with clarithromycin prior to coronary artery bypass graft surgery does not prevent subsequent cardiac events. Clinical Infectious Diseases2005;40:358-65. BergHF , MarahaB , van derZeeA , GielisSK , RohollPJ , SchefferGJ , et al. Effect of clarithromycin treatment on Chlamydia pneumoniae in vascular tissue of patients with coronary artery disease: a randomized, double-blind, placebo-controlled trial. Journal of Clinical Microbiology2005;43(3):1325-9. BergHF , TjhieJH , SchefferGJ , PeetersMF , vanKeulenPH , KluytmansJA , et al. Emergence and persistence of macrolide resistance in oropharyngeal flora and elimination of nasal carriage of Staphylococcus aureus after therapy with slow-release clarithromycin: a randomized, double-blind, placebo-controlled study. Antimicrobial Agents and Chemotherapy2004;48(11):4183-8. ">Berg 2005</a>; <a href="./references#CD003610-bbs2-0025" title="CannonCP , BraunwaldE , McCabeCH , GraystonJT , MuhlesteinB , GiuglianoRP , et al. Antibiotic treatment of chlamydia pneumoniae after acute coronary syndrome. New England Journal of Medicine2005;352:1646-54. CannonCP , BraunwaldE , McCabeCH , RaderDJ , RouleauJL , BelderR , et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. New England Journal of Medicine2004;350(15):1495-504. CannonCP , McCabeCH , BelderR , BreenJ , BraunwaldE . Design of the pravastatin or atorvastatin evaluation and infection therapy (PROVE IT)-TIMI 22 trial. American Journal of Cardiology2002;89:860-1. ">PROVE‐IT 2005</a>) were both at low risk of bias in the majority of domains. We therefore decided to assess the risk of bias of the outcome result at low risk of bias. </p> <p>The sensitivity analysis of trials at low risk of bias showed that antibiotics versus placebo or no intervention probably increased the risk of all‐cause mortality (RR 1.25; 95% CI 1.03 to 1.51; P = 0.02; I<sup>2</sup> = 0%; 4674 participants; 2 trials; moderate certainty of evidence; <a href="./references#CD003610-fig-0090" title="">Analysis 2.2</a>). The corresponding ARI was 1.86% and the NNTH was 54 (95% CI 446 to 26). </p> <p>The sensitivity analyses on incomplete outcome data showed that incomplete outcome data bias alone did not have the potential to influence the results (best‐worst fixed‐effect meta‐analysis: RR 1.22; 95% CI 1.03 to 1.43; P = 0.02; 9518 participants; 6 trials; <a href="./references#CD003610-fig-0091" title="">Analysis 2.3</a>); (worst‐best fixed‐effect meta‐analysis: RR 1.31; 95% CI 1.11 to 1.54; P = 0.001; 9518 participants; 6 trials; <a href="./references#CD003610-fig-0092" title="">Analysis 2.4</a>); (modified best‐worst fixed‐effect meta‐analysis: RR 1.24; 95% CI 1.05 to 1.46; P = 0.01; 9518 participants; 6 trials; <a href="./references#CD003610-fig-0093" title="">Analysis 2.5</a>); (modified worst‐best fixed‐effect meta‐analysis: RR 1.28; 95% CI 1.09 to 1.51; P = 0.003; 9518 participants; 6 trials; <a href="./references#CD003610-fig-0094" title="">Analysis 2.6</a>). Data were imputed for 2 trials. </p> <p>The sensitivity analysis on trials with optimal medical therapy showed that antibiotics versus placebo or no intervention probably increased the risk of all‐cause mortality (RR 1.27; 95% CI 1.07 to 1.50; I<sup>2</sup> = 0%; P = 0.006; 8682 participants; 3 trials; moderate certainty of evidence; <a href="./references#CD003610-fig-0095" title="">Analysis 2.7</a>). The corresponding ARI was 1.36% and the NNTH was 73 (95% CI 279 to 39). </p> </section> <section id="CD003610-sec-0073"> <p><b>Subgroup analyses</b></p> <p>We found no evidence of a difference in subgroups analyses according to antibiotic type (<a href="./references#CD003610-fig-0096" title="">Analysis 2.8</a>); antibody status (<a href="./references#CD003610-fig-0097" title="">Analysis 2.9</a>); use of statins (<a href="./references#CD003610-fig-0098" title="">Analysis 2.10</a>); age above or under 60 years (<a href="./references#CD003610-fig-0099" title="">Analysis 2.11</a>); clinical trial registration status (<a href="./references#CD003610-fig-0100" title="">Analysis 2.12</a>); antibiotic class (<a href="./references#CD003610-fig-0101" title="">Analysis 2.13</a>); and funding (<a href="./references#CD003610-fig-0102" title="">Analysis 2.14</a>). Subgroup analysis according to control intervention could not be conducted due to all trials being placebo‐controlled (<a href="./references#CD003610-fig-0103" title="">Analysis 2.15</a>). </p> </section> </section> </section> <section id="CD003610-sec-0074"> <h5 class="title">Serious adverse events</h5> <section id="CD003610-sec-0075"> <h6 class="title">Maximum follow‐up</h6> <p>None of the trials specifically assessed serious adverse event according toInternational Conference on Harmonization ‐ Good Clinical Practice (ICH‐GCP). Instead, the trials either reported composites of several specific serious adverse events or one specific serious adverse event. </p> <p>We narratively reported the individual types of serious adverse events in each trial at maximum follow‐up in <a href="#CD003610-tbl-0007">Table 5</a>. </p> <div class="table" id="CD003610-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Serious adverse events ‐ maximum follow‐up</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Year</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Type and number of serious adverse event (antibiotics group)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Type and number of serious adverse event (control group)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ACADEMIC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0029"> <li> <p>5 deaths;</p> </li> <li> <p>4 reinfarctions;</p> </li> <li> <p>1 stroke;</p> </li> <li> <p>8 hospitalisations for unstable angina pectoris;</p> </li> <li> <p>9 revascularisations; and</p> </li> <li> <p>1 resuscitated cardiac arrest</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0030"> <li> <p>4 deaths;</p> </li> <li> <p>6 reinfarctions;</p> </li> <li> <p>3 strokes;</p> </li> <li> <p>7 hospitalisations for unstable angina pectoris; and</p> </li> <li> <p>15 revascularisations</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ACES</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0031"> <li> <p>143 deaths;</p> </li> <li> <p>136 reinfarctions;</p> </li> <li> <p>45 strokes;</p> </li> <li> <p>50 hospitalisations for unstable angina pectoris;</p> </li> <li> <p>264 percutaneous coronary revascularisations;</p> </li> <li> <p>117 coronary‐artery bypass surgeries;</p> </li> <li> <p>13 cardiac collapses followed by resuscitation;</p> </li> <li> <p>37 carotid endarterectomies; and</p> </li> <li> <p>30 peripheral revascularisations</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0032"> <li> <p>132 deaths;</p> </li> <li> <p>130 reinfarctions;</p> </li> <li> <p>40 strokes;</p> </li> <li> <p>55 hospitalisations for unstable angina pectoris;</p> </li> <li> <p>259 percutaneous coronary revascularisations;</p> </li> <li> <p>110 coronary‐artery bypass surgeries;</p> </li> <li> <p>8 cardiac collapses followed by resuscitation;</p> </li> <li> <p>30 carotid endarterectomies; and</p> </li> <li> <p>35 peripheral revascularisations</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ANTIBIO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0033"> <li> <p>28 deaths;</p> </li> <li> <p>21 reinfarctions;</p> </li> <li> <p>7 strokes;</p> </li> <li> <p>73 hospitalisations caused by unstable angina pectoris;</p> </li> <li> <p>67 coronary bypass surgeries;</p> </li> <li> <p>182 percutaneous coronary interventions; and</p> </li> <li> <p>21 resuscitations</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0034"> <li> <p>26 deaths;</p> </li> <li> <p>24 reinfarctions;</p> </li> <li> <p>9 strokes;</p> </li> <li> <p>58 hospitalisations caused by unstable angina pectoris;</p> </li> <li> <p>60 coronary bypass surgeries;</p> </li> <li> <p>191 percutaneous coronary interventions; and</p> </li> <li> <p>15 resuscitations</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AZACS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0035"> <li> <p>23 deaths;</p> </li> <li> <p>17 reinfarctions;</p> </li> <li> <p>65 coronary artery bypass grafting/percutaneous transluminal coronary angioplasty; and </p> </li> <li> <p>62 worsening of angina or ischaemia needing admission, or new or worsening of congestive heart failure needing admission </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0036"> <li> <p>29 deaths;</p> </li> <li> <p>22 reinfarctions;</p> </li> <li> <p>59 coronary artery bypass grafting/percutaneous transluminal coronary angioplasty; and </p> </li> <li> <p>59 worsening of angina or ischaemia needing admission, or new or worsening of congestive heart failure needing admission </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Berg 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0037"> <li> <p>10 deaths;</p> </li> <li> <p>1 reinfarction;</p> </li> <li> <p>9 strokes;</p> </li> <li> <p>10 unstable angina pectoris;</p> </li> <li> <p>9 revascularisations;</p> </li> <li> <p>2 peripheral vascular surgeries; and</p> </li> <li> <p>1 sternal wound infection</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0038"> <li> <p>9 deaths;</p> </li> <li> <p>3 reinfarction;</p> </li> <li> <p>5 strokes;</p> </li> <li> <p>12 unstable angina pectoris;</p> </li> <li> <p>4 revascularisations;</p> </li> <li> <p>2 peripheral vascular surgeries; and</p> </li> <li> <p>1 sternal wound infection</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CLARICOR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0039"> <li> <p>866 deaths;</p> </li> <li> <p>468 reinfarctions;</p> </li> <li> <p>364 cerebrovascular disease;</p> </li> <li> <p>397 unstable angina pectoris; and</p> </li> <li> <p>143 peripheral vascular disease</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0040"> <li> <p>815 deaths;</p> </li> <li> <p>488 reinfarctions;</p> </li> <li> <p>321 cerebrovascular disease;</p> </li> <li> <p>399 unstable angina pectoris; and</p> </li> <li> <p>148 peripheral vascular disease</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CLARIFY</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0041"> <li> <p>4 deaths;</p> </li> <li> <p>5 reinfarctions;</p> </li> <li> <p>2 strokes; and</p> </li> <li> <p>5 unstable angina pectoris</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0042"> <li> <p>1 death;</p> </li> <li> <p>14 reinfarctions;</p> </li> <li> <p>2 strokes; and</p> </li> <li> <p>11 unstable angina pectoris</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gupta 1997</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1997</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0043"> <li> <p>1 death; and</p> </li> <li> <p>2 unstable angina pectoris or myocardial infarctions</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0044"> <li> <p>1 death; and</p> </li> <li> <p>4 unstable angina pectoris or myocardial infarction</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hillis 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0045"> <li> <p>1 heart failure; and</p> </li> <li> <p>1 perforated diverticulum</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0046"> <li> <p>None</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ikeoka 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0047"> <li> <p>2 deaths;</p> </li> <li> <p>1 chronic obstructive pulmonary disease;</p> </li> <li> <p>1 sepsis; and</p> </li> <li> <p>1 limb revascularization surgery</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0048"> <li> <p>None</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ISAR‐3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0049"> <li> <p>16 deaths; and</p> </li> <li> <p>20 reinfarctions</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0050"> <li> <p>13 deaths; and</p> </li> <li> <p>17 reinfarctions</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Jackson1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0051"> <li> <p>1 surgery</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0052"> <li> <p>1 infection</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kaehler 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0053"> <li> <p>1 death;</p> </li> <li> <p>4 reinfarctions;</p> </li> <li> <p>3 strokes; and</p> </li> <li> <p>25 revascularisations</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0054"> <li> <p>1 death;</p> </li> <li> <p>2 reinfarctions; and</p> </li> <li> <p>32 revascularisations</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kim 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0055"> <li> <p>2 deaths;</p> </li> <li> <p>2 reinfarctions; and</p> </li> <li> <p>13 revascularisations</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0056"> <li> <p>2 deaths;</p> </li> <li> <p>1 reinfarction; and</p> </li> <li> <p>10 revascularisations</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Leowattana 2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0057"> <li> <p>1 death;</p> </li> <li> <p>4 recurrent angina pectoris/myocardial infarction;</p> </li> <li> <p>5 coronary artery bypass grafting; and</p> </li> <li> <p>7 percutaneous transluminal coronary angioplasty</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0058"> <li> <p>1 death;</p> </li> <li> <p>6 recurrent angina pectoris/myocardial infarction;</p> </li> <li> <p>4 coronary artery bypass grafting; and</p> </li> <li> <p>5 percutaneous transluminal coronary angioplasty</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MIDAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0059"> <li> <p>1 death; and</p> </li> <li> <p>2 reinfarctions</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0060"> <li> <p>None</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PROVE‐IT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0061"> <li> <p>64 deaths;</p> </li> <li> <p>137 reinfarctions;</p> </li> <li> <p>23 strokes;</p> </li> <li> <p>93 hospitalisations for unstable angina; and</p> </li> <li> <p>352 revascularisations</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0062"> <li> <p>50 deaths;</p> </li> <li> <p>154 reinfarctions;</p> </li> <li> <p>22 strokes;</p> </li> <li> <p>92 hospitalisations for unstable angina; and</p> </li> <li> <p>377 revascularisations</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Radoi 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0063"> <li> <p>7 deaths;</p> </li> <li> <p>9 reinfarctions; and</p> </li> <li> <p>21 hospitalisations for unstable angina</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0064"> <li> <p>5 deaths;</p> </li> <li> <p>8 reinfarctions; and</p> </li> <li> <p>34 hospitalisations for unstable angina</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ROXIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1997</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0065"> <li> <p>2 deaths; and</p> </li> <li> <p>6 severe recurrent ischaemia</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0066"> <li> <p>5 deaths;</p> </li> <li> <p>2 reinfarctions; and</p> </li> <li> <p>7 severe recurrent ischaemia</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sinisalo 1998</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1998</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0067"> <li> <p>1 erysipelas</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0068"> <li> <p>1 upper respiratory infection requiring antibiotic treatment</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TIPTOP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0069"> <li> <p>1 death;</p> </li> <li> <p>1 stroke; and</p> </li> <li> <p>4 worsening of NYHA class III‐IV and/or hospital admission for congestive heart failure</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0070"> <li> <p>4 deaths;</p> </li> <li> <p>1 reinfarction;</p> </li> <li> <p>2 strokes; and</p> </li> <li> <p>7 worsening of NYHA class III‐IV and/or hospital admission for congestive heart failure</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WIZARD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0071"> <li> <p>175 deaths;</p> </li> <li> <p>145 reinfarctions;</p> </li> <li> <p>326 revascularisations; and</p> </li> <li> <p>105 hospitalisations for angina pectoris</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0072"> <li> <p>188 deaths;</p> </li> <li> <p>153 reinfarctions;</p> </li> <li> <p>336 revascularisations; and</p> </li> <li> <p>103 hospitalisations for angina pectoris</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ütük 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0073"> <li> <p>2 deaths;</p> </li> <li> <p>2 reinfarctions;</p> </li> <li> <p>2 unstable angina pectoris;</p> </li> <li> <p>7 percutaneous coronary interventions; and</p> </li> <li> <p>5 coronary artery bypass graftings</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0074"> <li> <p>5 deaths;</p> </li> <li> <p>5 reinfarctions;</p> </li> <li> <p>1 unstable angina pectoris;</p> </li> <li> <p>4 percutaneous coronary interventions; and</p> </li> <li> <p>4 coronary artery bypass graftings</p> </li> </ul> </p> </td> </tr> </tbody> </table> </div> </section> <section id="CD003610-sec-0076"> <h6 class="title">24±6 months follow‐up</h6> <p>None of the trials specifically assessed serious adverse event according to ICH‐GCP. Instead, the trials either reported composites of several specific serious adverse events or one specific serious adverse event. </p> <p>We narratively reported the individual types of serious adverse events in each trial at 24±6 months follow‐up in <a href="#CD003610-tbl-0008">Table 6</a>. </p> <div class="table" id="CD003610-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Serious adverse events ‐ 24±6 months follow‐up</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Year</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Type and number of serious adverse event (antibiotics group)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Type and number of serious adverse event (control group)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ACADEMIC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0075"> <li> <p>5 deaths;</p> </li> <li> <p>4 reinfarctions;</p> </li> <li> <p>1 stroke;</p> </li> <li> <p>8 hospitalisations for unstable angina pectoris;</p> </li> <li> <p>9 revascularisations; and</p> </li> <li> <p>1 resuscitated cardiac arrest</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0076"> <li> <p>4 deaths;</p> </li> <li> <p>6 reinfarctions;</p> </li> <li> <p>3 strokes;</p> </li> <li> <p>7 hospitalisations for unstable angina pectoris; and</p> </li> <li> <p>15 revascularisations</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ACES</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0077"> <li> <p>261 deaths due to coronary heart disease, nonfatal myocardial infarctions, percutaneous or surgical coronary revascularisation procedures, or hospitalisations for unstable angina pectoris </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0078"> <li> <p>281 deaths due to coronary heart disease, nonfatal myocardial infarctions, percutaneous or surgical coronary revascularisation procedures, or hospitalisations for unstable angina pectoris </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Berg 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0079"> <li> <p>10 deaths;</p> </li> <li> <p>1 reinfarction;</p> </li> <li> <p>9 strokes;</p> </li> <li> <p>10 unstable angina pectoris;</p> </li> <li> <p>9 revascularisations;</p> </li> <li> <p>2 peripheral vascular surgeries; and</p> </li> <li> <p>1 sternal wound infection</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0080"> <li> <p>9 deaths;</p> </li> <li> <p>3 reinfarctions;</p> </li> <li> <p>5 strokes;</p> </li> <li> <p>12 unstable angina pectoris;</p> </li> <li> <p>4 revascularisations;</p> </li> <li> <p>2 peripheral vascular surgeries; and</p> </li> <li> <p>1 sternal wound infection</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CLARICOR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0081"> <li> <p>212 deaths;</p> </li> <li> <p>160 reinfarctions;</p> </li> <li> <p>81 strokes; and</p> </li> <li> <p>34 peripheral vascular disease</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0082"> <li> <p>172 deaths;</p> </li> <li> <p>148 reinfarctions;</p> </li> <li> <p>68 strokes; and</p> </li> <li> <p>26 peripheral vascular disease</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CLARIFY</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0083"> <li> <p>4 deaths;</p> </li> <li> <p>5 reinfarctions;</p> </li> <li> <p>2 strokes; and</p> </li> <li> <p>5 unstable angina pectoris</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0084"> <li> <p>1 death;</p> </li> <li> <p>14 reinfarctions;</p> </li> <li> <p>2 strokes; and</p> </li> <li> <p>11 unstable angina pectoris</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gupta 1997</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1997</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0085"> <li> <p>1 death; and</p> </li> <li> <p>2 unstable angina pectoris or reinfarctions</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0086"> <li> <p>1 death; and</p> </li> <li> <p>4 unstable angina pectoris or reinfarctions</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PROVE‐IT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0087"> <li> <p>64 deaths;</p> </li> <li> <p>137 reinfarctions;</p> </li> <li> <p>23 strokes;</p> </li> <li> <p>93 hospitalisations for unstable angina pectoris; and</p> </li> <li> <p>352 revascularisations</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0088"> <li> <p>50 deaths;</p> </li> <li> <p>154 reinfarctions;</p> </li> <li> <p>22 strokes;</p> </li> <li> <p>92 hospitalisations for unstable angina pectoris; and</p> </li> <li> <p>377 revascularisations</p> </li> </ul> </p> </td> </tr> </tbody> </table> </div> </section> </section> <section id="CD003610-sec-0077"> <h5 class="title">Quality of life</h5> <p>None of the included trials reported any data on quality of life either at maximum follow‐up or at 24±6 months follow‐up. </p> </section> </section> <section id="CD003610-sec-0078"> <h4 class="title">Secondary outcomes</h4> <section id="CD003610-sec-0079"> <h5 class="title">Cardiovascular mortality</h5> <section id="CD003610-sec-0080"> <h6 class="title">Maximum follow‐up</h6> <p>At maximum follow‐up, 14/38 trials with a total of 14,180 participants and a mean follow‐up of 25.3 months (range 3.0 to 120.0 months) reported cardiovascular mortality. The specific assessment time points in each trial are presented in <a href="#CD003610-tbl-0005">Table 3</a>. A total of 547/7096 (7.71%) antibiotic participants died from a cardiac cause versus 511/7084 (7.21%) control participants. Random‐effects meta‐analysis showed that antibiotics versus placebo or no intervention resulted in little to no difference between the treatment groups on the risk of cardiovascular mortality (RR 1.08; 95% CI 0.96 to 1.20; P = 0.20; I<sup>2</sup> = 0%; 14,180 participants; 14 trials; high certainty of evidence; <a href="./references#CD003610-fig-0023" title="">Analysis 1.17</a>). </p> <section id="CD003610-sec-0081"> <p><b>Heterogeneity</b></p> <p>Neither visual inspection of the forest plot nor tests for statistical heterogeneity (I<sup>2</sup> = 0%; P = 0.55) indicated any heterogeneity. </p> </section> <section id="CD003610-sec-0082"> <p><b>Risk of bias and sensitivity analyses</b></p> <p>Two trials were assessed at low risk of bias (<a href="./references#CD003610-bbs2-0001" title="AndersonJL , MuhlesteinJB , CarlquistJ , AllenA , TrehanS , NielsonC , et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection. The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) Study. Circulation1999;99:1540-7. MuhlesteinJB , AndersonJL , CarlquistJF , SalunkheK , HorneBD , PearsonRP , et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease. Primary clinical results of the ACADEMIC study. Circulation2000;102:1755-60. ">ACADEMIC 1999</a>; <a href="./references#CD003610-bbs2-0007" title="GluudC , Als-NielsenB , DamgaardB , HansenJF , HansenS , HeløOH , et al. Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease. Cardiology2008;111:280-7. HansenS , Als-NielsenB , DamgaardM , HeløOH , PetersenL , JespersenCM . Intervention with clarithromycin in patients with stable coronary heart disease. The CLARICOR trial design. Heart Drug2001;1:14-9. HildenJ , LindI , KolmosHJ , Als-NielsenB , DamgaardN , HansenJF , et al. Chlamydia pneumoniae IgG and IgA antibody titers and prognosis in patients with coronary heart disease: results from the CLARICOR trial. Diagnostic Microbiology and Infectious diseases2010;66(4):385-92. JensenGB , HildenJ , Als-NielsenB , DamgaardN , HansenJF , HansenS , et al. Statin treatment prevents increased cardiovascular and all-cause mortality associated with clarithromycin in patients with stable coronary heart disease. Journal of Cardiovascular Pharmacology2010;55(2):123-8. JespersenCM , Als-NielsenB , DamgaardM , HansenJF , HansenS , HeløOH , et al. Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with coronary heart disease: CLARICOR trial. BMJ2006;332(7532):22-7. JespersenCM , KolmosHJ , FrydendallN , HildenJ , GluudC , HansenJF . Compliance with and short-term adverse events from clarithromycin versus placebo in patients with stable coronary heart disease: the CLARICOR trial. Journal of Antimicrobial Chemotherapy2009;64(2):411-5. NCT00121550. The CLARICOR trial: effect of clarithromycin on mortality and morbidity in patients with ischemic heart disease. https://clinicaltrials.gov/ct2/show/NCT00121550 (first received 21 July 2005). WinkelP , HildenJ , Fischer HansenJ , HildebrandtP , KastrupJ , KolmosHJ , et al. Excess sudden cardiac deaths after short-term clarithromycin administration in the CLARICOR trial: why is this so, and why are statins protective?Cardiology2011;118(1):63-67. WinkelP , HildenJ , HansenJF , KastrupJ , KolmosHJ , KjøllerE , et al. Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular mortality and cerebrovascular mortality over 10 years in the CLARICOR randomised, blinded clinical trial. International Journal of Cardiology2015;182:459-65. ">CLARICOR 2006</a>). All other trials were assessed at high risk of bias. However, the overall outcome result was dominated by <a href="./references#CD003610-bbs2-0007" title="GluudC , Als-NielsenB , DamgaardB , HansenJF , HansenS , HeløOH , et al. Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease. Cardiology2008;111:280-7. HansenS , Als-NielsenB , DamgaardM , HeløOH , PetersenL , JespersenCM . Intervention with clarithromycin in patients with stable coronary heart disease. The CLARICOR trial design. Heart Drug2001;1:14-9. HildenJ , LindI , KolmosHJ , Als-NielsenB , DamgaardN , HansenJF , et al. Chlamydia pneumoniae IgG and IgA antibody titers and prognosis in patients with coronary heart disease: results from the CLARICOR trial. Diagnostic Microbiology and Infectious diseases2010;66(4):385-92. JensenGB , HildenJ , Als-NielsenB , DamgaardN , HansenJF , HansenS , et al. Statin treatment prevents increased cardiovascular and all-cause mortality associated with clarithromycin in patients with stable coronary heart disease. Journal of Cardiovascular Pharmacology2010;55(2):123-8. JespersenCM , Als-NielsenB , DamgaardM , HansenJF , HansenS , HeløOH , et al. Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with coronary heart disease: CLARICOR trial. BMJ2006;332(7532):22-7. JespersenCM , KolmosHJ , FrydendallN , HildenJ , GluudC , HansenJF . Compliance with and short-term adverse events from clarithromycin versus placebo in patients with stable coronary heart disease: the CLARICOR trial. Journal of Antimicrobial Chemotherapy2009;64(2):411-5. NCT00121550. The CLARICOR trial: effect of clarithromycin on mortality and morbidity in patients with ischemic heart disease. https://clinicaltrials.gov/ct2/show/NCT00121550 (first received 21 July 2005). WinkelP , HildenJ , Fischer HansenJ , HildebrandtP , KastrupJ , KolmosHJ , et al. Excess sudden cardiac deaths after short-term clarithromycin administration in the CLARICOR trial: why is this so, and why are statins protective?Cardiology2011;118(1):63-67. WinkelP , HildenJ , HansenJF , KastrupJ , KolmosHJ , KjøllerE , et al. Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular mortality and cerebrovascular mortality over 10 years in the CLARICOR randomised, blinded clinical trial. International Journal of Cardiology2015;182:459-65. ">CLARICOR 2006</a> (80.4% of weight), which was at low risk of bias in all domains. The next two highest‐weighted trials (<a href="./references#CD003610-bbs2-0002" title="GraystonJT , KronmalRA , JacksonLA , ParisiAF , MuhlesteinJB , CohenJD , et al. Azithromycin for the secondary prevention of coronary events. New England Journal of Medicine2005;352:1637-45. JacksonLA . Description and status of the azithromycin and coronary events study (ACES). Journal of Infectious Diseases2000;181(Suppl 3):S579-81. NCT00000617. Azithromycin and Coronary Events Study (ACES). https://clinicaltrials.gov/ct2/show/NCT00000617 (first received 28 October 1999). ">ACES 2005</a>; <a href="./references#CD003610-bbs2-0025" title="CannonCP , BraunwaldE , McCabeCH , GraystonJT , MuhlesteinB , GiuglianoRP , et al. Antibiotic treatment of chlamydia pneumoniae after acute coronary syndrome. New England Journal of Medicine2005;352:1646-54. CannonCP , BraunwaldE , McCabeCH , RaderDJ , RouleauJL , BelderR , et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. New England Journal of Medicine2004;350(15):1495-504. CannonCP , McCabeCH , BelderR , BreenJ , BraunwaldE . Design of the pravastatin or atorvastatin evaluation and infection therapy (PROVE IT)-TIMI 22 trial. American Journal of Cardiology2002;89:860-1. ">PROVE‐IT 2005</a>) were both at low risk of bias in the majority of domains. We therefore decided to assess the risk of bias of the outcome result at low risk of bias. </p> <p>The sensitivity analysis of trials at low risk of bias showed that antibiotics versus placebo or no intervention seemed to probably increase the risk of cardiovascular mortality (RR 1.11; 95% CI 0.98 to 1.25; P = 0.11; I<sup>2</sup>= 0%; 4674 participants; 2 trials; moderate certainty of evidence; <a href="./references#CD003610-fig-0024" title="">Analysis 1.18</a>). The corresponding ARI was 1.78% and the NNTH was 57. </p> <p>The sensitivity analyses on incomplete outcome data showed that incomplete outcome data bias alone had the potential to influence the results (best‐worst fixed‐effect meta‐analysis: RR 0.94; 95% CI 0.84 to 1.04; P = 0.22; 14,192 participants; 14 trials; <a href="./references#CD003610-fig-0025" title="">Analysis 1.19</a>); (worst‐best fixed‐effect meta‐analysis: RR 1.22; 95% CI 1.09 to 1.36; P = 0.0004; 14,192 participants; 14 trials; <a href="./references#CD003610-fig-0026" title="">Analysis 1.20</a>); (modified best‐worst fixed‐effect meta‐analysis: RR 1.00; 95% CI 0.89 to 1.11; P = 0.97; 14,192 participants; 14 trials; <a href="./references#CD003610-fig-0027" title="">Analysis 1.21</a>); (modified worst‐best fixed‐effects meta‐analysis: RR 1.15; 95% CI 1.03 to 1.28; P = 0.01; 14,192 participants; 14 trials; <a href="./references#CD003610-fig-0028" title="">Analysis 1.22</a>). Data were imputed for 5 trials. </p> <p>The sensitivity analysis on trials with optimal medical therapy showed that antibiotics versus placebo or no intervention resulted in no evidence of a difference on the risk of cardiovascular mortality (RR 1.07; 95% CI 0.96 to 1.20; P = 0.21; I<sup>2</sup>= 20%; 13,407 participants; 10 trials; high certainty of evidence; <a href="./references#CD003610-fig-0029" title="">Analysis 1.23</a>). </p> <p>Visual inspection of the funnel plot showed no signs of asymmetry (<a href="#CD003610-fig-0005">Figure 5</a>). Based on the visual inspection of the funnel plot, we assessed the risk of publication bias as low. </p> <div class="figure" id="CD003610-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, outcome: 1.17 CARDIOVASCULAR MORTALITY." data-id="CD003610-fig-0005" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-FIG-05.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, outcome: 1.17 CARDIOVASCULAR MORTALITY. </p> </div> </div> </div> </section> <section id="CD003610-sec-0083"> <p><b>Subgroup analyses</b></p> <p>We found no evidence of a difference in subgroups analyses according to antibiotic type (<a href="./references#CD003610-fig-0030" title="">Analysis 1.24</a>); antibody status (<a href="./references#CD003610-fig-0031" title="">Analysis 1.25</a>); use of statins (<a href="./references#CD003610-fig-0032" title="">Analysis 1.26</a>); age above or under 60 years (<a href="./references#CD003610-fig-0033" title="">Analysis 1.27</a>); clinical trial registration status (<a href="./references#CD003610-fig-0034" title="">Analysis 1.28</a>); length of follow‐up above or under 12 months follow‐up (<a href="./references#CD003610-fig-0035" title="">Analysis 1.29</a>); antibiotic class (<a href="./references#CD003610-fig-0036" title="">Analysis 1.30</a>); funding (<a href="./references#CD003610-fig-0037" title="">Analysis 1.31</a>); and control intervention (<a href="./references#CD003610-fig-0038" title="">Analysis 1.32</a>). </p> </section> </section> <section id="CD003610-sec-0084"> <h6 class="title">24±6 months follow‐up</h6> <p>At 24±6 months follow‐up, 5/38 trials with a total of 9044 participants and a mean follow‐up of 23.1 months (range 18.0 to 30.0 months) reported cardiovascular mortality. The specific assessment time points in each trial are presented in <a href="#CD003610-tbl-0006">Table 4</a>. A total of 152/4512 (3.37%) antibiotic participants died from a cardiac cause versus 102/4532 (2.25%) control participants. Fixed‐effect meta‐analysis showed that antibiotics versus placebo or no intervention increased the risk of cardiovascular mortality (RR 1.50; 95% CI 1.17 to 1.91; P = 0.001; I<sup>2</sup> = 0%; 9044 participants; 5 trials; high certainty of evidence; <a href="./references#CD003610-fig-0104" title="">Analysis 2.16</a>). The corresponding ARI was 1.12% and the NNTH was 89 (95% CI 261 to 49). </p> <section id="CD003610-sec-0085"> <p><b>Heterogeneity</b></p> <p>Neither visual inspection of the forest plot nor tests for statistical heterogeneity (I<sup>2</sup> = 0%; P = 0.68) indicated any heterogeneity. </p> </section> <section id="CD003610-sec-0086"> <p><b>Risk of bias and sensitivity analyses</b></p> <p>Two trials were assessed at low risk of bias (<a href="./references#CD003610-bbs2-0001" title="AndersonJL , MuhlesteinJB , CarlquistJ , AllenA , TrehanS , NielsonC , et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection. The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) Study. Circulation1999;99:1540-7. MuhlesteinJB , AndersonJL , CarlquistJF , SalunkheK , HorneBD , PearsonRP , et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease. Primary clinical results of the ACADEMIC study. Circulation2000;102:1755-60. ">ACADEMIC 1999</a>; <a href="./references#CD003610-bbs2-0007" title="GluudC , Als-NielsenB , DamgaardB , HansenJF , HansenS , HeløOH , et al. Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease. Cardiology2008;111:280-7. HansenS , Als-NielsenB , DamgaardM , HeløOH , PetersenL , JespersenCM . Intervention with clarithromycin in patients with stable coronary heart disease. The CLARICOR trial design. Heart Drug2001;1:14-9. HildenJ , LindI , KolmosHJ , Als-NielsenB , DamgaardN , HansenJF , et al. Chlamydia pneumoniae IgG and IgA antibody titers and prognosis in patients with coronary heart disease: results from the CLARICOR trial. Diagnostic Microbiology and Infectious diseases2010;66(4):385-92. JensenGB , HildenJ , Als-NielsenB , DamgaardN , HansenJF , HansenS , et al. Statin treatment prevents increased cardiovascular and all-cause mortality associated with clarithromycin in patients with stable coronary heart disease. Journal of Cardiovascular Pharmacology2010;55(2):123-8. JespersenCM , Als-NielsenB , DamgaardM , HansenJF , HansenS , HeløOH , et al. Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with coronary heart disease: CLARICOR trial. BMJ2006;332(7532):22-7. JespersenCM , KolmosHJ , FrydendallN , HildenJ , GluudC , HansenJF . Compliance with and short-term adverse events from clarithromycin versus placebo in patients with stable coronary heart disease: the CLARICOR trial. Journal of Antimicrobial Chemotherapy2009;64(2):411-5. NCT00121550. The CLARICOR trial: effect of clarithromycin on mortality and morbidity in patients with ischemic heart disease. https://clinicaltrials.gov/ct2/show/NCT00121550 (first received 21 July 2005). WinkelP , HildenJ , Fischer HansenJ , HildebrandtP , KastrupJ , KolmosHJ , et al. Excess sudden cardiac deaths after short-term clarithromycin administration in the CLARICOR trial: why is this so, and why are statins protective?Cardiology2011;118(1):63-67. WinkelP , HildenJ , HansenJF , KastrupJ , KolmosHJ , KjøllerE , et al. Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular mortality and cerebrovascular mortality over 10 years in the CLARICOR randomised, blinded clinical trial. International Journal of Cardiology2015;182:459-65. ">CLARICOR 2006</a>). All other trials were assessed at high risk of bias. However, the overall outcome result was dominated by <a href="./references#CD003610-bbs2-0007" title="GluudC , Als-NielsenB , DamgaardB , HansenJF , HansenS , HeløOH , et al. Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease. Cardiology2008;111:280-7. HansenS , Als-NielsenB , DamgaardM , HeløOH , PetersenL , JespersenCM . Intervention with clarithromycin in patients with stable coronary heart disease. The CLARICOR trial design. Heart Drug2001;1:14-9. HildenJ , LindI , KolmosHJ , Als-NielsenB , DamgaardN , HansenJF , et al. Chlamydia pneumoniae IgG and IgA antibody titers and prognosis in patients with coronary heart disease: results from the CLARICOR trial. Diagnostic Microbiology and Infectious diseases2010;66(4):385-92. JensenGB , HildenJ , Als-NielsenB , DamgaardN , HansenJF , HansenS , et al. Statin treatment prevents increased cardiovascular and all-cause mortality associated with clarithromycin in patients with stable coronary heart disease. Journal of Cardiovascular Pharmacology2010;55(2):123-8. JespersenCM , Als-NielsenB , DamgaardM , HansenJF , HansenS , HeløOH , et al. Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with coronary heart disease: CLARICOR trial. BMJ2006;332(7532):22-7. JespersenCM , KolmosHJ , FrydendallN , HildenJ , GluudC , HansenJF . Compliance with and short-term adverse events from clarithromycin versus placebo in patients with stable coronary heart disease: the CLARICOR trial. Journal of Antimicrobial Chemotherapy2009;64(2):411-5. NCT00121550. The CLARICOR trial: effect of clarithromycin on mortality and morbidity in patients with ischemic heart disease. https://clinicaltrials.gov/ct2/show/NCT00121550 (first received 21 July 2005). WinkelP , HildenJ , Fischer HansenJ , HildebrandtP , KastrupJ , KolmosHJ , et al. Excess sudden cardiac deaths after short-term clarithromycin administration in the CLARICOR trial: why is this so, and why are statins protective?Cardiology2011;118(1):63-67. WinkelP , HildenJ , HansenJF , KastrupJ , KolmosHJ , KjøllerE , et al. Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular mortality and cerebrovascular mortality over 10 years in the CLARICOR randomised, blinded clinical trial. International Journal of Cardiology2015;182:459-65. ">CLARICOR 2006</a> (75.8% of weight), which was at low risk of bias in all domains. The next two highest‐weighted trials (<a href="./references#CD003610-bbs2-0001" title="AndersonJL , MuhlesteinJB , CarlquistJ , AllenA , TrehanS , NielsonC , et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection. The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) Study. Circulation1999;99:1540-7. MuhlesteinJB , AndersonJL , CarlquistJF , SalunkheK , HorneBD , PearsonRP , et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease. Primary clinical results of the ACADEMIC study. Circulation2000;102:1755-60. ">ACADEMIC 1999</a>; <a href="./references#CD003610-bbs2-0025" title="CannonCP , BraunwaldE , McCabeCH , GraystonJT , MuhlesteinB , GiuglianoRP , et al. Antibiotic treatment of chlamydia pneumoniae after acute coronary syndrome. New England Journal of Medicine2005;352:1646-54. CannonCP , BraunwaldE , McCabeCH , RaderDJ , RouleauJL , BelderR , et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. New England Journal of Medicine2004;350(15):1495-504. CannonCP , McCabeCH , BelderR , BreenJ , BraunwaldE . Design of the pravastatin or atorvastatin evaluation and infection therapy (PROVE IT)-TIMI 22 trial. American Journal of Cardiology2002;89:860-1. ">PROVE‐IT 2005</a>) were either at low risk of bias in all domains or at low risk of bias in the majority of domains, respectively. We therefore decided to assess the risk of bias of the outcome result at low risk of bias. </p> <p>The sensitivity analysis of trials at low risk of bias showed that antibiotics versus placebo or no intervention probably increased the risk of cardiovascular mortality (RR 1.43; 95% CI 1.09 to 1.89; P = 0.01; I<sup>2</sup> = 0%; 4674 participants; 2 trials; moderate certainty of evidence; <a href="./references#CD003610-fig-0105" title="">Analysis 2.17</a>). The corresponding ARI was 1.51% and the NNTH was 66 (95% CI 319 to 32). </p> <p>The sensitivity analyses on incomplete outcome data showed that incomplete outcome data bias alone did not have the potential to influence the results (best‐worst fixed‐effect meta‐analysis: RR 1.39; 95% CI 1.09 to 1.77; P = 0.007; 9045 participants; 5 trials; <a href="./references#CD003610-fig-0106" title="">Analysis 2.18</a>); (worst‐best fixed‐effect meta‐analysis: RR 1.60; 95% CI 1.26 to 2.04; P = 0.0001; 9045 participants; 5 trials; <a href="./references#CD003610-fig-0107" title="">Analysis 2.19</a>); (modified best‐worst fixed‐effect meta‐analysis: RR 1.44; 95% CI 1.13 to 1.84; P = 0.003; 9045 participants; 5 trials; <a href="./references#CD003610-fig-0108" title="">Analysis 2.20</a>); (modified worst‐best fixed‐effect meta‐analysis: RR 1.56; 95% CI 1.22 to 1.98; P = 0.0004; 9045 participants; 5 trials; <a href="./references#CD003610-fig-0109" title="">Analysis 2.21</a>). Data were imputed for 2 trials. </p> <p>The sensitivity analysis on trials with optimal medical therapy showed that antibiotics versus placebo or no intervention probably increased the risk of cardiovascular mortality (RR 1.52; 95% CI 1.18 to 1.95; I<sup>2</sup> = 0%; 8682 participants; 3 trials; moderate certainty of evidence; <a href="./references#CD003610-fig-0110" title="">Analysis 2.22</a>). The corresponding ARI was 1.15% and the NNTH was 87 (95% CI 250 to 47). </p> </section> <section id="CD003610-sec-0087"> <p><b>Subgroup analyses</b></p> <p>We found no evidence of a difference in subgroups analyses according to antibiotic type (<a href="./references#CD003610-fig-0111" title="">Analysis 2.23</a>); antibody status (<a href="./references#CD003610-fig-0112" title="">Analysis 2.24</a>); use of statins (<a href="./references#CD003610-fig-0113" title="">Analysis 2.25</a>); age above or under 60 years (<a href="./references#CD003610-fig-0114" title="">Analysis 2.26</a>); clinical trial registration status (<a href="./references#CD003610-fig-0115" title="">Analysis 2.27</a>); antibiotic class (<a href="./references#CD003610-fig-0116" title="">Analysis 2.28</a>); and funding (<a href="./references#CD003610-fig-0117" title="">Analysis 2.29</a>). Subgroup analysis according to control intervention could not be conducted due to all trials being placebo‐controlled (<a href="./references#CD003610-fig-0118" title="">Analysis 2.30</a>). </p> </section> </section> </section> <section id="CD003610-sec-0088"> <h5 class="title">Myocardial infarction</h5> <section id="CD003610-sec-0089"> <h6 class="title">Maximum follow‐up</h6> <p>At maximum follow‐up, 17/38 trials with a total of 25,523 participants and a mean follow‐up of 20.7 months (range 3.0 to 120.0 months) reported myocardial infarction. The specific assessment time points in each trial are presented in <a href="#CD003610-tbl-0005">Table 3</a>. A total of 968/12,745 (7.60%) antibiotic participants had a myocardial infarction versus 1028/12,778 (8.05%) control participants. Random‐effects meta‐analysis showed that antibiotics versus placebo or no intervention resulted in little to no difference between the treatment groups on the risk of myocardial infarction (RR 0.95; 95% CI 0.88 to 1.03; P = 0.23; I<sup>2</sup> = 0%; 25,523 participants; 17 trials; high certainty of evidence; <a href="./references#CD003610-fig-0039" title="">Analysis 1.33</a>). </p> <section id="CD003610-sec-0090"> <p><b>Heterogeneity</b></p> <p>Neither visual inspection of the forest plot nor tests for statistical heterogeneity (I<sup>2</sup> = 0%; P = 0.72) indicated any heterogeneity. </p> </section> <section id="CD003610-sec-0091"> <p><b>Risk of bias and sensitivity analyses</b></p> <p>Three trials were assessed at low risk of bias (<a href="./references#CD003610-bbs2-0001" title="AndersonJL , MuhlesteinJB , CarlquistJ , AllenA , TrehanS , NielsonC , et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection. The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) Study. Circulation1999;99:1540-7. MuhlesteinJB , AndersonJL , CarlquistJF , SalunkheK , HorneBD , PearsonRP , et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease. Primary clinical results of the ACADEMIC study. Circulation2000;102:1755-60. ">ACADEMIC 1999</a>; <a href="./references#CD003610-bbs2-0005" title="CercekB , ShahPK , NocM , ZahgerD , ZeymerU , MatetzkyS , et al. Effect of short-term treatment with azithromycin on recurrent ischaemic events in patients with acute coronary syndrome in the Azithromycin in Acute Coronary Syndrome (AZACS) trial: a randomised controlled trial. Lancet2003;361:809-13. ">AZACS 2003</a>; <a href="./references#CD003610-bbs2-0007" title="GluudC , Als-NielsenB , DamgaardB , HansenJF , HansenS , HeløOH , et al. Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease. Cardiology2008;111:280-7. HansenS , Als-NielsenB , DamgaardM , HeløOH , PetersenL , JespersenCM . Intervention with clarithromycin in patients with stable coronary heart disease. The CLARICOR trial design. Heart Drug2001;1:14-9. HildenJ , LindI , KolmosHJ , Als-NielsenB , DamgaardN , HansenJF , et al. Chlamydia pneumoniae IgG and IgA antibody titers and prognosis in patients with coronary heart disease: results from the CLARICOR trial. Diagnostic Microbiology and Infectious diseases2010;66(4):385-92. JensenGB , HildenJ , Als-NielsenB , DamgaardN , HansenJF , HansenS , et al. Statin treatment prevents increased cardiovascular and all-cause mortality associated with clarithromycin in patients with stable coronary heart disease. Journal of Cardiovascular Pharmacology2010;55(2):123-8. JespersenCM , Als-NielsenB , DamgaardM , HansenJF , HansenS , HeløOH , et al. Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with coronary heart disease: CLARICOR trial. BMJ2006;332(7532):22-7. JespersenCM , KolmosHJ , FrydendallN , HildenJ , GluudC , HansenJF . Compliance with and short-term adverse events from clarithromycin versus placebo in patients with stable coronary heart disease: the CLARICOR trial. Journal of Antimicrobial Chemotherapy2009;64(2):411-5. NCT00121550. The CLARICOR trial: effect of clarithromycin on mortality and morbidity in patients with ischemic heart disease. https://clinicaltrials.gov/ct2/show/NCT00121550 (first received 21 July 2005). WinkelP , HildenJ , Fischer HansenJ , HildebrandtP , KastrupJ , KolmosHJ , et al. Excess sudden cardiac deaths after short-term clarithromycin administration in the CLARICOR trial: why is this so, and why are statins protective?Cardiology2011;118(1):63-67. WinkelP , HildenJ , HansenJF , KastrupJ , KolmosHJ , KjøllerE , et al. Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular mortality and cerebrovascular mortality over 10 years in the CLARICOR randomised, blinded clinical trial. International Journal of Cardiology2015;182:459-65. ">CLARICOR 2006</a>). All other trials were assessed at high risk of bias. However, the overall outcome result was dominated by <a href="./references#CD003610-bbs2-0007" title="GluudC , Als-NielsenB , DamgaardB , HansenJF , HansenS , HeløOH , et al. Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease. Cardiology2008;111:280-7. HansenS , Als-NielsenB , DamgaardM , HeløOH , PetersenL , JespersenCM . Intervention with clarithromycin in patients with stable coronary heart disease. The CLARICOR trial design. Heart Drug2001;1:14-9. HildenJ , LindI , KolmosHJ , Als-NielsenB , DamgaardN , HansenJF , et al. Chlamydia pneumoniae IgG and IgA antibody titers and prognosis in patients with coronary heart disease: results from the CLARICOR trial. Diagnostic Microbiology and Infectious diseases2010;66(4):385-92. JensenGB , HildenJ , Als-NielsenB , DamgaardN , HansenJF , HansenS , et al. Statin treatment prevents increased cardiovascular and all-cause mortality associated with clarithromycin in patients with stable coronary heart disease. Journal of Cardiovascular Pharmacology2010;55(2):123-8. JespersenCM , Als-NielsenB , DamgaardM , HansenJF , HansenS , HeløOH , et al. Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with coronary heart disease: CLARICOR trial. BMJ2006;332(7532):22-7. JespersenCM , KolmosHJ , FrydendallN , HildenJ , GluudC , HansenJF . Compliance with and short-term adverse events from clarithromycin versus placebo in patients with stable coronary heart disease: the CLARICOR trial. Journal of Antimicrobial Chemotherapy2009;64(2):411-5. NCT00121550. The CLARICOR trial: effect of clarithromycin on mortality and morbidity in patients with ischemic heart disease. https://clinicaltrials.gov/ct2/show/NCT00121550 (first received 21 July 2005). WinkelP , HildenJ , Fischer HansenJ , HildebrandtP , KastrupJ , KolmosHJ , et al. Excess sudden cardiac deaths after short-term clarithromycin administration in the CLARICOR trial: why is this so, and why are statins protective?Cardiology2011;118(1):63-67. WinkelP , HildenJ , HansenJF , KastrupJ , KolmosHJ , KjøllerE , et al. Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular mortality and cerebrovascular mortality over 10 years in the CLARICOR randomised, blinded clinical trial. International Journal of Cardiology2015;182:459-65. ">CLARICOR 2006</a> (52.9% of weight), which was at low risk of bias in all domains. The next three highest‐weighted trials (<a href="./references#CD003610-bbs2-0002" title="GraystonJT , KronmalRA , JacksonLA , ParisiAF , MuhlesteinJB , CohenJD , et al. Azithromycin for the secondary prevention of coronary events. New England Journal of Medicine2005;352:1637-45. JacksonLA . Description and status of the azithromycin and coronary events study (ACES). Journal of Infectious Diseases2000;181(Suppl 3):S579-81. NCT00000617. Azithromycin and Coronary Events Study (ACES). https://clinicaltrials.gov/ct2/show/NCT00000617 (first received 28 October 1999). ">ACES 2005</a>; <a href="./references#CD003610-bbs2-0025" title="CannonCP , BraunwaldE , McCabeCH , GraystonJT , MuhlesteinB , GiuglianoRP , et al. Antibiotic treatment of chlamydia pneumoniae after acute coronary syndrome. New England Journal of Medicine2005;352:1646-54. CannonCP , BraunwaldE , McCabeCH , RaderDJ , RouleauJL , BelderR , et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. New England Journal of Medicine2004;350(15):1495-504. CannonCP , McCabeCH , BelderR , BreenJ , BraunwaldE . Design of the pravastatin or atorvastatin evaluation and infection therapy (PROVE IT)-TIMI 22 trial. American Journal of Cardiology2002;89:860-1. ">PROVE‐IT 2005</a>; <a href="./references#CD003610-bbs2-0038" title="DunneMW . Rationale and design of a secondary prevention trial of antibiotic use in patients after myocardial infarction: the WIZARD (Weekly Intervention With Zithromax (azithromycin) for Atherosclerosis and its Related Disorders) trial. Journal of Infectious Diseases2000;181(Suppl 3):S572-8. O'ConnerCM , DunneMW , PfefferMA , MuhlesteinJB , YaoL , GuptaS , et al. Azithromycin for the secondary prevention of coronary heart disease events. The WIZARD study: a randomized controlled trial. JAMA2003;290(11):1459-66. ">WIZARD 2003</a>) were all at low risk of bias in the majority of domains. We therefore decided to assess the risk of bias of the outcome result at low risk of bias. </p> <p>The sensitivity analysis of trials at low risk of bias showed that antibiotics versus placebo or no intervention probably resulted in no evidence of a difference on the risk of myocardial infarction (RR 0.96; 95% CI 0.86 to 1.07; P = 0.46; I<sup>2</sup> = 0%; 6113 participants; 3 trials; moderate certainty of evidence; <a href="./references#CD003610-fig-0040" title="">Analysis 1.34</a>). </p> <p>The sensitivity analyses on incomplete outcome data showed that incomplete outcome data bias alone had the potential to influence the results (best‐worst random‐effects meta‐analysis: RR 0.82; 95% CI 0.72 to 0.94; 25,564 participants; P = 0.004; 17 trials; <a href="./references#CD003610-fig-0041" title="">Analysis 1.35</a>); (worst‐best random‐effects meta‐analysis: RR 1.05; 95% CI 0.90 to 1.24; P = 0.53; 25,564 participants; 17 trials; <a href="./references#CD003610-fig-0042" title="">Analysis 1.36</a>); (modified best‐worst random‐effects meta‐analysis: RR 0.91; 95% CI 0.84 to 0.99; P = 0.02; 25,564 participants; 17 trials; <a href="./references#CD003610-fig-0043" title="">Analysis 1.37</a>); (modified worst‐best random‐effects meta‐analysis: RR 1.00; 95% CI 0.90 to 1.10; P = 0.98; 25,564 participants; 17 trials; <a href="./references#CD003610-fig-0044" title="">Analysis 1.38</a>). Data were imputed for 8 trials. </p> <p>The sensitivity analysis on trials with optimal medical therapy showed that antibiotics versus placebo or no intervention resulted in no evidence of a difference on the risk of myocardial infarction (RR 0.95; 95% CI 0.88 to 1.03; P = 0.24; I<sup>2</sup>= 0%; 23,327 participants; 12 trials; high certainty of evidence; <a href="./references#CD003610-fig-0045" title="">Analysis 1.39</a>). </p> <p>Visual inspection of the funnel plot showed no signs of asymmetry (<a href="#CD003610-fig-0006">Figure 6</a>). Based on the visual inspection of the funnel plot, we assessed the risk of publication bias as low. </p> <div class="figure" id="CD003610-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, outcome: 1.33 MYOCARDIAL INFARCTION." data-id="CD003610-fig-0006" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-FIG-06.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, outcome: 1.33 MYOCARDIAL INFARCTION. </p> </div> </div> </div> </section> <section id="CD003610-sec-0092"> <p><b>Subgroup analyses</b></p> <p>We found no evidence of a difference in subgroups analyses according to antibiotic type (<a href="./references#CD003610-fig-0046" title="">Analysis 1.40</a>); antibody status (<a href="./references#CD003610-fig-0047" title="">Analysis 1.41</a>); use of statins (<a href="./references#CD003610-fig-0048" title="">Analysis 1.42</a>); age above or under 60 years (<a href="./references#CD003610-fig-0049" title="">Analysis 1.43</a>); clinical trial registration status (<a href="./references#CD003610-fig-0050" title="">Analysis 1.44</a>); length of follow‐up above or under 12 months follow‐up (<a href="./references#CD003610-fig-0051" title="">Analysis 1.45</a>); antibiotic class (<a href="./references#CD003610-fig-0052" title="">Analysis 1.46</a>); funding (<a href="./references#CD003610-fig-0053" title="">Analysis 1.47</a>); and control intervention (<a href="./references#CD003610-fig-0054" title="">Analysis 1.48</a>). </p> </section> </section> <section id="CD003610-sec-0093"> <h6 class="title">24±6 months follow‐up</h6> <p>At 24±6 months follow‐up, 5/38 trials with a total of 9457 participants and a mean follow‐up of 24.3 months (range 18.5 to 30.0 months) reported myocardial infarction. The specific assessment time points in each trial are presented in <a href="#CD003610-tbl-0006">Table 4</a>. A total of 307/4710 (6.52%) antibiotic participants had a myocardial infarction versus 325/4747 (6.85%) control participants. Fixed‐effect meta‐analysis showed that antibiotics versus placebo or no intervention probably resulted in no evidence of a difference on the risk of myocardial infarction (RR 0.95; 95% CI 0.82 to 1.11; P = 0.53; I<sup>2</sup> = 43%; 9457 participants; 5 trials; moderate certainty of evidence; <a href="./references#CD003610-fig-0119" title="">Analysis 2.31</a>). </p> <section id="CD003610-sec-0094"> <p><b>Heterogeneity</b></p> <p>Both visual inspection of the forest plot and tests for statistical heterogeneity (I<sup>2</sup> = 43%; P = 0.14) indicated moderate heterogeneity. </p> </section> <section id="CD003610-sec-0095"> <p><b>Risk of bias and sensitivity analyses</b></p> <p>Two trials were assessed at low risk of bias (<a href="./references#CD003610-bbs2-0001" title="AndersonJL , MuhlesteinJB , CarlquistJ , AllenA , TrehanS , NielsonC , et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection. The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) Study. Circulation1999;99:1540-7. MuhlesteinJB , AndersonJL , CarlquistJF , SalunkheK , HorneBD , PearsonRP , et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease. Primary clinical results of the ACADEMIC study. Circulation2000;102:1755-60. ">ACADEMIC 1999</a>; <a href="./references#CD003610-bbs2-0007" title="GluudC , Als-NielsenB , DamgaardB , HansenJF , HansenS , HeløOH , et al. Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease. Cardiology2008;111:280-7. HansenS , Als-NielsenB , DamgaardM , HeløOH , PetersenL , JespersenCM . Intervention with clarithromycin in patients with stable coronary heart disease. The CLARICOR trial design. Heart Drug2001;1:14-9. HildenJ , LindI , KolmosHJ , Als-NielsenB , DamgaardN , HansenJF , et al. Chlamydia pneumoniae IgG and IgA antibody titers and prognosis in patients with coronary heart disease: results from the CLARICOR trial. Diagnostic Microbiology and Infectious diseases2010;66(4):385-92. JensenGB , HildenJ , Als-NielsenB , DamgaardN , HansenJF , HansenS , et al. Statin treatment prevents increased cardiovascular and all-cause mortality associated with clarithromycin in patients with stable coronary heart disease. Journal of Cardiovascular Pharmacology2010;55(2):123-8. JespersenCM , Als-NielsenB , DamgaardM , HansenJF , HansenS , HeløOH , et al. Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with coronary heart disease: CLARICOR trial. BMJ2006;332(7532):22-7. JespersenCM , KolmosHJ , FrydendallN , HildenJ , GluudC , HansenJF . Compliance with and short-term adverse events from clarithromycin versus placebo in patients with stable coronary heart disease: the CLARICOR trial. Journal of Antimicrobial Chemotherapy2009;64(2):411-5. NCT00121550. The CLARICOR trial: effect of clarithromycin on mortality and morbidity in patients with ischemic heart disease. https://clinicaltrials.gov/ct2/show/NCT00121550 (first received 21 July 2005). WinkelP , HildenJ , Fischer HansenJ , HildebrandtP , KastrupJ , KolmosHJ , et al. Excess sudden cardiac deaths after short-term clarithromycin administration in the CLARICOR trial: why is this so, and why are statins protective?Cardiology2011;118(1):63-67. WinkelP , HildenJ , HansenJF , KastrupJ , KolmosHJ , KjøllerE , et al. Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular mortality and cerebrovascular mortality over 10 years in the CLARICOR randomised, blinded clinical trial. International Journal of Cardiology2015;182:459-65. ">CLARICOR 2006</a>). All other trials were assessed at high risk of bias. However, the overall outcome result was dominated by <a href="./references#CD003610-bbs2-0007" title="GluudC , Als-NielsenB , DamgaardB , HansenJF , HansenS , HeløOH , et al. Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease. Cardiology2008;111:280-7. HansenS , Als-NielsenB , DamgaardM , HeløOH , PetersenL , JespersenCM . Intervention with clarithromycin in patients with stable coronary heart disease. The CLARICOR trial design. Heart Drug2001;1:14-9. HildenJ , LindI , KolmosHJ , Als-NielsenB , DamgaardN , HansenJF , et al. Chlamydia pneumoniae IgG and IgA antibody titers and prognosis in patients with coronary heart disease: results from the CLARICOR trial. Diagnostic Microbiology and Infectious diseases2010;66(4):385-92. JensenGB , HildenJ , Als-NielsenB , DamgaardN , HansenJF , HansenS , et al. Statin treatment prevents increased cardiovascular and all-cause mortality associated with clarithromycin in patients with stable coronary heart disease. Journal of Cardiovascular Pharmacology2010;55(2):123-8. JespersenCM , Als-NielsenB , DamgaardM , HansenJF , HansenS , HeløOH , et al. Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with coronary heart disease: CLARICOR trial. BMJ2006;332(7532):22-7. JespersenCM , KolmosHJ , FrydendallN , HildenJ , GluudC , HansenJF . Compliance with and short-term adverse events from clarithromycin versus placebo in patients with stable coronary heart disease: the CLARICOR trial. Journal of Antimicrobial Chemotherapy2009;64(2):411-5. NCT00121550. The CLARICOR trial: effect of clarithromycin on mortality and morbidity in patients with ischemic heart disease. https://clinicaltrials.gov/ct2/show/NCT00121550 (first received 21 July 2005). WinkelP , HildenJ , Fischer HansenJ , HildebrandtP , KastrupJ , KolmosHJ , et al. Excess sudden cardiac deaths after short-term clarithromycin administration in the CLARICOR trial: why is this so, and why are statins protective?Cardiology2011;118(1):63-67. WinkelP , HildenJ , HansenJF , KastrupJ , KolmosHJ , KjøllerE , et al. Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular mortality and cerebrovascular mortality over 10 years in the CLARICOR randomised, blinded clinical trial. International Journal of Cardiology2015;182:459-65. ">CLARICOR 2006</a> (45.4% of weight) and <a href="./references#CD003610-bbs2-0025" title="CannonCP , BraunwaldE , McCabeCH , GraystonJT , MuhlesteinB , GiuglianoRP , et al. Antibiotic treatment of chlamydia pneumoniae after acute coronary syndrome. New England Journal of Medicine2005;352:1646-54. CannonCP , BraunwaldE , McCabeCH , RaderDJ , RouleauJL , BelderR , et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. New England Journal of Medicine2004;350(15):1495-504. CannonCP , McCabeCH , BelderR , BreenJ , BraunwaldE . Design of the pravastatin or atorvastatin evaluation and infection therapy (PROVE IT)-TIMI 22 trial. American Journal of Cardiology2002;89:860-1. ">PROVE‐IT 2005</a> (47.5% of weight), which were at low risk of bias in all domains and in the majority of domains, respectively. We therefore decided to assess the risk of bias of the outcome result at low risk of bias. </p> <p>The sensitivity analysis of trials at low risk of bias showed that antibiotics versus placebo or no intervention probably resulted in no evidence of a difference on the risk of myocardial infarction (RR 1.08; 95% CI 0.87 to 1.33; P = 0.48; I<sup>2</sup> = 0%; 4674 participants; 2 trials; moderate certainty of evidence; <a href="./references#CD003610-fig-0120" title="">Analysis 2.32</a>). </p> <p>The sensitivity analyses on incomplete outcome data showed that incomplete outcome data bias alone did not have the potential to influence the results (best‐worst fixed‐effect meta‐analysis: RR 0.93; 95% CI 0.80 to 1.08; P = 0.34; 9458 participants; 5 trials; <a href="./references#CD003610-fig-0121" title="">Analysis 2.33</a>); (worst‐best fixed‐effect meta‐analysis: RR 0.99; 95% CI 0.85 to 1.15; P = 0.86; 9458 participants; 5 trials; <a href="./references#CD003610-fig-0122" title="">Analysis 2.34</a>); (modified best‐worst fixed‐effect meta‐analysis: RR 0.94; 95% CI 0.81 to 1.09; P = 0.42; 9458 participants; 5 trials; <a href="./references#CD003610-fig-0123" title="">Analysis 2.35</a>); (modified worst‐best fixed‐effect meta‐analysis: RR 0.97; 95% CI 0.84 to 1.13; P = 0.71; 9458 participants; 5 trials; <a href="./references#CD003610-fig-0124" title="">Analysis 2.36</a>). Data were imputed for 2 trials. </p> <p>The sensitivity analysis on trials with optimal medical therapy suggested that antibiotics versus placebo or no intervention resulted in no evidence of a difference on the risk of myocardial infarction (RR 0.96; 95% CI 0.83 to 1.12; P = 0.64; I<sup>2</sup> = 66%; 8682 participants; 3 trials; low certainty of evidence; <a href="./references#CD003610-fig-0125" title="">Analysis 2.37</a>). </p> </section> <section id="CD003610-sec-0096"> <p><b>Subgroup analyses</b></p> <p>We found evidence of a difference in subgroup analysis according to clinical trial registration status (I<sup>2</sup>= 77.8%; P = 0.03; <a href="./references#CD003610-fig-0130" title="">Analysis 2.42</a>). The unregistered trials suggested that antibiotics versus placebo or no intervention reduced the risk of myocardial infarction (RR 0.44; 95% CI 0.21 to 0.91; P = 0.03; I<sup>2</sup> = 0%; 923 participants; 3 trials; low certainty of evidence; <a href="./references#CD003610-fig-0130" title="">Analysis 2.42</a>), while the registered trials showed that antibiotics versus placebo or no intervention probably resulted in no evidence of a difference on the risk of myocardial infarction (RR 0.99; 95% CI 0.81 to 1.21; P = 0.93; I<sup>2</sup>= 39%; 8534 participants; 2 trials; moderate certainty of evidence; <a href="./references#CD003610-fig-0130" title="">Analysis 2.42</a>). </p> <p>All remaining tests for subgroup differences showed no evidence of a difference in subgroups analyses according to antibiotic type (<a href="./references#CD003610-fig-0126" title="">Analysis 2.38</a>); antibody status (<a href="./references#CD003610-fig-0127" title="">Analysis 2.39</a>); use of statins (<a href="./references#CD003610-fig-0128" title="">Analysis 2.40</a>); age above or under 60 years (<a href="./references#CD003610-fig-0129" title="">Analysis 2.41</a>); antibiotic class (<a href="./references#CD003610-fig-0131" title="">Analysis 2.43</a>); and funding (<a href="./references#CD003610-fig-0132" title="">Analysis 2.44</a>). Subgroup analysis according to control intervention could not be conducted due to all trials being placebo‐controlled (<a href="./references#CD003610-fig-0133" title="">Analysis 2.45</a>). </p> </section> </section> </section> <section id="CD003610-sec-0097"> <h5 class="title">Stroke</h5> <section id="CD003610-sec-0098"> <h6 class="title">Maximum follow‐up</h6> <p>At maximum follow‐up, 9/38 trials with a total of 14,774 participants and a mean follow‐up of 31.9 months (range 6.0 to 120.0 months) reported stroke. The specific assessment time points in each trial are presented in <a href="#CD003610-tbl-0005">Table 3</a>. A total of 455/7365 (6.18%) antibiotic participants had a stroke versus 404/7409 (5.45%) control participants. Fixed‐effect meta‐analysis showed that antibiotics versus placebo or no intervention seemed to increase the risk of stroke (RR 1.14; 95% CI 1.00 to 1.29; P = 0.04; I<sup>2</sup> = 0%; 14,774 participants; 9 trials; high certainty of evidence; <a href="./references#CD003610-fig-0055" title="">Analysis 1.49</a>). The corresponding ARI was 0.73% and the NNTH was 138. </p> <section id="CD003610-sec-0099"> <p><b>Heterogeneity</b></p> <p>Neither visual inspection of the forest plot nor tests for statistical heterogeneity (I<sup>2</sup> = 0%; P = 0.83) indicated any heterogeneity. </p> </section> <section id="CD003610-sec-0100"> <p><b>Risk of bias and sensitivity analyses</b></p> <p>Two trials were assessed at low risk of bias (<a href="./references#CD003610-bbs2-0001" title="AndersonJL , MuhlesteinJB , CarlquistJ , AllenA , TrehanS , NielsonC , et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection. The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) Study. Circulation1999;99:1540-7. MuhlesteinJB , AndersonJL , CarlquistJF , SalunkheK , HorneBD , PearsonRP , et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease. Primary clinical results of the ACADEMIC study. Circulation2000;102:1755-60. ">ACADEMIC 1999</a>; <a href="./references#CD003610-bbs2-0007" title="GluudC , Als-NielsenB , DamgaardB , HansenJF , HansenS , HeløOH , et al. Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease. Cardiology2008;111:280-7. HansenS , Als-NielsenB , DamgaardM , HeløOH , PetersenL , JespersenCM . Intervention with clarithromycin in patients with stable coronary heart disease. The CLARICOR trial design. Heart Drug2001;1:14-9. HildenJ , LindI , KolmosHJ , Als-NielsenB , DamgaardN , HansenJF , et al. Chlamydia pneumoniae IgG and IgA antibody titers and prognosis in patients with coronary heart disease: results from the CLARICOR trial. Diagnostic Microbiology and Infectious diseases2010;66(4):385-92. JensenGB , HildenJ , Als-NielsenB , DamgaardN , HansenJF , HansenS , et al. Statin treatment prevents increased cardiovascular and all-cause mortality associated with clarithromycin in patients with stable coronary heart disease. Journal of Cardiovascular Pharmacology2010;55(2):123-8. JespersenCM , Als-NielsenB , DamgaardM , HansenJF , HansenS , HeløOH , et al. Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with coronary heart disease: CLARICOR trial. BMJ2006;332(7532):22-7. JespersenCM , KolmosHJ , FrydendallN , HildenJ , GluudC , HansenJF . Compliance with and short-term adverse events from clarithromycin versus placebo in patients with stable coronary heart disease: the CLARICOR trial. Journal of Antimicrobial Chemotherapy2009;64(2):411-5. NCT00121550. The CLARICOR trial: effect of clarithromycin on mortality and morbidity in patients with ischemic heart disease. https://clinicaltrials.gov/ct2/show/NCT00121550 (first received 21 July 2005). WinkelP , HildenJ , Fischer HansenJ , HildebrandtP , KastrupJ , KolmosHJ , et al. Excess sudden cardiac deaths after short-term clarithromycin administration in the CLARICOR trial: why is this so, and why are statins protective?Cardiology2011;118(1):63-67. WinkelP , HildenJ , HansenJF , KastrupJ , KolmosHJ , KjøllerE , et al. Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular mortality and cerebrovascular mortality over 10 years in the CLARICOR randomised, blinded clinical trial. International Journal of Cardiology2015;182:459-65. ">CLARICOR 2006</a>). All other trials were assessed at high risk of bias. However, the overall outcome result was dominated by <a href="./references#CD003610-bbs2-0007" title="GluudC , Als-NielsenB , DamgaardB , HansenJF , HansenS , HeløOH , et al. Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease. Cardiology2008;111:280-7. HansenS , Als-NielsenB , DamgaardM , HeløOH , PetersenL , JespersenCM . Intervention with clarithromycin in patients with stable coronary heart disease. The CLARICOR trial design. Heart Drug2001;1:14-9. HildenJ , LindI , KolmosHJ , Als-NielsenB , DamgaardN , HansenJF , et al. Chlamydia pneumoniae IgG and IgA antibody titers and prognosis in patients with coronary heart disease: results from the CLARICOR trial. Diagnostic Microbiology and Infectious diseases2010;66(4):385-92. JensenGB , HildenJ , Als-NielsenB , DamgaardN , HansenJF , HansenS , et al. Statin treatment prevents increased cardiovascular and all-cause mortality associated with clarithromycin in patients with stable coronary heart disease. Journal of Cardiovascular Pharmacology2010;55(2):123-8. JespersenCM , Als-NielsenB , DamgaardM , HansenJF , HansenS , HeløOH , et al. Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with coronary heart disease: CLARICOR trial. BMJ2006;332(7532):22-7. JespersenCM , KolmosHJ , FrydendallN , HildenJ , GluudC , HansenJF . Compliance with and short-term adverse events from clarithromycin versus placebo in patients with stable coronary heart disease: the CLARICOR trial. Journal of Antimicrobial Chemotherapy2009;64(2):411-5. NCT00121550. The CLARICOR trial: effect of clarithromycin on mortality and morbidity in patients with ischemic heart disease. https://clinicaltrials.gov/ct2/show/NCT00121550 (first received 21 July 2005). WinkelP , HildenJ , Fischer HansenJ , HildebrandtP , KastrupJ , KolmosHJ , et al. Excess sudden cardiac deaths after short-term clarithromycin administration in the CLARICOR trial: why is this so, and why are statins protective?Cardiology2011;118(1):63-67. WinkelP , HildenJ , HansenJF , KastrupJ , KolmosHJ , KjøllerE , et al. Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular mortality and cerebrovascular mortality over 10 years in the CLARICOR randomised, blinded clinical trial. International Journal of Cardiology2015;182:459-65. ">CLARICOR 2006</a> (79.3% of weight), which was at low risk of bias in all domains. The next two highest‐weighted trials (<a href="./references#CD003610-bbs2-0002" title="GraystonJT , KronmalRA , JacksonLA , ParisiAF , MuhlesteinJB , CohenJD , et al. Azithromycin for the secondary prevention of coronary events. New England Journal of Medicine2005;352:1637-45. JacksonLA . Description and status of the azithromycin and coronary events study (ACES). Journal of Infectious Diseases2000;181(Suppl 3):S579-81. NCT00000617. Azithromycin and Coronary Events Study (ACES). https://clinicaltrials.gov/ct2/show/NCT00000617 (first received 28 October 1999). ">ACES 2005</a>; <a href="./references#CD003610-bbs2-0025" title="CannonCP , BraunwaldE , McCabeCH , GraystonJT , MuhlesteinB , GiuglianoRP , et al. Antibiotic treatment of chlamydia pneumoniae after acute coronary syndrome. New England Journal of Medicine2005;352:1646-54. CannonCP , BraunwaldE , McCabeCH , RaderDJ , RouleauJL , BelderR , et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. New England Journal of Medicine2004;350(15):1495-504. CannonCP , McCabeCH , BelderR , BreenJ , BraunwaldE . Design of the pravastatin or atorvastatin evaluation and infection therapy (PROVE IT)-TIMI 22 trial. American Journal of Cardiology2002;89:860-1. ">PROVE‐IT 2005</a>) were both at low risk of bias in the majority of domains. We therefore decided to assess the risk of bias of the outcome result at low risk of bias. </p> <p>The sensitivity analysis of trials at low risk of bias showed that antibiotics versus placebo or no intervention seemed to increase the risk of stroke (RR 1.14; 95% CI 0.99 to 1.31; P = 0.06; I<sup>2</sup> = 12%; 4674 participants; 2 trials; moderate certainty of evidence; <a href="./references#CD003610-fig-0056" title="">Analysis 1.50</a>). The corresponding ARI was 1.94% and the NNTH was 52. </p> <p>The sensitivity analyses on incomplete outcome data showed that incomplete outcome data bias alone had the potential to influence the results (best‐worst fixed‐effect meta‐analysis: RR 0.98; 95% CI 0.87 to 1.11; 14,779 participants; P = 0.75; 9 trials; <a href="./references#CD003610-fig-0057" title="">Analysis 1.51</a>); (worst‐best fixed‐effect meta‐analysis: RR 1.29; 95% CI 1.14 to 1.45; P &lt; 0.0001; 14,779 participants; 9 trials; <a href="./references#CD003610-fig-0058" title="">Analysis 1.52</a>); (modified best‐worst fixed‐effect meta‐analysis: RR 1.05; 95% CI 0.93 to 1.19; P = 0.41; 14,779 participants; 9 trials; <a href="./references#CD003610-fig-0059" title="">Analysis 1.53</a>); (modified worst‐best fixed‐effect meta‐analysis: RR 1.21; 95% CI 1.07 to 1.37; P = 0.002; 14,779 participants; 9 trials; <a href="./references#CD003610-fig-0060" title="">Analysis 1.54</a>). Data were imputed for 4 trials. </p> <p>The sensitivity analysis on trials with optimal medical therapy showed that antibiotics versus placebo or no intervention seemed to increase the risk of stroke (RR 1.13; 95% CI 0.99 to 1.28; P = 0.06; I<sup>2</sup>= 0%; 13,672 participants; 6 trials; high certainty of evidence; <a href="./references#CD003610-fig-0061" title="">Analysis 1.55</a>). The corresponding ARI was 0.72% and the NNTH was 140. </p> </section> <section id="CD003610-sec-0101"> <p><b>Subgroup analyses</b></p> <p>We found no evidence of a difference in subgroups analyses according to antibiotic type (<a href="./references#CD003610-fig-0062" title="">Analysis 1.56</a>); antibody status (<a href="./references#CD003610-fig-0063" title="">Analysis 1.57</a>); use of statins (<a href="./references#CD003610-fig-0064" title="">Analysis 1.58</a>); age above or under 60 years (<a href="./references#CD003610-fig-0065" title="">Analysis 1.59</a>); clinical trial registration status (<a href="./references#CD003610-fig-0066" title="">Analysis 1.60</a>); length of follow‐up above or under 12 months follow‐up (<a href="./references#CD003610-fig-0067" title="">Analysis 1.61</a>); antibiotic class (<a href="./references#CD003610-fig-0068" title="">Analysis 1.62</a>); funding (<a href="./references#CD003610-fig-0069" title="">Analysis 1.63</a>); and control intervention (<a href="./references#CD003610-fig-0070" title="">Analysis 1.64</a>). </p> </section> </section> <section id="CD003610-sec-0102"> <h6 class="title">24±6 months follow‐up</h6> <p>At 24±6 months follow‐up, 5/38 trials with a total of 9457 participants and a mean follow‐up of 24.3 months (range 18.5 to 30.0 months) reported stroke. The specific assessment time points in each trial are presented in <a href="#CD003610-tbl-0006">Table 4</a>. A total of 116/4710 (2.46%) antibiotic participants had a stroke versus 100/4747 (2.11%) control participants. Fixed‐effect meta‐analysis showed that antibiotics versus placebo or no intervention resulted in no evidence of a difference on the risk of stroke (RR 1.17; 95% CI 0.90 to 1.52; P = 0.24; I<sup>2</sup> = 0%; 9457 participants; 5 trials; high certainty of evidence; <a href="./references#CD003610-fig-0134" title="">Analysis 2.46</a>). </p> <section id="CD003610-sec-0103"> <p><b>Heterogeneity</b></p> <p>Neither visual inspection of the forest plot nor tests for statistical heterogeneity (I<sup>2</sup> = 0%; P = 0.75) indicated any heterogeneity. </p> </section> <section id="CD003610-sec-0104"> <p><b>Risk of bias and sensitivity analyses</b></p> <p>Two trials were assessed at low risk of bias (<a href="./references#CD003610-bbs2-0001" title="AndersonJL , MuhlesteinJB , CarlquistJ , AllenA , TrehanS , NielsonC , et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection. The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) Study. Circulation1999;99:1540-7. MuhlesteinJB , AndersonJL , CarlquistJF , SalunkheK , HorneBD , PearsonRP , et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease. Primary clinical results of the ACADEMIC study. Circulation2000;102:1755-60. ">ACADEMIC 1999</a>; <a href="./references#CD003610-bbs2-0007" title="GluudC , Als-NielsenB , DamgaardB , HansenJF , HansenS , HeløOH , et al. Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease. Cardiology2008;111:280-7. HansenS , Als-NielsenB , DamgaardM , HeløOH , PetersenL , JespersenCM . Intervention with clarithromycin in patients with stable coronary heart disease. The CLARICOR trial design. Heart Drug2001;1:14-9. HildenJ , LindI , KolmosHJ , Als-NielsenB , DamgaardN , HansenJF , et al. Chlamydia pneumoniae IgG and IgA antibody titers and prognosis in patients with coronary heart disease: results from the CLARICOR trial. Diagnostic Microbiology and Infectious diseases2010;66(4):385-92. JensenGB , HildenJ , Als-NielsenB , DamgaardN , HansenJF , HansenS , et al. Statin treatment prevents increased cardiovascular and all-cause mortality associated with clarithromycin in patients with stable coronary heart disease. Journal of Cardiovascular Pharmacology2010;55(2):123-8. JespersenCM , Als-NielsenB , DamgaardM , HansenJF , HansenS , HeløOH , et al. Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with coronary heart disease: CLARICOR trial. BMJ2006;332(7532):22-7. JespersenCM , KolmosHJ , FrydendallN , HildenJ , GluudC , HansenJF . Compliance with and short-term adverse events from clarithromycin versus placebo in patients with stable coronary heart disease: the CLARICOR trial. Journal of Antimicrobial Chemotherapy2009;64(2):411-5. NCT00121550. The CLARICOR trial: effect of clarithromycin on mortality and morbidity in patients with ischemic heart disease. https://clinicaltrials.gov/ct2/show/NCT00121550 (first received 21 July 2005). WinkelP , HildenJ , Fischer HansenJ , HildebrandtP , KastrupJ , KolmosHJ , et al. Excess sudden cardiac deaths after short-term clarithromycin administration in the CLARICOR trial: why is this so, and why are statins protective?Cardiology2011;118(1):63-67. WinkelP , HildenJ , HansenJF , KastrupJ , KolmosHJ , KjøllerE , et al. Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular mortality and cerebrovascular mortality over 10 years in the CLARICOR randomised, blinded clinical trial. International Journal of Cardiology2015;182:459-65. ">CLARICOR 2006</a>). All other trials were assessed at high risk of bias. However, the overall outcome result was dominated by <a href="./references#CD003610-bbs2-0007" title="GluudC , Als-NielsenB , DamgaardB , HansenJF , HansenS , HeløOH , et al. Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease. Cardiology2008;111:280-7. HansenS , Als-NielsenB , DamgaardM , HeløOH , PetersenL , JespersenCM . Intervention with clarithromycin in patients with stable coronary heart disease. The CLARICOR trial design. Heart Drug2001;1:14-9. HildenJ , LindI , KolmosHJ , Als-NielsenB , DamgaardN , HansenJF , et al. Chlamydia pneumoniae IgG and IgA antibody titers and prognosis in patients with coronary heart disease: results from the CLARICOR trial. Diagnostic Microbiology and Infectious diseases2010;66(4):385-92. JensenGB , HildenJ , Als-NielsenB , DamgaardN , HansenJF , HansenS , et al. Statin treatment prevents increased cardiovascular and all-cause mortality associated with clarithromycin in patients with stable coronary heart disease. Journal of Cardiovascular Pharmacology2010;55(2):123-8. JespersenCM , Als-NielsenB , DamgaardM , HansenJF , HansenS , HeløOH , et al. Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with coronary heart disease: CLARICOR trial. BMJ2006;332(7532):22-7. JespersenCM , KolmosHJ , FrydendallN , HildenJ , GluudC , HansenJF . Compliance with and short-term adverse events from clarithromycin versus placebo in patients with stable coronary heart disease: the CLARICOR trial. Journal of Antimicrobial Chemotherapy2009;64(2):411-5. NCT00121550. The CLARICOR trial: effect of clarithromycin on mortality and morbidity in patients with ischemic heart disease. https://clinicaltrials.gov/ct2/show/NCT00121550 (first received 21 July 2005). WinkelP , HildenJ , Fischer HansenJ , HildebrandtP , KastrupJ , KolmosHJ , et al. Excess sudden cardiac deaths after short-term clarithromycin administration in the CLARICOR trial: why is this so, and why are statins protective?Cardiology2011;118(1):63-67. WinkelP , HildenJ , HansenJF , KastrupJ , KolmosHJ , KjøllerE , et al. Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular mortality and cerebrovascular mortality over 10 years in the CLARICOR randomised, blinded clinical trial. International Journal of Cardiology2015;182:459-65. ">CLARICOR 2006</a> (67.9% of weight), which was at low risk of bias in all domains. The next two highest‐weighted trials (<a href="./references#CD003610-bbs2-0006" title="BergHF , MarahaB , SchefferGJ , PeetersMF , KluytmansJA . Effect of clarithromycin on inflammatory markers in patients with atherosclerosis. Clinical and Diagnostic Laboratory Immunology2003;10(4):525-8. BergHF , MarahaB , SchefferGJ , UffordMQ , Vandenbroucke-GraulsCME , PeetersMF , et al. Treatment with clarithromycin prior to coronary artery bypass graft surgery does not prevent subsequent cardiac events. Clinical Infectious Diseases2005;40:358-65. BergHF , MarahaB , van derZeeA , GielisSK , RohollPJ , SchefferGJ , et al. Effect of clarithromycin treatment on Chlamydia pneumoniae in vascular tissue of patients with coronary artery disease: a randomized, double-blind, placebo-controlled trial. Journal of Clinical Microbiology2005;43(3):1325-9. BergHF , TjhieJH , SchefferGJ , PeetersMF , vanKeulenPH , KluytmansJA , et al. Emergence and persistence of macrolide resistance in oropharyngeal flora and elimination of nasal carriage of Staphylococcus aureus after therapy with slow-release clarithromycin: a randomized, double-blind, placebo-controlled study. Antimicrobial Agents and Chemotherapy2004;48(11):4183-8. ">Berg 2005</a>; <a href="./references#CD003610-bbs2-0025" title="CannonCP , BraunwaldE , McCabeCH , GraystonJT , MuhlesteinB , GiuglianoRP , et al. Antibiotic treatment of chlamydia pneumoniae after acute coronary syndrome. New England Journal of Medicine2005;352:1646-54. CannonCP , BraunwaldE , McCabeCH , RaderDJ , RouleauJL , BelderR , et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. New England Journal of Medicine2004;350(15):1495-504. CannonCP , McCabeCH , BelderR , BreenJ , BraunwaldE . Design of the pravastatin or atorvastatin evaluation and infection therapy (PROVE IT)-TIMI 22 trial. American Journal of Cardiology2002;89:860-1. ">PROVE‐IT 2005</a>) were both at low risk of bias in the majority of domains. We therefore decided to assess the risk of bias of the outcome result at low risk of bias. </p> <p>The sensitivity analysis of trials at low risk of bias showed that antibiotics versus placebo or no intervention probably resulted in no evidence of a difference on the risk of stroke (RR 1.17; 95% CI 0.86 to 1.60; P = 0.33; I<sup>2</sup> = 17%; 4674 participants; 2 trials; moderate certainty of evidence; <a href="./references#CD003610-fig-0135" title="">Analysis 2.47</a>). </p> <p>The sensitivity analyses on incomplete outcome data showed that incomplete outcome data bias alone had the potential to influence the results (best‐worst fixed‐effect meta‐analysis: RR 1.08; 95% CI 0.84 to 1.40; 9458 participants; P = 0.54; 5 trials; <a href="./references#CD003610-fig-0136" title="">Analysis 2.48</a>); (worst‐best fixed‐effect meta‐analysis: RR 1.28; 95% CI 0.99 to 1.66; P = 0.06; 9458 participants; 5 trials; <a href="./references#CD003610-fig-0137" title="">Analysis 2.49</a>); (modified best‐worst fixed‐effect meta‐analysis: RR 1.13; 95% CI 0.87 to 1.46; P = 0.37; 9458 participants; 5 trials; <a href="./references#CD003610-fig-0138" title="">Analysis 2.50</a>); (modified worst‐best fixed‐effect meta‐analysis: RR 1.23; 95% CI 0.95 to 1.60; P = 0.12; 9458 participants; 5 trials; <a href="./references#CD003610-fig-0139" title="">Analysis 2.51</a>). Data were imputed for 2 trials. </p> <p>The sensitivity analysis on trials with optimal medical therapy showed that antibiotics versus placebo or no intervention probably resulted in no evidence of a difference on the risk of stroke (RR 1.16; 95% CI 0.88 to 1.53; I<sup>2</sup> = 0%; 8682 participants; P = 0.28; 3 trials; moderate certainty of evidence; <a href="./references#CD003610-fig-0140" title="">Analysis 2.52</a>). </p> </section> <section id="CD003610-sec-0105"> <p><b>Subgroup analyses</b></p> <p>We found no evidence of a difference in subgroups analyses according to antibiotic type (<a href="./references#CD003610-fig-0141" title="">Analysis 2.53</a>); antibody status (<a href="./references#CD003610-fig-0142" title="">Analysis 2.54</a>); use of statins (<a href="./references#CD003610-fig-0143" title="">Analysis 2.55</a>); age above or under 60 years (<a href="./references#CD003610-fig-0144" title="">Analysis 2.56</a>); clinical trial registration status (<a href="./references#CD003610-fig-0145" title="">Analysis 2.57</a>); antibiotic class (<a href="./references#CD003610-fig-0146" title="">Analysis 2.58</a>); and funding (<a href="./references#CD003610-fig-0147" title="">Analysis 2.59</a>). Subgroup analysis according to control intervention could not be conducted due to all trials being placebo‐controlled (<a href="./references#CD003610-fig-0148" title="">Analysis 2.60</a>). </p> </section> </section> </section> <section id="CD003610-sec-0106"> <h5 class="title">Sudden cardiac death</h5> <section id="CD003610-sec-0107"> <h6 class="title">Maximum follow‐up</h6> <p>At maximum follow‐up, 2/38 trials with a total of 4520 participants and a mean follow‐up of 69.3 months (range 18.5 to 120.0 months) reported sudden cardiac death. The specific assessment time points in each trial are presented in <a href="#CD003610-tbl-0005">Table 3</a>. A total of 203/2246 (9.04%) antibiotic participants died suddenly versus 190/2274 (8.36%) control participants. Fixed‐effect meta‐analysis showed that antibiotics versus placebo or no intervention probably resulted in no evidence of a difference on the risk of sudden cardiac death (RR 1.08; 95% CI 0.90 to 1.31; P = 0.41; I<sup>2</sup> = 0%; 4520 participants; 2 trials; moderate certainty of evidence; <a href="./references#CD003610-fig-0071" title="">Analysis 1.65</a>). </p> <section id="CD003610-sec-0108"> <p><b>Heterogeneity</b></p> <p>Neither visual inspection of the forest plot nor tests for statistical heterogeneity (I<sup>2</sup> = 0%; P = 0.53) indicated any heterogeneity. </p> </section> <section id="CD003610-sec-0109"> <p><b>Risk of bias and sensitivity analyses</b></p> <p>One trial was assessed at low risk of bias (<a href="./references#CD003610-bbs2-0007" title="GluudC , Als-NielsenB , DamgaardB , HansenJF , HansenS , HeløOH , et al. Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease. Cardiology2008;111:280-7. HansenS , Als-NielsenB , DamgaardM , HeløOH , PetersenL , JespersenCM . Intervention with clarithromycin in patients with stable coronary heart disease. The CLARICOR trial design. Heart Drug2001;1:14-9. HildenJ , LindI , KolmosHJ , Als-NielsenB , DamgaardN , HansenJF , et al. Chlamydia pneumoniae IgG and IgA antibody titers and prognosis in patients with coronary heart disease: results from the CLARICOR trial. Diagnostic Microbiology and Infectious diseases2010;66(4):385-92. JensenGB , HildenJ , Als-NielsenB , DamgaardN , HansenJF , HansenS , et al. Statin treatment prevents increased cardiovascular and all-cause mortality associated with clarithromycin in patients with stable coronary heart disease. Journal of Cardiovascular Pharmacology2010;55(2):123-8. JespersenCM , Als-NielsenB , DamgaardM , HansenJF , HansenS , HeløOH , et al. Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with coronary heart disease: CLARICOR trial. BMJ2006;332(7532):22-7. JespersenCM , KolmosHJ , FrydendallN , HildenJ , GluudC , HansenJF . Compliance with and short-term adverse events from clarithromycin versus placebo in patients with stable coronary heart disease: the CLARICOR trial. Journal of Antimicrobial Chemotherapy2009;64(2):411-5. NCT00121550. The CLARICOR trial: effect of clarithromycin on mortality and morbidity in patients with ischemic heart disease. https://clinicaltrials.gov/ct2/show/NCT00121550 (first received 21 July 2005). WinkelP , HildenJ , Fischer HansenJ , HildebrandtP , KastrupJ , KolmosHJ , et al. Excess sudden cardiac deaths after short-term clarithromycin administration in the CLARICOR trial: why is this so, and why are statins protective?Cardiology2011;118(1):63-67. WinkelP , HildenJ , HansenJF , KastrupJ , KolmosHJ , KjøllerE , et al. Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular mortality and cerebrovascular mortality over 10 years in the CLARICOR randomised, blinded clinical trial. International Journal of Cardiology2015;182:459-65. ">CLARICOR 2006</a>). The other trial (<a href="./references#CD003610-bbs2-0008" title="PaakkanenR , PalikheA , SeppänenM , NieminenMS , VauhkonenH , SaikkuP , et al. Beneficial effect of clarithromycin in patients with acute coronary syndrome and complement C4 deficiencies. Scandinavian Cardiovascular Journal2009;43(6):395-401. SinisaloJ , MattilaK , ValtonenV , AnttonenO , JuvonenJ , MelinJ , et al. Effect of 3 months of antimicrobial treatment with clarithromycin in acute non-q-wave coronary syndrome. Circulation2002;105:1555-60. ">CLARIFY 2002</a>) only had one bias risk domain of minor concern (selective outcome reporting) at unclear risk of bias. Hence, the risk of bias of the outcome result was assessed at low risk of bias. </p> <p>The sensitivity analysis of trials at low risk of bias showed that antibiotics versus placebo or no intervention probably resulted in no evidence of a difference on the risk of sudden cardiac death (RR 1.08; 95% CI 0.89 to 1.30; P = 0.44; 4372 participants; 1 trial; moderate certainty of evidence; <a href="./references#CD003610-fig-0072" title="">Analysis 1.66</a>). </p> <p>The sensitivity analyses on incomplete outcome data showed that incomplete outcome data bias alone did not have the potential to influence the results (best‐worst fixed‐effect meta‐analysis: RR 1.00; 95% CI 0.83 to 1.20; 4521 participants; P = 0.99; 2 trials; <a href="./references#CD003610-fig-0073" title="">Analysis 1.67</a>); (worst‐best fixed‐effect meta‐analysis: RR 1.14; 95% CI 0.95 to 1.37; P = 0.16; 4521 participants; 2 trials; <a href="./references#CD003610-fig-0074" title="">Analysis 1.68</a>); (modified best‐worst fixed‐effect meta‐analysis: RR 1.04; 95% CI 0.86 to 1.25; P = 0.69; 4521 participants; 2 trials; <a href="./references#CD003610-fig-0075" title="">Analysis 1.69</a>); (modified worst‐best fixed‐effect meta‐analysis: RR 1.11; 95% CI 0.92 to 1.34; P = 0.28; 4521 participants; 2 trials; <a href="./references#CD003610-fig-0076" title="">Analysis 1.70</a>). Data were imputed for 1 trial. </p> <p>Sensitivity analysis on optimal medical therapy was not conducted due to both trials including optimal medical therapy. </p> </section> <section id="CD003610-sec-0110"> <p><b>Subgroup analyses</b></p> <p>We found no evidence of a difference in subgroups analyses according to clinical trial registration status (<a href="./references#CD003610-fig-0077" title="">Analysis 1.71</a>) and funding (<a href="./references#CD003610-fig-0078" title="">Analysis 1.72</a>). Subgroup analyses according to antibiotic type (<a href="./references#CD003610-fig-0079" title="">Analysis 1.73</a>); antibody status (<a href="./references#CD003610-fig-0080" title="">Analysis 1.74</a>); use of statins (<a href="./references#CD003610-fig-0081" title="">Analysis 1.75</a>); age above or under 60 years (<a href="./references#CD003610-fig-0082" title="">Analysis 1.76</a>); length of follow‐up above or under 12 months follow‐up (<a href="./references#CD003610-fig-0083" title="">Analysis 1.77</a>); antibiotic class (<a href="./references#CD003610-fig-0084" title="">Analysis 1.78</a>); and control intervention (<a href="./references#CD003610-fig-0085" title="">Analysis 1.79</a>) could not be conducted due to both trials being included in the same subgroup. </p> </section> </section> <section id="CD003610-sec-0111"> <h6 class="title">24±6 months follow‐up</h6> <p>At 24±6 months follow‐up, 2/38 trials with a total of 4520 participants and a mean follow‐up of 24.3 months (range 18.5 to 30.0 months) reported sudden cardiac death. The specific assessment time points in each trial are presented in <a href="#CD003610-tbl-0006">Table 4</a>. A total of 98/2246 (4.36%) antibiotic participants died suddenly versus 56/2274 (2.46%) control participants. Fixed‐effect meta‐analysis showed that antibiotics versus placebo or no intervention probably increased the risk of sudden cardiac death (RR 1.77; 95% CI 1.28 to 2.44; P = 0.0005; I<sup>2</sup> = 0%; 4520 participants; 2 trials; moderate certainty of evidence; <a href="./references#CD003610-fig-0149" title="">Analysis 2.61</a>). The corresponding ARI was 1.9% and the NNTH was 53 (95% CI 145 to 28). </p> <section id="CD003610-sec-0112"> <p><b>Heterogeneity</b></p> <p>Neither visual inspection of the forest plot nor tests for statistical heterogeneity (I<sup>2</sup> = 0%; P = 0.74) indicated any heterogeneity. </p> </section> <section id="CD003610-sec-0113"> <p><b>Risk of bias and sensitivity analyses</b></p> <p>One trial was assessed at low risk of bias (<a href="./references#CD003610-bbs2-0007" title="GluudC , Als-NielsenB , DamgaardB , HansenJF , HansenS , HeløOH , et al. Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease. Cardiology2008;111:280-7. HansenS , Als-NielsenB , DamgaardM , HeløOH , PetersenL , JespersenCM . Intervention with clarithromycin in patients with stable coronary heart disease. The CLARICOR trial design. Heart Drug2001;1:14-9. HildenJ , LindI , KolmosHJ , Als-NielsenB , DamgaardN , HansenJF , et al. Chlamydia pneumoniae IgG and IgA antibody titers and prognosis in patients with coronary heart disease: results from the CLARICOR trial. Diagnostic Microbiology and Infectious diseases2010;66(4):385-92. JensenGB , HildenJ , Als-NielsenB , DamgaardN , HansenJF , HansenS , et al. Statin treatment prevents increased cardiovascular and all-cause mortality associated with clarithromycin in patients with stable coronary heart disease. Journal of Cardiovascular Pharmacology2010;55(2):123-8. JespersenCM , Als-NielsenB , DamgaardM , HansenJF , HansenS , HeløOH , et al. Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with coronary heart disease: CLARICOR trial. BMJ2006;332(7532):22-7. JespersenCM , KolmosHJ , FrydendallN , HildenJ , GluudC , HansenJF . Compliance with and short-term adverse events from clarithromycin versus placebo in patients with stable coronary heart disease: the CLARICOR trial. Journal of Antimicrobial Chemotherapy2009;64(2):411-5. NCT00121550. The CLARICOR trial: effect of clarithromycin on mortality and morbidity in patients with ischemic heart disease. https://clinicaltrials.gov/ct2/show/NCT00121550 (first received 21 July 2005). WinkelP , HildenJ , Fischer HansenJ , HildebrandtP , KastrupJ , KolmosHJ , et al. Excess sudden cardiac deaths after short-term clarithromycin administration in the CLARICOR trial: why is this so, and why are statins protective?Cardiology2011;118(1):63-67. WinkelP , HildenJ , HansenJF , KastrupJ , KolmosHJ , KjøllerE , et al. Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular mortality and cerebrovascular mortality over 10 years in the CLARICOR randomised, blinded clinical trial. International Journal of Cardiology2015;182:459-65. ">CLARICOR 2006</a>). The other trial (<a href="./references#CD003610-bbs2-0008" title="PaakkanenR , PalikheA , SeppänenM , NieminenMS , VauhkonenH , SaikkuP , et al. Beneficial effect of clarithromycin in patients with acute coronary syndrome and complement C4 deficiencies. Scandinavian Cardiovascular Journal2009;43(6):395-401. SinisaloJ , MattilaK , ValtonenV , AnttonenO , JuvonenJ , MelinJ , et al. Effect of 3 months of antimicrobial treatment with clarithromycin in acute non-q-wave coronary syndrome. Circulation2002;105:1555-60. ">CLARIFY 2002</a>) only had one bias risk domain of minor concern (selective outcome reporting) at unclear risk of bias. Hence, the risk of bias of the outcome result was assessed at low risk of bias. </p> <p>The sensitivity analysis of trials at low risk of bias showed that antibiotics versus placebo or no intervention probably increased the risk of sudden cardiac death (RR 1.75; 95% CI 1.27 to 2.42; P = 0.0007; 4372 participants; 1 trial; moderate certainty of evidence; <a href="./references#CD003610-fig-0150" title="">Analysis 2.62</a>). The corresponding ARI was 1.92% and the NNTH was 52 (95% CI 147 to 28). </p> <p>The sensitivity analyses on incomplete outcome data showed that incomplete outcome data bias alone did not have the potential to influence the results (best‐worst fixed‐effect meta‐analysis: RR 1.68; 95% CI 1.22 to 2.30; 4521 participants; P = 0.001; 2 trials; <a href="./references#CD003610-fig-0151" title="">Analysis 2.63</a>); (worst‐best fixed‐effect meta‐analysis: RR 1.91; 95% CI 1.39 to 2.62; P &lt; 0.0001; 4521 participants; 2 trials; <a href="./references#CD003610-fig-0152" title="">Analysis 2.64</a>); (modified best‐worst fixed‐effect meta‐analysis: RR 1.74; 95% CI 1.26 to 2.39; P = 0.0007; 4521 participants; 2 trials; <a href="./references#CD003610-fig-0153" title="">Analysis 2.65</a>); (modified worst‐best fixed‐effect meta‐analysis: RR 1.84; 95% CI 1.34 to 2.53; P = 0.0002; 4521 participants; 2 trials; <a href="./references#CD003610-fig-0154" title="">Analysis 2.66</a>). Data were imputed for 1 trial. </p> <p>Sensitivity analysis on optimal medical therapy was not conducted due to both trials including optimal medical therapy. </p> </section> <section id="CD003610-sec-0114"> <p><b>Subgroup analyses</b></p> <p>We found no evidence of a difference in subgroups analyses according to clinical trial registration status (<a href="./references#CD003610-fig-0155" title="">Analysis 2.67</a>) and funding (<a href="./references#CD003610-fig-0156" title="">Analysis 2.68</a>). Subgroup analyses according to antibiotic type (<a href="./references#CD003610-fig-0157" title="">Analysis 2.69</a>); antibody status (<a href="./references#CD003610-fig-0158" title="">Analysis 2.70</a>); use of statins (<a href="./references#CD003610-fig-0159" title="">Analysis 2.71</a>); age above or under 60 years (<a href="./references#CD003610-fig-0160" title="">Analysis 2.72</a>); antibiotic class (<a href="./references#CD003610-fig-0161" title="">Analysis 2.73</a>); and control intervention (<a href="./references#CD003610-fig-0162" title="">Analysis 2.74</a>) could not be conducted due to both trials being included in the same subgroup. </p> </section> </section> </section> </section> <section id="CD003610-sec-0115"> <h4 class="title">Additional post hoc outcomes</h4> <section id="CD003610-sec-0116"> <h5 class="title">Hospitalisation for any cause</h5> <section id="CD003610-sec-0117"> <h6 class="title">Maximum follow‐up</h6> <p>At maximum follow‐up, 7/38 trials with a total of 18,615 participants and a mean follow‐up of 17.9 months reported hospitalisation for any cause. The specific assessment time points in each trial are presented in <a href="#CD003610-tbl-0005">Table 3</a>. A total of 395/9298 (4.25%) antibiotics participants were hospitalised for any cause versus 381/9317 (4.09%) control participants. Fixed‐effect meta‐analysis showed that antibiotics versus placebo or no intervention resulted in no evidence of a difference on the risk of hospitalisation for any cause (RR 1.04; 95% CI 0.91 to 1.19; P = 0.56; I<sup>2</sup>= 0%; 18,615 participants; 7 trials; high certainty of evidence, <a href="./references#CD003610-fig-0086" title="">Analysis 1.80</a>). </p> </section> <section id="CD003610-sec-0118"> <h6 class="title">24±6 months follow‐up</h6> <p>At 24±6 months follow‐up, 2/38 trials with a total of 4464 participants and a mean follow‐up of 24 months reported hospitalisation for any cause. The specific assessment time points in each trial are presented in <a href="#CD003610-tbl-0006">Table 4</a>. A total of 101/2226 (4.54%) antibiotics participants were hospitalised for any cause versus 99/2238 (4.42%) control participants. Fixed‐effect meta‐analysis showed that antibiotics versus placebo or no intervention probably resulted in no evidence of a difference on the risk of hospitalisation for any cause (RR 1.02; 95% CI 0.78 to 1.34; P = 0.85; I<sup>2</sup>= 0%; 4464 participants; 2 trials; moderate certainty of evidence; <a href="./references#CD003610-fig-0163" title="">Analysis 2.75</a>). </p> </section> </section> <section id="CD003610-sec-0119"> <h5 class="title">Revascularisation</h5> <section id="CD003610-sec-0120"> <h6 class="title">Maximum follow‐up</h6> <p>At maximum follow‐up, 11/38 trials with a total of 19,631 participants and a mean follow‐up of 16.7 months reported revascularisation. The specific assessment time points in each trial are presented in <a href="#CD003610-tbl-0005">Table 3</a>. A total of 1259/9810 (12.8%) antibiotics participants were revascularised versus 1292/9821 (13.2%) control participants. Fixed‐effect meta‐analysis showed that antibiotics versus placebo or no intervention resulted in no evidence of a difference on the risk of revascularisation (RR 0.98; 95% CI 0.91 to 1.05; P = 0.53; I<sup>2</sup>= 0%; 19,631 participants; 11 trials; high certainty of evidence; <a href="./references#CD003610-fig-0087" title="">Analysis 1.81</a>). </p> </section> <section id="CD003610-sec-0121"> <h6 class="title">24±6 months follow‐up</h6> <p>At 24±6 months follow‐up, 3/38 trials with a total of 4937 participants and a mean follow‐up of 24 months reported revascularisation. The specific assessment time points in each trial are presented in <a href="#CD003610-tbl-0006">Table 4</a>. A total of 370/2464 (15.0%) antibiotics participants were revascularised versus 396/2473 (16.0%) control participants. Fixed‐effect meta‐analysis showed that antibiotics versus placebo or no intervention probably resulted in no evidence of a difference on the risk of revascularisation (RR 0.94; 95% CI 0.83 to 1.07; P = 0.34; I<sup>2</sup>= 38%; 4937 participants; 3 trials; moderate certainty of evidence; <a href="./references#CD003610-fig-0164" title="">Analysis 2.76</a>). </p> </section> </section> <section id="CD003610-sec-0122"> <h5 class="title">Unstable angina pectoris</h5> <section id="CD003610-sec-0123"> <h6 class="title">Maximum follow‐up</h6> <p>At maximum follow‐up, 9/38 trials with a total of 22,172 participants and a mean follow‐up of 32.2 months reported unstable angina pectoris. The specific assessment time points in each trial are presented in <a href="#CD003610-tbl-0005">Table 3</a>. A total of 743/11,068 (6.71%) antibiotics participants had unstable angina pectoris versus 738/11,104 (6.65%) control participants. Fixed‐effect meta‐analysis showed that antibiotics versus placebo or no intervention resulted in no evidence of a difference on the risk of unstable angina pectoris (RR 1.02; 95% CI 0.92 to 1.12; P = 0.76; I<sup>2</sup>= 0%; 22,172 participants; 9 trials; high certainty of evidence; <a href="./references#CD003610-fig-0088" title="">Analysis 1.82</a>). </p> </section> <section id="CD003610-sec-0124"> <h6 class="title">24±6 months follow‐up</h6> <p>At 24±6 months follow‐up, 4/38 trials with a total of 5085 participants and a mean follow‐up of 22.6 months reported unstable angina pectoris. The specific assessment time points in each trial are presented in <a href="#CD003610-tbl-0006">Table 4</a>. A total of 116/2538 (4.57%) antibiotics participants had unstable angina pectoris versus 122/2547 (4.79%) control participants. Random‐effects meta‐analysis showed that antibiotics probably resulted in no evidence of a difference on the risk of unstable angina pectoris (RR 0.96; 95% CI 0.75 to 1.23; P = 0.72; I<sup>2</sup>= 0%; 5085 participants; 4 trials; moderate certainty of evidence; <a href="./references#CD003610-fig-0165" title="">Analysis 2.77</a>). </p> </section> </section> </section> <section id="CD003610-sec-0125"> <h4 class="title">'Summary of findings' tables</h4> <p>Our main results (i.e. primary and secondary outcomes) are summarised in the <a href="./full#CD003610-tbl-0001">summary of findings Table 1</a> (maximum follow‐up) and the <a href="./full#CD003610-tbl-0002">summary of findings Table 2</a> (24±6 months follow‐up). </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD003610-sec-0126" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD003610-sec-0126"></div> <section id="CD003610-sec-0127"> <h3 class="title" id="CD003610-sec-0127">Summary of main results</h3> <p>We were able to include 38 trials reported in 61 publications randomising a total of 26,638 participants with coronary heart disease. A total of 23/38 trials including 26,078 participants reported data that could be meta‐analysed. Three trials (<a href="./references#CD003610-bbs2-0001" title="AndersonJL , MuhlesteinJB , CarlquistJ , AllenA , TrehanS , NielsonC , et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection. The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) Study. Circulation1999;99:1540-7. MuhlesteinJB , AndersonJL , CarlquistJF , SalunkheK , HorneBD , PearsonRP , et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease. Primary clinical results of the ACADEMIC study. Circulation2000;102:1755-60. ">ACADEMIC 1999</a>; <a href="./references#CD003610-bbs2-0005" title="CercekB , ShahPK , NocM , ZahgerD , ZeymerU , MatetzkyS , et al. Effect of short-term treatment with azithromycin on recurrent ischaemic events in patients with acute coronary syndrome in the Azithromycin in Acute Coronary Syndrome (AZACS) trial: a randomised controlled trial. Lancet2003;361:809-13. ">AZACS 2003</a>; <a href="./references#CD003610-bbs2-0007" title="GluudC , Als-NielsenB , DamgaardB , HansenJF , HansenS , HeløOH , et al. Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease. Cardiology2008;111:280-7. HansenS , Als-NielsenB , DamgaardM , HeløOH , PetersenL , JespersenCM . Intervention with clarithromycin in patients with stable coronary heart disease. The CLARICOR trial design. Heart Drug2001;1:14-9. HildenJ , LindI , KolmosHJ , Als-NielsenB , DamgaardN , HansenJF , et al. Chlamydia pneumoniae IgG and IgA antibody titers and prognosis in patients with coronary heart disease: results from the CLARICOR trial. Diagnostic Microbiology and Infectious diseases2010;66(4):385-92. JensenGB , HildenJ , Als-NielsenB , DamgaardN , HansenJF , HansenS , et al. Statin treatment prevents increased cardiovascular and all-cause mortality associated with clarithromycin in patients with stable coronary heart disease. Journal of Cardiovascular Pharmacology2010;55(2):123-8. JespersenCM , Als-NielsenB , DamgaardM , HansenJF , HansenS , HeløOH , et al. Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with coronary heart disease: CLARICOR trial. BMJ2006;332(7532):22-7. JespersenCM , KolmosHJ , FrydendallN , HildenJ , GluudC , HansenJF . Compliance with and short-term adverse events from clarithromycin versus placebo in patients with stable coronary heart disease: the CLARICOR trial. Journal of Antimicrobial Chemotherapy2009;64(2):411-5. NCT00121550. The CLARICOR trial: effect of clarithromycin on mortality and morbidity in patients with ischemic heart disease. https://clinicaltrials.gov/ct2/show/NCT00121550 (first received 21 July 2005). WinkelP , HildenJ , Fischer HansenJ , HildebrandtP , KastrupJ , KolmosHJ , et al. Excess sudden cardiac deaths after short-term clarithromycin administration in the CLARICOR trial: why is this so, and why are statins protective?Cardiology2011;118(1):63-67. WinkelP , HildenJ , HansenJF , KastrupJ , KolmosHJ , KjøllerE , et al. Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular mortality and cerebrovascular mortality over 10 years in the CLARICOR randomised, blinded clinical trial. International Journal of Cardiology2015;182:459-65. ">CLARICOR 2006</a>) and all outcome results were assessed at low risk of bias. The remaining trials were at high risk of bias mainly due to domains being at unclear risk of bias. Trials assessing the effects of macrolides (28 trials randomising 22,059 participants) and quinolones (two trials randomising 4162 participants) contributed with the vast majority of the data, while tetracyclines (eight trials randomising 417 participants) contributed with insufficient data to evaluate its effect for secondary prevention of coronary heart disease. </p> <p>At maximum follow‐up, meta‐analyses showed that antibiotics seemed to increase the risk of all‐cause mortality, stroke, and probably also cardiovascular mortality. Regarding the risk of myocardial infarction, meta‐analysis showed little to no difference between the treatment groups. For sudden cardiac death, meta‐analysis showed no evidence of a difference. </p> <p>At 24±6 months follow‐up, meta‐analyses showed that antibiotics increased the risk of all‐cause mortality, cardiovascular mortality, and probably also sudden cardiac death. Regarding the risk of myocardial infarction and stroke, meta‐analyses showed no evidence of a difference. </p> <p>None of the trials specifically assessed serious adverse event according to International Conference on Harmonization ‐ Good Clinical Practice (ICH‐GCP). Instead, the trials either reported composites of several specific serious adverse events or one specific serious adverse event. Hence, no meta‐analysis could be conducted. </p> <p>No data were provided on quality of life.</p> </section> <section id="CD003610-sec-0128"> <h3 class="title" id="CD003610-sec-0128">Overall completeness and applicability of evidence</h3> <p>This review provides the most comprehensive and contemporary appraisal of the evidence on antibiotics for secondary prevention of patients with coronary heart disease to date. We searched for published and unpublished trials irrespective of setting, blinding, publication status, publication year, language, and reporting of our outcomes. None of our funnel plots indicated any significant signs of publication bias. However, all but three trials were at high risk of bias which suggests that our results might overestimate benefits and underestimate harms (<a href="./references#CD003610-bbs2-0179" title="SchulzKF , ChalmersI , HayesRJ , AltmanDG . Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA1995;273(5):408-12.">Schulz 1995</a>; <a href="./references#CD003610-bbs2-0153" title="MoherD , PhamB , JonesA , CookDJ , JadadAR , MoherM , et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?Lancet1998;352(9128):609-13.">Moher 1998</a>; <a href="./references#CD003610-bbs2-0133" title="KjaergardLL , VillumsenJ , GluudC . Reported methodological quality and discrepancies between small and large randomized trials in meta-analyses. Annals of Internal Medicine2001;135:982-9.">Kjaergard 2001</a>; <a href="./references#CD003610-bbs2-0104" title="GluudLL . Bias in clinical intervention research. American Journal of Epidemiology2006;163(6):493-501.">Gluud 2006</a>; <a href="./references#CD003610-bbs2-0204" title="WoodL , EggerM , GluudLL , SchulzKF , JuniP , AltmanDG , et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ2008;336(7644):601-5.">Wood 2008</a>; <a href="./references#CD003610-bbs2-0177" title="SavovicJ , JonesHE , AltmanDG , HarrisRJ , JuniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine2012;157(6):429-38.">Savovic 2012</a>; <a href="./references#CD003610-bbs2-0144" title="LundhA , LexchinJ , MintzesB , SchrollJB , BeroL . Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews2017;2:Mr000033.">Lundh 2017</a>; <a href="./references#CD003610-bbs2-0178" title="SavovicJ , TurnerRM , MawdsleyD , JonesHE , BeynonR , HigginsJPT , et al. Association between risk-of-bias assessments and results of randomized trials in Cochrane reviews: the ROBES meta-epidemiologic study. American Journal of Epidemiology2018;187(5):1113-22.">Savovic 2018</a>). </p> <p>We included all adult (≥ 18 years) participants with coronary heart disease irrespective of sex, antibody status, severity of the disease, type of antibiotic used, and type of control group intervention (placebo or no intervention). Nevertheless, we found limited signs of statistical heterogeneity (except for myocardial infarction at 24±6 months follow‐up (see <a href="#CD003610-sec-0136">Potential biases in the review process</a>)) which indicates that the pooling of these diverse participants and interventions was appropriate. </p> <p>A limitation of the study design is that the presented results depends on the available extractable trial data. Hence, even though our inclusion criteria are broad, we might not have included all conceivable subgroups, and the majority of our results might include data from some specific subgroups. An example is that we have included more men than women. It is known that coronary heart disease affects men and women differently in regard to baseline risk and control event rate. However, we were not able to obtain individual participant data from the included trials. Therefore, it was not possible to conduct a subgroup analysis. Another example is that one trial weighted most in our analyses (<a href="./references#CD003610-bbs2-0007" title="GluudC , Als-NielsenB , DamgaardB , HansenJF , HansenS , HeløOH , et al. Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease. Cardiology2008;111:280-7. HansenS , Als-NielsenB , DamgaardM , HeløOH , PetersenL , JespersenCM . Intervention with clarithromycin in patients with stable coronary heart disease. The CLARICOR trial design. Heart Drug2001;1:14-9. HildenJ , LindI , KolmosHJ , Als-NielsenB , DamgaardN , HansenJF , et al. Chlamydia pneumoniae IgG and IgA antibody titers and prognosis in patients with coronary heart disease: results from the CLARICOR trial. Diagnostic Microbiology and Infectious diseases2010;66(4):385-92. JensenGB , HildenJ , Als-NielsenB , DamgaardN , HansenJF , HansenS , et al. Statin treatment prevents increased cardiovascular and all-cause mortality associated with clarithromycin in patients with stable coronary heart disease. Journal of Cardiovascular Pharmacology2010;55(2):123-8. JespersenCM , Als-NielsenB , DamgaardM , HansenJF , HansenS , HeløOH , et al. Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with coronary heart disease: CLARICOR trial. BMJ2006;332(7532):22-7. JespersenCM , KolmosHJ , FrydendallN , HildenJ , GluudC , HansenJF . Compliance with and short-term adverse events from clarithromycin versus placebo in patients with stable coronary heart disease: the CLARICOR trial. Journal of Antimicrobial Chemotherapy2009;64(2):411-5. NCT00121550. The CLARICOR trial: effect of clarithromycin on mortality and morbidity in patients with ischemic heart disease. https://clinicaltrials.gov/ct2/show/NCT00121550 (first received 21 July 2005). WinkelP , HildenJ , Fischer HansenJ , HildebrandtP , KastrupJ , KolmosHJ , et al. Excess sudden cardiac deaths after short-term clarithromycin administration in the CLARICOR trial: why is this so, and why are statins protective?Cardiology2011;118(1):63-67. WinkelP , HildenJ , HansenJF , KastrupJ , KolmosHJ , KjøllerE , et al. Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular mortality and cerebrovascular mortality over 10 years in the CLARICOR randomised, blinded clinical trial. International Journal of Cardiology2015;182:459-65. ">CLARICOR 2006</a>). This might result in our results and conclusions being limited to the participants included in <a href="./references#CD003610-bbs2-0007" title="GluudC , Als-NielsenB , DamgaardB , HansenJF , HansenS , HeløOH , et al. Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease. Cardiology2008;111:280-7. HansenS , Als-NielsenB , DamgaardM , HeløOH , PetersenL , JespersenCM . Intervention with clarithromycin in patients with stable coronary heart disease. The CLARICOR trial design. Heart Drug2001;1:14-9. HildenJ , LindI , KolmosHJ , Als-NielsenB , DamgaardN , HansenJF , et al. Chlamydia pneumoniae IgG and IgA antibody titers and prognosis in patients with coronary heart disease: results from the CLARICOR trial. Diagnostic Microbiology and Infectious diseases2010;66(4):385-92. JensenGB , HildenJ , Als-NielsenB , DamgaardN , HansenJF , HansenS , et al. Statin treatment prevents increased cardiovascular and all-cause mortality associated with clarithromycin in patients with stable coronary heart disease. Journal of Cardiovascular Pharmacology2010;55(2):123-8. JespersenCM , Als-NielsenB , DamgaardM , HansenJF , HansenS , HeløOH , et al. Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with coronary heart disease: CLARICOR trial. BMJ2006;332(7532):22-7. JespersenCM , KolmosHJ , FrydendallN , HildenJ , GluudC , HansenJF . Compliance with and short-term adverse events from clarithromycin versus placebo in patients with stable coronary heart disease: the CLARICOR trial. Journal of Antimicrobial Chemotherapy2009;64(2):411-5. NCT00121550. The CLARICOR trial: effect of clarithromycin on mortality and morbidity in patients with ischemic heart disease. https://clinicaltrials.gov/ct2/show/NCT00121550 (first received 21 July 2005). WinkelP , HildenJ , Fischer HansenJ , HildebrandtP , KastrupJ , KolmosHJ , et al. Excess sudden cardiac deaths after short-term clarithromycin administration in the CLARICOR trial: why is this so, and why are statins protective?Cardiology2011;118(1):63-67. WinkelP , HildenJ , HansenJF , KastrupJ , KolmosHJ , KjøllerE , et al. Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular mortality and cerebrovascular mortality over 10 years in the CLARICOR randomised, blinded clinical trial. International Journal of Cardiology2015;182:459-65. ">CLARICOR 2006</a>. On the contrary, all meta‐analyses except for myocardial infarction at 24+6 months follow‐up had, as mentioned above limited signs of statistical heterogeneity concluding that the other trials had results pointing in the same direction as <a href="./references#CD003610-bbs2-0007" title="GluudC , Als-NielsenB , DamgaardB , HansenJF , HansenS , HeløOH , et al. Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease. Cardiology2008;111:280-7. HansenS , Als-NielsenB , DamgaardM , HeløOH , PetersenL , JespersenCM . Intervention with clarithromycin in patients with stable coronary heart disease. The CLARICOR trial design. Heart Drug2001;1:14-9. HildenJ , LindI , KolmosHJ , Als-NielsenB , DamgaardN , HansenJF , et al. Chlamydia pneumoniae IgG and IgA antibody titers and prognosis in patients with coronary heart disease: results from the CLARICOR trial. Diagnostic Microbiology and Infectious diseases2010;66(4):385-92. JensenGB , HildenJ , Als-NielsenB , DamgaardN , HansenJF , HansenS , et al. Statin treatment prevents increased cardiovascular and all-cause mortality associated with clarithromycin in patients with stable coronary heart disease. Journal of Cardiovascular Pharmacology2010;55(2):123-8. JespersenCM , Als-NielsenB , DamgaardM , HansenJF , HansenS , HeløOH , et al. Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with coronary heart disease: CLARICOR trial. BMJ2006;332(7532):22-7. JespersenCM , KolmosHJ , FrydendallN , HildenJ , GluudC , HansenJF . Compliance with and short-term adverse events from clarithromycin versus placebo in patients with stable coronary heart disease: the CLARICOR trial. Journal of Antimicrobial Chemotherapy2009;64(2):411-5. NCT00121550. The CLARICOR trial: effect of clarithromycin on mortality and morbidity in patients with ischemic heart disease. https://clinicaltrials.gov/ct2/show/NCT00121550 (first received 21 July 2005). WinkelP , HildenJ , Fischer HansenJ , HildebrandtP , KastrupJ , KolmosHJ , et al. Excess sudden cardiac deaths after short-term clarithromycin administration in the CLARICOR trial: why is this so, and why are statins protective?Cardiology2011;118(1):63-67. WinkelP , HildenJ , HansenJF , KastrupJ , KolmosHJ , KjøllerE , et al. Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular mortality and cerebrovascular mortality over 10 years in the CLARICOR randomised, blinded clinical trial. International Journal of Cardiology2015;182:459-65. ">CLARICOR 2006</a>. This shows that even though <a href="./references#CD003610-bbs2-0007" title="GluudC , Als-NielsenB , DamgaardB , HansenJF , HansenS , HeløOH , et al. Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease. Cardiology2008;111:280-7. HansenS , Als-NielsenB , DamgaardM , HeløOH , PetersenL , JespersenCM . Intervention with clarithromycin in patients with stable coronary heart disease. The CLARICOR trial design. Heart Drug2001;1:14-9. HildenJ , LindI , KolmosHJ , Als-NielsenB , DamgaardN , HansenJF , et al. Chlamydia pneumoniae IgG and IgA antibody titers and prognosis in patients with coronary heart disease: results from the CLARICOR trial. Diagnostic Microbiology and Infectious diseases2010;66(4):385-92. JensenGB , HildenJ , Als-NielsenB , DamgaardN , HansenJF , HansenS , et al. Statin treatment prevents increased cardiovascular and all-cause mortality associated with clarithromycin in patients with stable coronary heart disease. Journal of Cardiovascular Pharmacology2010;55(2):123-8. JespersenCM , Als-NielsenB , DamgaardM , HansenJF , HansenS , HeløOH , et al. Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with coronary heart disease: CLARICOR trial. BMJ2006;332(7532):22-7. JespersenCM , KolmosHJ , FrydendallN , HildenJ , GluudC , HansenJF . Compliance with and short-term adverse events from clarithromycin versus placebo in patients with stable coronary heart disease: the CLARICOR trial. Journal of Antimicrobial Chemotherapy2009;64(2):411-5. NCT00121550. The CLARICOR trial: effect of clarithromycin on mortality and morbidity in patients with ischemic heart disease. https://clinicaltrials.gov/ct2/show/NCT00121550 (first received 21 July 2005). WinkelP , HildenJ , Fischer HansenJ , HildebrandtP , KastrupJ , KolmosHJ , et al. Excess sudden cardiac deaths after short-term clarithromycin administration in the CLARICOR trial: why is this so, and why are statins protective?Cardiology2011;118(1):63-67. WinkelP , HildenJ , HansenJF , KastrupJ , KolmosHJ , KjøllerE , et al. Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular mortality and cerebrovascular mortality over 10 years in the CLARICOR randomised, blinded clinical trial. International Journal of Cardiology2015;182:459-65. ">CLARICOR 2006</a> weighted most, there is a small risk of the other trials showing different results. </p> <p>There were no data on the effects of antibiotics versus placebo or no intervention on serious adverse event as defined by ICH‐GCP or quality of life. Hence, the effects of antibiotics on these outcomes are unclear. Another limitation of the completeness of evidence is that the vast majority of the data was only contributed by trials assessing the effects of either macrolides (28 trials randomising 22,059 participants) or quinolones (two trials randomising 4162 participants), while only a very small amount of the data was contributed by trials assessing the effects of tetracyclines (eight trials randomising 417 participants). We found no trials assessing the effects of other antibiotic classes. Hence, we do not know the benefits and harms of tetracyclines or other antibiotic classes for secondary prevention of coronary heart disease. </p> <p>In our review, most of the findings showed harm. When assessing harms, it is important to remember the recommendations from the European Medical Agency (EMA). According to the EMA, in the case of adverse events, P values are of limited value as substantial differences (expressed as relative risk of risk differences) require careful assessment and will, in addition, raise concern, depending on seriousness, severity, or outcome, irrespective of the P value observed (<a href="./references#CD003610-bbs2-0094" title="Guideline on multiplicity issues in clinical trials. European Medicines Agency2017.">EMA 2017</a>). A non‐significant difference between treatments will not allow for a conclusion on the absence of a difference in safety. In other words, in line with general principles, a non‐significant test result should not be confused with the demonstration of equivalence (<a href="./references#CD003610-bbs2-0094" title="Guideline on multiplicity issues in clinical trials. European Medicines Agency2017.">EMA 2017</a>). Hence, even though several of our meta‐analyses did not show significant harmful results, we should not conclude that no harmful effect exists. Instead, we should look at the results which indicate that there seem to be a very high possibility of serious harm while there is a small possibility of a neutral result or benefit. </p> <p>A limitation of the applicability of our results is that we chose maximum follow‐up as our time point of primary interest. Winkel and colleagues stated when discussing the findings from the 10‐years follow‐up of the CLARICOR trial that after three years follow‐up, the observed harmful effect of clarithromycin vanished (<a href="./references#CD003610-bbs2-0201" title="WinkelP , HildenJ , HansenJF , KastrupJ , KolmosHJ , KjollerE , et al. Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular mortality and cerebrovascular morbidity over 10 years in the CLARICOR randomised, blinded clinical trial. International Journal of Cardiology2015;182:459-65.">Winkel 2015</a>). They found that the placebo‐treated participants seemed to catch up with the clarithromycin‐treated participants. They interpreted this as frailty attrition, i.e. the harmful events occurred 'prematurely' in a subset of participants vulnerable to the antibiotic, so after some time the survivors in the antibiotic group were on the whole more resistant. At the same time, the frail participants in the placebo group began experiencing harmful events because of natural causes unrelated to the trial, which did not happen to the survivors in the antibiotic group as the frail participants might already have died. This lead to the results being 'diluted' by events unrelated to the trial. Our other time point of interest was at 24±6 months follow‐up. It might be that the findings at 24±6 months follow‐up are showing a more true picture, as they may have not been affected by frailty attrition. Nevertheless, our findings at 24±6 months follow‐up are limited by possible imprecision, as only few trials reported their findings at 24±6 months follow‐up. Overall, even though this review provides the most comprehensive and contemporary appraisal of the evidence on antibiotics for secondary prevention of patients with coronary heart disease to date, our results might not show the actual true results. The actual true results might even be more harmful. </p> </section> <section id="CD003610-sec-0129"> <h3 class="title" id="CD003610-sec-0129">Quality of the evidence</h3> <section id="CD003610-sec-0130"> <h4 class="title">Risk of systematic error ('bias')</h4> <p>Our 'risk of bias' assessment showed that only three trials were at low risk of bias (<a href="./references#CD003610-bbs2-0001" title="AndersonJL , MuhlesteinJB , CarlquistJ , AllenA , TrehanS , NielsonC , et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection. The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) Study. Circulation1999;99:1540-7. MuhlesteinJB , AndersonJL , CarlquistJF , SalunkheK , HorneBD , PearsonRP , et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease. Primary clinical results of the ACADEMIC study. Circulation2000;102:1755-60. ">ACADEMIC 1999</a>; <a href="./references#CD003610-bbs2-0005" title="CercekB , ShahPK , NocM , ZahgerD , ZeymerU , MatetzkyS , et al. Effect of short-term treatment with azithromycin on recurrent ischaemic events in patients with acute coronary syndrome in the Azithromycin in Acute Coronary Syndrome (AZACS) trial: a randomised controlled trial. Lancet2003;361:809-13. ">AZACS 2003</a>; <a href="./references#CD003610-bbs2-0007" title="GluudC , Als-NielsenB , DamgaardB , HansenJF , HansenS , HeløOH , et al. Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease. Cardiology2008;111:280-7. HansenS , Als-NielsenB , DamgaardM , HeløOH , PetersenL , JespersenCM . Intervention with clarithromycin in patients with stable coronary heart disease. The CLARICOR trial design. Heart Drug2001;1:14-9. HildenJ , LindI , KolmosHJ , Als-NielsenB , DamgaardN , HansenJF , et al. Chlamydia pneumoniae IgG and IgA antibody titers and prognosis in patients with coronary heart disease: results from the CLARICOR trial. Diagnostic Microbiology and Infectious diseases2010;66(4):385-92. JensenGB , HildenJ , Als-NielsenB , DamgaardN , HansenJF , HansenS , et al. Statin treatment prevents increased cardiovascular and all-cause mortality associated with clarithromycin in patients with stable coronary heart disease. Journal of Cardiovascular Pharmacology2010;55(2):123-8. JespersenCM , Als-NielsenB , DamgaardM , HansenJF , HansenS , HeløOH , et al. Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with coronary heart disease: CLARICOR trial. BMJ2006;332(7532):22-7. JespersenCM , KolmosHJ , FrydendallN , HildenJ , GluudC , HansenJF . Compliance with and short-term adverse events from clarithromycin versus placebo in patients with stable coronary heart disease: the CLARICOR trial. Journal of Antimicrobial Chemotherapy2009;64(2):411-5. NCT00121550. The CLARICOR trial: effect of clarithromycin on mortality and morbidity in patients with ischemic heart disease. https://clinicaltrials.gov/ct2/show/NCT00121550 (first received 21 July 2005). WinkelP , HildenJ , Fischer HansenJ , HildebrandtP , KastrupJ , KolmosHJ , et al. Excess sudden cardiac deaths after short-term clarithromycin administration in the CLARICOR trial: why is this so, and why are statins protective?Cardiology2011;118(1):63-67. WinkelP , HildenJ , HansenJF , KastrupJ , KolmosHJ , KjøllerE , et al. Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular mortality and cerebrovascular mortality over 10 years in the CLARICOR randomised, blinded clinical trial. International Journal of Cardiology2015;182:459-65. ">CLARICOR 2006</a>), while all other trials were at high risk of bias (see '<a href="#CD003610-sec-0057">Risk of bias in included studies</a>' for details). However, most information was either from trials at low risk of bias, or trials at low risk of bias in the majority of domains. We, therefore, interpreted that the potential limitations of the trials were unlikely to lower the confidence in the outcome results. Hence, we did not downgrade any outcome for risk of bias. </p> </section> <section id="CD003610-sec-0131"> <h4 class="title">Risk of random error ‐ imprecision ('play of chance')</h4> <p>For all outcome results at both our time points, we either reached the optimal information size or the sample sizes were large (&gt; 4000 participants). Accordingly, no outcome result was downgraded for risk of imprecision. </p> </section> <section id="CD003610-sec-0132"> <h4 class="title">Indirectness</h4> <p>We assessed the differences between the population of interest and the included participants as low for all outcome results beside the sensitivity analysis of cardiovascular mortality only including low risk of bias trials at maximum follow‐up and the overall analyses of sudden cardiac death at both our time points. For these analyses, only very few trials were included. Hence, there is a risk of genetic differences and correspondingly the effect of antibiotics between the included participants in these analyses and patients in other parts of the world might differ. For all other analyses, several or more trials were included with significantly more participants which indicate a lower risk of difference. However, it might be discussed whether the low inclusion of women (22.9%) might affect the primary results. We acknowledge that the baseline risk of coronary heart disease and control event rate of mortality and cardiovascular events might be different in men and women. However, we do not think that there is a significant sex‐based difference in antibiotic activity (<a href="./references#CD003610-bbs2-0187" title="Soldin OP , Chung SH , Mattison DR . Sex differences in drug disposition. J Biomed Biotechnol2011;2011:187103.">Soldin 2011</a>; <a href="./references#CD003610-bbs2-0197" title="WhitleyH , LindseyW . Sex-based differences in drug activity. Am Fam Physician2009;80(11):1254-8.">Whitley 2009</a>). </p> <p>We assessed the differences between the intervention of interest and the included interventions as low for all outcome results beside the sensitivity analysis of cardiovascular mortality only including low risk of bias trials at maximum follow‐up and the overall analyses of sudden cardiac death at both our time points. For these analyses, only two and one type of antibiotic was included, respectively. Hence, the results from these analyses might have been difference if several different types of antibiotics had been included. </p> <p>We assessed the differences between the planned outcomes and the included outcomes as low. This was due to the trials reporting the outcomes in a similar way. Moreover, all outcomes were patient‐important. </p> <p>Based on the above, we downgraded the sensitivity analysis of cardiovascular mortality only including low risk of bias trials at maximum follow‐up and the overall meta‐analyses of sudden cardiac death at both our time points by one level for serious risk of indirectness. </p> </section> <section id="CD003610-sec-0133"> <h4 class="title">Heterogeneity ‐ inconsistency</h4> <p>We assessed the statistical heterogeneity in the planned analyses of our primary and secondary outcomes as low to moderate. Only the meta‐analysis of all trials on myocardial infarction at 24±6 months follow‐up had significant heterogeneity (I<sup>2</sup> = 43%; P = 0.14). For all other meta‐analyses, the heterogeneity was low (I<sup>2</sup> &lt; 30%). The limited signs of statistical heterogeneity increases the validity of our results on all outcomes beside myocardial infarction at 24±6 months follow‐up. Accordingly, we downgraded the meta‐analysis of all trials on myocardial infarction at 24±6 months follow‐up by one level for serious risk of inconsistency. </p> </section> <section id="CD003610-sec-0134"> <h4 class="title">Publication bias</h4> <p>We only assessed the risk of publication bias in meta‐analyses including at least 10 trials. Hence, meta‐analysis of stroke and sudden cardiac death at maximum follow‐up and all meta‐analyses at 24±6 follow‐up could not be assessed. For the remaining meta‐analyses, our funnel plots and corresponding tests did not show any clear sign of asymmetry. Accordingly, we did not downgrade any meta‐analysis for risk of publication bias. </p> </section> <section id="CD003610-sec-0135"> <h4 class="title">GRADE</h4> <p>We have assessed the certainty of the evidence of each outcome results using GRADE (<a href="./full#CD003610-tbl-0001">summary of findings Table 1</a> (maximum follow‐up) and <a href="./full#CD003610-tbl-0002">summary of findings Table 2</a> (24±6 months follow‐up)). The GRADE assessment showed that the certainty of the evidence was high to moderate both at maximum follow‐up and at 24±6 months follow‐up. Reasons for the GRADE assessment are given in the footnotes of the table (<a href="./full#CD003610-tbl-0001">summary of findings Table 1</a> (maximum follow‐up) and <a href="./full#CD003610-tbl-0002">summary of findings Table 2</a> (24±6 months follow‐up)). </p> </section> </section> <section id="CD003610-sec-0136"> <h3 class="title" id="CD003610-sec-0136">Potential biases in the review process</h3> <section id="CD003610-sec-0137"> <h4 class="title">Strengths</h4> <p>Our review has several strengths. We are the first to conduct a systematic review using Cochrane methodology comparing antibiotics versus placebo or no intervention for secondary prevention in patients with coronary heart disease. We followed our peer‐reviewed protocol which was published before the literature search began (<a href="./references#CD003610-bbs2-0210" title="SethiNJ , SafiS , KorangSK , HróbjartssonA , SkoogM , GluudC , et al. Antibiotics for secondary prevention of coronary heart disease. Cochrane Database of Systematic Reviews2017, Issue 7. Art. No: CD003610. [DOI: 10.1002/14651858.CD003610.pub3]">Sethi 2017</a>), and we conducted the review using the methods recommended by Cochrane (<a href="./references#CD003610-bbs2-0117" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011a</a>). We included trials regardless of language of publication and whether they reported data on the outcomes we had planned to assess. We contacted all relevant authors if additional information was needed. We included more trials and more participants than any previous systematic review or meta‐analysis which gives us increased power and precision to detect any evidence of a difference between the intervention and control group. Data were double‐extracted by independent review authors minimising the risk of inaccurate data extraction, and we assessed the risk of bias in all trials according to <i>The</i> <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD003610-bbs2-0119" title="HigginsJPT , AltmanDG , Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook.">Higgins 2017</a>). We used GRADE to assess the certainty of the body of evidence, subgroup analysis to assess possible heterogeneity, and sensitivity analyses to test the potential impact of overall bias risk, incomplete outcome data bias, and sub‐optimal medical therapy. Hence, this systematic review considered both risks of random errors and risks of systematic errors which adds further robustness to our results and conclusions. </p> <p>Our meta‐analyses, except for the meta‐analysis of all trials on myocardial infarction at 24±6 months follow‐up, had little statistical heterogeneity strengthening the validity of our results. </p> </section> <section id="CD003610-sec-0138"> <h4 class="title">Limitations</h4> <p>Our systematic review also has several limitations. Our findings, interpretations, and conclusions are affected by the quality, quantity, and outcome reporting of the included trials. Some limitations have already been discussed in the above section '<a href="#CD003610-sec-0128">Overall completeness and applicability of evidence</a>'. </p> <p><b>Bias risk assessment</b> </p> <p>We only found three trials at low risk of bias (<a href="./references#CD003610-bbs2-0001" title="AndersonJL , MuhlesteinJB , CarlquistJ , AllenA , TrehanS , NielsonC , et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection. The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) Study. Circulation1999;99:1540-7. MuhlesteinJB , AndersonJL , CarlquistJF , SalunkheK , HorneBD , PearsonRP , et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease. Primary clinical results of the ACADEMIC study. Circulation2000;102:1755-60. ">ACADEMIC 1999</a>; <a href="./references#CD003610-bbs2-0005" title="CercekB , ShahPK , NocM , ZahgerD , ZeymerU , MatetzkyS , et al. Effect of short-term treatment with azithromycin on recurrent ischaemic events in patients with acute coronary syndrome in the Azithromycin in Acute Coronary Syndrome (AZACS) trial: a randomised controlled trial. Lancet2003;361:809-13. ">AZACS 2003</a>; <a href="./references#CD003610-bbs2-0007" title="GluudC , Als-NielsenB , DamgaardB , HansenJF , HansenS , HeløOH , et al. Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease. Cardiology2008;111:280-7. HansenS , Als-NielsenB , DamgaardM , HeløOH , PetersenL , JespersenCM . Intervention with clarithromycin in patients with stable coronary heart disease. The CLARICOR trial design. Heart Drug2001;1:14-9. HildenJ , LindI , KolmosHJ , Als-NielsenB , DamgaardN , HansenJF , et al. Chlamydia pneumoniae IgG and IgA antibody titers and prognosis in patients with coronary heart disease: results from the CLARICOR trial. Diagnostic Microbiology and Infectious diseases2010;66(4):385-92. JensenGB , HildenJ , Als-NielsenB , DamgaardN , HansenJF , HansenS , et al. Statin treatment prevents increased cardiovascular and all-cause mortality associated with clarithromycin in patients with stable coronary heart disease. Journal of Cardiovascular Pharmacology2010;55(2):123-8. JespersenCM , Als-NielsenB , DamgaardM , HansenJF , HansenS , HeløOH , et al. Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with coronary heart disease: CLARICOR trial. BMJ2006;332(7532):22-7. JespersenCM , KolmosHJ , FrydendallN , HildenJ , GluudC , HansenJF . Compliance with and short-term adverse events from clarithromycin versus placebo in patients with stable coronary heart disease: the CLARICOR trial. Journal of Antimicrobial Chemotherapy2009;64(2):411-5. NCT00121550. The CLARICOR trial: effect of clarithromycin on mortality and morbidity in patients with ischemic heart disease. https://clinicaltrials.gov/ct2/show/NCT00121550 (first received 21 July 2005). WinkelP , HildenJ , Fischer HansenJ , HildebrandtP , KastrupJ , KolmosHJ , et al. Excess sudden cardiac deaths after short-term clarithromycin administration in the CLARICOR trial: why is this so, and why are statins protective?Cardiology2011;118(1):63-67. WinkelP , HildenJ , HansenJF , KastrupJ , KolmosHJ , KjøllerE , et al. Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular mortality and cerebrovascular mortality over 10 years in the CLARICOR randomised, blinded clinical trial. International Journal of Cardiology2015;182:459-65. ">CLARICOR 2006</a>). We conducted sensitivity analyses only including low risk of bias trials to assess if the results differed compared to the overall analyses. We planned to base our primary analyses and primary conclusions on trials at low risk of bias, since meta‐epidemiological studies have shown that trials at high risk of bias overestimate benefit and underestimate harm (<a href="./references#CD003610-bbs2-0179" title="SchulzKF , ChalmersI , HayesRJ , AltmanDG . Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA1995;273(5):408-12.">Schulz 1995</a>; <a href="./references#CD003610-bbs2-0153" title="MoherD , PhamB , JonesA , CookDJ , JadadAR , MoherM , et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?Lancet1998;352(9128):609-13.">Moher 1998</a>; <a href="./references#CD003610-bbs2-0133" title="KjaergardLL , VillumsenJ , GluudC . Reported methodological quality and discrepancies between small and large randomized trials in meta-analyses. Annals of Internal Medicine2001;135:982-9.">Kjaergard 2001</a>; <a href="./references#CD003610-bbs2-0104" title="GluudLL . Bias in clinical intervention research. American Journal of Epidemiology2006;163(6):493-501.">Gluud 2006</a>; <a href="./references#CD003610-bbs2-0204" title="WoodL , EggerM , GluudLL , SchulzKF , JuniP , AltmanDG , et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ2008;336(7644):601-5.">Wood 2008</a>; <a href="./references#CD003610-bbs2-0177" title="SavovicJ , JonesHE , AltmanDG , HarrisRJ , JuniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine2012;157(6):429-38.">Savovic 2012</a>; <a href="./references#CD003610-bbs2-0178" title="SavovicJ , TurnerRM , MawdsleyD , JonesHE , BeynonR , HigginsJPT , et al. Association between risk-of-bias assessments and results of randomized trials in Cochrane reviews: the ROBES meta-epidemiologic study. American Journal of Epidemiology2018;187(5):1113-22.">Savovic 2018</a>). The outcome result for cardiovascular mortality at maximum follow‐up differed between the overall analysis and the sensitivity analysis only including low risk of bias trials. For all other outcome results, the results did not differ. Hence, for cardiovascular mortality at maximum follow‐up, we based our primary analysis and primary conclusion on the sensitivity analysis only including low risk of bias trials. For all other outcomes, we based our primary analyses and primary conclusions on the overall analyses. </p> <p>Our assessment of publication bias was uncertain for all outcomes at 24±6 months follow‐up, as a relatively low number of trials was included. </p> <p><b>Incomplete outcome data</b> </p> <p>In total, 19/38 trials were assessed at unclear or high risk of bias on the incomplete outcome data bias domain. Our 'best‐worst', 'worst‐best', modified 'best‐worst', and modified 'worst‐best' case analyses confirmed that there was a high risk of incomplete outcome data bias, especially for the analyses at maximum follow‐up. In 13/38 trials, it was not reported in sufficient detail if any participant was lost to follow‐up. It was often only reported that a certain number of participants died or experienced a type of serious adverse event without reporting if any of the participants were lost to follow‐up, etc. If insufficient data were reported by the trialists, we tried to contact the authors, but often the authors did not reply. Hence, the extent of the incomplete outcome data was often unclear. Our 'best‐worst', 'worst‐best', modified 'best‐worst', and modified 'worst‐best' case analyses might underestimate the potential impact of missing data because only the data on the reported population were used if no other information was available. Incomplete outcome data might potentially have an even greater bias impact than our 'best‐worst', 'worst‐best', modified 'best‐worst', and modified 'worst‐best' case analyses show, i.e. the 'true' differences between the actually observed cases and the intention‐to‐treat population might be larger than our data suggest. </p> <p><b>Serious adverse event</b> </p> <p>The trials included in this review reported harms inadequately. None of the trials specifically assessed serious adverse event according to ICH‐GCP. Instead, the trials either reported composites of several specific serious adverse events or one specific serious adverse event. We could, therefore, not conduct a meta‐analysis as planned on all serious adverse events. Hence, it was not possible to assess the overall safety of antibiotics in patients with coronary heart disease. This is very problematic, as the reporting of harm is as important as the reporting of efficacy. Without adequate reporting of both harm and benefit, it is not possible to estimate if an intervention is useful or not (<a href="./references#CD003610-bbs2-0124" title="IoannidisJP . Adverse events in randomized trials: neglected, restricted, distorted, and silenced. Archives of Internal Medicine2009;169(19):1737-9.">Ioannidis 2009</a>; <a href="./references#CD003610-bbs2-0190" title="StorebøOJ , PedersenN , RamstadE , KielsholmML , NielsenSS , KroghHB , et al. Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents – assessment of adverse events in non-randomised studies. Cochrane Database of Systematic Reviews2018, Issue 5. Art. No: CD012069. [DOI: 10.1002/14651858.CD012069]">Storebø 2018</a>). </p> <p><b>Multiplicity</b> </p> <p>We used broad inclusion criteria to fully assess the effects of antibiotics for secondary prevention of patients with coronary heart disease. Therefore, we included a large number of outcomes, time points, subgroup analyses, and sensitivity analyses. We are aware that this increases the risk of type 1 error due to multiplicity. To minimise the potential risk, we used a more conservative alpha of 2.5% for our primary outcomes and 2.0% for our secondary outcomes (<a href="./references#CD003610-bbs2-0125" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology2014;14:120.">Jakobsen 2014</a>; <a href="./references#CD003610-bbs2-0126" title="JakobsenJC , WetterslevJ , LangeT , GluudC . Viewpoint: taking into account risks of random errors when analysing multiple outcomes in systematic reviews. Cochrane Database of Systematic Reviews2016;3:Ed000111.">Jakobsen 2016</a>). Nevertheless, as mentioned in the '<a href="#CD003610-sec-0154">Differences between protocol and review</a>', we did not use P values to determine whether a result was significant. </p> </section> </section> <section id="CD003610-sec-0139"> <h3 class="title" id="CD003610-sec-0139">Agreements and disagreements with other studies or reviews</h3> <p><b>Systematic reviews and meta‐analyses of randomised clinical trials</b> </p> <p>We identified five systematic reviews and meta‐analyses of randomised clinical trials assessing the effects of antibiotics versus placebo or no intervention for secondary prevention in patients with coronary heart disease (<a href="./references#CD003610-bbs2-0195" title="WellsBJ , Mainous AG 3rd, DickersonLM . Antibiotics for the secondary prevention of ischaemic heart disease: a meta-analysis of randomized controlled trials. Archives of Internal Medicine2004;164:2156-61.">Wells 2004</a>; <a href="./references#CD003610-bbs2-0095" title="EtminanM , CarletonB , DelaneyJA , PadwalR . Macrolide therapy for Chlamydia pneumoniae in the secondary prevention of coronary artery disease: a meta-analysis of randomized controlled trials. Pharmacotherapy2004;24(3):338-43.">Etminan 2004</a>; <a href="./references#CD003610-bbs2-0066" title="AndrawsR , BergerJS , BrownDL . Effects of antibiotic therapy on outcomes of patients with coronary artery disease: a meta-analysis of randomized controlled trials. JAMA2005;293(21):2641-7.">Andraws 2005</a>; <a href="./references#CD003610-bbs2-0069" title="BakerWL , CouchKA . Azithromycin for the secondary prevention of coronary artery disease: a meta-analysis. American Journal of Health-System Pharmacy2007;64(8):830-6.">Baker 2007</a>; <a href="./references#CD003610-bbs2-0105" title="GluudC , Als-NielsenB , DamgaardM , Fischer HansenJ , HansenS , HeløOH , et al, CLARICOR Trial Group. Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease. Cardiology2008;111(4):280-7.">Gluud 2008</a>). None of the former reviews or meta‐analyses systematically assessed the risks of random error, used the GRADE approach to assess the certainty of the body of evidence, or assessed other time points than maximum follow‐up, and most of the reviews or meta‐analyses did not employ adequate assessments of risks of bias. </p> <p>We also identified four systematic reviews of randomised clinical trials assessing the effects of antibiotics for secondary prevention in patients with any vascular disease (<a href="./references#CD003610-bbs2-0122" title="IllohKO , IllohOC , FesehaHB , HallenbeckJM . Antibiotics for vascular diseases: a meta-analysis of randomized controlled trials. Atherosclerosis2005;179:403-12.">Illoh 2005</a>), and any disease (<a href="./references#CD003610-bbs2-0060" title="AlmalkiZS , GuoJJ . Cardiovascular events and safety outcomes associated with azithromycin therapy: a meta-analysis of randomized controlled trials. American Health &amp; Drug Benefits2014;7(6):318-28.">Almalki 2014</a>; <a href="./references#CD003610-bbs2-0203" title="WongAYS , ChanEW , AnandS , WorsleyAJ , WongICK . Managing cardiovascular risk of macrolides: systematic review and meta-analysis. Drug Safety2017;40:663-77.">Wong 2017</a>; <a href="./references#CD003610-bbs2-0113" title="HansenMP , ScottAM , McCulloughA , ThorningS , AronsonJK , BellerEM , et al. Adverse events in people taking macrolide antibiotics versus placebo for any indication. Cochrane Database of Systematic Reviews2019;1:CD011825.">Hansen 2019</a>), respectively. </p> <p><a href="./references#CD003610-bbs2-0195" title="WellsBJ , Mainous AG 3rd, DickersonLM . Antibiotics for the secondary prevention of ischaemic heart disease: a meta-analysis of randomized controlled trials. Archives of Internal Medicine2004;164:2156-61.">Wells 2004</a> assessed the effects of antibiotics for the secondary prevention of patients with ischaemic heart disease and included nine trials enrolling 11,015 participants. They found no evidence of a difference on all‐cause mortality (risk ratio (RR) 0.94, 95% confidence interval (CI) 0.79 to 1.12) and any cardiac event (RR 0.94, 95% CI 0.86 to 1.03). Our results are not similar in regard to all‐cause mortality, as we found that antibiotics seem to have a harmful effect. We did not assess the effects of antibiotics on 'any cardiac event'. </p> <p><a href="./references#CD003610-bbs2-0095" title="EtminanM , CarletonB , DelaneyJA , PadwalR . Macrolide therapy for Chlamydia pneumoniae in the secondary prevention of coronary artery disease: a meta-analysis of randomized controlled trials. Pharmacotherapy2004;24(3):338-43.">Etminan 2004</a> assessed the effects of macrolides for the secondary prevention of patients with coronary artery disease and included nine trials enrolling 12,032 participants. They found no evidence of a difference on all‐cause mortality (RR 0.95, 95% CI 0.81 to 1.12), myocardial infarction or angina (RR 0.89, 95% CI 0.68 to 1.16), and any coronary event (RR 0.98, 95% CI 0.88 to 1.08). Our results are not similar in regard to all‐cause mortality, as we found that antibiotics seem to have a harmful effect. We did not assess the effects of antibiotics on 'myocardial or angina' or 'any coronary event'. </p> <p><a href="./references#CD003610-bbs2-0122" title="IllohKO , IllohOC , FesehaHB , HallenbeckJM . Antibiotics for vascular diseases: a meta-analysis of randomized controlled trials. Atherosclerosis2005;179:403-12.">Illoh 2005</a> assessed the effects of antibiotics for the secondary prevention of patients with vascular disease and included 12 trials enrolling 12,236 participants. They found no evidence of a difference on any vascular event or death (odds ratio (OR) 0.84, 95% CI 0.67 to 1.05). We did not assess the effects of antibiotics on 'any vascular event or death'. </p> <p><a href="./references#CD003610-bbs2-0066" title="AndrawsR , BergerJS , BrownDL . Effects of antibiotic therapy on outcomes of patients with coronary artery disease: a meta-analysis of randomized controlled trials. JAMA2005;293(21):2641-7.">Andraws 2005</a> assessed the effects of antibiotics for secondary prevention of patients with coronary artery disease and included 11 trials enrolling 19,216 participants. They found no evidence of a difference on all‐cause mortality (OR 1.02, 95% CI 0.89 to 1.16), myocardial infarction (OR 0.92, 95% CI 0.81 to 1.04), and myocardial infarction or angina (OR 0.91, 95% CI 0.76 to 1.07). Their results on myocardial infarction are similar to ours, as we too did not find any evidence of a difference on the risk of myocardial infarction. With regards to all‐cause mortality, our results are not similar, as we found that antibiotics seem to have a harmful effect. We did not assess the effects of antibiotics on 'myocardial infarction or angina'. </p> <p><a href="./references#CD003610-bbs2-0069" title="BakerWL , CouchKA . Azithromycin for the secondary prevention of coronary artery disease: a meta-analysis. American Journal of Health-System Pharmacy2007;64(8):830-6.">Baker 2007</a> assessed the effects of azithromycin for the secondary prevention of patients with coronary artery disease and included six trials enrolling 13,778 participants. They found no evidence of a difference on all‐cause mortality (OR 0.91, 95% CI 0.77 to 1.09), myocardial infarction (OR 0.95, 95% CI 0.80 to 1.13), hospitalisation (OR 0.97, 95% CI 0.80 to 1.17), and any cardiac event (OR 0.93, 95% CI 0.84 to 1.03). Their results on myocardial infarction and hospitalisation are similar to ours, as we too did not find any evidence of a difference on the risk of myocardial infarction and hospitalisation. In regards to all‐cause mortality, our results are not similar, as we found that antibiotics seem to have a harmful effect. We did not assess the effects of antibiotics on 'any cardiac event'. </p> <p><a href="./references#CD003610-bbs2-0105" title="GluudC , Als-NielsenB , DamgaardM , Fischer HansenJ , HansenS , HeløOH , et al, CLARICOR Trial Group. Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease. Cardiology2008;111(4):280-7.">Gluud 2008</a> assessed the effects of antibiotics for the secondary prevention of patients with coronary heart disease and included 17 trials enrolling 25,271 participants. The meta‐analysis found evidence of a harmful effect of antibiotics on all‐cause mortality (RR 1.10, 95% CI 1.01 to 1.20), which is similar to our results, as we also found that antibiotics seem to have a harmful effect on the risk of all‐cause mortality. </p> <p><a href="./references#CD003610-bbs2-0060" title="AlmalkiZS , GuoJJ . Cardiovascular events and safety outcomes associated with azithromycin therapy: a meta-analysis of randomized controlled trials. American Health &amp; Drug Benefits2014;7(6):318-28.">Almalki 2014</a> assessed the effects of azithromycin for the secondary prevention of patients with any disease and included 12 trials enrolling 15,588 participants. They found no evidence of a difference on all‐cause mortality (RR 0.88, 95% CI 0.75 to 1.02), hospitalisation (RR 1.01, 95% CI 0.92 to 1.09), and any cardiac event (RR 1.00, 95% CI 0.90 to 1.13). Their results on hospitalisation are similar to ours, as we too did not find any evidence of a difference on the risk of hospitalisation. In regards to all‐cause mortality, our results are not similar, as we found that antibiotics seem to have a harmful effect on the risk of all‐cause mortality. We did not assess the effects of antibiotics on 'any cardiac event'. </p> <p><a href="./references#CD003610-bbs2-0203" title="WongAYS , ChanEW , AnandS , WorsleyAJ , WongICK . Managing cardiovascular risk of macrolides: systematic review and meta-analysis. Drug Safety2017;40:663-77.">Wong 2017</a> assessed the effects of macrolides for the secondary prevention of patients with any disease and included 16 trials. They found no evidence of a difference on any cardiac event (RR 1.03, 95% CI 0.96 to 1.10), myocardial infarction (RR 0.95, 95% CI 0.87 to 1.04), and stroke (RR 1.13, 95% CI 0.91 to 1.41). Their results on myocardial infarction are similar to ours, as we too did not find any evidence of a difference on the risk of myocardial infarction. In regards to stroke, our results are not similar, as we found that antibiotics seem to have a harmful effect on the risk of stroke. We did not assess the effects of antibiotics on 'any cardiac event'. </p> <p><a href="./references#CD003610-bbs2-0113" title="HansenMP , ScottAM , McCulloughA , ThorningS , AronsonJK , BellerEM , et al. Adverse events in people taking macrolide antibiotics versus placebo for any indication. Cochrane Database of Systematic Reviews2019;1:CD011825.">Hansen 2019</a> assessed the effects of macrolides for the secondary prevention of patients with any disease and included 183 trials enrolling 252,886 participants. They found no evidence of a difference on all‐cause mortality (OR 0.96, 95% CI 0.87 to 1.06) or cardiac disorders (i.e. arrhythmia, acute coronary syndrome, and not specified cardiac events) (OR 0.87, 95% CI 0.54 to 1.40). Their results on all‐cause mortality are not similar to ours, as we found that antibiotics seem to have a harmful effect on the risk of all‐cause mortality. We did not assess the effects of antibiotics on 'any cardiac disorder'. </p> <p>Overall, especially when regarding all‐cause mortality, we disagree with the above‐mentioned reviews. A likely explanation might be that previous reviews did not have enough power to assess mortality both in regard to a much lower number of participants and event rate. A comparison with <a href="./references#CD003610-bbs2-0066" title="AndrawsR , BergerJS , BrownDL . Effects of antibiotic therapy on outcomes of patients with coronary artery disease: a meta-analysis of randomized controlled trials. JAMA2005;293(21):2641-7.">Andraws 2005</a> (which is the latest review with nearly the same inclusion criteria as us) in regard to all‐cause mortality shows that we included 10 more trials with a total of 6787 participants (<a href="./references#CD003610-bbs2-0014" title="NeumannFJ , KastratiA , MiethkeT , Pogatsa-MurrayG , MehilliJ , ValinaC , et al. Treatment of Chlamydia pneumoniae infection with roxithromycin and effect on neointima proliferation after coronary stent placement (ISAR-3): a randomised, double-blind, placebo-controlled trial. Lancet2001;357:2085-9. ">ISAR‐3 2001</a>; <a href="./references#CD003610-bbs2-0022" title="BrownDL , DesaiKK , VakiliBA , NounehC , LeeHM , GolubLM . Clinical and biochemical results of the metalloproteinase inhibition with subantimicrobial doses of doxycycline to prevent acute coronary syndromes (MIDAS) pilot trial. Arteriosclerosis, Thrombosis, and Vascular Biology2004;24:733-8. ">MIDAS 2003</a>; <a href="./references#CD003610-bbs2-0026" title="RadoiM , BobescuE , AgacheI . Rovamycine as add-on treatment in unstable angina and 4 year evolution with major cardiovascular events. Romanian Journal of Internal Medicine2003;41(3):237-46. ">Radoi 2003</a>; <a href="./references#CD003610-bbs2-0017" title="KimW , JeongMH , HongYJ , LeeSH , LimSY , HongSN , et al. A randomized trial for the secondary prevention by azithromycin in korean patients with acute coronary syndrome after percutaneous coronary intervention. Korean Circulation Journal2004;34(8):743-51. ">Kim 2004</a>; <a href="./references#CD003610-bbs2-0037" title="ÜtükO , SekuriC , Bayturan Ö, BilgeAR , TikizH , TavhT , et al. The effects of clarithromycin treatment on cardiac events in acute coronary syndrome patients. Anatolian Journal of Cardiology2004;4:213-6. ">Ütük 2004</a>; <a href="./references#CD003610-bbs2-0006" title="BergHF , MarahaB , SchefferGJ , PeetersMF , KluytmansJA . Effect of clarithromycin on inflammatory markers in patients with atherosclerosis. Clinical and Diagnostic Laboratory Immunology2003;10(4):525-8. BergHF , MarahaB , SchefferGJ , UffordMQ , Vandenbroucke-GraulsCME , PeetersMF , et al. Treatment with clarithromycin prior to coronary artery bypass graft surgery does not prevent subsequent cardiac events. Clinical Infectious Diseases2005;40:358-65. BergHF , MarahaB , van derZeeA , GielisSK , RohollPJ , SchefferGJ , et al. Effect of clarithromycin treatment on Chlamydia pneumoniae in vascular tissue of patients with coronary artery disease: a randomized, double-blind, placebo-controlled trial. Journal of Clinical Microbiology2005;43(3):1325-9. BergHF , TjhieJH , SchefferGJ , PeetersMF , vanKeulenPH , KluytmansJA , et al. Emergence and persistence of macrolide resistance in oropharyngeal flora and elimination of nasal carriage of Staphylococcus aureus after therapy with slow-release clarithromycin: a randomized, double-blind, placebo-controlled study. Antimicrobial Agents and Chemotherapy2004;48(11):4183-8. ">Berg 2005</a>; <a href="./references#CD003610-bbs2-0016" title="KaehlerJ , HaarA , SchapsKP , GaedeA , CarstensenM , SchalwatI , et al. A randomized trial in patients undergoing percutaneous coronary angioplasty: roxithromycin does not reduce clinical restenosis but angioplasty increases antibody concentrations against Chlamydia pneumoniae . American Heart Journal2005;150:987-93. ">Kaehler 2005</a>; <a href="./references#CD003610-bbs2-0007" title="GluudC , Als-NielsenB , DamgaardB , HansenJF , HansenS , HeløOH , et al. Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease. Cardiology2008;111:280-7. HansenS , Als-NielsenB , DamgaardM , HeløOH , PetersenL , JespersenCM . Intervention with clarithromycin in patients with stable coronary heart disease. The CLARICOR trial design. Heart Drug2001;1:14-9. HildenJ , LindI , KolmosHJ , Als-NielsenB , DamgaardN , HansenJF , et al. Chlamydia pneumoniae IgG and IgA antibody titers and prognosis in patients with coronary heart disease: results from the CLARICOR trial. Diagnostic Microbiology and Infectious diseases2010;66(4):385-92. JensenGB , HildenJ , Als-NielsenB , DamgaardN , HansenJF , HansenS , et al. Statin treatment prevents increased cardiovascular and all-cause mortality associated with clarithromycin in patients with stable coronary heart disease. Journal of Cardiovascular Pharmacology2010;55(2):123-8. JespersenCM , Als-NielsenB , DamgaardM , HansenJF , HansenS , HeløOH , et al. Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with coronary heart disease: CLARICOR trial. BMJ2006;332(7532):22-7. JespersenCM , KolmosHJ , FrydendallN , HildenJ , GluudC , HansenJF . Compliance with and short-term adverse events from clarithromycin versus placebo in patients with stable coronary heart disease: the CLARICOR trial. Journal of Antimicrobial Chemotherapy2009;64(2):411-5. NCT00121550. The CLARICOR trial: effect of clarithromycin on mortality and morbidity in patients with ischemic heart disease. https://clinicaltrials.gov/ct2/show/NCT00121550 (first received 21 July 2005). WinkelP , HildenJ , Fischer HansenJ , HildebrandtP , KastrupJ , KolmosHJ , et al. Excess sudden cardiac deaths after short-term clarithromycin administration in the CLARICOR trial: why is this so, and why are statins protective?Cardiology2011;118(1):63-67. WinkelP , HildenJ , HansenJF , KastrupJ , KolmosHJ , KjøllerE , et al. Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular mortality and cerebrovascular mortality over 10 years in the CLARICOR randomised, blinded clinical trial. International Journal of Cardiology2015;182:459-65. ">CLARICOR 2006</a>; <a href="./references#CD003610-bbs2-0013" title="IkeokaDT , VieiraCZ , LemosPA , StrabelliTV , Ribeiro da SilvaEE , PerinMA , et al. Azithromycin does not prevent six-month myointimal proliferation but attenuates the transient systemic inflammation occurring after coronary stenting. Clinical Research in Cardiology2009;98:44-51. ">Ikeoka 2009</a>; <a href="./references#CD003610-bbs2-0034" title="CerisanoG , BuonamiciP , ParodiG , SantiniA , MoschiG , ValentiR , et al. Early changes of left ventricular filling pattern after reperfused ST-elevation myocardial infarction and doxycycline therapy: Insights from the TIPTOP trial. International Journal of Cardiology2017;240:43-8. CerisanoG , BuonamiciP , ValentiR , SciagráR , RaspantiS , SantiniA , et al. Early short-term doxycycline therapy in patients with acute myocardial infarction and left ventricular dysfunction to prevent the ominous progression to adverse remodelling: the TIPTOP trial. European Heart Journal2014;35(3):184-91. CerisanoG , BuonamiciP , ValentiR , SciagraR , RaspantiS , CarrabbaN , et al. Early short-term doxycycline therapy in patients with acute myocardial infarction and left ventricular dysfunction and the ominous progression to adverse remodeling (TIPTOP). A randomized controlled trial. Journal of the American College of Cardiology2012;59(13 (supplement)):E349. NCT00469261. Tetracycline (Doxycycline) and post myocardial infarction remodeling (TIPTOP). https://clinicaltrials.gov/ct2/show/NCT00469261 (first received 4 May 2007). ">TIPTOP 2014</a>). Moreover, most previous trials before <a href="./references#CD003610-bbs2-0007" title="GluudC , Als-NielsenB , DamgaardB , HansenJF , HansenS , HeløOH , et al. Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease. Cardiology2008;111:280-7. HansenS , Als-NielsenB , DamgaardM , HeløOH , PetersenL , JespersenCM . Intervention with clarithromycin in patients with stable coronary heart disease. The CLARICOR trial design. Heart Drug2001;1:14-9. HildenJ , LindI , KolmosHJ , Als-NielsenB , DamgaardN , HansenJF , et al. Chlamydia pneumoniae IgG and IgA antibody titers and prognosis in patients with coronary heart disease: results from the CLARICOR trial. Diagnostic Microbiology and Infectious diseases2010;66(4):385-92. JensenGB , HildenJ , Als-NielsenB , DamgaardN , HansenJF , HansenS , et al. Statin treatment prevents increased cardiovascular and all-cause mortality associated with clarithromycin in patients with stable coronary heart disease. Journal of Cardiovascular Pharmacology2010;55(2):123-8. JespersenCM , Als-NielsenB , DamgaardM , HansenJF , HansenS , HeløOH , et al. Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with coronary heart disease: CLARICOR trial. BMJ2006;332(7532):22-7. JespersenCM , KolmosHJ , FrydendallN , HildenJ , GluudC , HansenJF . Compliance with and short-term adverse events from clarithromycin versus placebo in patients with stable coronary heart disease: the CLARICOR trial. Journal of Antimicrobial Chemotherapy2009;64(2):411-5. NCT00121550. The CLARICOR trial: effect of clarithromycin on mortality and morbidity in patients with ischemic heart disease. https://clinicaltrials.gov/ct2/show/NCT00121550 (first received 21 July 2005). WinkelP , HildenJ , Fischer HansenJ , HildebrandtP , KastrupJ , KolmosHJ , et al. Excess sudden cardiac deaths after short-term clarithromycin administration in the CLARICOR trial: why is this so, and why are statins protective?Cardiology2011;118(1):63-67. WinkelP , HildenJ , HansenJF , KastrupJ , KolmosHJ , KjøllerE , et al. Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular mortality and cerebrovascular mortality over 10 years in the CLARICOR randomised, blinded clinical trial. International Journal of Cardiology2015;182:459-65. ">CLARICOR 2006</a> had a short follow‐up which lead to a low event rate. </p> <p><b>Systematic reviews of observational studies and recent large observational studies</b> </p> <p>We identified three systematic reviews of observational studies assessing the effects of macrolides compared to non‐use of macrolides in any patient regardless of disease (<a href="./references#CD003610-bbs2-0078" title="ChengYJ , NieXY , ChenXM , LinXX , TangK , ZengWT , et al. The role of macrolide antibiotics in increasing cardiovascular risk. Journal of the American College of Cardiology2015;66(20):2173-84.">Cheng 2015</a>; <a href="./references#CD003610-bbs2-0203" title="WongAYS , ChanEW , AnandS , WorsleyAJ , WongICK . Managing cardiovascular risk of macrolides: systematic review and meta-analysis. Drug Safety2017;40:663-77.">Wong 2017</a>; <a href="./references#CD003610-bbs2-0106" title="GorelikE , MasarwaR , PerlmanA , RotshildV , MuszkatM , MatokI . Systematic review, meta-analysis, and network meta-analysis of the cardiovascular safety of macrolides. Antimicrobial Agents Chemotherapy2018;62(6):e00438-18.">Gorelik 2018</a>). Moreover, we identified two recent observational studies, respectively, one conducted by the FDA (<a href="./references#CD003610-bbs2-0156" title="MosholderAD , LeeJY , ZhouEH , KangEM , GhoshM , IzemR , et al. Long-term risk of acute myocardial infarction, stroke, and death with outpatient use of clarithromycin: a retrospective cohort study. American Journal of Epidemiology2018;187(4):786-92.">Mosholder 2018</a>) and one supported by Pfizer (<a href="./references#CD003610-bbs2-0206" title="ZaroffJG , CheethamTC , PalmettoN , AlmersL , QuesenberryC , SchneiderJ , et al. Association of azithromycin use with cardiovascular mortality. JAMA Network Open2020;3(6):e208199.">Zaroff 2020</a>). </p> <p><a href="./references#CD003610-bbs2-0078" title="ChengYJ , NieXY , ChenXM , LinXX , TangK , ZengWT , et al. The role of macrolide antibiotics in increasing cardiovascular risk. Journal of the American College of Cardiology2015;66(20):2173-84.">Cheng 2015</a> compared macrolides to non‐use of macrolides in any participant and included 33 studies enrolling 20,779,963 participants. They found evidence of a harmful effect of macrolides on 'sudden cardiac death or ventricular tachyarrhythmias' (RR 2.42, 95% CI 1.61 to 3.63), sudden cardiac death (RR 2.52, 95% CI 1.91 to 3.31), cardiovascular mortality (RR 1.31, 95% CI 1.06 to 1.62), and myocardial infarction (RR 1.08, 95% CI 1.01 to 1.15). They found no evidence of a difference on all‐cause mortality (RR 1.03, 95% CI 0.86 to 1.22), stroke (RR 1.10, 95% Ci 0.74 to 1.64), or any cardiac event (RR 1.05, 95% CI 0.94 to 1.17). Their results on cardiovascular mortality and myocardial infarction are not similar to ours, as we did not find any harmful effect of antibiotics on cardiovascular mortality and myocardial infarction. In regards to all‐cause mortality and stroke, our results are not similar, as we found that antibiotics seem to have a harmful effect on the risk of all‐cause mortality and stroke. We did not assess the effects of antibiotics on 'sudden cardiac death or ventricular tachyarrhythmias' and 'any cardiac event'. </p> <p><a href="./references#CD003610-bbs2-0203" title="WongAYS , ChanEW , AnandS , WorsleyAJ , WongICK . Managing cardiovascular risk of macrolides: systematic review and meta-analysis. Drug Safety2017;40:663-77.">Wong 2017</a> compared macrolides to non‐use of macrolides in any participant and included 17 studies. They found evidence of a harmful effect of macrolides on myocardial infarction (RR 1.10, 95% CI 1.04 to 1.17). They found no evidence of a difference on any cardiac event (RR 1.05, 95% CI 0.91 to 1.22), arrhythmia (RR 1.10, 95% CI 0.99 to 1.21), and stroke (RR 1.07, 95% CI 0.80 to 1.42). Their results on myocardial infarction are not similar to ours, as we did not find any harmful effect of antibiotics on the risk of myocardial infarction. In regards to stroke, our results are not similar, as we found that antibiotics seem to have a harmful effect on the risk of stroke. We did not assess the effects of antibiotics on 'any cardiac event' and 'arrhythmia'. </p> <p><a href="./references#CD003610-bbs2-0106" title="GorelikE , MasarwaR , PerlmanA , RotshildV , MuszkatM , MatokI . Systematic review, meta-analysis, and network meta-analysis of the cardiovascular safety of macrolides. Antimicrobial Agents Chemotherapy2018;62(6):e00438-18.">Gorelik 2018</a> compared macrolides to non‐use of macrolides in any participant and included 33 studies enrolling 22,601,032 participants. They found evidence of a harmful effect of macrolides on myocardial infarction (OR 1.15, 95% CI 1.01 to 1.30). They found no evidence of a difference on cardiovascular mortality (OR 1.22, 95% CI 0.94 to 1.59) or arrhythmia (OR 1.20, 95% CI 0.91 to 1.57). Their results on cardiovascular mortality and myocardial infarction are not similar to ours, as we did not find any harmful effect of antibiotics on the risk of cardiovascular mortality and myocardial infarction. We did not assess the effects of antibiotics on the risk of 'arrhythmia'. </p> <p><a href="./references#CD003610-bbs2-0156" title="MosholderAD , LeeJY , ZhouEH , KangEM , GhoshM , IzemR , et al. Long-term risk of acute myocardial infarction, stroke, and death with outpatient use of clarithromycin: a retrospective cohort study. American Journal of Epidemiology2018;187(4):786-92.">Mosholder 2018</a> compared clarithromycin and erythromycin to doxycyline and enrolled 998,476 participants. They found evidence of a harmful effect of clarithromycin compared to doxycyline on all‐cause mortality and the harmful effect size increased based on the number of prescriptions of clarithromycin. After one prescription the hazard ratio (HR) was 1.25 (95% CI 1.21 to 1.29) and increased to 1.62 (95% CI 1.43 to 1.84) after five or more prescriptions. They also found evidence of a harmful effect of clarithromycin compared to doxycycline on myocardial infarction (HR 1.13, 95% CI 1.06 to 1.20) and stroke (HR 1.15, 95% CI 1.08 to 1.22), but the harmful effect size remained the same based on the number of prescriptions. Compareable results with smaller hazard ratios were shown when comparing erythromycin to doxycycline. This study showed that macrolides, especially clarithromycin, compared to doxycycline seem to increase the risk of all‐cause mortality, myocardial infarction, and stroke. Hence, it might be that macrolides have more harmful effects than other antibiotics. </p> <p><a href="./references#CD003610-bbs2-0206" title="ZaroffJG , CheethamTC , PalmettoN , AlmersL , QuesenberryC , SchneiderJ , et al. Association of azithromycin use with cardiovascular mortality. JAMA Network Open2020;3(6):e208199.">Zaroff 2020</a> compared azithromycin to amoxicillin and enrolled 2,929,008 participants. They found evidence of a harmful effect of azithromycin compared to amoxicillin within five days of antibiotic exposure on all‐cause mortality (hazard ratio (HR) 2.00; 95% CI 1.51 to 2.63), cardiovascular mortality (HR 1.82, 95% CI 1.23 to 2.67), and non‐cardiovascular mortality (HR 2.17, 95% CI 1.44 to 3.26). No increased risk was found on any outcome when assessing events six to 10 days after antibiotic exposure. No increased risk was found on sudden cardiac death at both time points. This study showed that azithromycin compared to amoxicillin seem to increase the risk of mortality during the first five days after antibiotic exposure. The higher risk of mortality was both driven by cardiovascular and non‐cardiovascular events such as lung disease and cancer. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD003610-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow chart." data-id="CD003610-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow chart.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/full#CD003610-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-FIG-02" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. Multiple eligible treatments were used in two trials generating two further comparisons (= 38 trials reporting on 40 experimental groups)." data-id="CD003610-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. Multiple eligible treatments were used in two trials generating two further comparisons (= 38 trials reporting on 40 experimental groups). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/full#CD003610-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-FIG-03" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD003610-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/full#CD003610-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, outcome: 1.1 ALL‐CAUSE MORTALITY." data-id="CD003610-fig-0004" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, outcome: 1.1 ALL‐CAUSE MORTALITY. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/full#CD003610-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, outcome: 1.17 CARDIOVASCULAR MORTALITY." data-id="CD003610-fig-0005" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-FIG-05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, outcome: 1.17 CARDIOVASCULAR MORTALITY. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/full#CD003610-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-FIG-05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-FIG-06" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, outcome: 1.33 MYOCARDIAL INFARCTION." data-id="CD003610-fig-0006" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-FIG-06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-FIG-06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, outcome: 1.33 MYOCARDIAL INFARCTION. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/full#CD003610-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-FIG-06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 1: ALL‐CAUSE MORTALITY" data-id="CD003610-fig-0007" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 1: ALL‐CAUSE MORTALITY </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 2: All‐cause mortality ‐ trials at low risk of bias" data-id="CD003610-fig-0008" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 2: All‐cause mortality ‐ trials at low risk of bias </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 3: All‐cause mortality ‐ 'best‐worst case' scenario" data-id="CD003610-fig-0009" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 3: All‐cause mortality ‐ 'best‐worst case' scenario </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 4: All‐cause mortality ‐ 'worst‐best case' scenario" data-id="CD003610-fig-0010" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 4: All‐cause mortality ‐ 'worst‐best case' scenario </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 5: All‐cause mortality ‐ modified 'best‐worst case' scenario" data-id="CD003610-fig-0011" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 5: All‐cause mortality ‐ modified 'best‐worst case' scenario </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 6: All‐cause mortality ‐ modified 'worst‐best case' scenario" data-id="CD003610-fig-0012" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 6: All‐cause mortality ‐ modified 'worst‐best case' scenario </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 7: All‐cause mortality ‐ trials with optimal medical therapy" data-id="CD003610-fig-0013" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 7: All‐cause mortality ‐ trials with optimal medical therapy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 8: All‐cause mortality according to type of antibiotic" data-id="CD003610-fig-0014" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 8: All‐cause mortality according to type of antibiotic </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 9: All‐cause mortality according to antibody status" data-id="CD003610-fig-0015" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 9: All‐cause mortality according to antibody status </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 10: All‐cause mortality according to use of statins" data-id="CD003610-fig-0016" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 10: All‐cause mortality according to use of statins </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 11: All‐cause mortality according to the mean age" data-id="CD003610-fig-0017" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 11: All‐cause mortality according to the mean age </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 12: All‐cause mortality according to clinical trial registration status" data-id="CD003610-fig-0018" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 12: All‐cause mortality according to clinical trial registration status </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 13: All‐cause mortality according to length of follow‐up" data-id="CD003610-fig-0019" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 13: All‐cause mortality according to length of follow‐up </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 14: All‐cause mortality according to class of antibiotic" data-id="CD003610-fig-0020" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 14: All‐cause mortality according to class of antibiotic </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 15: All‐cause mortality according to funding" data-id="CD003610-fig-0021" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 15: All‐cause mortality according to funding </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 16: All‐cause mortality according to control intervention" data-id="CD003610-fig-0022" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 16: All‐cause mortality according to control intervention </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 17: CARDIOVASCULAR MORTALITY" data-id="CD003610-fig-0023" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 17: CARDIOVASCULAR MORTALITY </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 18: Cardiovascular mortality ‐ trials at low risk of bias" data-id="CD003610-fig-0024" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 18: Cardiovascular mortality ‐ trials at low risk of bias </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.19" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 19: Cardiovascular mortality ‐ 'best‐worst case' scenario" data-id="CD003610-fig-0025" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.19.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.19.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 19: Cardiovascular mortality ‐ 'best‐worst case' scenario </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.19.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.20" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 20: Cardiovascular mortality ‐ 'worst‐best case' scenario" data-id="CD003610-fig-0026" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.20.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.20.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 20: Cardiovascular mortality ‐ 'worst‐best case' scenario </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.20.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.21" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 21: Cardiovascular mortality ‐ modified 'best‐worst case' scenario" data-id="CD003610-fig-0027" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.21.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.21.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.21</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 21: Cardiovascular mortality ‐ modified 'best‐worst case' scenario </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.21.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.22" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 22: Cardiovascular mortality ‐ modified 'worst‐best case' scenario" data-id="CD003610-fig-0028" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.22.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.22.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.22</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 22: Cardiovascular mortality ‐ modified 'worst‐best case' scenario </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.22.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.23" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 23: Cardiovascular mortality ‐ trials with optimal medical therapy" data-id="CD003610-fig-0029" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.23.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.23.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.23</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 23: Cardiovascular mortality ‐ trials with optimal medical therapy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.23.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.24" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 24: Cardiovascular mortality according to type of antibiotic" data-id="CD003610-fig-0030" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.24.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.24.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.24</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 24: Cardiovascular mortality according to type of antibiotic </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.24.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.25" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 25: Cardiovascular mortality according to antibody status" data-id="CD003610-fig-0031" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.25.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.25.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.25</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 25: Cardiovascular mortality according to antibody status </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.25.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.26" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 26: Cardiovascular mortality according to use of statins" data-id="CD003610-fig-0032" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.26.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.26.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.26</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 26: Cardiovascular mortality according to use of statins </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.26.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.27" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 27: Cardiovascular mortality according to the mean age" data-id="CD003610-fig-0033" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.27.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.27.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.27</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 27: Cardiovascular mortality according to the mean age </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.27.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.28" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 28: Cardiovascular mortality according to clinical trial registration status" data-id="CD003610-fig-0034" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.28.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.28.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.28</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 28: Cardiovascular mortality according to clinical trial registration status </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.28.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.29" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 29: Cardiovascular mortality according to length of follow‐up" data-id="CD003610-fig-0035" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.29.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.29.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.29</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 29: Cardiovascular mortality according to length of follow‐up </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.29.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.30" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 30: Cardiovascular mortality according to class of antibiotic" data-id="CD003610-fig-0036" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.30.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.30.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.30</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 30: Cardiovascular mortality according to class of antibiotic </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.30.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.31" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 31: Cardiovascular mortality according to funding" data-id="CD003610-fig-0037" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.31.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.31.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.31</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 31: Cardiovascular mortality according to funding </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.31.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.32" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 32: Cardiovascular mortality according to control intervention" data-id="CD003610-fig-0038" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.32.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.32.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.32</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 32: Cardiovascular mortality according to control intervention </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.32.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.33" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 33: MYOCARDIAL INFARCTION" data-id="CD003610-fig-0039" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.33.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.33.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.33</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 33: MYOCARDIAL INFARCTION </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.33.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.34" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 34: Myocardial infarction ‐ trials at low risk of bias" data-id="CD003610-fig-0040" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.34.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.34.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.34</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 34: Myocardial infarction ‐ trials at low risk of bias </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.34.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.35" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 35: Myocardial infarction ‐ 'best‐worst case' scenario" data-id="CD003610-fig-0041" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.35.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.35.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.35</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 35: Myocardial infarction ‐ 'best‐worst case' scenario </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.35.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.36" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 36: Myocardial infarction ‐ 'worst‐best case' scenario" data-id="CD003610-fig-0042" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.36.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.36.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.36</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 36: Myocardial infarction ‐ 'worst‐best case' scenario </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.36.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.37" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 37: Myocardial infarction ‐ modified 'best‐worst case' scenario" data-id="CD003610-fig-0043" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.37.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.37.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.37</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 37: Myocardial infarction ‐ modified 'best‐worst case' scenario </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.37.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.38" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 38: Myocardial infarction ‐ modified 'worst‐best case' scenario" data-id="CD003610-fig-0044" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.38.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.38.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.38</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 38: Myocardial infarction ‐ modified 'worst‐best case' scenario </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.38.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.39" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 39: Myocardial infarction ‐ trials with optimal medical therapy" data-id="CD003610-fig-0045" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.39.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.39.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.39</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 39: Myocardial infarction ‐ trials with optimal medical therapy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.39.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.40" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 40: Myocardial infarction according to type of antibiotic" data-id="CD003610-fig-0046" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.40.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.40.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.40</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 40: Myocardial infarction according to type of antibiotic </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.40.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.41" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 41: Myocardial infarction according to antibody status" data-id="CD003610-fig-0047" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.41.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.41.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.41</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 41: Myocardial infarction according to antibody status </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.41.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.42" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 42: Myocardial infarction according to use of statins" data-id="CD003610-fig-0048" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.42.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.42.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.42</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 42: Myocardial infarction according to use of statins </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.42.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.43" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 43: Myocardial infarction according to the mean age" data-id="CD003610-fig-0049" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.43.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.43.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.43</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 43: Myocardial infarction according to the mean age </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.43.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.44" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 44: Myocardial infarction according to clinical trial registration status" data-id="CD003610-fig-0050" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.44.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.44.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.44</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 44: Myocardial infarction according to clinical trial registration status </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.44.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.45" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 45: Myocardial infarction according to length of follow‐up" data-id="CD003610-fig-0051" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.45.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.45.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.45</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 45: Myocardial infarction according to length of follow‐up </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.45.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.46" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 46: Myocardial infarction according to class of antibiotic" data-id="CD003610-fig-0052" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.46.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.46.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.46</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 46: Myocardial infarction according to class of antibiotic </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.46.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.47" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 47: Myocardial infarction according to funding" data-id="CD003610-fig-0053" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.47.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.47.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.47</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 47: Myocardial infarction according to funding </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.47.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.48" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 48: Myocardial infarction according to control intervention" data-id="CD003610-fig-0054" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.48.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.48.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.48</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 48: Myocardial infarction according to control intervention </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.48.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.49" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 49: STROKE" data-id="CD003610-fig-0055" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.49.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.49.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.49</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 49: STROKE </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.49.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.50" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 50: Stroke ‐ trials at low risk of bias" data-id="CD003610-fig-0056" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.50.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.50.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.50</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 50: Stroke ‐ trials at low risk of bias </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.50.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.51" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 51: Stroke ‐ 'best‐worst case' scenario" data-id="CD003610-fig-0057" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.51.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.51.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.51</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 51: Stroke ‐ 'best‐worst case' scenario </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.51.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.52" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 52: Stroke ‐ 'worst‐best case' scenario" data-id="CD003610-fig-0058" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.52.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.52.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.52</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 52: Stroke ‐ 'worst‐best case' scenario </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.52.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.53" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 53: Stroke ‐ modified 'best‐worst case' scenario" data-id="CD003610-fig-0059" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.53.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.53.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.53</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 53: Stroke ‐ modified 'best‐worst case' scenario </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.53.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.54" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 54: Stroke ‐ modified 'worst‐best case' scenario" data-id="CD003610-fig-0060" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.54.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.54.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.54</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 54: Stroke ‐ modified 'worst‐best case' scenario </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.54.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.55" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 55: Stroke ‐ trials with optimal medical therapy" data-id="CD003610-fig-0061" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.55.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.55.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.55</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 55: Stroke ‐ trials with optimal medical therapy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.55.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.56" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 56: Stroke according to type of antibiotic" data-id="CD003610-fig-0062" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.56.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.56.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.56</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 56: Stroke according to type of antibiotic </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.56.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.57" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 57: Stroke according to antibody status" data-id="CD003610-fig-0063" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.57.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.57.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.57</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 57: Stroke according to antibody status </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.57.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.58" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 58: Stroke according to use of statins" data-id="CD003610-fig-0064" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.58.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.58.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.58</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 58: Stroke according to use of statins </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.58.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.59" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 59: Stroke according to the mean age" data-id="CD003610-fig-0065" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.59.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.59.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.59</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 59: Stroke according to the mean age </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.59.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.60" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 60: Stroke according to clinical trial registration status" data-id="CD003610-fig-0066" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.60.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.60.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.60</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 60: Stroke according to clinical trial registration status </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.60.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.61" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 61: Stroke according to length of follow‐up" data-id="CD003610-fig-0067" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.61.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.61.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.61</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 61: Stroke according to length of follow‐up </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.61.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.62" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 62: Stroke according to class of antibiotic" data-id="CD003610-fig-0068" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.62.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.62.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.62</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 62: Stroke according to class of antibiotic </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.62.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.63" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 63: Stroke according to funding" data-id="CD003610-fig-0069" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.63.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.63.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.63</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 63: Stroke according to funding </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.63.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.64" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 64: Stroke according to control intervention" data-id="CD003610-fig-0070" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.64.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.64.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.64</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 64: Stroke according to control intervention </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.64.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.65" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 65: SUDDEN CARDIAC DEATH" data-id="CD003610-fig-0071" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.65.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.65.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.65</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 65: SUDDEN CARDIAC DEATH </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.65.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.66" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 66: Sudden cardiac death ‐ trials at low risk of bias" data-id="CD003610-fig-0072" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.66.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.66.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.66</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 66: Sudden cardiac death ‐ trials at low risk of bias </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.66.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.67" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 67: Sudden cardiac death ‐ 'best‐worst case' scenario" data-id="CD003610-fig-0073" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.67.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.67.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.67</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 67: Sudden cardiac death ‐ 'best‐worst case' scenario </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.67.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.68" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 68: Sudden cardiac death ‐ 'worst‐best case' scenario" data-id="CD003610-fig-0074" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.68.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.68.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.68</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 68: Sudden cardiac death ‐ 'worst‐best case' scenario </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.68.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.69" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 69: Sudden cardiac death ‐ modified 'best‐worst case' scenario" data-id="CD003610-fig-0075" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.69.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.69.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.69</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 69: Sudden cardiac death ‐ modified 'best‐worst case' scenario </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.69.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.70" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 70: Sudden cardiac death ‐ modified 'worst‐best case' scenario" data-id="CD003610-fig-0076" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.70.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.70.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.70</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 70: Sudden cardiac death ‐ modified 'worst‐best case' scenario </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.70.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.71" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 71: Sudden cardiac death according to clinical trial registration status" data-id="CD003610-fig-0077" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.71.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.71.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.71</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 71: Sudden cardiac death according to clinical trial registration status </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.71.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.72" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 72: Sudden cardiac death according to funding" data-id="CD003610-fig-0078" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.72.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.72.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.72</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 72: Sudden cardiac death according to funding </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.72.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.73" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 73: Sudden cardiac death according to type of antibiotic" data-id="CD003610-fig-0079" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.73.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.73.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.73</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 73: Sudden cardiac death according to type of antibiotic </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.73.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0080"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.74" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 74: Sudden cardiac death according to antibody status" data-id="CD003610-fig-0080" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.74.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.74.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.74</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 74: Sudden cardiac death according to antibody status </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0080">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.74.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0081"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.75" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 75: Sudden cardiac death according to use of statins" data-id="CD003610-fig-0081" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.75.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.75.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.75</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 75: Sudden cardiac death according to use of statins </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0081">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.75.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0082"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.76" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 76: Sudden cardiac death according to the mean age" data-id="CD003610-fig-0082" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.76.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.76.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.76</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 76: Sudden cardiac death according to the mean age </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0082">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.76.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0083"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.77" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 77: Sudden cardiac death according to length of follow‐up" data-id="CD003610-fig-0083" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.77.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.77.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.77</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 77: Sudden cardiac death according to length of follow‐up </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0083">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.77.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0084"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.78" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 78: Sudden cardiac death according to class of antibiotic" data-id="CD003610-fig-0084" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.78.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.78.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.78</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 78: Sudden cardiac death according to class of antibiotic </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0084">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.78.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0085"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.79" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 79: Sudden cardiac death according to control intervention" data-id="CD003610-fig-0085" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.79.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.79.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.79</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 79: Sudden cardiac death according to control intervention </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0085">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.79.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0086"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.80" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 80: HOSPITALISATION FOR ANY CAUSE" data-id="CD003610-fig-0086" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.80.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.80.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.80</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 80: HOSPITALISATION FOR ANY CAUSE </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0086">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.80.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0087"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.81" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 81: REVASCULARISATION" data-id="CD003610-fig-0087" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.81.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.81.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.81</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 81: REVASCULARISATION </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0087">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.81.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0088"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-001.82" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 82: UNSTABLE ANGINA PECTORIS" data-id="CD003610-fig-0088" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.82.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-001.82.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.82</div> <div class="figure-caption"> <p>Comparison 1: Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up, Outcome 82: UNSTABLE ANGINA PECTORIS </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0088">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-001.82.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0089"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 1: ALL‐CAUSE MORTALITY" data-id="CD003610-fig-0089" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 1: ALL‐CAUSE MORTALITY </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0089">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0090"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 2: All‐cause mortality ‐ trials at low risk of bias" data-id="CD003610-fig-0090" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 2: All‐cause mortality ‐ trials at low risk of bias </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0090">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0091"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 3: All‐cause mortality ‐ 'best‐worst case' scenario" data-id="CD003610-fig-0091" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 3: All‐cause mortality ‐ 'best‐worst case' scenario </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0091">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0092"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 4: All‐cause mortality ‐ 'worst‐best case' scenario" data-id="CD003610-fig-0092" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 4: All‐cause mortality ‐ 'worst‐best case' scenario </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0092">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0093"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 5: All‐cause mortality ‐ modified 'best‐worst case' scenario" data-id="CD003610-fig-0093" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 5: All‐cause mortality ‐ modified 'best‐worst case' scenario </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0093">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0094"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 6: All‐cause mortality ‐ modified 'worst‐best case' scenario" data-id="CD003610-fig-0094" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 6: All‐cause mortality ‐ modified 'worst‐best case' scenario </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0094">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0095"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 7: All‐cause mortality ‐ trials with optimal medical therapy" data-id="CD003610-fig-0095" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 7: All‐cause mortality ‐ trials with optimal medical therapy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0095">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0096"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 8: All‐cause mortality according to type of antibiotic" data-id="CD003610-fig-0096" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 8: All‐cause mortality according to type of antibiotic </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0096">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0097"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 9: All‐cause mortality according to antibody status" data-id="CD003610-fig-0097" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 9: All‐cause mortality according to antibody status </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0097">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0098"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 10: All‐cause mortality according to use of statins" data-id="CD003610-fig-0098" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 10: All‐cause mortality according to use of statins </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0098">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0099"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 11: All‐cause mortality according to the mean age" data-id="CD003610-fig-0099" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 11: All‐cause mortality according to the mean age </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0099">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0100"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 12: All‐cause mortality according to clinical trial registration status" data-id="CD003610-fig-0100" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 12: All‐cause mortality according to clinical trial registration status </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0100">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0101"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 13: All‐cause mortality according to class of antibiotic" data-id="CD003610-fig-0101" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 13: All‐cause mortality according to class of antibiotic </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0101">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0102"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 14: All‐cause mortality according to funding" data-id="CD003610-fig-0102" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.14</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 14: All‐cause mortality according to funding </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0102">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0103"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 15: All‐cause mortality according to control intervention" data-id="CD003610-fig-0103" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.15</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 15: All‐cause mortality according to control intervention </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0103">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0104"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 16: CARDIOVASCULAR MORTALITY" data-id="CD003610-fig-0104" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.16</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 16: CARDIOVASCULAR MORTALITY </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0104">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0105"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 17: Cardiovascular mortality ‐ trials at low risk of bias" data-id="CD003610-fig-0105" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.17</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 17: Cardiovascular mortality ‐ trials at low risk of bias </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0105">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0106"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 18: Cardiovascular mortality ‐ 'best‐worst case' scenario" data-id="CD003610-fig-0106" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.18</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 18: Cardiovascular mortality ‐ 'best‐worst case' scenario </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0106">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0107"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.19" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 19: Cardiovascular mortality ‐ 'worst‐best case' scenario" data-id="CD003610-fig-0107" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.19.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.19.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.19</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 19: Cardiovascular mortality ‐ 'worst‐best case' scenario </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0107">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.19.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0108"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.20" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 20: Cardiovascular mortality ‐ modified 'best‐worst case' scenario" data-id="CD003610-fig-0108" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.20.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.20.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.20</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 20: Cardiovascular mortality ‐ modified 'best‐worst case' scenario </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0108">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.20.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0109"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.21" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 21: Cardiovascular mortality ‐ modified 'worst‐best case' scenario" data-id="CD003610-fig-0109" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.21.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.21.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.21</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 21: Cardiovascular mortality ‐ modified 'worst‐best case' scenario </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0109">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.21.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0110"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.22" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 22: Cardiovascular mortality ‐ trials with optimal medical therapy" data-id="CD003610-fig-0110" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.22.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.22.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.22</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 22: Cardiovascular mortality ‐ trials with optimal medical therapy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0110">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.22.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0111"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.23" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 23: Cardiovascular mortality according to type of antibiotic" data-id="CD003610-fig-0111" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.23.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.23.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.23</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 23: Cardiovascular mortality according to type of antibiotic </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0111">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.23.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0112"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.24" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 24: Cardiovascular mortality according to antibody status" data-id="CD003610-fig-0112" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.24.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.24.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.24</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 24: Cardiovascular mortality according to antibody status </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0112">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.24.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0113"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.25" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 25: Cardiovascular mortality according to use of statins" data-id="CD003610-fig-0113" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.25.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.25.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.25</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 25: Cardiovascular mortality according to use of statins </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0113">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.25.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0114"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.26" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 26: Cardiovascular mortality according to the mean age" data-id="CD003610-fig-0114" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.26.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.26.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.26</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 26: Cardiovascular mortality according to the mean age </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0114">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.26.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0115"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.27" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 27: Cardiovascular mortality according to clinical trial registration status" data-id="CD003610-fig-0115" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.27.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.27.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.27</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 27: Cardiovascular mortality according to clinical trial registration status </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0115">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.27.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0116"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.28" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 28: Cardiovascular mortality according to class of antibiotic" data-id="CD003610-fig-0116" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.28.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.28.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.28</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 28: Cardiovascular mortality according to class of antibiotic </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0116">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.28.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0117"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.29" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 29: Cardiovascular mortality according to funding" data-id="CD003610-fig-0117" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.29.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.29.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.29</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 29: Cardiovascular mortality according to funding </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0117">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.29.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0118"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.30" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 30: Cardiovascular mortality according to control intervention" data-id="CD003610-fig-0118" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.30.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.30.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.30</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 30: Cardiovascular mortality according to control intervention </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0118">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.30.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0119"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.31" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 31: MYOCARDIAL INFARCTION" data-id="CD003610-fig-0119" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.31.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.31.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.31</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 31: MYOCARDIAL INFARCTION </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0119">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.31.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0120"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.32" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 32: Myocardial infarction ‐ trials at low risk of bias" data-id="CD003610-fig-0120" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.32.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.32.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.32</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 32: Myocardial infarction ‐ trials at low risk of bias </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0120">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.32.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0121"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.33" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 33: Myocardial infarction ‐ 'best‐worst case' scenario" data-id="CD003610-fig-0121" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.33.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.33.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.33</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 33: Myocardial infarction ‐ 'best‐worst case' scenario </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0121">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.33.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0122"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.34" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 34: Myocardial infarction ‐ 'worst‐best case' scenario" data-id="CD003610-fig-0122" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.34.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.34.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.34</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 34: Myocardial infarction ‐ 'worst‐best case' scenario </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0122">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.34.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0123"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.35" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 35: Myocardial infarction ‐ modified 'best‐worst case' scenario" data-id="CD003610-fig-0123" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.35.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.35.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.35</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 35: Myocardial infarction ‐ modified 'best‐worst case' scenario </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0123">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.35.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0124"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.36" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 36: Myocardial infarction ‐ modified 'worst‐best case' scenario" data-id="CD003610-fig-0124" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.36.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.36.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.36</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 36: Myocardial infarction ‐ modified 'worst‐best case' scenario </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0124">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.36.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0125"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.37" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 37: Myocardial infarction ‐ trials with optimal medical therapy" data-id="CD003610-fig-0125" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.37.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.37.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.37</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 37: Myocardial infarction ‐ trials with optimal medical therapy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0125">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.37.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0126"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.38" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 38: Myocardial infarction according to type of antibiotic" data-id="CD003610-fig-0126" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.38.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.38.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.38</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 38: Myocardial infarction according to type of antibiotic </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0126">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.38.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0127"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.39" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 39: Myocardial infarction according to antibody status" data-id="CD003610-fig-0127" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.39.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.39.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.39</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 39: Myocardial infarction according to antibody status </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0127">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.39.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0128"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.40" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 40: Myocardial infarction according to use of statins" data-id="CD003610-fig-0128" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.40.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.40.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.40</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 40: Myocardial infarction according to use of statins </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0128">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.40.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0129"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.41" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 41: Myocardial infarction according to the mean age" data-id="CD003610-fig-0129" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.41.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.41.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.41</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 41: Myocardial infarction according to the mean age </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0129">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.41.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0130"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.42" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 42: Myocardial infarction according to clinical trial registration status" data-id="CD003610-fig-0130" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.42.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.42.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.42</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 42: Myocardial infarction according to clinical trial registration status </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0130">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.42.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0131"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.43" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 43: Myocardial infarction according to class of antibiotic" data-id="CD003610-fig-0131" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.43.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.43.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.43</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 43: Myocardial infarction according to class of antibiotic </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0131">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.43.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0132"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.44" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 44: Myocardial infarction according to funding" data-id="CD003610-fig-0132" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.44.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.44.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.44</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 44: Myocardial infarction according to funding </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0132">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.44.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0133"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.45" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 45: Myocardial infarction according to control intervention" data-id="CD003610-fig-0133" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.45.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.45.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.45</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 45: Myocardial infarction according to control intervention </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0133">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.45.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0134"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.46" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 46: STROKE" data-id="CD003610-fig-0134" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.46.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.46.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.46</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 46: STROKE </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0134">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.46.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0135"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.47" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 47: Stroke ‐ trials at low risk of bias" data-id="CD003610-fig-0135" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.47.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.47.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.47</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 47: Stroke ‐ trials at low risk of bias </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0135">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.47.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0136"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.48" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 48: Stroke ‐ 'best‐worst case' scenario" data-id="CD003610-fig-0136" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.48.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.48.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.48</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 48: Stroke ‐ 'best‐worst case' scenario </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0136">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.48.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0137"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.49" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 49: Stroke ‐ 'worst‐best case' scenario" data-id="CD003610-fig-0137" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.49.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.49.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.49</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 49: Stroke ‐ 'worst‐best case' scenario </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0137">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.49.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0138"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.50" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 50: Stroke ‐ modified 'best‐worst case' scenario" data-id="CD003610-fig-0138" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.50.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.50.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.50</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 50: Stroke ‐ modified 'best‐worst case' scenario </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0138">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.50.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0139"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.51" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 51: Stroke ‐ modified 'worst‐best case' scenario" data-id="CD003610-fig-0139" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.51.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.51.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.51</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 51: Stroke ‐ modified 'worst‐best case' scenario </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0139">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.51.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0140"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.52" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 52: Stroke ‐ trials with optimal medical therapy" data-id="CD003610-fig-0140" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.52.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.52.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.52</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 52: Stroke ‐ trials with optimal medical therapy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0140">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.52.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0141"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.53" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 53: Stroke according to type of antibiotic" data-id="CD003610-fig-0141" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.53.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.53.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.53</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 53: Stroke according to type of antibiotic </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0141">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.53.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0142"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.54" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 54: Stroke according to antibody status" data-id="CD003610-fig-0142" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.54.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.54.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.54</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 54: Stroke according to antibody status </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0142">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.54.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0143"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.55" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 55: Stroke according to use of statins" data-id="CD003610-fig-0143" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.55.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.55.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.55</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 55: Stroke according to use of statins </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0143">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.55.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0144"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.56" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 56: Stroke according to the mean age" data-id="CD003610-fig-0144" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.56.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.56.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.56</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 56: Stroke according to the mean age </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0144">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.56.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0145"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.57" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 57: Stroke according to clinical trial registration status" data-id="CD003610-fig-0145" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.57.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.57.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.57</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 57: Stroke according to clinical trial registration status </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0145">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.57.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0146"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.58" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 58: Stroke according to class of antibiotic" data-id="CD003610-fig-0146" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.58.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.58.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.58</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 58: Stroke according to class of antibiotic </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0146">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.58.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0147"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.59" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 59: Stroke according to funding" data-id="CD003610-fig-0147" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.59.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.59.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.59</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 59: Stroke according to funding </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0147">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.59.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0148"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.60" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 60: Stroke according to control intervention" data-id="CD003610-fig-0148" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.60.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.60.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.60</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 60: Stroke according to control intervention </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0148">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.60.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0149"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.61" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 61: SUDDEN CARDIAC DEATH" data-id="CD003610-fig-0149" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.61.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.61.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.61</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 61: SUDDEN CARDIAC DEATH </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0149">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.61.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0150"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.62" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 62: Sudden cardiac death ‐ trials at low risk of bias" data-id="CD003610-fig-0150" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.62.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.62.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.62</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 62: Sudden cardiac death ‐ trials at low risk of bias </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0150">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.62.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0151"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.63" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 63: Sudden cardiac death ‐ 'best‐worst case' scenario" data-id="CD003610-fig-0151" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.63.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.63.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.63</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 63: Sudden cardiac death ‐ 'best‐worst case' scenario </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0151">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.63.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0152"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.64" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 64: Sudden cardiac death ‐ 'worst‐best case' scenario" data-id="CD003610-fig-0152" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.64.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.64.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.64</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 64: Sudden cardiac death ‐ 'worst‐best case' scenario </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0152">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.64.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0153"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.65" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 65: Sudden cardiac death ‐ modified 'best‐worst case' scenario" data-id="CD003610-fig-0153" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.65.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.65.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.65</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 65: Sudden cardiac death ‐ modified 'best‐worst case' scenario </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0153">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.65.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0154"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.66" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 66: Sudden cardiac death ‐ modified 'worst‐best case' scenario" data-id="CD003610-fig-0154" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.66.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.66.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.66</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 66: Sudden cardiac death ‐ modified 'worst‐best case' scenario </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0154">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.66.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0155"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.67" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 67: Sudden cardiac death according to clinical trial registration status" data-id="CD003610-fig-0155" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.67.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.67.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.67</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 67: Sudden cardiac death according to clinical trial registration status </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0155">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.67.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0156"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.68" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 68: Sudden cardiac death according to funding" data-id="CD003610-fig-0156" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.68.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.68.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.68</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 68: Sudden cardiac death according to funding </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0156">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.68.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0157"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.69" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 69: Sudden cardiac death according to type of antibiotic" data-id="CD003610-fig-0157" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.69.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.69.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.69</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 69: Sudden cardiac death according to type of antibiotic </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0157">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.69.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0158"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.70" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 70: Sudden cardiac death according to antibody status" data-id="CD003610-fig-0158" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.70.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.70.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.70</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 70: Sudden cardiac death according to antibody status </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0158">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.70.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0159"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.71" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 71: Sudden cardiac death according to use of statins" data-id="CD003610-fig-0159" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.71.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.71.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.71</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 71: Sudden cardiac death according to use of statins </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0159">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.71.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0160"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.72" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 72: Sudden cardiac death according to the mean age" data-id="CD003610-fig-0160" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.72.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.72.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.72</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 72: Sudden cardiac death according to the mean age </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0160">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.72.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0161"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.73" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 73: Sudden cardiac death according to class of antibiotic" data-id="CD003610-fig-0161" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.73.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.73.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.73</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 73: Sudden cardiac death according to class of antibiotic </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0161">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.73.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0162"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.74" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 74: Sudden cardiac death according to control intervention" data-id="CD003610-fig-0162" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.74.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.74.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.74</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 74: Sudden cardiac death according to control intervention </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0162">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.74.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0163"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.75" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 75: HOSPITALISATION FOR ANY CAUSE" data-id="CD003610-fig-0163" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.75.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.75.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.75</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 75: HOSPITALISATION FOR ANY CAUSE </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0163">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.75.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0164"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.76" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 76: REVASCULARISATION" data-id="CD003610-fig-0164" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.76.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.76.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.76</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 76: REVASCULARISATION </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0164">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.76.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003610-fig-0165"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/urn:x-wiley:14651858:media:CD003610:CD003610-CMP-002.77" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 77: UNSTABLE ANGINA PECTORIS" data-id="CD003610-fig-0165" src="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.77.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_t/tCD003610-CMP-002.77.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.77</div> <div class="figure-caption"> <p>Comparison 2: Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up, Outcome 77: UNSTABLE ANGINA PECTORIS </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-fig-0165">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/media/CDSR/CD003610/image_n/nCD003610-CMP-002.77.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD003610-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Antibiotics versus placebo or no intervention for secondary prevention of patients with coronary heart disease at maximum follow‐up</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Antibiotics compared with placebo or no intervention for coronary heart disease at maximum follow‐up</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with coronary heart disease </p> <p><b>Settings:</b> any setting </p> <p><b>Intervention:</b> any antibiotic </p> <p><b>Comparison:</b> placebo or no intervention </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo or no intervention</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with antibiotics</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality at maximum follow‐up.</p> <p>Follow‐up: mean 21.4 months (range 3 to 120 months).</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>100 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>106 per 1000<br/>(99 to 113) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.06 (0.99 to 1.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25,774 (20 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall low risk of bias due to the four trials carrying most of the weight were either at overall low risk of bias or were low risk of bias in the majority of domains. </p> <p>Low risk of imprecision due to inclusion of more participants than the estimated optimal information size<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse event at maximum follow‐up.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data were reported in the included trials.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life at maximum follow‐up.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data were reported in the included trials.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiovascular mortality at maximum follow‐up.</p> <p>Follow‐up: mean 72.0 months (range 24 to 120 months).</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>167 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>185 per 1000<br/>(164 to 209) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.11 (0.98 to 1.25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4674 (2 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The sensitivity analysis only including low risk of bias trials differed from the overall analysis. Hence, for this outcome, we based our primary analysis and primary conclusion on trials at low risk of bias. </p> <p>Overall low risk of bias due to the three trials carrying most of the weight were either at overall low risk of bias or were low risk of bias in the majority of domains. </p> <p>Low risk of imprecision due to the sample size being very large (&gt; 4000 participants)<sup>3</sup>. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Myocardial infarction at maximum follow‐up.</p> <p>Follow‐up: mean 20.7 months (range 3 to 120 months).</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>80 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>76 per 1000<br/>(71 to 83) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.95 (0.88 to 1.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25,523 (17 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall low risk of bias due to the four trials carrying most of the weight were either at overall low risk of bias or were low risk of bias in the majority of domains. </p> <p>Low risk of imprecision due to inclusion of more participants than the estimated optimal information size<sup>4</sup>. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stroke at maximum follow‐up.</p> <p>Follow‐up: mean 31.9 months (range 6 to 120 months).</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>55 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>62 per 1000<br/>(55 to 70) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.14 (1.00 to 1.29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14,774 (9 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall low risk of bias due to the three trials carrying most of the weight were either at overall low risk of bias or were low risk of bias in the majority of domains. </p> <p>Low risk of imprecision due to the sample size being very large (&gt; 4000 participants)<sup>5</sup>. </p> <p>The risk of publication bias could not be assessed due to too few included trials.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sudden cardiac death at maximum follow‐up.</p> <p>Follow‐up: mean 69.3 months (range 18.5 to 120 months).</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>84 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>90 per 1000 (75 to 109)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.08 (0.90 to 1.31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4520 (2 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall low risk of bias due to both trials included in the meta‐analyses being at overall low risk of bias or low risk of bias in the majority of domains, respectively. </p> <p>Low risk of imprecision due to the sample size being very large (&gt; 4000 participants)<sup>6</sup>. </p> <p>The risk of publication bias could not be assessed due to too few included trials.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High</b> certainty<b>:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate</b> certainty<b>:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low</b> certainty<b>:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low</b> certainty<b>:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of the effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>No downgrading for imprecision: the optimal information size according to the GRADE Handbook using a RRR of 15%, an incidence in the control group of 10.0%, an alpha of 2.5%, and a beta of 10% was estimated to be 18,576 participants and we included 25,774 participants. </p> <p><sup>2</sup>Downgrading one level due to serious indirectness: risk of difference between the population of interest and the included participants, and between the intervention of interest and the included interventions. </p> <p><sup>3</sup>No downgrading for imprecision: the optimal information size according to the GRADE Handbook using a RRR of 15%, an incidence of 16.7%, an alpha of 2.0%, and a beta of 10% was estimated to be 10,883 participants and we only included 4674 participants. Nevertheless, the sample size was very large (&gt;4000 participants). </p> <p><sup>4</sup>No downgrading for imprecision: the optimal information size according to the GRADE Handbook using a RRR of 15%, an incidence of 8.09%, an alpha of 2.0%, and a beta of 10% was estimated to be 24,627 participants and we included 25,523 participants. </p> <p><sup>5</sup>No downgrading for imprecision: the optimal information size according to the GRADE Handbook using a RRR of 15%, an incidence of 5.49%, an alpha of 2.0%, and a beta of 10% was estimated to be 37,339 participants and we only included 14,774 participants. Nevertheless, the sample size was very large (&gt;4000 participants). </p> <p><sup>6</sup>No downgrading for imprecision. the optimal information size according to the GRADE Handbook using a RRR of 15%, an incidence of 8.36%, an alpha of 2.0%, and a beta of 10% was estimated to be 23,782 participants and we only included 4520 participants. Nevertheless, the sample size was very large (&gt;4000 participants). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Antibiotics versus placebo or no intervention for secondary prevention of patients with coronary heart disease at maximum follow‐up</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/full#CD003610-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003610-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Antibiotics versus placebo or no intervention for secondary prevention of patients with coronary heart disease at 24±6 months follow‐up</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Antibiotics compared with placebo or no intervention for coronary heart disease at 24±6 months follow‐up</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with coronary heart disease </p> <p><b>Settings:</b> any setting </p> <p><b>Intervention:</b> any antibiotic </p> <p><b>Comparison:</b> placebo or no intervention </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo or no intervention</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with antibiotics</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality at 24±6 months follow‐up.</p> <p>Follow‐up: mean 23.3 months (range 18 to 30 months).</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>62 per 1000<br/>(53 to 74) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.25 (1.06 to 1.48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9517 (6 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall low risk of bias due to the three trials carrying most of the weight were either at overall low risk of bias or were low risk of bias in the majority of domains. </p> <p>Low risk of imprecision due to the sample size being very large (&gt; 4000 participants)<sup>1</sup>. </p> <p>The risk of publication bias could not be assessed due to too few included trials.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse event at 24±6 months follow‐up.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data were reported in the included trials.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life at 24±6 months follow‐up.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data were reported in the included trials.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiovascular mortality at 24±6 months follow‐up.</p> <p>Follow‐up: mean 23.1 months (range 18 to 30 months).</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>23 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>34 per 1000<br/>(26 to 43) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.50 (1.17 to 1.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9044 (5 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall low risk of bias due to the three trials carrying most of the weight were either at overall low risk of bias or were low risk of bias in the majority of domains. </p> <p>Low risk of imprecision due to the sample size being very large (&gt; 4000 participants)<sup>2</sup>. </p> <p>The risk of publication bias could not be assessed due to too few included trials.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Myocardial infarction at 24±6 months follow‐up.</p> <p>Follow‐up: mean 24.3 months (range 18.5 to 30.0 months).</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>68 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>65 per 1000<br/>(56 to 76) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.95 (0.82 to 1.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9457 (5 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall low risk of bias due to the two trials carrying most of the weight were either at overall low risk of bias or were low risk of bias in the majority of domains. </p> <p>Low risk of imprecision due to the sample size being very large (&gt; 4000 participants)<sup>4</sup>. </p> <p>The risk of publication bias could not be assessed due to too few included trials.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stroke at 24±6 months follow‐up.</p> <p>Follow‐up: mean 24.3 months (range 18.5 to 30 months).</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>21 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>25 per 1000<br/>(19 to 32) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.17 (0.90 to 1.52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9457 (5 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall low risk of bias due to the three trials carrying most of the weight were either at overall low risk of bias or were low risk of bias in the majority of domains. </p> <p>Low risk of imprecision due to the sample size being very large (&gt; 4000 participants)<sup>5</sup>. </p> <p>The risk of publication bias could not be assessed due to too few included trials.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sudden cardiac death at 24±6 months follow‐up.</p> <p>Follow‐up: mean 24.3 months (range 18.5 to 30 months).</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>44 per 1000 (33 to 63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.77 (1.28 to 2.44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4520 (2 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall low risk of bias due to both trials included in the meta‐analyses being at overall low risk of bias or low risk of bias in the majority of domains, respectively. </p> <p>Low risk of imprecision due to the sample size being very large (&gt; 4000 participants)<sup>7</sup>. </p> <p>The risk of publication bias could not be assessed due to too few included trials.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High</b> certainty<b>:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate</b> certainty<b>:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low</b> certainty<b>:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low</b> certainty<b>:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of the effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>No downgrade for imprecision: the optimal information size according to the GRADE Handbook using a RRR of 15%, an incidence of 4.98%, an alpha of 2.5%, and a beta of 10% was estimated to be 38,771 participants and we only included 9509 participants. Nevertheless, the sample size was very large (&gt;4000 participants). </p> <p><sup>2</sup>No downgrade for imprecision: the optimal information size according to the GRADE Handbook using a RRR of 15%, an incidence of 2.25%, an alpha of 2.0%, and a beta of 10% was estimated to be 91,738 participants and we only included 9036 participants. Nevertheless, the sample size was very large (&gt;4000 participants). </p> <p><sup>3</sup>Downgrading one level due to serious inconsistency: the statistical heterogeneity was I<sup>2</sup> = 43%; P = 0.14. Moreover, the forest plot showed trials with results in opposite direction. </p> <p><sup>4</sup>No downgrade for imprecision: the optimal information size according to the GRADE Handbook using a RRR of 15%, an incidence of 6.85%, an alpha of 2.0%, and a beta of 10% was estimated to be 96,669 participants and we only included 9457 participants. Nevertheless, the sample size was very large (&gt;4000 participants). </p> <p><sup>5</sup>No downgrade for imprecision: The optimal information size according to the GRADE Handbook using a RRR of 15%, an incidence of 2.11%, an alpha of 2.0%, and a beta of 10% was estimated to be 97,219 participants and we only included 9449 participants. Nevertheless, the sample size was very large (&gt;4000 participants). </p> <p><sup>6</sup>Downgrading one level due to serious indirectness: Risk of difference between the population of interest and the included participants, and between the intervention of interest and the included interventions. </p> <p><sup>7</sup>No downgrade for imprecision: the optimal information size according to the GRADE Handbook using a RRR of 15%, an incidence of 2.59%, an alpha of 2.0%, and a beta of 10% was estimated to be 80,024 participants and we only included 4520 participants. Nevertheless, the sample size was very large (&gt;4000 participants). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Antibiotics versus placebo or no intervention for secondary prevention of patients with coronary heart disease at 24±6 months follow‐up</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/full#CD003610-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003610-tbl-0003"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Cochrane tool for assessing risk of bias</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Domain</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Description</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Random sequence generation</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0008"> <li> <p>Low risk: if sequence generation was achieved using computer random number generator or a random numbers table. Drawing lots, tossing a coin, shuffling cards, and throwing dice were also considered adequate if performed by an independent adjudicator. </p> </li> <li> <p>Unclear risk: if the method of randomisation was not specified, but the trial was still presented as being randomised. </p> </li> <li> <p>High risk: if the allocation sequence was not randomised or only quasi‐randomised. We excluded these trials. </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Allocation concealment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0009"> <li> <p>Low risk: if the allocation of participants was performed by a central independent unit, on‐site locked computer, identical‐looking numbered sealed envelopes, drug bottles, or containers prepared by an independent pharmacist or investigator. </p> </li> <li> <p>Uncertain risk: if the trial was classified as randomised but the allocation concealment process was not described. </p> </li> <li> <p>High risk: if the allocation sequence was familiar to the investigators who assigned participants. </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Blinding of participants and personnel</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0010"> <li> <p>Low risk: if the participants and the personnel were blinded to intervention allocation and this was described. </p> </li> <li> <p>Uncertain risk: if the procedure of blinding was insufficiently described.</p> </li> <li> <p>High risk: if blinding of participants and the personnel was not performed.</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Blinding of outcome assessment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0011"> <li> <p>Low risk of bias: if it was mentioned that outcome assessors were blinded and this was described. </p> </li> <li> <p>Uncertain risk of bias: if it was not mentioned if the outcome assessors in the trial were blinded, or the extent of blinding was insufficiently described. </p> </li> <li> <p>High risk of bias: if no blinding or incomplete blinding of outcome assessors was performed. </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Incomplete outcome data</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0012"> <li> <p>Low risk of bias: if missing data were unlikely to make treatment effects depart from plausible values. This could either be: 1) there were no dropouts or withdrawals for all outcomes, or 2) the numbers and reasons for the withdrawals and dropouts for all outcomes were clearly stated and could be described as being similar in both groups. Generally, the trial was judged as at low risk of bias due to incomplete outcome data if dropouts were less than 5%. However, the 5% cut‐off was not definitive. </p> </li> <li> <p>Uncertain risk of bias: if there was insufficient information to assess whether missing data were likely to induce bias on the results. </p> </li> <li> <p>High risk of bias: if the results were likely to be biased due to missing data either because the pattern of dropouts could be described as being different in the two intervention groups or the trial used improper methods in dealing with the missing data (e.g. last observation carried forward). </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Selective outcome reporting</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0013"> <li> <p>Low risk of bias: if a protocol was published/registered before or at the time the trial was begun and the outcomes specified in the protocol were reported on. If there was no protocol or the protocol was published/registered after the trial had begun, reporting of all‐cause mortality and various types of serious adverse event granted the trial a grade of low risk of bias. </p> </li> <li> <p>Uncertain risk of bias: if no protocol was published and the outcomes all‐cause mortality and serious adverse event were not adequately reported on. </p> </li> <li> <p>High risk of bias: if the outcomes in the protocol were not reported on.</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Other risks of bias</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0014"> <li> <p>Low risk of bias: if the trial appeared to be free of other components that could put it at risk of bias. </p> </li> <li> <p>Unclear risk of bias: if the trial might or might not be free of other components that could put it at risk of bias. </p> </li> <li> <p>High risk of bias: if there were other factors in the trial that could put it at risk of bias. </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Overall risk of bias</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0015"> <li> <p>Low risk of bias: the trial was classified as at overall 'low risk of bias' only if all of the bias domains described in the above paragraphs were classified as at 'low risk of bias'. </p> </li> <li> <p>High risk of bias: the outcome result was classified as at overall 'high risk of bias' if any of the bias risk domains described in the above were classified as at 'unclear' or 'high risk of bias'. </p> </li> </ul> </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Cochrane tool for assessing risk of bias</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/full#CD003610-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003610-tbl-0004"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Baseline information of each included trial</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Year</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants currently smoking</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants with diabetes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants with hypertension</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants with hyperlipidaemia</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ACADEMIC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>112 out of 302</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34 out of 302</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>127 out of 302</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ACES</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>542 out of 4012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>883 out of 4012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2688 out of 4012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3309 of 4012</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aleksiadi 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ANTIBIO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>428 out of 851</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>139 out of 861</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>439 out of 851</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AZACS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>348 out of 1439</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>398 out of 1439</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>832 out of 1439</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>864 out of 1439</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Berg 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>92 out of 473</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74 out of 473</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>195 out of 473</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>278 out of 473</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CLARICOR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1572 out of 4372</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>678 out of 4372</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1761 out of 4372</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CLARIFY</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40 out of 148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28 out of 148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62 out of 148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>113 out of 148</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gabriel 2003l</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 out of 38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9 out of 38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14 out of 38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 out of 38</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gupta 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1997</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19 out of 60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 out of 60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11 out of 60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25 out of 60</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hillis 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25 out of 141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19 out of 141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57 out of 141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hyodo 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 out of 31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 out of 31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17 out of 31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17 out of 31</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ikeoka 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41 out of 82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 out of 82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46 out of 82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ISAR‐3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>224 out of 1010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>202 out of 1010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>771 out of 1010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Jackson 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kaehler 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67 out of 327</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18 out of 327</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>259 out of 327</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kim 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55 out of 129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38 out of 129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69 out of 129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35 out of 129</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kim 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26 out of 50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 out of 50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27 out of 50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 out of 50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kormi 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kuvin 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32 out of 58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 out of 58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34 out of 58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45 out of 58</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Leowattana 2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44 out of 84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37 out of 84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44 out of 84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53 out of 84</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MIDAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21 out of 50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 out of 50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39 out of 50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41 out of 50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parchure 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 out of 40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 out of 40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 out of 40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27 out of 40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pieniazek 2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PROVE‐IT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1529 out of 4162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>734 out of 4162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2091 out of 4162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Radoi 2003l</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39 out of 109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27 out of 109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67 out of 109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78 out of 109</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ROXIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1997</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53 out of 202</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26 out of 202</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>112 out of 202</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>129 out of 202</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sanati2019</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2019</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26 out of 68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27 out of 68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26 out of 68</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Schulze 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 out of 42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15 out of 42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37 out of 42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37 out of 42</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Semaan 2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sinisalo 1998</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1998</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11 out of 33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stojanovic 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18 out of 165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37 out of 165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29 out of 165</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thomaidou 2017</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2017</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 out of 40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15 out of 40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21 out of 40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TIPTOP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61 out of 80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23 out of 80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55 out of 80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54 out of 80</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Torgano 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23 out of 110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26 out of 110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15 out of 110</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tüter 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26 out of 36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WIZARD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1266 out of 7722</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1637 out of 7722</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3482 out of 7722</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4786 out of 7722</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ütük 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52 out of 113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 out of 113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34 out of 113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 out of 113</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Baseline information of each included trial</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/full#CD003610-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003610-tbl-0005"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Time points used at maximum follow‐up</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Year</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All‐cause mortality (months)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cardiovascular mortality (months)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Myocardial infarction (months)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Stroke (months)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Sudden cardiac death (months)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Hospitalisation for any cause (months)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Revascularisation (months)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Unstable angina pectoris (months)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ACADEMIC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ACES</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aleksiadi 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ANTIBIO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AZACS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Berg 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CLARICOR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>120</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CLARIFY</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gabriel 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gupta 1997</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1997</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hillis 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hyodo2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ikeoka 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ISAR‐3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Jackson 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kaehler2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kim 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kim 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kormi 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kuvin 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Leowattana2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MIDAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parchure 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pieniazek 2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PROVE‐IT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Radoi et al</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ROXIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1997</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sanati 2019</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2019</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Schulze 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Semaan 2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sinisalo 1998</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1998</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stojanovic 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thomaidou 2017</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2017</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TIPTOP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Torgano 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tüter 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WIZARD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ütük 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>NR: Not reported.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Time points used at maximum follow‐up</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/full#CD003610-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003610-tbl-0006"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Time points used at 24±6 months follow‐up</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Year</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All‐cause mortality (months)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cardiovascular mortality (months)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Myocardial infarction (months)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Stroke (months)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Sudden cardiac death (months)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Hospitalisation for any cause (months)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Revascularisation (months)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Unstable angina pectoris (months)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ACADEMIC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ACES</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aleksiadi 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ANTIBIO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AZACS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Berg 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CLARICOR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CLARIFY</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gabriel 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gupta 1997</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1997</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hillis 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hyodo 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ikeoka 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ISAR‐3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Jackson 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kaehler 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kim 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kim 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kormi 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kuvin 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Leowattana 2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MIDAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parchure2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pieniazek 2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PROVE‐IT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Radoi 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ROXIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1997</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sanati 2019</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2019</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Schulze 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Semaan2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sinisalo 1998</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1998</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stojanovic 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thomaidou 2017</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2017</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TIPTOP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Torgano 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tüter 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WIZARD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ütük 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>NR: Not reported.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Time points used at 24±6 months follow‐up</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/full#CD003610-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003610-tbl-0007"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Serious adverse events ‐ maximum follow‐up</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Year</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Type and number of serious adverse event (antibiotics group)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Type and number of serious adverse event (control group)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ACADEMIC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0029"> <li> <p>5 deaths;</p> </li> <li> <p>4 reinfarctions;</p> </li> <li> <p>1 stroke;</p> </li> <li> <p>8 hospitalisations for unstable angina pectoris;</p> </li> <li> <p>9 revascularisations; and</p> </li> <li> <p>1 resuscitated cardiac arrest</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0030"> <li> <p>4 deaths;</p> </li> <li> <p>6 reinfarctions;</p> </li> <li> <p>3 strokes;</p> </li> <li> <p>7 hospitalisations for unstable angina pectoris; and</p> </li> <li> <p>15 revascularisations</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ACES</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0031"> <li> <p>143 deaths;</p> </li> <li> <p>136 reinfarctions;</p> </li> <li> <p>45 strokes;</p> </li> <li> <p>50 hospitalisations for unstable angina pectoris;</p> </li> <li> <p>264 percutaneous coronary revascularisations;</p> </li> <li> <p>117 coronary‐artery bypass surgeries;</p> </li> <li> <p>13 cardiac collapses followed by resuscitation;</p> </li> <li> <p>37 carotid endarterectomies; and</p> </li> <li> <p>30 peripheral revascularisations</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0032"> <li> <p>132 deaths;</p> </li> <li> <p>130 reinfarctions;</p> </li> <li> <p>40 strokes;</p> </li> <li> <p>55 hospitalisations for unstable angina pectoris;</p> </li> <li> <p>259 percutaneous coronary revascularisations;</p> </li> <li> <p>110 coronary‐artery bypass surgeries;</p> </li> <li> <p>8 cardiac collapses followed by resuscitation;</p> </li> <li> <p>30 carotid endarterectomies; and</p> </li> <li> <p>35 peripheral revascularisations</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ANTIBIO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0033"> <li> <p>28 deaths;</p> </li> <li> <p>21 reinfarctions;</p> </li> <li> <p>7 strokes;</p> </li> <li> <p>73 hospitalisations caused by unstable angina pectoris;</p> </li> <li> <p>67 coronary bypass surgeries;</p> </li> <li> <p>182 percutaneous coronary interventions; and</p> </li> <li> <p>21 resuscitations</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0034"> <li> <p>26 deaths;</p> </li> <li> <p>24 reinfarctions;</p> </li> <li> <p>9 strokes;</p> </li> <li> <p>58 hospitalisations caused by unstable angina pectoris;</p> </li> <li> <p>60 coronary bypass surgeries;</p> </li> <li> <p>191 percutaneous coronary interventions; and</p> </li> <li> <p>15 resuscitations</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AZACS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0035"> <li> <p>23 deaths;</p> </li> <li> <p>17 reinfarctions;</p> </li> <li> <p>65 coronary artery bypass grafting/percutaneous transluminal coronary angioplasty; and </p> </li> <li> <p>62 worsening of angina or ischaemia needing admission, or new or worsening of congestive heart failure needing admission </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0036"> <li> <p>29 deaths;</p> </li> <li> <p>22 reinfarctions;</p> </li> <li> <p>59 coronary artery bypass grafting/percutaneous transluminal coronary angioplasty; and </p> </li> <li> <p>59 worsening of angina or ischaemia needing admission, or new or worsening of congestive heart failure needing admission </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Berg 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0037"> <li> <p>10 deaths;</p> </li> <li> <p>1 reinfarction;</p> </li> <li> <p>9 strokes;</p> </li> <li> <p>10 unstable angina pectoris;</p> </li> <li> <p>9 revascularisations;</p> </li> <li> <p>2 peripheral vascular surgeries; and</p> </li> <li> <p>1 sternal wound infection</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0038"> <li> <p>9 deaths;</p> </li> <li> <p>3 reinfarction;</p> </li> <li> <p>5 strokes;</p> </li> <li> <p>12 unstable angina pectoris;</p> </li> <li> <p>4 revascularisations;</p> </li> <li> <p>2 peripheral vascular surgeries; and</p> </li> <li> <p>1 sternal wound infection</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CLARICOR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0039"> <li> <p>866 deaths;</p> </li> <li> <p>468 reinfarctions;</p> </li> <li> <p>364 cerebrovascular disease;</p> </li> <li> <p>397 unstable angina pectoris; and</p> </li> <li> <p>143 peripheral vascular disease</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0040"> <li> <p>815 deaths;</p> </li> <li> <p>488 reinfarctions;</p> </li> <li> <p>321 cerebrovascular disease;</p> </li> <li> <p>399 unstable angina pectoris; and</p> </li> <li> <p>148 peripheral vascular disease</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CLARIFY</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0041"> <li> <p>4 deaths;</p> </li> <li> <p>5 reinfarctions;</p> </li> <li> <p>2 strokes; and</p> </li> <li> <p>5 unstable angina pectoris</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0042"> <li> <p>1 death;</p> </li> <li> <p>14 reinfarctions;</p> </li> <li> <p>2 strokes; and</p> </li> <li> <p>11 unstable angina pectoris</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gupta 1997</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1997</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0043"> <li> <p>1 death; and</p> </li> <li> <p>2 unstable angina pectoris or myocardial infarctions</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0044"> <li> <p>1 death; and</p> </li> <li> <p>4 unstable angina pectoris or myocardial infarction</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hillis 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0045"> <li> <p>1 heart failure; and</p> </li> <li> <p>1 perforated diverticulum</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0046"> <li> <p>None</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ikeoka 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0047"> <li> <p>2 deaths;</p> </li> <li> <p>1 chronic obstructive pulmonary disease;</p> </li> <li> <p>1 sepsis; and</p> </li> <li> <p>1 limb revascularization surgery</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0048"> <li> <p>None</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ISAR‐3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0049"> <li> <p>16 deaths; and</p> </li> <li> <p>20 reinfarctions</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0050"> <li> <p>13 deaths; and</p> </li> <li> <p>17 reinfarctions</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Jackson1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0051"> <li> <p>1 surgery</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0052"> <li> <p>1 infection</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kaehler 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0053"> <li> <p>1 death;</p> </li> <li> <p>4 reinfarctions;</p> </li> <li> <p>3 strokes; and</p> </li> <li> <p>25 revascularisations</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0054"> <li> <p>1 death;</p> </li> <li> <p>2 reinfarctions; and</p> </li> <li> <p>32 revascularisations</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kim 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0055"> <li> <p>2 deaths;</p> </li> <li> <p>2 reinfarctions; and</p> </li> <li> <p>13 revascularisations</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0056"> <li> <p>2 deaths;</p> </li> <li> <p>1 reinfarction; and</p> </li> <li> <p>10 revascularisations</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Leowattana 2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0057"> <li> <p>1 death;</p> </li> <li> <p>4 recurrent angina pectoris/myocardial infarction;</p> </li> <li> <p>5 coronary artery bypass grafting; and</p> </li> <li> <p>7 percutaneous transluminal coronary angioplasty</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0058"> <li> <p>1 death;</p> </li> <li> <p>6 recurrent angina pectoris/myocardial infarction;</p> </li> <li> <p>4 coronary artery bypass grafting; and</p> </li> <li> <p>5 percutaneous transluminal coronary angioplasty</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MIDAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0059"> <li> <p>1 death; and</p> </li> <li> <p>2 reinfarctions</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0060"> <li> <p>None</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PROVE‐IT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0061"> <li> <p>64 deaths;</p> </li> <li> <p>137 reinfarctions;</p> </li> <li> <p>23 strokes;</p> </li> <li> <p>93 hospitalisations for unstable angina; and</p> </li> <li> <p>352 revascularisations</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0062"> <li> <p>50 deaths;</p> </li> <li> <p>154 reinfarctions;</p> </li> <li> <p>22 strokes;</p> </li> <li> <p>92 hospitalisations for unstable angina; and</p> </li> <li> <p>377 revascularisations</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Radoi 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0063"> <li> <p>7 deaths;</p> </li> <li> <p>9 reinfarctions; and</p> </li> <li> <p>21 hospitalisations for unstable angina</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0064"> <li> <p>5 deaths;</p> </li> <li> <p>8 reinfarctions; and</p> </li> <li> <p>34 hospitalisations for unstable angina</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ROXIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1997</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0065"> <li> <p>2 deaths; and</p> </li> <li> <p>6 severe recurrent ischaemia</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0066"> <li> <p>5 deaths;</p> </li> <li> <p>2 reinfarctions; and</p> </li> <li> <p>7 severe recurrent ischaemia</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sinisalo 1998</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1998</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0067"> <li> <p>1 erysipelas</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0068"> <li> <p>1 upper respiratory infection requiring antibiotic treatment</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TIPTOP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0069"> <li> <p>1 death;</p> </li> <li> <p>1 stroke; and</p> </li> <li> <p>4 worsening of NYHA class III‐IV and/or hospital admission for congestive heart failure</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0070"> <li> <p>4 deaths;</p> </li> <li> <p>1 reinfarction;</p> </li> <li> <p>2 strokes; and</p> </li> <li> <p>7 worsening of NYHA class III‐IV and/or hospital admission for congestive heart failure</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WIZARD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0071"> <li> <p>175 deaths;</p> </li> <li> <p>145 reinfarctions;</p> </li> <li> <p>326 revascularisations; and</p> </li> <li> <p>105 hospitalisations for angina pectoris</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0072"> <li> <p>188 deaths;</p> </li> <li> <p>153 reinfarctions;</p> </li> <li> <p>336 revascularisations; and</p> </li> <li> <p>103 hospitalisations for angina pectoris</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ütük 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0073"> <li> <p>2 deaths;</p> </li> <li> <p>2 reinfarctions;</p> </li> <li> <p>2 unstable angina pectoris;</p> </li> <li> <p>7 percutaneous coronary interventions; and</p> </li> <li> <p>5 coronary artery bypass graftings</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0074"> <li> <p>5 deaths;</p> </li> <li> <p>5 reinfarctions;</p> </li> <li> <p>1 unstable angina pectoris;</p> </li> <li> <p>4 percutaneous coronary interventions; and</p> </li> <li> <p>4 coronary artery bypass graftings</p> </li> </ul> </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Serious adverse events ‐ maximum follow‐up</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/full#CD003610-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003610-tbl-0008"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Serious adverse events ‐ 24±6 months follow‐up</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Year</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Type and number of serious adverse event (antibiotics group)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Type and number of serious adverse event (control group)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ACADEMIC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0075"> <li> <p>5 deaths;</p> </li> <li> <p>4 reinfarctions;</p> </li> <li> <p>1 stroke;</p> </li> <li> <p>8 hospitalisations for unstable angina pectoris;</p> </li> <li> <p>9 revascularisations; and</p> </li> <li> <p>1 resuscitated cardiac arrest</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0076"> <li> <p>4 deaths;</p> </li> <li> <p>6 reinfarctions;</p> </li> <li> <p>3 strokes;</p> </li> <li> <p>7 hospitalisations for unstable angina pectoris; and</p> </li> <li> <p>15 revascularisations</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ACES</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0077"> <li> <p>261 deaths due to coronary heart disease, nonfatal myocardial infarctions, percutaneous or surgical coronary revascularisation procedures, or hospitalisations for unstable angina pectoris </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0078"> <li> <p>281 deaths due to coronary heart disease, nonfatal myocardial infarctions, percutaneous or surgical coronary revascularisation procedures, or hospitalisations for unstable angina pectoris </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Berg 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0079"> <li> <p>10 deaths;</p> </li> <li> <p>1 reinfarction;</p> </li> <li> <p>9 strokes;</p> </li> <li> <p>10 unstable angina pectoris;</p> </li> <li> <p>9 revascularisations;</p> </li> <li> <p>2 peripheral vascular surgeries; and</p> </li> <li> <p>1 sternal wound infection</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0080"> <li> <p>9 deaths;</p> </li> <li> <p>3 reinfarctions;</p> </li> <li> <p>5 strokes;</p> </li> <li> <p>12 unstable angina pectoris;</p> </li> <li> <p>4 revascularisations;</p> </li> <li> <p>2 peripheral vascular surgeries; and</p> </li> <li> <p>1 sternal wound infection</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CLARICOR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0081"> <li> <p>212 deaths;</p> </li> <li> <p>160 reinfarctions;</p> </li> <li> <p>81 strokes; and</p> </li> <li> <p>34 peripheral vascular disease</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0082"> <li> <p>172 deaths;</p> </li> <li> <p>148 reinfarctions;</p> </li> <li> <p>68 strokes; and</p> </li> <li> <p>26 peripheral vascular disease</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CLARIFY</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0083"> <li> <p>4 deaths;</p> </li> <li> <p>5 reinfarctions;</p> </li> <li> <p>2 strokes; and</p> </li> <li> <p>5 unstable angina pectoris</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0084"> <li> <p>1 death;</p> </li> <li> <p>14 reinfarctions;</p> </li> <li> <p>2 strokes; and</p> </li> <li> <p>11 unstable angina pectoris</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gupta 1997</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1997</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0085"> <li> <p>1 death; and</p> </li> <li> <p>2 unstable angina pectoris or reinfarctions</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0086"> <li> <p>1 death; and</p> </li> <li> <p>4 unstable angina pectoris or reinfarctions</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PROVE‐IT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0087"> <li> <p>64 deaths;</p> </li> <li> <p>137 reinfarctions;</p> </li> <li> <p>23 strokes;</p> </li> <li> <p>93 hospitalisations for unstable angina pectoris; and</p> </li> <li> <p>352 revascularisations</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD003610-list-0088"> <li> <p>50 deaths;</p> </li> <li> <p>154 reinfarctions;</p> </li> <li> <p>22 strokes;</p> </li> <li> <p>92 hospitalisations for unstable angina pectoris; and</p> </li> <li> <p>377 revascularisations</p> </li> </ul> </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Serious adverse events ‐ 24±6 months follow‐up</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/full#CD003610-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003610-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 ALL‐CAUSE MORTALITY <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25774</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.99, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 All‐cause mortality ‐ trials at low risk of bias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.99, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 All‐cause mortality ‐ 'best‐worst case' scenario <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25815</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.92, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 All‐cause mortality ‐ 'worst‐best case' scenario <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25815</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [1.06, 1.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 All‐cause mortality ‐ modified 'best‐worst case' scenario <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25815</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.95, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 All‐cause mortality ‐ modified 'worst‐best case' scenario <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25815</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [1.02, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 All‐cause mortality ‐ trials with optimal medical therapy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23294</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.99, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 All‐cause mortality according to type of antibiotic <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25774</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.99, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.1 Azithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13746</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.85, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.2 Roxithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2491</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.71, 1.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.3 Clarithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [1.00, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.4 Doxycycline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.06, 6.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.5 Gatifloxacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.89, 1.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.6 Spiramycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.29, 2.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 All‐cause mortality according to antibody status <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25774</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.99, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.1 People with antibodies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8084</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.76, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.2 People without antibodies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.3 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17690</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [1.01, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 All‐cause mortality according to use of statins <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23680</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [1.00, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.1 People with use of statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4514</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.44, 1.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.2 People without use of statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.3 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.99, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 All‐cause mortality according to the mean age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25774</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.99, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.1 0 to 59 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4573</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.83, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.2 60 and above</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.99, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 All‐cause mortality according to clinical trial registration status <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25774</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.99, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.1 Pre‐registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16366</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.91, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.2 Post‐registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.86, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.3 No registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5396</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.75, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.13 All‐cause mortality according to length of follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25774</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.99, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.1 Trials with less than 12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2080</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.46, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.2 Trials with equal to or longer than 12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23694</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [1.00, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.14 All‐cause mortality according to class of antibiotic <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25760</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.99, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.1 Macrolide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21438</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.99, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.2 Tetracycline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.06, 6.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.3 Quinolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.89, 1.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.15 All‐cause mortality according to funding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25774</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.99, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.1 Industry funded or unknown funded trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19073</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.91, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.2 Non‐industry funded trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6701</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.99, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.16 All‐cause mortality according to control intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25774</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.99, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.1 Placebo‐controlled trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25442</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [1.00, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.2 No control intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>332</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.25, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.17 CARDIOVASCULAR MORTALITY <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.96, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.18 Cardiovascular mortality ‐ trials at low risk of bias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4674</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.98, 1.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.19 Cardiovascular mortality ‐ 'best‐worst case' scenario <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14192</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.84, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.20 Cardiovascular mortality ‐ 'worst‐best case' scenario <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14192</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [1.09, 1.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.21 Cardiovascular mortality ‐ modified 'best‐worst case' scenario <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14192</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.89, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.22 Cardiovascular mortality ‐ modified 'worst‐best case' scenario <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14192</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [1.03, 1.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.23 Cardiovascular mortality ‐ trials with optimal medical therapy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13407</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.96, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.24 Cardiovascular mortality according to type of antibiotic <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.96, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.24.1 Azithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4503</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.65, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.24.2 Roxithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>613</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.16, 1.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.24.3 Clarithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4633</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.38, 2.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.24.4 Doxycycline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.06, 6.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.24.5 Gatifloxacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.64 [0.93, 2.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.24.6 Spiramycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.29, 2.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.25 Cardiovascular mortality according to antibody status <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.96, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.25.1 People with antibodies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>362</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.33, 3.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.25.2 People without antibodies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.25.3 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13818</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.92, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.26 Cardiovascular mortality according to use of statins <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13096</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.83, 1.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.26.1 People with use of statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4514</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.35, 2.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.26.2 People without use of statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.26.3 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8582</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.82, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.27 Cardiovascular mortality according to the mean age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.96, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.27.1 18 to 59 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4573</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.77, 1.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.27.2 60 and above</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9607</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.95, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.28 Cardiovascular mortality according to clinical trial registration status <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.96, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.28.1 Pre‐registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8644</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.77, 1.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.28.2 Post‐registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.63, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.28.3 No registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1524</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.49, 1.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.29 Cardiovascular mortality according to length of follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.96, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.29.1 Trials with less than 12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>559</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.19, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.29.2 Trials with equal to or longer than 12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13621</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.97, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.30 Cardiovascular mortality according to class of antibiotic <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.96, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.30.1 Macrolide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9858</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.95, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.30.2 Tetracycline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.06, 6.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.30.3 Quinolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.64 [0.93, 2.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.31 Cardiovascular mortality according to funding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.96, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.31.1 Industry funded or unknown funded trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.72, 1.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.31.2 Non‐industry funded trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.97, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.32 Cardiovascular mortality according to control intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.96, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.32.1 Placebo‐controlled trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13848</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.97, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.32.2 No control intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>332</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.25, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.33 MYOCARDIAL INFARCTION <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25523</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.88, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.34 Myocardial infarction ‐ trials at low risk of bias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.86, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.35 Myocardial infarction ‐ 'best‐worst case' scenario <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25564</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.72, 0.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.36 Myocardial infarction ‐ 'worst‐best case' scenario <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25564</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.90, 1.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.37 Myocardial infarction ‐ modified 'best‐worst case' scenario <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25564</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.84, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.38 Myocardial infarction ‐ modified 'worst‐best case' scenario <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25564</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.90, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.39 Myocardial infarction ‐ trials with optimal medical therapy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23327</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.88, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.40 Myocardial infarction according to type of antibiotic <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25523</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.88, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.40.1 Azithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13604</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.84, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.40.2 Roxithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2491</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.66, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.40.3 Clarithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.30, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.40.4 Doxycycline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [0.10, 17.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.40.5 Gatifloxacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.72, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.40.6 Spiramycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.41 Myocardial infarction according to antibody status <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25523</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.88, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.41.1 People with antibodies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8024</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.75, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.41.2 People without antibodies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.41.3 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17499</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.87, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.42 Myocardial infarction according to use of statins <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23598</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.88, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.42.1 People with use of statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4514</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.71, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.42.2 People without use of statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.42.3 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19084</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.88, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.43 Myocardial infarction according to the mean age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25523</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.88, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.43.1 18 to 59 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4404</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.71, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.43.2 60 and above</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.88, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.44 Myocardial infarction according to clinical trial registration status <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25523</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.88, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.44.1 Pre‐registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16366</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.87, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.44.2 Post‐registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.83, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.44.3 No registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.61, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.45 Myocardial infarction according to length of follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25523</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.88, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.45.1 Trials with less than 12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1998</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.42, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.45.2 Trials with equal to or longer than 12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23525</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.88, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.46 Myocardial infarction according to class of antibiotic <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25523</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.88, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.46.1 Macrolide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.88, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.46.2 Tetracycline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [0.10, 17.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.46.3 Quinolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.72, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.47 Myocardial infarction according to funding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25523</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.88, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.47.1 Industry funded or unknown funded trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18964</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.84, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.47.2 Non‐industry funded trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6559</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.86, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.48 Myocardial infarction according to control intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25515</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.88, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.48.1 Placebo‐controlled trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25292</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.88, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.48.2 No control intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>223</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.09, 1.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.49 STROKE <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14774</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [1.00, 1.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.50 Stroke ‐ trials at low risk of bias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4674</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.99, 1.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.51 Stroke ‐ 'best‐worst case' scenario <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14779</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.87, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.52 Stroke ‐ 'worst‐best case' scenario <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14779</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [1.14, 1.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.53 Stroke ‐ modified 'best‐worst case' scenario <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14779</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.93, 1.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.54 Stroke ‐ modified 'worst‐best case' scenario <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14779</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [1.07, 1.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.55 Stroke ‐ trials with optimal medical therapy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13672</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.99, 1.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.56 Stroke according to type of antibiotic <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14774</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [1.00, 1.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.56.1 Azithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4314</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.59, 1.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.56.2 Roxithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1195</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.49 [0.21, 10.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.56.3 Clarithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4993</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [1.01, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.56.4 Gatifloxacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.59, 1.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.56.5 Doxycycline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.05, 5.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.57 Stroke according to antibody status <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14774</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [1.00, 1.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.57.1 People with antibodies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>302</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.04, 3.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.57.2 People without antibodies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.57.3 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14472</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [1.01, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.58 Stroke according to use of statins <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [1.00, 1.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.58.1 People with use of statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4272</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.57, 1.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.58.2 People without use of statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.58.3 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9873</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [1.01, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.59 Stroke according to the mean age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14774</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [1.00, 1.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.59.1 18 to 59 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.59, 1.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.59.2 60 and above</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10612</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [1.00, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.60 Stroke according to clinical trial registration status <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14774</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [1.00, 1.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.60.1 Pre‐registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8644</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [1.00, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.60.2 Post‐registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.74, 1.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.60.3 No registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.59, 2.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.61 Stroke according to length of follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14774</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [1.00, 1.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.61.1 Trials with less than 12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.05, 5.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.61.2 Trials with equal to or longer than 12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14664</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [1.01, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.62 Stroke according to class of antibiotic <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14774</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [1.00, 1.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.62.1 Macrolide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10502</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [1.01, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.62.2 Tetracycline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.05, 5.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.62.3 Quinolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.59, 1.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.63 Stroke according to funding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14774</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [1.00, 1.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.63.1 Industry funded or unknown funded trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9990</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.83, 1.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.63.2 Non‐industry funded trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4784</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.99, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.64 Stroke according to control intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14774</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [1.00, 1.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.64.1 Placebo‐controlled trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14664</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [1.01, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.64.2 No control intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.05, 5.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.65 SUDDEN CARDIAC DEATH <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4520</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.90, 1.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.66 Sudden cardiac death ‐ trials at low risk of bias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4372</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.89, 1.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.67 Sudden cardiac death ‐ 'best‐worst case' scenario <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4521</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.83, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.68 Sudden cardiac death ‐ 'worst‐best case' scenario <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4521</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.95, 1.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.69 Sudden cardiac death ‐ modified 'best‐worst case' scenario <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4521</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.86, 1.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.70 Sudden cardiac death ‐ modified 'worst‐best case' scenario <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4521</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.92, 1.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.71 Sudden cardiac death according to clinical trial registration status <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4520</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.90, 1.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.71.1 Pre‐registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4372</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.89, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.71.2 Post‐registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.71.3 No registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.12, 72.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.72 Sudden cardiac death according to funding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4520</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.90, 1.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.72.1 Industry funded or unknown funded trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.12, 72.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.72.2 Non‐industry funded trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4372</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.89, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.73 Sudden cardiac death according to type of antibiotic <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4520</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.90, 1.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.73.1 Clarithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4520</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.90, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.74 Sudden cardiac death according to antibody status <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4520</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.90, 1.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.74.1 People with antibodies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.74.2 People without antibodies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.74.3 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4520</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.90, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.75 Sudden cardiac death according to use of statins <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4520</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.90, 1.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.75.1 People with use of statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.75.2 People without use of statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.75.3 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4520</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.90, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.76 Sudden cardiac death according to the mean age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4520</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.90, 1.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.76.1 18 to 59 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.76.2 60 and above</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4520</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.90, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.77 Sudden cardiac death according to length of follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4520</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.90, 1.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.77.1 Trials with less than 12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.77.2 Trials with equal to or longer than 12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4520</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.90, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.78 Sudden cardiac death according to class of antibiotic <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4520</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.90, 1.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.78.1 Macrolide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4520</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.90, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.78.2 Tetracycline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.78.3 Quinolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.79 Sudden cardiac death according to control intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4520</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.90, 1.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.79.1 Placebo‐controlled trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4520</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.90, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.79.2 No control intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.80 HOSPITALISATION FOR ANY CAUSE <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18615</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.91, 1.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.81 REVASCULARISATION <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19631</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.91, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.82 UNSTABLE ANGINA PECTORIS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.92, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Antibiotics versus placebo for secondary prevention of coronary heart disease at maximum follow‐up</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003610-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 ALL‐CAUSE MORTALITY <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9517</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [1.06, 1.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 All‐cause mortality ‐ trials at low risk of bias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4674</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [1.03, 1.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 All‐cause mortality ‐ 'best‐worst case' scenario <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9518</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [1.03, 1.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 All‐cause mortality ‐ 'worst‐best case' scenario <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9518</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [1.11, 1.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 All‐cause mortality ‐ modified 'best‐worst case' scenario <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9518</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [1.05, 1.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 All‐cause mortality ‐ modified 'worst‐best case' scenario <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9518</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [1.09, 1.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 All‐cause mortality ‐ trials with optimal medical therapy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8682</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [1.07, 1.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.8 All‐cause mortality according to type of antibiotic <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9517</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [1.06, 1.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8.1 Azithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>362</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.33, 3.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8.2 Clarithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4993</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [1.04, 1.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8.3 Gatifloxacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.89, 1.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.9 All‐cause mortality according to antibody status <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9517</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [1.06, 1.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.1 People with antibodies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>362</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.33, 3.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.2 People without antibodies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.3 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9155</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [1.07, 1.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.10 All‐cause mortality according to use of statins <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9155</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [1.07, 1.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10.1 People with use of statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.89, 1.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10.2 People without use of statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10.3 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4993</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [1.04, 1.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.11 All‐cause mortality according to the mean age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9517</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [1.06, 1.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11.1 18 to 59 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4222</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.88, 1.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11.2 60 and above</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5295</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [1.04, 1.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.12 All‐cause mortality according to clinical trial registration status <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9517</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [1.06, 1.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.12.1 Pre‐registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8534</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [1.06, 1.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.12.2 Post‐registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.12.3 No registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>983</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.63, 2.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.13 All‐cause mortality according to class of antibiotic <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9517</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [1.06, 1.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.13.1 Macrolides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5355</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [1.04, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.13.2 Tetracycline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.13.3 Quinolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.89, 1.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.14 All‐cause mortality according to funding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9517</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [1.06, 1.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.14.1 Industry funded or unknown funded trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4783</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.93, 1.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.14.2 Non‐industry funded trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4734</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [1.03, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.15 All‐cause mortality according to control intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9517</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [1.06, 1.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.15.1 Placebo‐controlled trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9517</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [1.06, 1.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.15.2 No control intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.16 CARDIOVASCULAR MORTALITY <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9044</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [1.17, 1.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.17 Cardiovascular mortality ‐ trials at low risk of bias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4674</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [1.09, 1.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.18 Cardiovascular mortality ‐ 'best‐worst case' scenario <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9045</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [1.09, 1.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.19 Cardiovascular mortality ‐ 'worst‐best case' scenario <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9045</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.60 [1.26, 2.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.20 Cardiovascular mortality ‐ modified 'best‐worst case' scenario <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9045</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.44 [1.13, 1.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.21 Cardiovascular mortality ‐ modified 'worst‐best case' scenario <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9045</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.56 [1.22, 1.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.22 Cardiovascular mortality ‐ trials with optimal medical therapy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8682</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.52 [1.18, 1.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.23 Cardiovascular mortality according to type of antibiotic <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9044</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [1.15, 1.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.23.1 Azithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>362</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.33, 3.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.23.2 Clarithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4520</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.00 [0.50, 7.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.23.3 Gatifloxacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.64 [0.93, 2.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.24 Cardiovascular mortality according to antibody status <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9044</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [1.15, 1.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.24.1 People with antibodies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>362</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.33, 3.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.24.2 People without antibodies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.24.3 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8682</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [1.16, 1.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.25 Cardiovascular mortality according to use of statins <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8682</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [1.16, 1.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.25.1 People with use of statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.64 [0.93, 2.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.25.2 People without use of statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.25.3 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4520</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.00 [0.50, 7.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.26 Cardiovascular mortality according to the mean age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9044</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [1.15, 1.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.26.1 18 to 59 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4222</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.56 [0.89, 2.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.26.2 60 and above</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4822</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [1.11, 1.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.27 Cardiovascular mortality according to clinical trial registration status <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9044</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [1.15, 1.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.27.1 Pre‐registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8534</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [1.15, 1.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.27.2 Post‐registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.27.3 No registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>510</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [0.43, 5.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.28 Cardiovascular mortality according to class of antibiotic <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9044</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [1.15, 1.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.28.1 Macrolides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4882</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.44 [1.10, 1.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.28.2 Tetracycline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.28.3 Quinolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.64 [0.93, 2.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.29 Cardiovascular mortality according to funding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9044</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [1.15, 1.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.29.1 Industry funded or unknown funded trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4310</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.09 [0.64, 6.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.29.2 Non‐industry funded trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4734</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [1.08, 1.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.30 Cardiovascular mortality according to control intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9044</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [1.15, 1.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.30.1 Placebo‐controlled trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9044</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [1.15, 1.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.30.2 No control intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.31 MYOCARDIAL INFARCTION <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.82, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.32 Myocardial infarction ‐ trials at low risk of bias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4674</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.87, 1.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.33 Myocardial infarction ‐ 'best‐worst case' scenario <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.80, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.34 Myocardial infarction ‐ 'worst‐best case' scenario <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.85, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.35 Myocardial infarction ‐ modified 'best‐worst case' scenario <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.81, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.36 Myocardial infarction ‐ modified 'worst‐best case' scenario <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.84, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.37 Myocardial infarction ‐ trials with optimal medical therapy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8682</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.83, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.38 Myocardial infarction according to type of antibiotic <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.68, 1.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.38.1 Azithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>302</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.19, 2.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.38.2 Clarithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4993</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.25, 1.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.38.3 Gatifloxacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.72, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.39 Myocardial infarction according to antibody status <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.68, 1.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.39.1 People with antibodies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>302</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.19, 2.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.39.2 People without antibodies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.39.3 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9155</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.65, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.40 Myocardial infarction according to use of statins <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.68, 1.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.40.1 People with use of statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.72, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.40.2 People without use of statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.40.3 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5295</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.35, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.41 Myocardial infarction according to the mean age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.68, 1.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.41.1 18 to 59 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.72, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.41.2 60 and above</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5295</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.35, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.42 Myocardial infarction according to clinical trial registration status <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.68, 1.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.42.1 Pre‐registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8534</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.81, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.42.2 Post‐registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.42.3 No registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>923</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.21, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.43 Myocardial infarction according to class of antibiotic <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.68, 1.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.43.1 Macrolide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5295</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.35, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.43.2 Tetracycline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.43.3 Quinolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.72, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.44 Myocardial infarction according to funding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.68, 1.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.44.1 Industry funded or unknown funded trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4783</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.30, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.44.2 Non‐industry funded trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4674</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.87, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.45 Myocardial infarction according to control intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.68, 1.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.45.1 Placebo‐controlled trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.68, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.45.2 No control intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.46 STROKE <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.90, 1.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.47 Stroke ‐ trials at low risk of bias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4674</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.86, 1.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.48 Stroke ‐ 'best‐worst case' scenario <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.84, 1.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.49 Stroke ‐ 'worst‐best case' scenario <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [0.99, 1.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.50 Stroke ‐ modified 'best‐worst case' scenario <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.87, 1.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.51 Stroke ‐ modified 'worst‐best case' scenario <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.95, 1.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.52 Stroke ‐ trials with optimal medical therapy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8682</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.88, 1.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.53 Stroke according to type of antibiotic <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.90, 1.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.53.1 Azithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>302</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.04, 3.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.53.2 Clarithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4993</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.92, 1.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.53.3 Gatifloxacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.59, 1.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.54 Stroke according to antibody status <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.90, 1.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.54.1 People with antibodies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>302</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.04, 3.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.54.2 People without antibodies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.54.3 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9155</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.92, 1.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.55 Stroke according to use of statins <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.90, 1.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.55.1 People with use of statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.59, 1.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.55.2 People without use of statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.55.3 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5295</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.90, 1.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.56 Stroke according to the mean age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9453</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.90, 1.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.56.1 18 to 59 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.59, 1.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.56.2 60 and above</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5291</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.90, 1.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.57 Stroke according to clinical trial registration status <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.90, 1.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.57.1 Pre‐registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8534</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.88, 1.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.57.2 Post‐registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.57.3 No registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>923</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.52, 2.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.58 Stroke according to class of antibiotic <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.90, 1.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.58.1 Macrolide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5295</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.90, 1.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.58.2 Tetracycline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.58.3 Quinolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.59, 1.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.59 Stroke according to funding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.90, 1.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.59.1 Industry funded or unknown funded trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4783</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.71, 1.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.59.2 Non‐industry funded trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4674</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.50, 2.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.60 Stroke according to control intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.90, 1.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.60.1 Placebo‐controlled trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.90, 1.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.60.2 No control intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.61 SUDDEN CARDIAC DEATH <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4520</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.77 [1.28, 2.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.62 Sudden cardiac death ‐ trials at low risk of bias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4372</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.75 [1.27, 2.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.63 Sudden cardiac death ‐ 'best‐worst case' scenario <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4521</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.68 [1.22, 2.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.64 Sudden cardiac death ‐ 'worst‐best case' scenario <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4521</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.91 [1.39, 2.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.65 Sudden cardiac death ‐ modified 'best‐worst case' scenario <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4521</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.74 [1.26, 2.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.66 Sudden cardiac death ‐ modified 'worst‐best case' scenario <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4521</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.84 [1.34, 2.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.67 Sudden cardiac death according to clinical trial registration status <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4520</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.77 [1.28, 2.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.67.1 Pre‐registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4372</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.75 [1.27, 2.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.67.2 Post‐registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.67.3 No registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.12, 72.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.68 Sudden cardiac death according to funding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4520</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.77 [1.28, 2.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.68.1 Industry funded or unknown funded trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.12, 72.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.68.2 Non‐industry funded trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4372</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.75 [1.27, 2.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.69 Sudden cardiac death according to type of antibiotic <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4520</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.77 [1.28, 2.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.69.1 Clarithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4520</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.77 [1.28, 2.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.70 Sudden cardiac death according to antibody status <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4520</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.77 [1.28, 2.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.70.1 People with antibodies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.70.2 People without antibodies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.70.3 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4520</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.77 [1.28, 2.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.71 Sudden cardiac death according to use of statins <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4520</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.77 [1.28, 2.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.71.1 People with use of statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.71.2 People without use of statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.71.3 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4520</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.77 [1.28, 2.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.72 Sudden cardiac death according to the mean age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4520</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.77 [1.28, 2.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.72.1 18 to 59 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.72.2 60 and above</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4520</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.77 [1.28, 2.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.73 Sudden cardiac death according to class of antibiotic <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4520</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.77 [1.28, 2.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.73.1 Macrolide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4520</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.77 [1.28, 2.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.73.2 Tetracycline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.73.3 Quinolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.74 Sudden cardiac death according to control intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4520</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.77 [1.28, 2.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.74.1 Placebo‐controlled trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4520</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.77 [1.28, 2.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.74.2 No control intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.75 HOSPITALISATION FOR ANY CAUSE <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4464</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.78, 1.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.76 REVASCULARISATION <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4937</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.83, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.77 UNSTABLE ANGINA PECTORIS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5085</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.75, 1.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Antibiotics versus placebo for secondary prevention of coronary heart disease at 24±6 months follow‐up</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003610.pub4/references#CD003610-tbl-0010">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD003610.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD003610-note-0016">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD003610-note-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD003610-note-0015">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD003610-note-0013">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD003610-note-0012">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD003610-note-0011">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD003610-note-0010">Português</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD003610-note-0008">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD003610-note-0009">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003610\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003610\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003610\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003610\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003610\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003610\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003610\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003610\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003610\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003610\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003610\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003610\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003610\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003610\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003610\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003610\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003610\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003610\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Ko3zGe0H&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003610.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003610.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD003610.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD003610.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003610.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740726024757"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003610.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740726024761"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003610.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e8989fd4d9379',t:'MTc0MDcyNjAyNS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 